

JOHN P.A. IOANNIDIS

Short biosketch, April 2023

Professor of Medicine, Professor of Epidemiology and Population Health, and Professor (by courtesy) of Biomedical Data Science at the School of Medicine; Professor (by courtesy) of Statistics at the School of Humanities and Sciences; co-Director, Meta-Research Innovation Center at Stanford (METRICS). My work aims to improve research methods and to enhance approaches to integrating information and generating reliable evidence. Science is the best thing that can happen to humans, but doing research is like swimming in an ocean at night. Science thrives in darkness.

Born in New York City in 1965 and raised in Athens, Greece. Valedictorian (1984) at Athens College; National Award of the Greek Mathematical Society (1984); MD (top rank of medical school class) from the National University of Athens in 1990; also received DSc in biopathology from the same institution. Trained at Harvard and Tufts-New England Medical Center (internal medicine, Infectious diseases), then held positions at NIH, Johns Hopkins and Tufts. Chaired the Department of Hygiene and Epidemiology, University of Ioannina Medical School in 1999-2010 while also holding adjunct professor positions at Harvard School of Public Health (epidemiology), Tufts (medicine, also Director of the Center for Genetic Epidemiology and Modeling in 2008-2010), and Imperial College (epidemiology and biostatistics). Moved to Stanford in 2010, initially as Director/C.F. Rehnborg Chair at Stanford Prevention Research Center, then diversified with appointments in 4 departments and membership in 8 centers/institutes at Stanford. Launched the PhD program in Epidemiology & Clinical Research and the MS program in Community Health & Prevention Research. Launched METRICS at Stanford in 2014, a center that has gained wide international recognition and that has become the epicentre of a large international network of researchers interested in studying and improving research practices.

Member of executive board of the Human Genome Epidemiology Network and Senior Advisor on Knowledge Integration at NCI/NIH (2012-6). Served as President, Society for Research Synthesis Methodology, and editorial board member of many leading journals (including PLoS Medicine, PLoS Biology, Lancet, Annals of Internal Medicine, JNCI, Science Translational Medicine, Clinical Chemistry, Molecular and Cellular Proteomics, AIDS, IJE, JCE, Clinical Trials, PLoS ONE, Royal Society Open Science, Research Integrity and Peer Review, Physiological Reviews among others) and as Editor-in-Chief of the European Journal of Clinical Investigation (2010-2019). President Elect of Association of American Physicians, the most prestigious honorific society for physician-scientists (serving as Vice President for 2022-2023, President for 2023-2024). Delivered over 700 invited and honorary lectures. Recipient of many awards (e.g. European Award for Excellence in Clinical Science [2007], Medal for Distinguished Service, Teachers College, Columbia University [2015], Chanchlani Global Health Award [2017], Epiphany Science Courage Award [2018], Einstein fellow [2018], Gordon award for epidemiology at NIH [2019], Albert Stuyvenberg Medal [2021], inaugural Harwood Prize for Intellectual Courage [2022], European Research Agency chair holder [2023-2028]). Inducted in the Association of American Physicians (2009), European Academy of Cancer Sciences (2010) American Epidemiological Society (2015), European Academy of Sciences and Arts (2015), National Academy of Medicine (2018), Academy of Sciences of the Institute of Bologna (2020). Honorary titles from FORTH (2014) and University of Ioannina (2015) and honorary doctorates from Erasmus University Rotterdam (2015) University of Athens (2017), University of Tilburg (2019), University of Edinburgh (2021). Multiple honorary lectureships/visiting professorships (Caltech, Oxford, LSHTM, Yale, U Utah, U Conn, UC Davis, U Penn, Wash U St. Louis, NIH among others).

The PLoS Medicine paper on “Why most published research findings are false” has been the most-

accessed article in the history of Public Library of Science (over 3 million hits) and the most used article in Mendeley across all science. Author of 9 literary books (8 in Greek and 1 in English), three of which (“Toccata for the Girl with the Burnt Face” (Kedros 2012), “Variations on the Art of the Fugue and a Desperate Ricercar” (Kedros 2014), and “Meta-A-Physics” (Kedros, 2018)) were shortlisted for best book of the year Anagnostis awards. Brave Thinker scientist for 2010 according to Atlantic, “may be one of the most influential scientists alive”.

Highly Cited Researcher according to Clarivate in both Clinical Medicine and in Social Sciences. Citation indices: h=242, m=8 per Google Scholar (h=180 per WoK and Scopus). Current citation rates: ~6,000 new citations per month per Google Scholar, >3,500 new citations per month per Scopus or Web of Knowledge (among the 6 living scientists worldwide who are currently the most commonly cited, perhaps also the currently most-cited physician). When contrasted against my vast ignorance, these values offer excellent proof that citation metrics can be horribly unreliable. I have no personal social media accounts - I admire people who can outpour their error-free wisdom in them, but I make a lot of errors, I need to revisit my writings multiple times before publishing, and I see no reason to make a fool of myself more frequently than it is sadly unavoidable. I consider myself privileged to have learned and to continue to learn from interactions with students and young scientists (of all ages) from all over the world and I love to be constantly reminded that I know next to nothing.

Detailed CV, April 2023

John P.A. Ioannidis, MD, DSc
Professor of Medicine
Professor of Epidemiology and Population Health
Professor (by courtesy) of Biomedical Data Science
Stanford University School of Medicine
Professor (by courtesy) of Statistics
Stanford University School of Humanities and Sciences
Co-Director, Meta-Research Innovation Center at Stanford (METRICS)
Member, Stanford Cancer Institute
Member, Stanford Cardiovascular Institute
Member, Stanford Bio-X
Member, Stanford Diabetes Research Center
Affiliate, Stanford Center on Longevity
Affiliated faculty, Woods Institute for the Environment
Member, Stanford Center for Population Health Sciences
Faculty Fellow, Stanford Center for Innovation in Global Health
Founding director and currently committee member, PhD program in Epidemiology and Clinical Research, Stanford University
Course director for courses MED73N (undergraduate), STATS211/MED206/HRP206/CHPR206 (medicine and statistics), COMPLIT208 (comparative literature)

ADDRESS

Medical School Office Building
Room X306
1265 Welch Rd
Stanford, CA 94305
USA

E-mail: jioannid@stanford.edu

Administrative assistant: Darlyne Esparza, desparza@stanford.edu

WEB:

Stanford – personal profile: med.stanford.edu/profiles/John_Ioannidis

SPRC/Medicine: prevention.stanford.edu/

METRICS: metrics.stanford.edu, metaresearch.stanford.edu

Google Scholar: <http://scholar.google.com/citations?hl=en&user=A9e6sPYAAAAJ>

BACKGROUND

- * Born 8/21/1965 in New York, NY, USA; married in 1993 to Despina Contopoulos-Ioannidis, MD (Clinical Associate Professor of Pediatrics/Pediatric Infectious Diseases, Stanford University School of Medicine); children: one daughter (Angeliki Diotima, born in Boston in 1994, graduate of UC Davis in Environmental Toxicology (BSc) and Forensic Sciences (MSc), currently pursuing PhD in Molecular Toxicology at UCLA)
- * Citizenships: USA and Greece/European Union
- * Languages: Greek, English, French, German, and Italian.

EDUCATION

<i>Undergraduate:</i>	Athens College, Athens, Greece (1984). Valedictorian, rank number 1 in my class
<i>Medical degree:</i>	University of Athens, Athens, Greece, M.D. (1990). Grade: Excellent, rank number 1 in my class
<i>Residency:</i>	Internal Medicine, New England Deaconess Hospital, Harvard Medical School, Boston, MA, USA 1990-3.
<i>Fellowship:</i>	Infectious Diseases, New England Medical Center Hospitals, Tufts University School of Medicine, Boston, MA, USA 7/93-6/96 (concurrently doing research at the Division of Clinical Care Research, subsequently Institute for Clinical Research and Health Policy Studies).
<i>Doctoral thesis:</i>	Department of Biopathology, University of Athens School of Medicine (“Development of human brain cultures, isolation of microglial cells and study of their infection with HIV-1”) – DSc Grade: Excellent, defended and awarded in 1996.

CURRENT APPOINTMENTS

2010-	Professor of Medicine, Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, USA (appointed 8/2010)
2010-	Member, Stanford Cancer Institute
2010-	Member, Stanford Cardiovascular Institute
2011-	Professor of Health Research and Policy, Stanford University School of Medicine (joint appointment), Professor of Epidemiology and Population Health (after renaming of department, 2019-)
2011-	Professor of Statistics, Stanford University School of Humanities and Sciences (courtesy appointment)
2011-	Affiliated faculty, Woods Institute for the Environment
2013-	Affiliate, Stanford Center on Longevity
2013-	Co-Director, Meta-Research Innovation Center at Stanford (METRICS)
2013-	Founding Program Director (2013-2019) and member of program committee (2019-), PhD in Epidemiology and Clinical Research, Stanford University
2015-	Member, Stanford Center for Population Health Sciences
2015-	Faculty Fellow, Stanford Center for Innovation in Global Health
2016-	Member, Stanford Bio-X
2017-	Professor of Biomedical Data Science, Stanford University School of Medicine (courtesy appointment)
2018-	Member, Stanford Diabetes Research Center

PAST APPOINTMENTS AND TITLES

1990-3	Clinical Fellow in Medicine, Harvard Medical School, Boston, Massachusetts, USA
1993-6	Clinical and Research Fellow, New England Medical Center Hospitals, Tufts University School of Medicine, Boston, Massachusetts, USA
1996-8	Medical Officer, HIV Research Branch, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA (career position; responsible for the co-ordination, design, support and medical monitoring of NIAID-sponsored clinical trials of HIV therapeutics research with emphasis on concept trials, large trials and community trials)
1996-8	Assistant Professor of Medicine (part-time), Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
1996-8	Assistant Professor of Medicine (adjunct), Department of Medicine, Tufts University

	School of Medicine, Boston, Massachusetts, USA
1996-8	Associate Medical Staff, Johns Hopkins Hospital, Baltimore, Maryland, USA. Attending, HIV Clinic
1998-2001	Associate Professor of Medicine (adjunct), Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA
2002-	Professor of Medicine (adjunct), Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA. Since 10/2008, Director of the Genetics/Genomics component of the Tufts Clinical and Translational Science Institute (2008-2010) and of the Center for Genetic Epidemiology and Modeling, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA. Adjunct Professor, Tufts Clinical and Translational Science Institute.
1998-2003	[Elected 5/98], Associate Professor (tenured) and Chairman, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
2003-2010	[Elected 12/2003], Professor (tenured) and Chairman, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
2010-	Professor of Epidemiology (adjunct), Harvard School of Public Health, Boston, USA
2010-2014	Visiting Professor of Epidemiology and Biostatistics, Imperial College London, UK
2010-2016	Division chief, Department of Medicine, Stanford University School of Medicine
2010-2020	C.F. Rehnborg Chair in Disease Prevention (Director's chair for Stanford Prevention Research Center, Stanford University School of Medicine)

PUBLICATIONS IN INTERNATIONAL PEER-REVIEWED JOURNALS

1. Ioannidis JPA, Samarel MD, Lau J, Drapkin MS. Risk of gastrointestinal bleeding from dexamethasone in children with bacterial meningitis. **Lancet** 1994, 343:792 (letter).
2. Ioannidis JPA, Iacoviello VR, Samore MH. Insulin-dependent diabetes in AIDS. **AIDS** 1994, 8:556-7 (letter).
3. Ioannidis JPA, Snyderman DR, Rohrer RJ, Freeman RB, Haug CE. Aspergillus fumigatus infection in a biloma. **Clinical Infectious Diseases** 1995, 20:1427-8 (letter).
4. Ioannidis JPA, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, Sacks HS. Early or deferred zidovudine in HIV-infected patients without an AIDS-defining illness. A meta-analysis. **Annals of Internal Medicine** 1995, 122:856-66.
5. Ioannidis JPA, Skolnik PR, Chalmers TC, Lau J. Human leukocyte antigen associations of epidemic Kaposi's sarcoma. **AIDS** 1995, 9:649-51 (letter).
6. Ioannidis JPA, Griffiths J, Worthington M, Snyderman DR. Spectrum and significance of bacteremia due to Moraxella catarrhalis. **Clinical Infectious Diseases** 1995, 21:390-7.
7. Ioannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. **Archives of Internal Medicine** 1996, 156:177-88.
8. Ioannidis JPA, Merino F, Drapkin M, Lew M, Cohn L. Pneumococcal aortitis in the antibiotic era. **Archives of Internal Medicine** 1995, 155:1678-80.
9. Ioannidis JPA, Reichlin S, Skolnik PR. Long-term productive HIV-1 infection in human infant microglia. **American Journal of Pathology** 1995, 147:1200-6.
10. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. **British Medical Journal** 1996, 312:338-45. See also accompanying editor-invited commentary in the same issue. See also comments and reply in 1996, 313:490-1.
11. Ioannidis JPA, Cappelleri JC, Lau J, Sacks HS, Skolnik PR. Predictive value of viral load in asymptomatic untreated HIV-1 infection. A mathematical model. **AIDS** 1996, 10:255-62.

12. *Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J.* Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. An example from populations of trials of human immunodeficiency virus infection. **American Journal of Epidemiology** 1996, 144:1074-85.
13. *Ioannidis JPA, Cappelleri JC, Lau J.* Viral load and response to treatment of HIV. **New England Journal of Medicine** 1996, 334:1671-3 (letter). (*)
14. *Cappelleri JC, Ioannidis JPA, Schmid CH, deFerranti SD, Aubert M, Chalmers TC, Lau J.* Large trials versus meta-analysis of smaller trials: how do their results compare? **JAMA** 1996, 276:1332-8. See also comments and reply in 1997, 277:376-77.
15. *Lau J, Ioannidis JPA, Schmid CH.* Quantitative synthesis in systematic reviews. **Annals of Internal Medicine** 1997, 127:820-6. (*)
16. *Ioannidis JPA, Lau J.* On meta-analyses of meta-analyses. **Lancet** 1996, 348:756 (letter). (*)
17. *Ioannidis JPA, Sacks HS, Cappelleri JC, Lau J.* Clinical efficacy of antiretroviral changes in HIV-infected patients with prior antiretroviral treatment. A meta-analysis **Online Journal of Current Clinical Trials** 15 May 1997, (Doc. 204).
18. *Bonis PAL, Ioannidis JPA, Cappelleri JC, Kaplan MM, Lau J.* Correlation of biochemical response to alpha interferon with histological improvement in hepatitis C: A meta-analysis of diagnostic test characteristics **Hepatology** 1997, 26:1035-44.
19. *Ioannidis JPA, Cappelleri JC, Melville B, Sacks HS, Lau J.* The relationship between study design, results and reporting of randomized clinical trials of HIV-1 infection. **Controlled Clinical Trials** 1997, 18:431-44.
20. *Ioannidis JPA, Bassett R, Hughes MD, Sacks HS, Volberding PA, Lau J.* Predictors and impact of patients lost to follow-up in a long-term trial of early versus deferred antiretroviral therapy. **Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology** 1997, 16:22-30.
21. *Ioannidis JPA.* Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. **JAMA** 1998, 279:281-6. See also accompanying editorial at 279:319-20.
22. *Ioannidis JPA, Dixon DO, McIntosh M, Albert JM, Bozzette S, Schnittman SM.* Relationship between event rates and treatment effects in clinical site differences within multicenter trials. **Controlled Clinical Trials** 1999, 20:253-66.
23. *Ioannidis JPA, Lau J.* The impact of high risk patients on the results of clinical trials. **Journal of Clinical Epidemiology** 1997, 50:1089-98.
24. *DeFerranti SD, Ioannidis JPA, Lau J, Anninger W, Barza M.* Are amoxicillin and folate inhibitors as effective as other antibiotics for acute sinusitis? A meta-analysis. **British Medical Journal** 1998, 317:632-7.
25. *Wynia M, Ioannidis JPA, Lau J.* Analysis of lifelong strategies to prevent *Pneumocystis carinii* pneumonia in patients with variable HIV progression rates. **AIDS** 1998, 12:1317-25.
26. *Ioannidis JPA, McQueen P, Goedert JJ, Kaslow RA.* Use of neural networks to model complex immunogenetic associations of disease: HLA impact on the progression of HIV infection **American Journal of Epidemiology** 1998, 147:464-71.
27. *Albert JM, Ioannidis JPA, Reichelderfer P, Conway B, Coombs RW, Crane L, Demasi R, Dixon DO, Flandre P, Hughes MD, Kalish LA, Larntz K, Lin D, Marschner IC, Munoz A, Murray J, Neaton J, Pettinelli C, Rida W, Taylor JMG, Welles SL for the NIAID workshop on surrogate endpoints participants.* Statistical issues for HIV surrogate endpoints: point/counterpoint. **Statistics in Medicine** 1998, 17:2735-62.
28. *Lau J, Ioannidis JPA, Schmid CH.* Summing up evidence: one answer is not always enough. **Lancet** 1998, 351:123-7. See also accompanying editorial in 351:8. (*)
29. *Contopoulos-Ioannidis DG, Ioannidis JPA.* Maternal cell-free viremia in the natural history of perinatal

- HIV-1 transmission. A meta-analysis. **Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology** 1998, 18:126-35.
30. *Ioannidis JPA, Cappelleri JC, Lau J.* Meta-analyses and large randomized controlled trials. **New England Journal of Medicine** 1998, 338:59-62 (letter). (*)
 31. *Ioannidis JPA, Goedert JJ, McQueen PG, Enger C, Kaslow RA.* Comparison of viral load and HLA statistical and neural network predictive models for the rate of HIV disease progression across two cohorts of homosexual men. **Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology** 1999, 20:129-36.
 32. *Ioannidis JPA, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard B, Griffiths PD, Contopoulos-Ioannidis DG, Lau J, Pavia AT, Saag MS, Spruance S, Youle MS.* Clinical efficacy of acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. **Journal of Infectious Diseases** 1998, 178:349-59.
 33. *Ioannidis JP, Lau J.* Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. **American Journal of Epidemiology** 1998, 148:1117-26.
 34. *Ioannidis JPA, Cappelleri JC, Lau J.* Issues in comparisons between meta-analyses and large trials. **JAMA** 1998, 279:1089-93.
 35. *Ioannidis JPA, Lau J.* Uncontrolled pearls, controlled evidence, meta-analysis and the individual patient. **Journal of Clinical Epidemiology** 1998, 51:709-11 (commentary). (*)
 36. *Ioannidis JPA, Contopoulos-Ioannidis DG.* Reporting of safety data from randomised trials. **Lancet** 1998, 352:1752-3.
 37. *Ioannidis JPA, Contopoulos-Ioannidis DG, Lau J.* Recursive cumulative meta-analysis: a diagnostic for the evolution of total randomized evidence from group and individual patient data. **Journal of Clinical Epidemiology** 1999, 52:281-91.
 38. *Ioannidis JPA, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG, Goedert JJ.* Genetic effects on HIV disease progression. **Nature Medicine** 1998, 4:536 (letter).
 39. *Havlir DV, Marschner I, Hirsch M, Colier AC, Tebas P, Bassett R, Ioannidis JPA, Holohan MK, Leavitt R, Boone G, Richman DD for the AIDS Clinical Trials Group 343 Study Team.* Maintenance antiretroviral therapy in HIV-infected patients who have achieved undetectable plasma HIV RNA with triple combination therapy. **New England Journal of Medicine** 1998, 339:1261-8. See also accompanying editorial in the same issue, pp. 1319-21.
 40. *Ioannidis JPA, Lau J.* Meta-analysis: a science of bias, dissent and diversity. **SGIM Forum** 1998, 21: 5,11 (invited editorial). (*)
 41. *Ioannidis JPA, Taha ET, Kumwenda N, Broadhead R, Mtimavalye L, Miotti P, Yellin F, Contopoulos-Ioannidis DG, Biggar RJ.* Predictors and impact of losses to follow-up in a HIV-1 perinatal transmission cohort in Malawi. **International Journal of Epidemiology** 1999, 28:769-75.
 42. *Ioannidis JPA, Lau J.* Can quality of clinical trials and meta-analysis be quantified? **Lancet** 1998, 352:590-1 (invited editorial). (*)
 43. *Ioannidis JPA, O'Brien TR, Goedert JJ.* Evaluation of guidelines for the initiation of highly active antiretroviral therapy in a longitudinal cohort of HIV-infected patients. **AIDS** 1998, 12: 2417-23.
 44. *Ioannidis JPA, Lau J.* Benefits and limitations of meta-analysis. **Joint Commission Journal of Quality Improvement** 1999, 25:462-9. (*)
 45. *Ioannidis JPA, Moutsopoulos HM.* Sjogren's syndrome: too many associations, too limited evidence. **Seminars in Arthritis and Rheumatism** 1999, 29:1-3 (invited commentary). (*)
 46. *Ioannidis JPA, Lau J.* State-of-the-evidence: current status and prospects of meta-analysis in infectious diseases. **Clinical Infectious Diseases** 1999, 29:1178-85. (*)
 47. *HIV Trialists' Collaborative Group (including Ioannidis JPA).* Meta-analyses of the randomised

- evidence on zidovudine, didanosine and zalcitabine in the treatment of HIV infection. **Lancet** 1999, 353:2014-25. See also editorial in the same issue, pp. 1989-90.
48. *Ioannidis JPA, Schmid CH, Lau J.* Meta-analysis in hematology and oncology. **Hematology/Oncology Clinics of North America** 2000, 14:973-91. (*)
 49. *Mavragani CP, Ioannidis JPA, Tzioufas AG, Hantoumi IE, Moutsopoulos HM.* Recurrent pregnancy loss and autoantibody profile in autoimmune diseases. **Rheumatology** 1999, 38:1228-33.
 50. *Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM.* Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. **Lancet** 1999, 354:569-70.
 51. *Sipsas NV, Kokori SI, Ioannidis JPA, Kyriaki D, Tzioufas AG, Kordossis T.* Circulating autoantibodies to erythropoietin are associated with HIV-1 related anemia. **Journal of Infectious Diseases** 1999, 180:2044-7.
 52. *Kokori SI, Ioannidis JPA, Voulgarelis M, Tzioufas AG, Moutsopoulos HM.* Autoimmune hemolytic anemia in patients with systemic lupus erythematosus. **American Journal of Medicine** 2000, 108:198-204.
 53. *Ioannidis JPA, Boki KA, Katsorida M, Drosos AA, Boletis JN, Skopouli FN, Moutsopoulos HM.* Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. **Kidney International** 2000, 57:258-64.
 54. *Ioannidis JPA, Tektonidou MG, Vlachoyiannopoulos PG, Stavropoulos-Giokas C, Spiropoulou M, Reveille J, Arnett FC, Moutsopoulos HM.* HLA associations of anti-beta2 glycoprotein I response in a Greek cohort with antiphospholipid syndrome and meta-analysis of four ethnic groups. **Human Immunology** 1999, 60:1274-80.
 55. *Skopouli FN, Dafni U, Ioannidis JPA, Moutsopoulos HM.* Clinical evolution, mortality and morbidity of primary Sjogren's syndrome. **Seminars in Arthritis and Rheumatism** 2000, 29:296-304.
 56. *Rizou C, Ioannidis JPA, Panou-Pomoni E, Sakarrellos, Sakarellos-Daitsiotis, Moutsopoulos HM, Vlachoyiannopoulos PG.* B-cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis. **American Journal of Respiratory Cell and Molecular Biology** 2000, 22:344-51.
 57. *Ioannidis JPA, Contopoulos-Ioannidis DG.* Maternal viral load and perinatal transmission of HIV-1. **New England Journal of Medicine** 1999, 341:1698-1700 (letter). (*)
 58. *Voulgarelis M, Kokori SIG, Ioannidis JPA, Tzioufas AG, Kyriaki D, Moutsopoulos HM.* Anaemia in systemic lupus erythematosus: aetiologic profile and the role of erythropoietin. **Annals of the Rheumatic Diseases** 2000, 59:217-22.
 59. *Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters M, Mannheimer S, Thompson M, Abrams DI, Brizz B, Ioannidis JPA, Merigan TC and the CPCRA 046 Study Team for the Terry Bein Community Programs for Clinical Research on AIDS.* A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. **AIDS** 2000, 14:F83-93.
 60. *O'Brien TR, McDermott DH, Ioannidis JPA, Carrington M, Murphy PM, Havlir DV, Richman DD.* Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy. **AIDS** 2000, 14:821-6.
 61. *Mathys JM, Melanson SM, Schiffer-Alberts DJ, Ioannidis JP, Koziel H, Skolnik PR.* NF-kB modulates TNF-alpha production by alveolar macrophages in asymptomatic HIV-seropositive individuals. **Journal of Immunology** 2000, 164:1588-94.
 62. *Tektonidou MG, Petrouvas CA, Ioannidis JPA, Vlachoyiannopoulos PG, Moutsopoulos HM.* Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations. **European Journal of Clinical Investigation** 2000, 30:646-52.

63. Karassa FB, Ioannidis JPA, Touloumi G, Boki KA, Moutsopoulos HM. Risk factors for central nervous system involvement in systemic lupus erythematosus. **Quarterly Journal of Medicine** 2000, 93:169-74.
64. Ioannidis JPA, Havlir DV, Tebas P, Hirsch MS, Collier AC, Richman DD. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication. **AIDS** 2000, 14:1481-8.
65. Goules A, Masouridi S, Tzioufas AG, Ioannidis JPA, Skopouli FN, Moutsopoulos HM. Clinically significant and biopsy-documented renal involvement in primary Sjogren's syndrome. **Medicine** 2000, 79:241-9.
66. Spoulou V, Victoratos P, Ioannidis JPA, Grafakos S. Kinetics of antibody concentration and avidity for the assessment of immune response to pneumococcal vaccine among children with bone marrow transplants. **Journal of Infectious Diseases** 2000, 182:965-9.
67. Ioannidis JPA, Lau J. Evidence for the diagnosis and treatment of acute uncomplicated sinusitis in children: a systematic overview. **Pediatrics** 2001, 108: e57.
68. Ioannidis JPA, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. **Journal of Clinical Oncology** 2000, 18:3409-22.
69. Tektonidou MT, Ioannidis JPA, Moyssakis I, Boki KA, Vassiliou V, Vlachoyiannopoulos PG, Moutsopoulos HM. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. **Annals of the Rheumatic Diseases** 2001, 60:43-48.
70. Karassa FB, Ioannidis JPA, Boki KA, Touloumi G, Argyropoulou MI, Strigaris KA, Moutsopoulos HM. Predictors of clinical outcome and radiographic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. **American Journal of Medicine** 2000, 109:628-34.
71. Tektonidou M, Ioannidis JPA, Boki KA, Vlachoyiannopoulos PG, Moutsopoulos HM. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome. **Quarterly Journal of Medicine** 2000, 93:523-30.
72. Katritis DG, Ioannidis JPA, Korovesis S, Giazitzoglou E, Kalivas P, Parissis J, Webb-Peploe MM. Comparison of coronary functional flow reserve and intravascular ultrasound for the assessment of slotted tube stents. **Catheterization and Cardiovascular Interventions** 2001, 52:322-6. See also accompanying editorial in the same issue.
73. Boki KA, Ioannidis JPA, Segas JV, Marangoudakis PV, Petrou D, Adamopoulos GK, Moutsopoulos HM. How significant is sensorineural hearing loss in primary Sjogren's syndrome? An individually-matched case-control study. **Journal of Rheumatology** 2001, 28:798-801.
74. Ioannidis JPA, Lau J. Evolution of treatment effects over time: empirical evidence from recursive cumulative meta-analyses. **Proceedings of the National Academy of Sciences, USA** 2001, 98:831-6.
75. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. **JAMA** 2001, 285:437-43.
76. Trikalinos TA, Ioannidis JPA. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. **Journal of Clinical Epidemiology** 2001, 54:245-52.
77. Ioannidis JPA, Galanos O, Katritsis D, Connery CP, Drossos GE, Swistel DG, Anagnostopoulos CE. Early mortality and morbidity of bilateral versus single internal thoracic artery revascularization: propensity and risk modeling. **Journal of the American College of Cardiology** 2001, 37:521-8.
78. Spoulou V, Theodoridou M, Papaevangelou VG, Mostrou GI, Ioannidis JPA. 23valent pneumococcal vaccination and HIV. **Lancet** 2000, 356:1027-8 (letter).
79. Ioannidis JPA, Lau J. Evidence on interventions to reduce medical errors: an overview and recommendations for future research. **Journal of General Internal Medicine** 2001, 16:325-34. See

also accompanying editorial in the same issue p. 344-6.

80. Ioannidis JPA, Abrams EJ, Ammann A, Bulterys M, Goedert JJ, Gray L, Korber BT, Mayaux MJ, Mofenson LM, Newell M-L, Shapiro DE, Teglas JP, Wilfert CM. Perinatal transmission of HIV-1 from pregnant women with RNA viral load less than 1000 copies/ml. **Journal of Infectious Diseases** 2001, 183:539-45.
81. Efstathiadou Z, Kranas V, Ioannidis JPA, Georgiou I, Tsatsoulis A. The Sp1 COLIA1 gene polymorphism, and not vitamin D receptor or estrogen receptor gene polymorphisms, determines bone mineral density in postmenopausal Greek women. **Osteoporosis International** 2001, 12:326-31.
82. Giannakakis I, Ioannidis JPA. Arabian nights: 1001 tales of how pharmaceutical companies cater to the material needs of doctors. **British Medical Journal** 2000, 321:1563-4. (*)
83. Balk EM, Ioannidis JPA, Salem D, Chew P, Lau J. Accuracy of biomarkers to diagnose acute cardiac ischemia in the emergency department: a meta-analysis. **Annals of Emergency Medicine** 2001, 37:478-94. See also accompanying editorial in the same issue pp. 450-2.
84. Lau J, Ioannidis JPA, Balk EM, Milch C, Terrin N, Chew P, Salem D. Diagnosing acute cardiac ischemia in the emergency department: a systematic review of the accuracy and clinical effect of current technologies. **Annals of Emergency Medicine** 2001, 37:453-60. See also accompanying editorial in the same issue pp. 450-2.
85. Ioannidis JPA, Salem D, Lau J. Accuracy and clinical effect of out-of-hospital electrocardiography in the diagnosis of acute cardiac ischemia: a meta-analysis. **Annals of Emergency Medicine** 2001, 37:461-70. See also accompanying editorial in the same issue pp. 450-2.
86. Ioannidis JPA, Salem D, Chew P, Lau J. Accuracy of imaging technologies in the diagnosis of acute cardiac ischemia in the emergency department: a meta-analysis. **Annals of Emergency Medicine** 2001, 37:471-7. See also accompanying editorial in the same issue pp. 450-2.
87. Contopoulos-Ioannidis DG, Koliofoti I, Koutroumpa I, Giannakakis IA, Ioannidis JPA. Pathways for inappropriate dispensing of antibiotics for rhinosinusitis: a randomized trial. **Clinical Infectious Diseases** 2001, 33:76-82.
88. Katritsis D, Korovesis S, Giazitzoglou E, Kalivas P, Parissis J, Webb-Peploe MM, Ioannidis JPA, Haliassos A. C-reactive protein concentrations and angiographic characteristics of coronary lesions. **Clinical Chemistry** 2001, 47:882-6.
89. Haidich A-B, Ioannidis JPA. Patterns of patient enrollment in randomized controlled trials. **Journal of Clinical Epidemiology** 2001, 54:877-83.
90. Ioannidis JPA, Karassa FB. Bias in uncontrolled therapeutic trials in rheumatology due to selection of populations with extreme characteristics. **Journal of Rheumatology** 2001, 28:1881-7. See also accompanying editorial in same issue, pp. 1747-8.
91. Efstathiadou Z, Tsatsoulis A, Ioannidis JPA. Association of collagen Ia 1 polymorphism with the risk of prevalent fractures: a meta-analysis. **Journal of Bone and Mineral Research** 2001, 16:1586-92.
92. Ioannidis JPA, Haidich A-B, Lau J. Any casualties in the clash of randomised and observational evidence? **British Medical Journal** 2001, 322:879-80 (editorial). (*)
93. Katritsis D, Ioannidis JPA, Anagnostopoulos CE, Sarris GE, Giazitzoglou E, Korovesis S, Camm AJ. Identification and catheter ablation of extracardiac and intercardiac components of ligament of Marshall tissue: a novel approach for the treatment of paroxysmal atrial fibrillation. **Journal of Cardiovascular Electrophysiology** 2001, 12:750-8.
94. Ioannidis JPA, Lau J. Improving safety reporting from randomized trials. **Drug Safety** 2002, 25:77-84 (*).
95. Ioannidis JPA, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA,

- Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie L, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardì GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zaguty Z-F, O'Brien TR for the International Meta-analysis of HIV Host Genetics. Effects of CCR5-Δ32, CCR2-64I and SDF-1 3'A polymorphisms on HIV disease progression: an international meta-analysis of individual patient data. **Annals of Internal Medicine** 2001, 135:782-795.
96. Trikalinos TA, Ioannidis JPA. Discontinuation of *Pneumocystis carinii* prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis. **Clinical Infectious Diseases** 2001, 33:1901-9.
 97. Ioannidis JPA, Haidich A-B, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J. Comparison of evidence of treatment effects in randomized and non-randomized studies. **JAMA** 2001, 286:821-30.
 98. Haidich A-B, Ioannidis JPA. Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. **American Journal of Epidemiology** 2001, 154:873-80.
 99. Pakas I, Ioannidis JPA, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisone for systemic sclerosis lung disease. **Journal of Rheumatology** 2002, 29:298-304.
 100. Papanikolaou GN, Baltogianni MS, Contopoulos-Ioannidis DG, Haidich A-B, Giannakakis IA, Ioannidis JPA. Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions. **BMC Medical Research Methodology** 2001, 1:3.
 101. Haidich A-B, Ioannidis JPA. Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies. **BMC Medical Research Methodology** 2001, 1:4.
 102. Trikalinos TA, Karassa FB, Ioannidis JPA. Meta-analysis of the association between low-affinity Fcγ receptor gene polymorphisms and hematological and autoimmune diseases. **Blood** 2001, 98:1634-6 (letter).
 103. Contopoulos-Ioannidis DG, Ioannidis JPA, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. **Journal of Antimicrobial Chemotherapy** 2001, 48:691-703.
 104. Ioannidis JPA, Contopoulos-Ioannidis DG, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tract infections. **Journal of Antimicrobial Chemotherapy** 2001, 48:677-690.
 105. Tatsioni A, Charchanti A, Kitsiou E, Ioannidis JPA. Appendicectomies in Albanians in Greece: outcomes in a highly mobile immigrant patient population. **BMC Health Services Research** 2001, 1:5 (28 June 2001).
 106. Kyriakidi M, Ioannidis JPA. Design and quality considerations for randomized controlled trials in systemic sclerosis. **Arthritis and Rheumatism** 2002, 47:73-81.
 107. Isaakidis P, Swingler GH, Pienaar E, Volmink J, Ioannidis JPA. Burden of disease and randomized evidence in sub-Saharan Africa: survey of research. **British Medical Journal** 2002, 324:702-5. See also editorial by Ncayiana in the same issue.
 108. Ioannidis JPA, Ntzani EA, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. **Nature Genetics** 2001, 29:306-9. Accompanying by editorial in the same issue, pp. 244-5.
 109. Ioannidis JPA, Rosenberg PS, Goedert JJ, O'Brien TR. Meta-analysis of individual participants' data in genetic epidemiology. **American Journal of Epidemiology** 2002, 156: 204-10.
 110. Giannakakis IA, Haidich A-B, Contopoulos-Ioannidis DG, Papanikolaou GN, Baltogianni MS,

- Ioannidis JPA*. Citation of randomized evidence in support of guidelines of therapeutic and preventive interventions. **Journal of Clinical Epidemiology** 2002, 55: 545-55.
111. *Ioannidis JPA, Tarassi K, Boki K, Papadopoulos IA, Voulgari PV, Papasteriades CA, Drosos AA*. Shared epitopes and rheumatoid arthritis: disease associations in Northwestern Greece and meta-analysis of Mediterranean European populations. **Seminars in Arthritis and Rheumatism** 2002, 31: 361-71.
 112. *Ioannidis JPA, Vassiliou VA, Moutsopoulos HM*. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. **Arthritis and Rheumatism** 2002, 46:741-7.
 113. *Papanikolaou GN, Ioannidis JPA*. Declaring competing interests: types of competing interests would be of interest. **British Medical Journal** 2001, 323:1187-8 (letter). (*)
 114. *Stavrou I, Zoes C, Ioannidis JPA, Tsatsoulis A*. Association of polymorphisms of the estrogen receptor gene with the age of menarche. **Human Reproduction** 2002, 17:1101-5.
 115. *Ioannidis JPA, Chew P, Lau J*. Standardized retrieval of side effects data for meta-analysis of safety outcomes: a feasibility study in acute sinusitis. **Journal of Clinical Epidemiology** 2002, 55:619-26.
 116. *Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Ioannidis JPA*. Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. **Rheumatology** 2002, 41:780-6.
 117. *Karassa FB, Trikalinos TA, Ioannidis JPA*. Role of the FcγRIIA polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. **Arthritis and Rheumatism** 2002, 46:1563-71.
 118. *Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, Lau J*. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. **JAMA** 2002, 287:2973-82.
 119. *Ioannidis JPA, Katsifis GE, Tzioufas AG, Moutsopoulos HM*. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. **Journal of Rheumatology** 2002, 29:2129-35.
 120. *Spoulou V, Gilks CS, Ioannidis JPA*. Protein conjugate pneumococcal vaccines. **British Medical Journal** 2002, 324:750-1 (editorial). (*)
 121. *Polycarpou A, Ntais C, Korber BT, Elrich HA, Winchester R, Krogstad P, Wolinsky S, Rostron T, Rowland-Jones SL, Ammann AJ, Ioannidis JP*. Association between maternal and infant class I and II HLA alleles and of their concordance with the risk of perinatal HIV type 1 transmission. **AIDS Research and Human Retroviruses**. 2002, 18:741-6.
 122. *Ioannidis JPA, Trikalinos TA, Danias PG*. ECG-gated SPECT versus cardiac MRI for evaluation of left ventricular volumes and ejection fraction: a meta-analysis. **Journal of the American College of Cardiology** 2002, 39:2059-68.
 123. *Ioannidis JP, Stavrou I, Trikalinos TA, Zois C, Brandi ML, Gennari L, Albagha O, Ralston SH, Tsatsoulis A*. Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. **Journal of Bone and Mineral Research** 2002, 17:2048-60.
 124. *Drossos GE, Toumpoulis IK, Katritsis DG, Ioannidis JPA, Kontogiorgi P, Svarna E, Siminelakis S, Anagnostopoulos CE*. Is vitamin C superior to diltiazem for radial artery vasodilation in patients awaiting coronary artery by-pass grafting? **Journal of Thoracic and Cardiovascular Surgery** 2003, 125:330-5.
 125. *Katritsis D, Ioannidis JP, Anagnostopoulos CE, Korovesis S, Giazitzoglou E, Camm AJ*. Conduction block within the coronary sinus in humans: implications for atrial arrhythmias. **Journal of**

- Cardiovascular Electrophysiology** 2002, 13:859-62. (see also editorial in the same issue pp. 863-4)
126. Ioannidis JPA, Katsifis GE, Stavropoulos ED, Manoussakis MN, Moutsopoulos HM. Evaluation of the association of autoantibodies with mortality in the very elderly: a cohort study. **Rheumatology** 2003, 42:357-61.
 127. Kapitsinou PP, Ioannidis JPA, Boletis JN, Sotsiou F, Nakopoulou L, Dafnis E, Moutsopoulos HM. Clinicopathologic predictors of mortality and ESRD in patients with pauci-immune necrotizing glomerulonephritis. **American Journal of Kidney Diseases** 2003, 41:29-37.
 128. Contopoulos-Ioannidis DG, O'Brien TR, Rosenberg PS, Goedert JJ, Ioannidis JPA. Effect of CCR5-Δ32 heterozygosity on the risk of perinatal HIV-1 transmission: a meta-analysis. **Journal of Acquired Immune Deficiency Syndromes** 2003, 32:70-6.
 129. Rizos E, Drosos AA, Ioannidis JP. Nail pigmentation and fatigue in a 39-year-old woman. **Clinical Infectious Diseases** 2003, 36:348, 378-9 (case report).
 130. Karvouni E, Katritsis DG, Ioannidis JPA. Intravenous glycoprotein IIb/IIIa antagonists reduce mortality in percutaneous coronary interventions. **Journal of the American College of Cardiology** 2003, 41:26-32.
 131. Mulherin SA, O'Brien TR, Ioannidis JP, Goedert JJ, Buchbinder SP, Coutinho RA, Jamieson BD, Meyer L, Michael NL, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Theodorou ID, Vlahov D, Rosenberg PS. Effects of CCR5-Δ32 and CCR2-64I on HIV-1 disease progression: the protection varies with the duration of infection. **AIDS** 2003, 17:377-87.
 132. Contopoulos-Ioannidis DG, Lau J, Ioannidis JP. Acute sinusitis in children: Current treatment strategies. **Pediatric Drugs** 2003, 5:71-80. (*)
 133. Contopoulos-Ioannidis DG, Ntzani E, Ioannidis JP. Time to translation of promising basic science research to clinical applications. **American Journal of Medicine** 2003, 114:477-84. See also editorial by WF Crowley in the same issue (pages 503-5).
 134. Vlachoyiannopoulos PG, Kenelopoulos PG, Ioannidis JPA, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. **Rheumatology** 2003, 42:645-51.
 135. Karassa FB, Tatsioni A, Ioannidis JPA. Design, quality and bias in randomized controlled trials of systemic lupus erythematosus. **Journal of Rheumatology** 2003, 30:979-84.
 136. Karassa FB, Trikalinos TA, Ioannidis JPA. The FcγRIIIA-F158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. **Kidney International** 2003, 63:1475-82.
 137. Ntais C, Polycarpou A, Ioannidis JPA. Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. **Cancer Epidemiology, Biomarkers and Prevention** 2003, 12:120-6.
 138. Sotiriadis A, Makrydimas G, Ioannidis JPA. Diagnostic performance of intracardiac echogenic foci for Down syndrome: a meta-analysis. **Obstetrics and Gynecology** 2003, 101:1009-16.
 139. The HIV Lipodystrophy Case Definition Study Group (including Ioannidis JPA as member of steering committee). An objective case definition of lipodystrophy in human immunodeficiency virus-infected adults. **Lancet** 2003, 361:726-35.
 140. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus smaller studies: an empirical assessment. **Lancet** 2003, 361:567-71.
 141. Ioannidis JPA, Lau J. FDG-PET for the diagnosis and grading of soft tissue sarcomas. **Journal of Nuclear Medicine** 2003, 44:717-24.
 142. Tatsioni A, Gerasi E, Charitidou E, Simou N, Mavreas V, Ioannidis JPA. Important drug safety information on the Internet. **Drug Safety** 2003, 26:519-27.

143. Kent D, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to anti-retroviral therapy in resource-poor settings: setting the research agenda. **Clinical Infectious Diseases** 2003, 37 (suppl 1):S13-24.
144. Ioannidis JPA, Pavlidis NA. Levels of absolute survival benefit for systemic therapies of advanced cancer: a call for standards. **European Journal of Cancer** 2003, 39:1094-8. (*)
145. Haidich AB, Ioannidis JPA. Late-starter sites in randomized controlled trials. **Journal of Clinical Epidemiology** 2003, 56:408-15.
146. Papanikolaou PN, Ioannidis JPA. Awareness of the side effects of possessed medications in a community setting. **European Journal of Clinical Pharmacology** 2003, 58:821-7.
147. Kosmas IP, Tatsioni A, Ioannidis JPA. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. **Journal of Hypertension** 2003, 21:1221-8.
148. Ioannidis JPA. Genetic associations: false or true? **Trends in Molecular Medicine** 2003, 9:135-8.
149. Ioannidis JPA, Contopoulos-Ioannidis DG, Rosenberg PS, Goedert JJ, de Rossi A, Espanol T, Frenkel L, Mayaux J-M, Newell M-L, Pahwa SG, Rousseau C, Scarlatti G, Sei S, Sen L, O'Brien TR for the International Meta-Analysis of HIV Host Genetics. Effects of CCR5 $\Delta 32$, and CCR2 64I polymorphisms on disease progression of perinatally HIV-infected children: An international meta-analysis. **AIDS** 2003, 17:1631-8.
150. Karassa FB, Bijl M, Davies KA, Kallenberg CGM, Khamashta MA, Manger K, Michel M, Piette JC, Salmon JE, Song YW, Tsuchiya N, Yoo D-H, Ioannidis JPA. The role of the *FcgammaRIIA* polymorphism in the antiphospholipid syndrome: an international meta-analysis. **Arthritis and Rheumatism** 2003, 48:1930-8.
151. Ntais C, Polycarpou A, Ioannidis JPA. *SRD5A2* gene polymorphisms and the risk of prostate cancer: a meta-analysis. **Cancer Epidemiology, Biomarkers and Prevention** 2003, 12:618-24.
152. Ioannidis JPA. Uses of error: clinical, teaching and research misunderstandings. **Lancet** 2004, 363:324 (invited note). (*)
153. Ntzani EE, Ioannidis JP. Pharmacogenetics and association studies in schizophrenia. **Drug Development Research** 2003, 60:152-63.
154. Ioannidis JPA, Karvouni E, Katritsis DG. Mortality risk conferred by small elevations of creatine-kinase MB isoenzyme after percutaneous coronary intervention. **Journal of the American College of Cardiology** 2003, 42:1406-11. Accompanied by editorial in the same issue (pp. 1412-4).
155. Ioannidis JPA, Tatsioni A, Abrams EJ, Bulterys M, Coombs RW, Goedert JJ, Korber BT, Mayaux JM, Mofenson LM, Moye J, Newell M-L, Shapiro DE, Teglus JP, Thompson B, Wiener J. Maternal viral load and the rate of disease progression among vertically HIV-1-infected children: An international meta-analysis. **AIDS** 2004, 18:99-108.
156. Pakos E, Ioannidis JPA. Association of P-glycoprotein with response to chemotherapy and clinical outcome in osteosarcoma. **Cancer** 2003, 98:581-9.
157. Ioannidis JP, Polycarpou A, Ntais C, Pavlidis N. Randomized trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time. **European Journal of Cancer** 2003, 39:2278-87.
158. Isaakidis P, Ioannidis JP. An evaluation of cluster randomised controlled trials in sub-Saharan Africa. **American Journal of Epidemiology** 2003, 158:921-6.
159. Makrydimas G, Sotiriadis A, Ioannidis JPA. Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. **American Journal of Obstetrics and Gynecology** 2003, 189:1330-5.

160. Rizos E, Drosos AA, Ioannidis JPA. Isolated intraparotid Kaposi sarcoma in HIV-1 infection: case report and review of the literature. **Mayo Clinic Proceedings** 2003, 78:1561-3.
161. Ioannidis JPA, Trikalinos TA, Law M, Carr A for the HIV Lipodystrophy Case Definition Study Group. HIV lipodystrophy case definition using artificial neural network modelling. **Antiviral Therapy** 2003, 8:435-41.
162. Swingler G, Volmink J, Ioannidis JPA. Number of published systematic reviews and global burden of disease: database analysis. **British Medical Journal** 2003, 327:1083-4.
163. Ntzani E, Ioannidis JPA. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. **Lancet** 2003, 362:1429-44. Accompanied by editorial in the same issue.
164. Carr DB, Goudas LC, Balk EM, Bloch R, Ioannidis JPA, Lau J. Evidence report on the treatment of pain in cancer patients. **Journal of the National Cancer Institute Monographs** 2004, 32:23-31.
165. Ntais C, Polycarpou A, Ioannidis JPA. Vitamin D receptor gene polymorphisms and the risk of prostate cancer: a meta-analysis. **Cancer Epidemiology Biomarkers and Prevention** 2003, 12:1395-402.
166. Zintzaras E, Ioannidis JPA. Modelling of escalating outpatient antibiotic expenditures. **Journal of Antimicrobial Chemotherapy** 2003, 52:1001-4
167. Menu E, Scarlatti G, Barre-Sinoussi F, Gray G, Bollinger B, Ioannidis JPA, Miotti P, and Osborne C for the participants of the Workshop. Mother-to-Child Transmission of HIV: developing integration of health care programmes with clinical, social and basic research studies. Report of the International Workshop held in Kasane, Botswana, 21-25 January 2003. **Acta Paediatrica** 2003, 92:1343-8.
168. Ziavra N, Kastanioudakis I, Trikalinos TA, Skevas A, Ioannidis JPA. Diagnosis of sensorineural hearing loss through neural network modeling and logistic regression modeling of distortion product otoacoustic emission patterns. **Audiology and Neuro-otology** 2004, 9:81-7.
169. Haidich AB, Ioannidis JPA. The Gini coefficient as a measure for understanding accrual inequalities in multicenter clinical studies. **Journal of Clinical Epidemiology** 2004, 57:341-8.
170. Ntais C, Polycarpou A, Ioannidis JPA. Meta-analysis of the association between the cathepsin D gene Ala224Val polymorphism with the risk of Alzheimer's disease. **American Journal of Epidemiology** 2004, 159:527-36.
171. Ioannidis JPA. Physical examination. **Lancet** 2003, 362:2023 (letter). (*)
172. Pakos EE, Ioannidis JPA. Radiotherapy or non-steroidal anti-inflammatory drugs for the prevention of heterotopic ossification after major hip procedures: A meta-analysis of randomized trials. **International Journal of Radiation Oncology, Biology, Physics** 2004, 60:888-95.
173. Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Kruger R, Hattori N, Mellick GD, Quattrone A, Satoh J, Toda T, Wang J, Ioannidis JP, de Andrade M, Rocca WA; UCHL1 Global Genetics Consortium. UCHL1 is a Parkinson's disease susceptibility gene. **Annals of Neurology** 2004, 55:512-21.
174. Karassa FB, Trikalinos TA, Ioannidis JPA. The role of FcgammaRIIA and FcgammaRIIIA polymorphisms in autoimmune diseases. **Biomedicine and Pharmacotherapy** 2004, 58:286-91 (invited review). (*)
175. Ioannidis JPA. Materializing research promises: opportunities, priorities and conflicts in translational medicine. **Journal of Translational Medicine** 2004, 2:5 (invited review). (*)
176. Papanikolaou PN, Churchill R, Wahlbeck K, Ioannidis JPA, for the EU-PSI project. Safety reporting in randomized trials of mental health interventions. **American Journal of Psychiatry** 2004, 161:1692-7.
177. Vranos G, Tatsioni A, Ioannidis JPA, Polyzoidis K. Randomized controlled trials of neurosurgical interventions: a systematic appraisal. **Neurosurgery** 2004, 55:18-25, discussion 25-26.

178. Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos K. Treating anemia early slows decline of renal function in chronic renal disease: a randomized controlled study. **Kidney International** 2004, 66:753-60.
179. Ioannidis JPA. Global estimates of high-level brain drain and deficit. **FASEB Journal** 2004, 18:936-9.
180. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, Ioannidis JPA for the EU-PSI project. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. **Journal of Clinical Epidemiology** 2004, 57:1124-30.
181. Contopoulos-Ioannidis DG, Giotis N, Baliatsa D, Ioannidis JPA. Extended interval aminoglycoside administration for children: a meta-analysis. **Pediatrics** 2004, 114:e111-8.
182. Pakos EE, Kyzas PA, Ioannidis JPA. Prognostic significance of p53 tumor suppressor gene expression and mutations in human osteosarcoma: a meta-analysis. **Clinical Cancer Research** 2004, 10:6208-14.
183. Ioannidis JP. The value of meta-analysis in rheumatology research. **Autoimmunity Reviews** 2004, 3:S57-9.
184. Ioannidis JPA, Vlachoyiannopoulos PG, Haidich A-B, Medsger TA Jr, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, te Boome L, van Laar JM, Verbeet NL, Matucci Cerinic M, Georgountzos A, Moutsopoulos HM. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. **American Journal of Medicine** 2005, 118:2-10.
185. Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG, Ioannidis JPA. Establishment of genetic associations for complex diseases is independent of early study findings. **European Journal of Human Genetics** 2004, 12:762-9.
186. Papanikolaou P, Ioannidis JPA. Availability of large-scale evidence for specific harms from systematic reviews of randomized trials. **American Journal of Medicine** 2004, 117:582-9.
187. Contopoulos-Ioannidis DG, Gilbody S, Trikalinos TA, Churchill R, Wahlbeck K, Ioannidis JPA. Comparison of large vs. smaller randomized trials for mental health related interventions. **American Journal of Psychiatry** 2005, 162:578-84.
188. DeRose, JJ, Toumpoulis IK, Balaram SK, Ioannidis JP, Anagnostopoulos CE, Ashton RC, Swistel DG. Preoperative prediction of long-term survival following coronary artery bypass grafting in patients with low left ventricular ejection fraction ($\leq 25\%$). **Journal of Thoracic and Cardiovascular Surgery** 2005, 129:314-21.
189. Kosmas I, Tatsioni A, Ioannidis JPA. Association of C677T polymorphism mutation in the methylene-tetrahydro-folate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. **Journal of Hypertension** 2004, 22:1655-62.
190. Danias PG, Roussakis A, Ioannidis JPA. Diagnostic performance of coronary magnetic resonance angiography as compared against conventional X-ray angiography: a meta-analysis. **Journal of the American College of Cardiology** 2004, 44:1867-76.
191. Makrydimas G, Sotiriadis A, Huggon IC, Simpson J, Sharland G, Carvalho JS, Daubeney PE, Ioannidis JPA. Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocardiography centers. **American Journal of Obstetrics and Gynecology** 2005, 192:89-95.
192. Ioannidis JPA, Evans S, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group. Better reporting of harms in randomized trials: an extension of the CONSORT statement. **Annals of Internal Medicine** 2004, 141:781-8. (*)
193. Kent DM, Mwamburi M, Bennish ML, Kupelnick B, Ioannidis JPA. Clinical trials in sub-Saharan Africa and established standards of care: a systematic review of HIV, tuberculosis, and malaria trials. **JAMA** 2004, 292:237-42. Accompanied by editorial in the same issue.

194. *Contopoulos-Ioannidis DG, Ioannidis JPA.* Treatment options for acute sinusitis in children. **Current Allergy and Asthma Reports** 2004, 4:471-7 (invited review). (*)
195. *Vlahoyiannopoulos PG, Ioannidis JPA.* Cyclophosphamide in systemic sclerosis: light and shadows. **Clinical Experimental Rheumatology** 2004, 22:551-2 (invited editorial). (*)
196. *Patsopoulos N, Ntzani EE, Zintzaras E, Ioannidis JPA.* CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. **Pharmacogenetics and Genomics** 2005, 15:151-8.
197. *Economou M, Trikalinos TA, Loizou K, Tsianos EV, Ioannidis JPA.* Differential effects of NOD2/CARD15 polymorphisms on Crohn's disease susceptibility and phenotype across diverse populations: a meta-analysis. **American Journal of Gastroenterology** 2004, 99:2393-404.
198. *Ntais C, Polycarpou A, Ioannidis JPA.* Association of GSTM1, GSTT1, and GSTP1 gene polymorphisms with the risk of prostate cancer: a meta-analysis. **Cancer Epidemiology, Biomarkers and Prevention** 2005, 14:176-81.
199. *The International Working Party to Promote and Revitalise Academic Medicine (including Ioannidis JPA).* ICRAM (the International Campaign to Revitalise Academic Medicine): agenda setting. **British Medical Journal** 2004, 329:787-9. Accompanied by editorial in the same issue. (*)
200. *The International Working Party to Promote and Revitalise Academic Medicine (including Ioannidis JPA as guarantor author).* Academic medicine: the evidence base. **British Medical Journal** 2004, 329:789-92. Accompanied by editorial in the same issue.
201. *Panidou ET, Trikalinos TA, Ioannidis JPA.* Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. **AIDS** 2004, 18:2153-61.
202. *Mantzavinis GD, Pappas N, Dimoliatis IA, Ioannidis JPA.* Multivariate models of self-reported health often neglected essential candidate determinants and methodological issues. **Journal of Clinical Epidemiology** 2005, 58:436-43.
203. *Ioannidis JPA.* Large-scale evidence and replication: insights from rheumatology and beyond. **Annals of the Rheumatic Diseases** 2005, 64:345-6 (invited editorial). (*)
204. *Ioannidis JPA.* Microarrays and molecular research: noise discovery? **Lancet** 2005, 365:454-5 (editorial). (*)
205. *Zintzaras E, Ioannidis JPA.* Heterogeneity testing in meta-analysis of genome searches. **Genetic Epidemiology** 2005, 28:123-37.
206. *Mauri D, Pavlidis N, Ioannidis JPA.* Neoadjuvant vs. adjuvant systemic treatment in breast cancer: a meta-analysis. **Journal of the National Cancer Institute** 2005, 97:188-94. Accompanied by editorial in the same issue.
207. *Ioannidis JPA, Ntzani EE, Trikalinos TA.* "Racial" differences in genetic effects for complex diseases. **Nature Genetics** 2004, 36:1312-8. Accompanied by editorial in the same issue.
208. *Ioannidis JPA, Ralston S, Bennett ST, Brandi ML, Ginberg D, Karassa FB, Langdahl B, Moselinde L, Scollen S, van Meurs JBJ, Albagha OME, Bustamante M, Carey AH, Dunning AM, Enjuanes A, Maviglia C, Masi L, McGuigan FEA, Nogues X, Pols HAP, Reid DM, Schuit SCE, Sherlock RE, van Leeuwen HPTM, Uitterlinden AG, for the GENOMOS Project.* Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. **JAMA** 2004, 292:2105-14.
209. *Katritsis DG, Karvouni E, Ioannidis JPA.* Drug-eluting vs. bare-metal stents: a meta-analysis of clinical outcomes. **American Journal of Cardiology** 2005, 95:640-3.
210. *Swingler GH, Pilay V, Pienaar ED, Ioannidis JPA.* International research collaboration and the relevance of African randomized trials. **Bulletin of the World Health Organization** 2005, 83:511-7. Accompanied by editorial in the same issue.

211. O'Neil-Callahan K, Katsimaglis G, Tepper M, Ryan J, Mosby C, Ioannidis JPA, Danias PG. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) Study. **Journal of the American College of Cardiology** 2005, 45:336-42.
212. Kavvoura FK, Ioannidis JPA. NeuroD1 Ala45Thr polymorphism and diabetes susceptibility: a meta-analysis. **Human Genetics** 2005, 116:192-9.
213. Ioannidis JPA, Trikalinos TA. Early extreme contradictory estimates may appear in published research: the Proteus phenomenon in molecular genetics research and randomized trials. **Journal of Clinical Epidemiology** 2005, 58:543-9.
214. Contopoulos-Ioannidis DG, Manoli E, Ioannidis JPA. Association of beta2-adrenergic receptor gene polymorphisms with asthma phenotypes: a meta-analysis. **Journal of Allergy and Clinical Immunology** 2005, 115:963-72. Accompanied by editorial in the same issue.
215. Berger W, Ioannidis JPA. The Decameron of poor research. **British Medical Journal** 2004, 329:1436-40. (*)
216. Kyzas PA, Kuhn WI, Ioannidis JPA. Prognostic significance of VEGF immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. **Clinical Cancer Research** 2005, 11:1434-40.
217. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JPA. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. **Annals of Internal Medicine** 2005, 142:359-69.
218. Pakos EE, Fotopoulos AD, Ioannidis JPA. 18F-FDG PET for the evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. **Journal of Nuclear Medicine** 2005, 46:958-63.
219. Salanti G, Amountza G, Ntzani EE, Ioannidis JPA. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. **European Journal of Human Genetics** 2005, 13:840-8.
220. Sotiriadis A, Markydimas A, Papatheodorou S, Ioannidis JPA. Expectant, medical or surgical management of first trimester miscarriage. **Obstetrics and Gynecology** 2005, 105:1104-13.
221. Kavvoura F, Ioannidis JPA. CTLA4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE disease-association review and meta-analysis. **American Journal of Epidemiology** 2005, 162:3-16.
222. Katritsis DG, Ioannidis JPA. Percutaneous coronary intervention vs. conservative therapy in non-acute coronary artery disease: a meta-analysis. **Circulation** 2005, 111:2906-12
223. Ioannidis JPA. Why most published research findings are false. **PLoS Medicine** 2005, 2:e124. Accompanied by editorial in the same issue.
224. Ntais C, Pakos E, Kyzas P, Ioannidis JPA. Benzodiazepines for the management of alcohol withdrawal syndrome. **Cochrane Database of Systematic Reviews** 2005, (3):CD005063
225. Polycarpou A, Papanikolaou P, Contopoulos-Ioannidis DG, Ioannidis JPA. Anticonvulsants for alcohol withdrawal. **Cochrane Database of Systematic Reviews** 2005, (3):CD005064.
226. Patsopoulos N, Analatos A, Ioannidis JPA. Relative citation impact of various study designs in the health sciences. **JAMA** 2005, 293:2362-6
227. Ioannidis JP, Bernstein J, Boffetta P, Danesh J, Dolan S, Hartge P, Hunter D, Inskip P, Jarvelin MR, Little J, Maraganore DM, Bishop JA, O'Brien TR, Petersen G, Riboli E, Seminara D, Taioli E, Uitterlinden AG, Vineis P, Winn DM, Salanti G, Higgins JP, Khoury MJ. A network of investigator networks in human genome epidemiology. **American Journal of Epidemiology** 2005, 162:302-4.
228. Ioannidis JPA. Contradicted and initial stronger effects in highly-cited clinical research. **JAMA** 2005, 294:218-28.

229. Zintzaras E, Ioannidis JPA. HEGESMA: Genome search meta-analysis and heterogeneity testing. **Bioinformatics** 2005, 21:3672-3.
230. Kyzas R, Loizou K, Ioannidis JPA. Selective reporting biases in cancer prognostic factor studies. **Journal of the National Cancer Institute** 2005, 97:1043-55. Accompanied by editorial in the same issue.
231. Ioannidis JP, Karvouni E, Katritsis DG. Creatine kinase-MB elevation following stent implantation. **Journal of the American College of Cardiology** 2005, 45:1908 (letter). (*)
232. Telenti A, Ioannidis JPA. Susceptibility to HIV – disentangling host genetics and host behavior. **Journal of Infectious Diseases** 2006, 193:4-6 (invited editorial). (*)
233. Ioannidis JPA. Grading the credibility of molecular evidence for complex diseases. **International Journal of Epidemiology** 2006, 35:572-8; invited review with discussion 593-6. Accompanied by editorial in the same issue. (*)
234. Ioannidis JPA. Molecular bias. **European Journal of Epidemiology** 2006, 20:739-45 (invited review). (*)
235. Mantzavinis GD, Trikalinos TA, Dimoliatis IA, Ioannidis JPA. Self-reported health in the high and very high income. **Quality of Life Research** 2006, 15:547-58
236. Ioannidis JP. Commentary of the Chinese translation of the CONSORT extension for harms. **Chinese Journal of Evidence-Based Medicine** 2005, 5:729-32 (invited editorial). (*)
237. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JPA. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. **American Journal of Epidemiology** 2006, 163:300-9.
238. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JPA. Local literature bias in genetic epidemiology: an empirical evaluation of the Chinese literature. **PLoS Medicine** 2005, 2:e334. Accompanied by editorial in the same issue.
239. Trikalinos TA, Karvouni A, Zintzaras E, Ylisaukko-oja T, Peltonen L, Jarvela I, Ioannidis JPA. A heterogeneity-based genome search meta-analysis for autism-spectrum disorders. **Molecular Psychiatry** 2006, 11:29-36.
240. Evangelou E, Trikalinos TA, Ioannidis JPA. Unavailability of online supplementary scientific information from articles published in major journals. **FASEB Journal** 2005, 19:1943-4.
241. Papanikolaou PN, Christidi G, Ioannidis JPA. Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. **Canadian Medical Association Journal** 2006, 174:635-41. Accompanied by editorial in the same issue.
242. Karassa FB, Afeltra A, Ambrozic A, Chang D-M, De Keyser F, Doria A, Galeazzi M, Hirohata S, Hoffman IEA, Inanc M, Massardo L, Mathieu A, Mok CC, Morozzi G, Sanna G, Spindler AJ, Tzioufas AG, Yoshio T, Ioannidis JPA. Accuracy of anti-ribosomal P protein antibody testing for diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. **Arthritis and Rheumatism** 2006, 54:312-24.
243. Ioannidis JPA. Journals should publish all “null results and should sparingly publish positive results. **Cancer Epidemiology Biomarkers and Prevention** 2006, 15:186 (invited editorial). (*)
244. Polyzos NP, Poavlidis N, Parakevaidis E, Ioannidis JPA. Randomized evidence on chemotherapy and hormonal therapy regimens in advanced endometrial cancer: an overview of survival data. **European Journal of Cancer** 2006, 42:319-26.
245. Ioannidis JPA, Trikalinos TA, Zintzaras E. Extreme between-study homogeneity in meta-analysis could offer useful insights. **Journal of Clinical Epidemiology** 2006, 59:1023-1032.
246. Ioannidis JPA, Mulrow CD, Goodman SN. Adverse events: the more you search, the more you find. **Annals of Internal Medicine** 2006, 144:298-300 (invited editorial). (*)

247. Contopoulos-Ioannidis DG, Alexiou G, Gouvias T, Ioannidis JPA. An empirical evaluation of multifarious outcomes in pharmacogenetics: beta2 adrenoreceptor gene polymorphisms in asthma treatment. **Pharmacogenetics and Genomics** 2006, 16:705-11.
248. Ralston SH, Uitterlinden AG, Brandi ML, Balcells S, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Scollen S, Bustamante M, Husted LB, Carey AH, Diez-Perez A, Dunning AM, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, del Monte F, Pols HA, Reeve J, Reid DM, Renner W, Rivadeneira F, van Schoor NM, Sherlock RE, Ioannidis JP; GENOMOS Investigators. Large-scale evidence for the effect of the COL1A1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. **PLoS Medicine** 2006, 3:e90.
249. Patsopoulos N, Analatos A, Ioannidis JPA. Origin and funding of the most frequently cited papers in medicine: database analysis. **BMJ** 2006, 332:1061-4. Accompanied by editorial in the same issue.
250. Ioannidis JPA, Gwinn ML, Little J, Higgins JPT, Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA, Casas JP, Chokkalingam A, Danesh J, Smith GD, Dolan S, Duncan R, Gruis NA, Hartge P, Hashibe M, Hunter DJ, Jarvelin M-R, Malmer B, Maraganore DM, Newton-Bishop JA, O'Brien TR, Petersen G, Riboli E, Salanti G, Seminara D, Smeeth L, Taioli E, Timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM, Zimmern R, Khoury MJ, for the Human Genome Epidemiology Network and the Network of Investigator Networks. A roadmap for efficient and reliable human genome epidemiology. **Nature Genetics** 2006, 38:3-5. Accompanied by editorial in the same issue.
251. Ioannidis JPA. Vad säger oss "efferstudier" och metaanalys om effektiviteten av interventioner för mental hälsa. **Finska Lakaresällskapets Handlingar** 2005, 165:8-11 (invited commentary, in Finnish). (*)
252. Ioannidis JPA. Why most published research findings are false. **Chance** 2005, 18:40-47 (reprinted publication). (*)
253. Pakos EE, Trikalinos TA, Fotopoulos AD, Ioannidis JPA. Prosthesis infection: diagnosis after total joint arthroplasty with antigranulocyte scintigraphy with 99mTc-labeled monoclonal antibodies-a meta-analysis. **Radiology** 2007, 242:101-108.
254. Tiihonen J, Walhbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J, Haukka J. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. **BMJ** 2006, 333:224-8. Accompanied by editorial in the same issue.
255. Ioannidis JPA. Meta-analysis in public health: potential and promises. **Italian Journal of Public Health** 2006, 3:9-14 (invited review). (*)
256. Salanti G, Higgins JPT, Trikalinos TA, Ioannidis JPA. Bayesian meta-analysis and meta-regression for gene-disease associations and deviations from Hardy-Weinberg equilibrium. **Statistics in Medicine** 2007, 26:553-67.
257. Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Reeve J, Reid DM, Amidei A, Bassiti A, Bustamante M, Husted LB, Diez-Perez A, Dobnig H, Dunning AM, Enjuanes A, Fahrleitner-Pammer A, Fang Y, Karczmarewicz E, Kruk M, van Leeuwen JP, Mavilia C, van Meurs JB, Mangion J, McGuigan FE, Pols HA, Renner W, Rivadeneira F, van Schoor NM, Scollen S, Sherlock RE, Ioannidis JP; APOSS Investigators; EPOS Investigators; EPOLOS Investigators; FAMOS Investigators; LASA Investigators; Rotterdam Study Investigators; GENOMOS Study. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. **Annals of Internal Medicine** 2006, 145:255-64. Accompanied by editorial in the same issue.
258. Ioannidis JPA, Trikalinos TA, Khoury MJ. Implications of small effect sizes of individual genetic

- variants on the design and interpretation of genetic association studies of complex diseases. **American Journal of Epidemiology** 2006, 164:609-14.
259. Fang Y, Rivadeneira F, van Meurs JBJ, Pols HAP, Ioannidis JPA. Vitamin D receptor gene Bsm I and TaqI polymorphisms and fracture risk: a meta-analysis. **Bone** 2006, 39:938-45.
 260. Zintzaras E, Kitsios G, Harrison GA, Laivuori H, Kivinen K, Kere J, Messinis I, Stefanidis I, Ioannidis JPA. Heterogeneity-based genome search meta-analysis for preeclampsia. **Human Genetics** 2006, 120:360-70
 261. Papanikolaou PN, Christidi G, Ioannidis JPA. Patient outcomes with teaching versus non-teaching healthcare: systematic review. **PLoS Medicine** 2006, 3:e341. Accompanied by editorial in the same issue.
 262. Ioannidis JPA. Indirect comparisons: the mesh and mess of clinical trials. **Lancet** 2006, 368:1470-2 (editorial).
 263. Ioannidis JPA. Gene expression profiling for individualized breast cancer chemotherapy: success – or not? **Nature Clinical Practice Oncology** 2006, 3:538-9 (invited editorial). (*)
 264. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. **BMJ** 2006, 333:597-600.
 265. Ioannidis JPA, Kavvoura FK. Concordance of functional in vitro biological data with epidemiological associations for complex diseases. **Genetics in Medicine** 2006, 8:583-593.
 266. Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, Econs MJ, Karasik D, Devoto M, Kammerer CM, Spector T, Andrew T, Cupples LA, Duncan EL, Foroud T, Kiel DP, Koller D, Langdahl B, Mitchell BD, Peacock M, Recker R, Shen H, Sol-Church K, Spotila LD, Uitterlinden AG, Wilson SG, Kung AW, Ralston SH. Meta-analysis of genome-wide scans provides evidence for sex- and site-specific regulation of bone mass. **Journal of Bone and Mineral Research** 2007, 22:173-83.
 267. Evangelou E, Trikalinos TA, Salanti G, Ioannidis JPA. Family-based versus unrelated case-control designs for genetic associations. **PLoS Genetics** 2006, 2:e123.
 268. Ioannidis JPA. Why most published research findings are false. **Science Focus** (journal of the Chinese Academy of Science) 2006, 1(4):1-9 (translated publication, accompanied by two editorials). (*)
 269. Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Krüger R, Rocca WA, Schneider NK, Lesnick TG, Lincoln SG, Hulihan MM, Aasly J, Ashizawa T, Chartier-Harlin M-C, Checkoway H, Ferrarese C, Hadjigeorgiou G, Hattori N, Kawakami H, Lambert J-C, Lynch T, Mellick GD, Papapetropoulos S, Parsian A, Quattrone A, Riess O, Tan E-K, van Broeckhoven C, on behalf of the Genetic Epidemiology of Parkinson's Disease Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson's disease. **JAMA** 2006, 296:661-70.
 270. Ioannidis JPA. Evolution and translation of research findings: from bench to where? **PLoS Clinical Trials** 2006, 1:e36 (invited review). (*)
 271. Seminara D, Khoury MJ, O'Brien TR, Manolio T, Gwinn ML, Little J, Higgins JPT, Bernstein JL, Boffetta P, Bondy M, Bray MS, Brenchley PE, Buffler PA, Casas JP, Chokkalingam A, Danesh J, Davey Smith G, Dolan S, Duncan R, Gruis NA, Hashibe M, Hunter D, Jarvelin M-R, Malmer B, Maraganore DM, Newton-Bishop JA, Riboli E, Salanti G, Taioli E, Timpson N, Uitterlinden AG, Vineis P, Wareham N, Winn DM, Zimmern R, Ioannidis JPA for the Human Genome Epidemiology Network and the Network of Investigator Networks. The emergence of networks in human genome epidemiology: challenges and opportunities. **Epidemiology** 2007, 18:1-8. (*)
 272. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JPA. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. **Journal of the National Cancer Institute** 2006, 98:1285-91. Accompanied by editorial in the same issue

273. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JPA. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. **Journal of the National Cancer Institute** 2006, 98:1655-63.
274. Elbaz A, Nelson LM, Payami H, Ioannidis JPA, Fiske BK, Annesi G, Carmine A, Factor SA, Ferrarese C, Hadjigeorgiou GM, Higgins D, Kawakami H, Krueger R, Marder K, Mayeux R, Mellick G, Nutt J, Ritz B, Samii A, Tanner CM, Van Broeckhoven C, Van Den Eeden SK, Wirdefeldt K, Zabetian CP, Dehem M, Montimurro JS, Myers RM, Southwick A, Trikalinos TA. Lack of replication of thirteen single nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. **Lancet Neurology** 2006, 5:917-23. Accompanied by editorial in the same issue.
275. Ioannidis JPA. Common genetic variants for breast cancer: 32 largely refuted candidates and larger prospects. **Journal of the National Cancer Institute** 2006, 98:1350-3 (invited editorial).
276. Toumpoulis IK, Anagnostopoulos CE, Ioannidis JP, Toumpoulis SK, Chamogeorgakis T, Swistel DG, Deroose JJ. The importance of independent risk-factors for long-term mortality prediction after cardiac surgery. **European Journal of Clinical Investigation** 2006, 36:599-607.
277. Christou MAC, Siontis GCM, Katritsis DG, Ioannidis JPA. Meta-analysis of fractional flow reserve against quantitative coronary angiography versus non-invasive imaging for evaluation of myocardial ischemia. **American Journal of Cardiology** 2007, 99:450-6.
278. Ioannidis JPA. Limitations are not properly acknowledged in the scientific literature. **Journal of Clinical Epidemiology** 2007, 60:324-9.
279. Contopoulos-Ioannidis DG, Kouri IN, Ioannidis JPA. Genetic predisposition to asthma and atopy. **Respiration** 2007, 74:8-12 (invited review).
280. Tzioras S, Pavlidis N, Paraskevaidis E, Ioannidis JPA. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. **Cancer Treatment Reviews** 2007, 33:24-38.
281. Ioannidis JPA. Concentration of the most-cited papers in the scientific literature: analysis of journal ecosystems **PLoS ONE** 2006, 1:e5.
282. Khoury MJ, Little J, Gwinn M, Ioannidis JP. On the synthesis and interpretation of consistent but weak gene-disease associations in the era of genome-wide association studies. **International Journal of Epidemiology** 2007, 36:439-45. Accompanied by editorial in the same issue.
283. Hernandez AV, Westerhout CM, Steyerberg EW, Ioannidis JP, Bueno H, White H, Theroux P, Moliterno DJ, Armstrong PW, Califf RM, Wallentin LC, Simoons ML, Boersma E. Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST-segment elevation acute coronary syndromes: Benefit and harm in different age subgroups. **Heart** 2007, 93:450-5.
284. Ntzani EE, Rizos EC, Ioannidis JPA. Genetic effects vs. bias for candidate polymorphisms in myocardial infarction: case-study and overview of large-scale evidence. **American Journal of Epidemiology** 2007, 165:973-84.
285. Kavvoura FK, Liberopoulos G, Ioannidis JPA. Selection in reported epidemiological risks: an empirical assessment. **PLoS Medicine** 2007, 4:e79.
286. Kyzas PA, Denaxa-Kyza D, Ioannidis JPA. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. **Journal of the National Cancer Institute** 2007, 99:1-8.
287. Ioannidis JP, Ahmed T, Awasthi S, Clarfield AM, Clark J, Dandona L, Howe A, Lozano JM, Li Y, Madani H, Marusic A, Mohammed I, Purcell GP, Rhoads M, Sliwa-Hahnle K, Straus SE, Edejer TT, Tugwell P, Ward R, Wilkes MS, Smith R. Open letter to the leader of academic medicine. **BMJ** 2007, 334:191-3. (*)
288. Stefanis NC, Trikalinos TA, Avramopoulos D, Smyrnis N, Evdokimidis I, Ntzani EE, Ioannidis

- JPA, Stefanis CN.* Impact of schizophrenia candidate genes on schizotypy and cognitive endophenotypes at the population level. **Biological Psychiatry** 2007, 62:784-92.
289. *Lathyrus DN, Trikalinos TA, Ioannidis JPA.* Evidence from crossover trials: empirical evaluation and comparison against parallel arm trials. **International Journal of Epidemiology** 2007, 36:422-30.
290. *Ioannidis JPA, Trikalinos TA.* An exploratory test for an excess of significant findings. **Clinical Trials** 2007, 4:245-253. Accompanied by editorial in the same issue.
291. *Ioannidis JPA* The JECH research agenda: genetic and molecular epidemiology. **Journal of Epidemiology and Community Health** 2007, 61:757-8 (invited short review). (*)
292. *Ioannidis JPA.* Molecular evidence-based medicine: evolution and integration of information in the genomic era. **European Journal of Clinical Investigation** 2007, 37:340-9 (invited article).
293. *Ioannidis JPA.* Is molecular profiling ready for use in clinical decision making? **The Oncologist** 2007, 12:301-11.
294. *Ioannidis JPA, Trikalinos TA.* The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. **CMAJ** 2007, 176:1091-6.
295. *Evangelou E, Maraganaore DM, Ioannidis JPA.* Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease. **PLoS ONE** 2007, 2:e196.
296. *Ioannidis JPA.* Non-replication and inconsistency in the genome-wide association setting. **Human Heredity** 2007, 64:203-213 (invited review). (*)
297. *Salanti G, Ades AE, Higgins JP, Ioannidis JPA.* Evaluation of networks of randomized trials. **Statistical Methods in Medical Research** 2008,17:279-301. Accompanied by editorial in the same issue.
298. *Kavvoura FK, Ioannidis JP.* Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. **Human Genetics** 2008, 123:1-14.
299. *Contopoulos-Ioannidis DG, Kouri I, Ioannidis JPA.* Pharmacogenetics of the response to b2 agonist drugs: a systematic overview of the field. **Pharmacogenomics** 2007, 8:933-58.
300. *Kavvoura FK, Akamizu T, Awata T, Ban Y, Chistiakov DA, Frydecka I, Ghaderi A, Gough SC, Hiromatsu Y, Ploski R, Wang P-W, Ban Y, Bednarczuk T, Chistiakova EI, Chojm M, Heward JM, Hiratani H, Hank Juo S-H, Karabon L, Katayama S, Kurihara S, Liu R-T, Miyake I, Omrani GR, Pawlak E, Taniyama M, Tozaki T, Ioannidis JPA.* CTLA- 4 gene polymorphisms and autoimmune thyroid diseases: a meta-analysis. **Journal of Clinical Endocrinology and Metabolism** 2007, 92:3162-70.
301. *Pakos E, Koumoulis HD, Fotopoulos AD, Ioannidis JPA.* Osteomyelitis: antigranulocyte scintigraphy with 9mTC radiolabeled monoclonal antibodies for diagnosis: meta-analysis. **Radiology** 2007;245:732-41.
302. *Ioannidis JP.* Why most published research findings are false: author's reply to Goodman and Greenland. **PLoS Medicine** 2007, 4:e215 (letter). (*)
303. *Khoury MJ, Little J, Higgins J, Ioannidis JP, Gwinn M.* Reporting of systematic reviews: the challenge of genetic association studies. **PLoS Medicine** 2007, 4:e211 (letter). (*)
304. *Bertsias GK, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Gordon C, Boumpas DT.* EULAR recommendations for the management of systemic lupus erythematosus (SLE): Report of a Task Force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). **Annals of the Rheumatic Diseases** 2008, 67:195-205. (*)
305. *Ioannidis JPA, Adami H-O.* Nested randomized trials in large cohorts and biobanks: studying the

- health effects of lifestyle factors. **Epidemiology** 2008, 19:75-82. (*)
306. *Katritsis DG, Ioannidis JP*. Percutaneous coronary intervention versus medical therapy for stable coronary artery disease. **New England Journal of Medicine** 2007, 357:414-5 (letter).
 307. *Ioannidis JPA, Polyzos NP, Trikalinos TA*. Selective discussion and transparency in microarray research findings for cancer outcomes. **European Journal of Cancer** 2007, 43:1999-2010.
 308. *Ioannidis JPA, Patsopoulos NA, Evangelou E*. Heterogeneity in meta-analyses of genome-wide association investigations. **PLoS ONE** 2007, 2:e841
 309. *Ioannidis JPA, Patsopoulos NA, Evangelou E*. Uncertainty in heterogeneity estimates in meta-analyses. **BMJ** 2007;335:914-6. Note: This work received the Thomas C. Chalmers award at the 2007 Cochrane Colloquium, young researcher presenter: Nikolaos Patsopoulos.
 310. *Patsopoulos NA, Tatsioni A, Ioannidis JPA*. Claims of sex differences: an empirical assessment in genetic associations. **JAMA** 2007, 298:880-93.
 311. *Papatheodorou SI, Trikalinos TA, Ioannidis JPA*. Inflated numbers of authors over time have not been just due to increasing research complexity. **Journal of Clinical Epidemiology** 2008, 61:546-51.
 312. *Higgins JPT, Little J, Ioannidis JPA, Bray MS, Manolio TA, Smeeth L, Sterne JA, Anagnostelis B, Butterworth AS, Danesh J, Dezateux C, Gallacher JE, Gwinn M, Lewis SJ, Minelli C, Pharoah PD, Salanti G, Sanderson S, Smith LA, Taioli E, Thompson JR, Thompson SG, Walker N, Zimmern RL, Khoury MJ*. Turning the pump handle: evolving methods for integrating the evidence on gene-disease association. **American Journal of Epidemiology** 2007, 166:863-6.
 313. *Ioannidis JPA, Katritsis DG*. Percutaneous coronary intervention for late reperfusion after myocardial infarction in stable patients. **American Heart Journal** 2007, 154:1065-71. Accompanied by editorial in the same issue.
 314. *Ioannidis JPA, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, Balding DJ, Chokkalingam A, Dolan SM, Flanders WD, Higgins JPT, McCarthy MI, McDermott DH, Page GP, Rebbeck TR, Seminara D, Khoury MJ*. Assessment of cumulative evidence on genetic associations: interim guidelines. **International Journal of Epidemiology** 2008, 37:120-32. Accompanied by editorial in the same issue.
 315. *Hernandez AV, Walker E, Ioannidis JPA, Kattan MW*. Challenges in meta-analyses of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone. **American Heart Journal** 2008, 156:23-30.
 316. *Kyzas P, Denaxa-Kyza D, Ioannidis JPA*. Almost all articles on cancer prognostic markers report statistically significant results. **European Journal of Cancer** 2007;43:2559-79.
 317. *Ioannidis JP, Patsopoulos NA, Kavvoura FK, Tatsioni A, Evangelou E, Kouri I, Contopoulos-Ioannidis DG, Liberopoulos G*. International ranking systems for universities and institutions: a critical appraisal. **BMC Medicine** 2007, 5:30.
 318. *Golfopoulos V, Salanti G, Pavlidis N, Ioannidis JP*. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. **Lancet Oncology** 2007, 8:898-911. Accompanied by editorial in the same issue.
 319. *Langdahl BL, Uitterlinden AG, Ralston SH, Trikalinos TA, Balcells S, Brandi ML, Scollen S, Lips P, Lorenc R, Obermayer-Pietsch B, Reid DM, Armas JB, Arp PP, Bassiti A, Bustamante M, Husted LB, Carey AH, Pérez Cano R, Dobnig H, Dunning AM, Fahrleitner-Pammer A, Falchetti A, Karczmarewicz E, Kruk M, van Leeuwen JP, Masi L, van Meurs JB, Mangion J, McGuigan FE, Mellibovsky L, Mosekilde L, Nogués X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Ioannidis JP*. Large-scale analysis of association between polymorphisms in the transforming growth

- factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. **Bone** 2008, 42:969-81.
320. *Moonesinghe R, Khoury MJ, Liu T, Ioannidis JP.* Required sample size and nonreplicability thresholds for heterogeneous genetic associations. **Proceedings of the National Academy of Sciences U S A** 2008, 105:617-22.
 321. *Tatsioni A, Bonitsis NG, Ioannidis JP.* Persistence of contradicted claims in the literature. **JAMA** 2007, 298:2517-26.
 322. *Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JPA.* Meta-analysis methods. **Advances in Genetics** 2008, 60:311-34 (invited review). (*)
 323. *Zintzaras E, Ioannidis JP.* Meta-analysis for ranked discovery datasets: Theoretical framework and empirical demonstration for microarrays. **Computational Biology and Chemistry** 2008, 32:38-46.
 324. *Salanti G, Kavvoura FK, Ioannidis JP.* Exploring the geometry of treatment networks. **Annals of Internal Medicine** 2008, 148:544-53.
 325. *Trikalinos NA, Evangelou E, Ioannidis JP.* Falsified papers in high-impact journals were slow to retract and indistinguishable from nonfraudulent papers. **Journal of Clinical Epidemiology** 2008, 61:464-70.
 326. *van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O, Lorenc R, Obermayer-Pietsch B, Ohlsson C, Pettersson U, Reid DM, Rousseau F, Scollen S, Van Hul W, Agueda L, Akesson K, Benevolenskaya LI, Ferrari SL, Hallmans G, Hofman A, Husted LB, Kruk M, Kaptoge S, Karasik D, Karlsson MK, Lorentzon M, Masi L, McGuigan FE, Mellström D, Mosekilde L, Nogues X, Pols HA, Reeve J, Renner W, Rivadeneira F, van Schoor NM, Weber K, Ioannidis JP, Uitterlinden AG; GENOMOS Study.* Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. **JAMA** 2008, 299:1277-90.
 327. *Ioannidis JPA.* Effect of formal statistical significance on the credibility of observational associations. **American Journal of Epidemiology** 2008, 168:374-83. Accompanied by commentary in the same issue.
 328. *Ioannidis JPA.* The author responds to "Evaluating p values and Bayes factors". **American Journal of Epidemiology** 2008, 168:389-90 (response commentary to commentary on above article). (*)
 329. *Ioannidis JPA.* Calibration of credibility of agnostic genome-wide associations. **American Journal of Medical Genetics B: Neuropsychiatric Genetics** 2008, 147B:964-72.
 330. *Ioannidis JPA.* Some main problems eroding the credibility and relevance of randomized trials. **Bulletin of the NYU Hospital for Joint Diseases** 2008, 66:135-9 (invited commentary). (*)
 331. *Patsopoulos NA, Ioannidis JPA.* The use of older studies in meta-analyses of medical interventions: a survey. **Open Medicine** 2009, 3:e62-8.
 332. *Ioannidis JPA.* Interpretation of tests of heterogeneity and bias in meta-analysis. **Journal of Evaluation in Clinical Practice** 2008, 14:951-7 (invited review). (*)
 333. *Ioannidis JPA.* Why most discovered true associations are inflated. **Epidemiology** 2008, 19:640-8. Accompanied by three commentaries in the same issue.
 334. *Ioannidis JPA.* Sequential discovery, thinking versus dredging, and shrink or sink. **Epidemiology** 2008, 19:657-658 (invited commentary in response to commentaries on the above article). (*)
 335. *Ioannidis JPA.* Interpretation of research results: an indispensable mission impossible? **Seminars in Hematology** 2008, 45:133-4 (editorial for guest editor issue). (*)
 336. *Ioannidis JPA.* Perfect study, poor evidence: interpretation of biases preceding study design. **Seminars in Hematology** 2008, 45:160-6.
 337. *Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JPA.* 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. **Journal of the National Cancer Institute** 2008, 100:712-20.

Accompanied by editorial in the same issue.

338. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JPA, Hirschhorn JN. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. **Nature Reviews Genetics** 2008, 9:356-69.
339. Gordon C, Bertsias GK, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostál C, Font G, Gilboe IM, Houssiau F, Huizinga TW, Isenberg D, Kallenberg CG, Khamashta MA, Piette JC, Schneider M, Smolen JS, Sturfelt G, Tincani A, Van Vollenhoven R, Boumpas DT. EULAR recommendations for points to consider in conducting clinical trials in systemic lupus erythematosus (SLE). **Annals of the Rheumatic Diseases** 2009, 68:470-6.
340. Ioannidis JP. Measuring co-authorship and networking-adjusted scientific impact. **PLoS ONE** 2008, 3:e2778.
341. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ, Tanzi RE, Bertram L. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. **Nature Genetics** 2008, 40:827-34.
342. Ioannidis JP, Patsopoulos NA, Rothstein HR. Reasons or excuses for avoiding meta-analysis in forest plots. **BMJ** 2008, 336:1413-5.
343. Ioannidis JPA. Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials? **Philosophy Ethics & Humanities in Medicine** 2008, 3:14 (invited review). (*)
344. Evangelou E, Tsianos G, Ioannidis JPA. Doctors' versus patients' global assessments of treatment effectiveness: empirical survey of diverse treatments in clinical trials. **BMJ** 2008, 336:1287-90. Accompanied by editorial in the same issue.
345. Yesupriya A, Evangelou E, Kavvoura FK, Patsopoulos NA, Clyne M, Walsh MC, Lin BK, Yu W, Gwinn M, Ioannidis JPA, Khoury MJ. Reporting of human genome epidemiology (HuGE) association studies: an empirical assessment. **BMC Medical Research Methodology** 2008, 8:31.
346. Bertsias GK, Ioannidis JPA, Boletis J, Bombardieri S, Cervera R, Dostál C, Font J, Gilboe IM, Houssiau F, Huizinga TW, Isenberg D, Kallenberg CG, Khamashta MA, Piette JC, Schneider M, Smolen JS, Sturfelt G, Tincani A, van Vollenhoven R, Boumpas DT, Gordon C. Evidence for selection of end-points for clinical trials in systemic lupus erythematosus (SLE): a systematic literature review. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). **Annals of the Rheumatic Diseases** 2009, 68:477-83.
347. Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. **International Journal of Epidemiology** 2008, 37:1148-57. Accompanied by commentary and by response to commentary.
348. Ioannidis JPA. Finding large effect sizes – good news or bad news? **The Psychologist** 2008, 21:690-1 (invited commentary). (*)
349. Alpers C, Bloom RD, Fabrizi F, Izopet J, Jadoul M, Lindley E, Martin P, Morales JM, Natov S, Pol S, Reddy KR, Rostaing L, Roth D, Wei L, Alter M, Lavanchy D, Meyers C, Seeff L, Eknayan G, Lameire N, Balk E, Craig J, Earley A, Gordon C, Ioannidis J, Jadoul M, Roth D. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. **Kidney International** 2008, 73 (suppl 109): S6-99.
350. Ioannidis JPA. Limits to forecasting in personalized medicine: an overview. **International Journal of Forecasting** 2009, 25:773-83 (invited review). Accompanied by editorial in the same issue.
351. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, Cronin E, Decullier E, Easterbrook PJ, Von Elm E, Gamble C, Ghera D, Ioannidis JPA, Simes J, Williamson PR. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. **PLoS ONE** 2008, 3:e3081.
352. Thorlund K, Devereaux PJ, Wetterslev J, Gyuatt G, Ioannidis JPA, Thabane L, Gluud L-L, Als-

- Nielsen B, Gluud C. Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? **International Journal of Epidemiology** 2009, 38:276-86.
353. Kavvoura FK, McQueen MB, Khoury MJ, Tanzi RE, Bertram L, Ioannidis JPA. Evaluation of the potential excess of statistically significant findings in reported genetic association studies: application to Alzheimer's disease. **American Journal of Epidemiology** 2008, 168:855-65.
354. Karassa FB, Ioannidis JPA. Mortality in systemic sclerosis. **Clinical and Experimental Rheumatology** 2008, 26:S85-93 (invited review).
355. Salanti G, Ioannidis JPA. Synthesis of observational studies should consider credibility ceilings. **Journal of Clinical Epidemiology** 2009, 62:115-22. Accompanied by commentary in the same issue.
356. Salanti G, Ioannidis JPA. Spurious meta-analyses: Both critical methodological assessment and statistical correction are needed. **Journal of Clinical Epidemiology** 2009, 62:126-7 (commentary in response to commentary on the above article). (*)
357. Ioannidis JPA. Integration of evidence from multiple meta-analyses. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. **CMAJ** 2009, 181:488-93. (*)
358. Zeggini E, Ioannidis JPA. Meta-analysis in genome-wide association studies. **Pharmacogenomics** 2009, 10:191-201 (invited review).
359. Mauri D, Polyzos NP, Salanti G, Pavlidis N, Ioannidis JPA. Multiple treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. **Journal of the National Cancer Institute** 2008, 100:1780-91. Accompanied by editorial in the same issue.
360. Young NS, Ioannidis JPA, Al-Ubaydli O. Why current publication practices may distort science. **PLoS Medicine** 2008, 5:e201. (*)
361. Contopoulos-Ioannidis DG, Alexiou GA, Gouvas TC, Ioannidis JPA. Life cycle of translational research for medical interventions. **Science** 2008, 321:1298-9.
362. Goufopoulos V, Pentheroudakis G, Salanti G, Nearchou A, Ioannidis JPA, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple treatments meta-analysis. **Cancer Treatment Reviews** 2009, 35:570-3.
363. Patsopoulos NA, Evangelou E, Ioannidis JP. Heterogeneous views on heterogeneity. **International Journal of Epidemiology** 2009, 38:740-2 (letter). (*)
364. Stefanis NC, Trikalinos TA, Avramopoulos D, Smyrnis N, Evdokimidis I, Ntzani EE, Hatzimanolis A, Ioannidis JPA, Stefanis CN. Association of RGS4 variants with schizotypy and cognitive endophenotypes at the population level. **Behavioural Brain Functions** 2008, 4:46.
365. Vineis P, Brennan P, Canzian F, Ioannidis JP, Matullo G, Ritchie M, Stromberg U, Taioli E, Thompson J. Expectations and challenges stemming from genome-wide association studies. **Mutagenesis** 2008, 23:439-44.
366. Khoury MJ, Bertram L, Boffetta P, Butterworth AS, Chanock SJ, Dolan SM, Fortier I, Garcia-Closas M, Gwinn M, Higgins JPT, Janssens CJW, Ostell J, Owen RP, Pagon RA, Rebeck TR, Rothman N, Bernstein JL, Burton PR, Campbell H, Chockalingham A, Furberg H, Little J, O'Brien TR, Seminara D, Vineis P, Winn DM, Yu W, Ioannidis JPA. Genome wide association studies, field synopses and the development of the knowledge base on genetic variation and human diseases. **American Journal of Epidemiology** 2009, 170:269-79. (*)
367. Vineis P, Manuguerra M, Kavvoura FK, Guarrera S, Allione A, Rosa F, DiGregorio A, Polidoro S, Saletta F, Ioannidis JPA (corresponding author), Matullo G. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. **Journal of the National Cancer Institute** 2009, 101:24-36. Accompanied by editorial in the same issue.

368. Janssens CJW, González-Zuloeta Ladd AM, López-Léon S, Ioannidis JPA, Oostra BA, Khoury MJ, van Duijn CM. An empirical comparison of meta-analyses of published gene-disease associations versus consortium analyses. **Genetics in Medicine** 2009, 11:153-62.
369. Liberopoulos G, Trikalinos N, Ioannidis JPA. The elderly were under-represented in osteoarthritis clinical trials. **Journal of Clinical Epidemiology** 2009, 62:1218-23.
370. Ioannidis JPA. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. **Circulation: Cardiovascular Genetics** 2009, 2:7-15.
371. Siontis GC, Tatsioni A, Katritsis DG, Ioannidis JP. Persistent reservations against contradicted percutaneous coronary intervention indications: citation content analysis. **American Heart Journal** 2009, 157:695-701. Accompanied by editorial in the same issue.
372. Ioannidis JPA, Allison DB, Ball CA, Coulibaly I, Cui X, Culhane AC, Falchi M, Furlanello C, Game L, Jurman G, Mehta T, Mangion J, Nitzberg M, Page G, Petretto E, van Noort V. Repeatability of published microarray gene expression analyses. **Nature Genetics** 2009, 41:199-205. Accompanied by editorial in the same issue.
373. Attia J, Ioannidis JPA, Thakkeinstian A, McEvoy M, Scott R, Minelli C, Thompson J, Infante-Rivard C, Guyatt G. Users' guides to the medical literature. How to use an article about genetic association. A. Background concepts. **JAMA** 2009, 301:74-81. (*)
374. Attia J, Ioannidis JPA, Thakkeinstian A, McEvoy M, Scott R, Minelli C, Thompson J, Infante-Rivard C, Guyatt G. Users' guides to the medical literature. How to use an article about genetic association. B. Are the results of the study valid? **JAMA** 2009, 301:191-7. (*)
375. Attia J, Ioannidis JPA, Thakkeinstian A, McEvoy M, Scott R, Minelli C, Thompson J, Infante-Rivard C, Guyatt G. Users' guides to the medical literature. How to use an article about genetic association. C. What are the results and will they help me in caring for my patients? **JAMA** 2009, 301:304-8. (*)
376. Ioannidis JPA. Personalized genetic prediction: too limited, too expensive, or too soon? **Annals of Internal Medicine** 2009, 150:139-41 (invited editorial). (*)
377. Contopoulos-Ioannidis DG, Karvouni A, Kouri I, Ioannidis JP. SF-36 outcomes in randomised trials: systematic review. **BMJ** 2009, 338:a3006. Accompanied by editorial in the same issue.
378. Lumbreras B, Parker LA, Porta M, Pollán M, Ioannidis JP, Hernández-Aguado I. Overinterpretation of clinical applicability in molecular diagnostic research. **Clinical Chemistry** 2009, 55:786-94.
379. Little J, Higgins JPT, Ioannidis JPA, Moher D, Gagnon F, von Elm E, Khoury MJ, Cohen B, Davey-Smith G, Grimshaw J, Scheet P, Gwinn M, Williamson RE, Zou GY, Hutchings K, Johnson CY, Tait V, Wiens M, Golding J, van Duijn C, McLaughlin J, Paterson A, Wells G, Fortier I, Freedman M, Zecevic M, King R, Infante-Rivard C, Stewart A, Birkett N. STrengthening the REporting of Genetic Association Studies (STREGA) – An Extension of the STROBE Statement. **PLoS Medicine** 2009, 6:e22. (*)
380. As above, concurrent STREGA publication in **Annals of Internal Medicine** 2009, 150:206-15. (*)
381. As above, concurrent STREGA publication in **Genetic Epidemiology** 2009, March 10 (*)
382. As above, concurrent STREGA publication in **Human Genetics** 2009, 125:131-51. Accompanied by editorial in the same issue. (*)
383. As above, concurrent STREGA publication in **European Journal of Clinical Investigation** 2009, 39:247-66. (*)
384. As above, concurrent STREGA publication in **Journal of Clinical Epidemiology** 2009, 62:597-608. Accompanied by editorial in the same issue. (*)
385. As above, concurrent STREGA publication in **European Journal of Clinical Epidemiology** 2009, 24:37-55. Accompanied by editorial in the same issue. (*)

386. As above, STREGA publication in **Italian Journal of Public Health** 2009, 6:238-55. (*)
387. Ioannidis JP, Thomas G, Daly MJ. Validating, augmenting and refining genome-wide association signals. **Nature Reviews Genetics** 2009, 10:318-29. (*)
388. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, Jeys LM, Franchi A, Scoccianti G, Campanacci D, Capanna R, Aparicio J, Tabone MD, Holzer G, Abdolvahab F, Funovics P, Dominkus M, Ilhan I, Berrak SG, Patino-Garcia A, Sierrasesumaga L, San-Julian M, Garraus M, Petrilli AS, Filho RJ, Macedo CR, Alves MT, Seiwerth S, Nagarajan R, Cripe TP, Ioannidis JP. Prognostic factors and outcomes for osteosarcoma: An international collaboration. **European Journal of Cancer** 2009, 45:2367-75.
389. Patsopoulos NA, Ioannidis JP. Susceptibility variants for rheumatoid arthritis in the TRAF1-C5 and 6q23 loci: a meta-analysis. **Annals of the Rheumatic Diseases** 2010, 69:561-6.
390. Salanti G, Southam L, Altshuler D, Ardlie K, Barroso I, Boehnke M, Cornelis MC, Frayling TM, Grallert H, Grarup N, Groop L, Hansen T, Hattersley AT, Hu FB, Hveem K, Illig T, Kuusisto J, Laakso M, Langednberg C, Lyssenko V, McCarthy MI, Morris A, Morris AD, Palmer CNA, Payne F, Platou CGP, Scott LJ, Voight BF, Wareham NJ, Zeggini E, Ioannidis JPA. Underlying genetic models of inheritance in established type 2 diabetes associations. **American Journal of Epidemiology** 2009, 170:537-45.
391. Evangelou E, Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krueger R, Lambert J-C, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quattrone A, Van Broeckhoven C, Sharma M, Silburn PA, Tan EK, Wirdefeldt K, Ioannidis JPA. Non-replication of association for 6 polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study. **American Journal of Medical Genetics B: Neuropsychiatric Genetics** 2010, 153B:220-8.
392. Kraft P, Zeggini E, Ioannidis JPA. Replication in genome-wide association studies. **Statistical Science** 2009, 24:561-73.
393. Ioannidis JPA. Ranking antidepressants. **Lancet** 2009, 373:1759-60 (letter).
394. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D, and the PRISMA Group. The PRISMA Statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. **PLoS Medicine** 2009, 6:e1000100. (*)
395. As above, concurrent publication of PRISMA in **Annals of Internal Medicine** 2009, 151:W65-94. (*)
396. As above, concurrent publication of PRISMA in **BMJ** 2009, 339:b2700. (*)
397. As above, concurrent publication of PRISMA in **Journal of Clinical Epidemiology** 2009, 62:e1-34. (*)
398. Evangelou E, Chapman K, Meulenbelt I, Karassa FB, Loughlin J, Bos SD, Doherty M, Doherty S, Gomez-Reino JJ, Gonzalez A, Halldorsson BV, Hauksson VB, Hofman A, Hart DJ, Ikegawa S, Ingvarsson T, Jiang Q, Jonsdottir I, Jonsson H, Kerkhof HJM, Lane NE, Li J, Lories RJ, van Meurs JBJ, Näkki A, Nevitt MC, Rodriguez-Lopez J, Shi D, Slagboom PE, Stefansson K, Tsezou A, Wallis GA, Watson C, Spector TD, Uitterlinden AG, Valdes AM, Ioannidis JPA. Large-scale analysis of association between GDF5 and FRZB variants and hip, knee and hand osteoarthritis. **Arthritis and Rheumatism** 2009, 60:1710-21. (*)
399. Khoury MJ, McBride C, Schully SD, Ioannidis JPA, Feero WG, Janssens ACJW, Gwinn M, Simons-Morton DG, Bernhardt JM, Cargill M, Chanock SJ, Church GM, Coates RJ, Collins FS, Croyle RT, Davis BR, Downing GJ, DuRoss A, Friedman S, Gail MH, Ginsburg GS, Green RC, Greene MH,

- Greenland P, Gulcher JR, Hsu A, Hudson KL, Kardia SLR, Kimmel PL, Lauer MS, Miller AM, Offit K, Ransohoff DF, Roberts S, Rasooly RS, Stefansson K, Terry SF, Teutsch SM, Trepanier A, Wanke KL, Witte JS, Xu J. The scientific foundation for personal genomics: recommendations from an NIH-CDC multidisciplinary workshop. **Genetics in Medicine** 2009, 11:559-67. (*)
400. Ioannidis JP. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. **Archives of Internal Medicine** 2009, 169:1737-9 (invited editorial).
401. Manzoli L, Salanti G, De Vito C, Boccia A, Ioannidis JP, Villari P. Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. **Lancet Infectious Diseases** 2009, 9:482-92.
402. Richards JB, Kavvoura FK, Rivadeneira F, Styrkársdóttir U, Estrada K, Halldórsson BV, Hsu YH, Zillikens MC, Wilson SG, Mullin BH, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra BA, Pols HA, Sigurdsson G, Thorsteinsdóttir U, Soranzo N, Williams FM, Zhou Y, Ralston SH, Thorleifsson G, van Duijn CM, Kiel DP, Stefansson K, Uitterlinden AG, Ioannidis JP, Spector TD; Genetic Factors for Osteoporosis Consortium. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. **Annals of Internal Medicine** 2009, 151:528-37.
403. Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. **JAMA** 2009, 302:2345-52. Accompanied by editorial in the same issue.
404. Yang Q, Flanders WD, Moonesinghe R, Ioannidis JP, Guessous I, Khoury MJ. Using lifetime risk estimates in personal genomic profiles: estimation of uncertainty. **American Journal of Human Genetics** 2009, 85:786-800.
405. Pereira TV, Patsopoulos NA, Salanti G, Ioannidis JP. Discovery properties of genome-wide association signals from cumulatively combined data sets. **American Journal of Epidemiology** 2009, 170:1197-206.
406. Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JP. Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. **Cochrane Database of Systematic Reviews** 2009, (4):CD006614.
407. Rivadeneira F, Styrkársdóttir U, Estrada K, Halldórsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdóttir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG; Genetic Factors for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. **Nature Genetics** 2009, 41:1199-206.
408. Ioannidis JP. Population-wide generalizability of genome-wide discovered associations. **Journal of the National Cancer Institute** 2009, 101:1297-9 (invited commentary).
409. Ioannidis JPA, Tatsioni A, Karassa FB. A vision for the European Journal of Clinical Investigation: note from the new editors. **European Journal of Clinical Investigation** 2010, 40:1-3 (editorial). (*)
410. Ioannidis JPA, Loy EY, Poulton R, Chia KS. Researching genetic versus nongenetic determinants of disease: a comparison and proposed unification. **Science Translational Medicine** 2009, 1:7ps8.
411. Galvan A, Ioannidis JPA, Galvani T. Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer. **Trends in Genetics** 2010, 26:132-41. (*)
412. Kitsos G, Petrou Z, Grigoriadou M, Samples JR, Hewitt AW, Kokotas H, Giannoulia-Karantana A, Mackey DA, Wirtz MK, Moschou M, Ioannidis JP, Petersen MB. Primary open angle glaucoma due to T377M MYOC: Population mapping of a Greek founder mutation in Northwestern Greece. **Clinical**

Ophthalmology 2010, 4:171-8.

413. Lathyrus DN, Patsopoulos NA, Salanti G, Ioannidis JP. Industry sponsorship and selection of comparators in randomized clinical trials. **European Journal of Clinical Investigation** 2010, 40:172-82.
414. Dimoliatis IDK, Vasilaki E, Anastassopoulos P, Ioannidis JPA, Roff S. Validation of the Greek translation of the Dundee Ready Education Environment Measure (DREEM). **Education for Health** 2010, 23:348
415. Tsianos GI, Evangelou E, Boot A, Zillikens MC, van Meurs JB, Uitterlinden AG, Ioannidis JP. Association of polymorphisms of eight muscle- or metabolism-related genes with performance in Mount Olympus marathon runners. **Journal of Applied Physiology** 2010, 108:567-74.
416. Siontis K, Patsopoulos NA, Ioannidis JPA. Replication of past candidate loci for common diseases and phenotypes in 100 genome-wide association studies. **European Journal of Human Genetics** 2010, 18:832-7.
417. Tatsioni A, Vavva E, Ioannidis JP. Sources of funding for Nobel Prize-winning work: public or private? **FASEB Journal** 2010, 24:1335-9.
418. Chavalarias D, Ioannidis JPA. Science mapping analysis characterizes 235 biases in biomedical research. **Journal of Clinical Epidemiology** 2010, 63:1205-15.
419. Krüger R, Sharma M, Riess O, Gasser T, Van Broeckhoven C, Theuns J, Aasly J, Annesi G, Bentivoglio AR, Brice A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Klein C, Lambert JC, Lesage S, Lin JJ, Lynch T, Mellick GD, de Nigris F, Opala G, Prigione A, Quattrone A, Ross OA, Satake W, Silburn PA, Tan EK, Toda T, Tomiyama H, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Maraganore DM; for the Genetic Epidemiology of Parkinson's disease consortium. A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. **Neurobiology of Aging** 2011, 32:548.e9-18
420. Katritsis DG, Siontis GC, Ioannidis JPA. Double versus single stenting for coronary bifurcation lesions: a meta-analysis. **Circulation Cardiovascular Interventions** 2009, 2:409-15.
421. Kerkhof HJM, Lories RJ, Meulenbelt I, Jonsdottir I, Valdes AM, Arp P, Ingvarsson T, Jhamai M, Jonsson H, Stolk L, Thorleifsson G, Zhai G, Zhang F, Zhu Y, van der Breggen R, Carr A, Doherty M, Doherty S, Felson DT, Gonzalez A, Halldorsson BV, Hart DJ, Hauksson VB, Hofman A, Ioannidis JPA, Kloppenburg M, Lane NE, Loughlin J, Luyten FP, Nevitt MC, Parimi N, Pols HAP, van de Putte T, Rivadeneira F, Slagboom EP, Styrrársdóttir U, Tsezou A, Zmuda J, Spector TD, Stefansson K, Uitterlinden AG, van Meurs JB. A genome-wide association study identifies a locus on chromosome 7q22 to influence susceptibility for osteoarthritis. **Arthritis and Rheumatism** 2010, 62:499-510.
422. Dolan SM, Hollegaard MV, Merialdi M, Betran AP, Allen T, Abelow C, Nace J, Lin BK, Khoury MJ, Ioannidis JPA, Bagade S, Zheng X, Dubin RA, Bertram L, Velez DR, Menon R. Synopsis of preterm birth genetic association studies: the preterm birth genetics knowledge base (PTBGene). **Public Health Genomics** 2010, 13:514-23.
423. Ioannidis JPA, Castaldi P, Evangelou E. A compendium of genome-wide associations for cancer: critical synopsis and reappraisal. **Journal of the National Cancer Institute** 2010, 102:846-58. Accompanied by editorial in the same issue.
424. Colditz GA, Boffetta P, Marantz PR, Sneeman BO, Liang AP, Wiseman MJ, Picciano MF, Livesey G, Kris-Etherton PM, Ioannidis JPA, Russell RM. Decision-making for recommendations and communication based on totality of food-related research: extended abstracts from an ILSI North America-sponsored workshop. Can lessons learned from genome-wide association studies be applied

to nutrition-wide and exposure-wide evidence. **Critical Reviews in Food Science and Nutrition** 2010, 50:31-32. (*)

425. *The Tobacco and Genetics Consortium, Furberg H, Kim Y, Dackor J, Boerwinkle E, Franceschini N, Ardissino D, Bernardinelli L, Mannucci PM, Mauri F, Merlini PA, Absher D, Assimes TL, Fortmann SP, Iribarren C, Knowles JW, Quertermous T, Ferrucci L, Tanaka T, Bis JC, Furberg CD, Haritunians T, McKnight B, Psaty BM, Taylor KD, Thacker EL, Almgren P, Groop L, Ladenvall C, Boehnke M, Jackson AU, Mohlke KL, Stringham HM, Tuomilehto J, Benjamin EJ, Hwang SJ, Levy D, Preis SR, Vasan RS, Duan J, Gejman PV, Levinson DF, Sanders AR, Shi J, Lips EH, McKay JD, Agudo A, Barzan L, Bencko V, Benhamou S, Castellsagué X, Canova C, Conway DI, Fabianova E, Foretova L, Janout V, Healy CM, Holcátová I, Kjaerheim K, Lagiou P, Lissowska J, Lowry R, Macfarlane TV, Mates D, Richiardi L, Rudnai P, Szeszenia-Dabrowska N, Zaridze D, Znaor A, Lathrop M, Brennan P, Bandinelli S, Frayling TM, Guralnik JM, Milaneschi Y, Perry JR, Altshuler D, Elosua R, Kathiresan S, Lucas G, Melander O, O'Donnell CJ, Salomaa V, Schwartz SM, Voight BF, Penninx BW, Smit JH, Vogelzangs N, Boomsma DI, de Geus EJ, Vink JM, Willemsen G, Chanock SJ, Gu F, Hankinson SE, Hunter DJ, Hofman A, Tiemeier H, Uitterlinden AG, van Duijn CM, Walter S, Chasman DI, Everett BM, Paré G, Ridker PM, Li MD, Maes HH, Audrain-McGovern J, Posthuma D, Thornton LM, Lerman C, Kaprio J, Rose JE, Ioannidis JP, Kraft P, Lin DY, Sullivan PF.* Genome-wide meta-analyses identify multiple loci associated with smoking behavior. **Nature Genetics** 2010, 42:441-7.
426. *Stergiou GS, Siontis KC, Ioannidis JPA.* Home blood pressure as a cardiovascular outcome predictor. It's time to take this method seriously. **Hypertension** 2010, 55:1301-3 (invited commentary). (*)
427. *Ioannidis JPA, Tzoulaki I.* What makes a good predictor? **JAMA** 2010, 303:1646-7 (commentary). (*)
428. *Tatsioni A, Siontis GCM, Ioannidis JPA.* Partisan perspectives in the medical literature: A study of high frequency editorialists favoring hormone replacement therapy. **Journal of General Internal Medicine** 2010, 25:914-9. Accompanied by editorial in the same issue.
429. *Khoury MJ, Gwinn M, Ioannidis JPA.* The emergence of translational epidemiology: from scientific discovery to population health impact. **American Journal of Epidemiology** 2010, 172:517-24. Accompanied by commentary and response to the commentary in the same issue.
430. *Contopoulos-Ioannidis DG, Baltogianni MS, Ioannidis JPA.* Comparative effectiveness of medical interventions in adults versus children. **Journal of Pediatrics** 2010, 127:322-30.
431. *Ioannidis JPA, Tatsioni A, Karassa FB.* Who is afraid of reviewers' comments? Or, why anything can be published and anything can be cited. **European Journal of Clinical Investigation** 2010, 40:285-7 (editorial). (*)
432. *Salanti G, Ades AE, Ioannidis JPA.* Graphical methods and numerical summaries for presenting results from multiple-treatments. **Journal of Clinical Epidemiology** 2011, 64:163-71.
433. *Ioannidis JPA.* Expectations, validity, and reality in -omics. **Journal of Clinical Epidemiology** 2010, 63:945-9. Invited review, accompanied by editorial in the same issue.
434. *Elliott KS, Zeggini E, McCarthy MI, Gudmundsson J, Sulem P, Stacey SN, Thorlacius S, Amundadottir L, Grönberg H, Xu J, Gaborieau V, Eeles RA, Neal DE, Donovan JL, Hamdy FC, Muir K, Hwang SJ, Spitz MR, Zanke B, Carvajal-Carmona L, Brown KM; Australian Melanoma Family Study Investigators, Hayward NK, Macgregor S, Tomlinson IP, Lemire M, Amos CI, Murabito JM, Isaacs WB, Easton DF, Brennan P; PanScan Consortium, Barkardottir RB, Gudbjartsson DF, Rafnar T, Hunter DJ, Chanock SJ, Stefansson K, Ioannidis JP.* Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. **PLoS One** 2010, 5:e10858.

435. Siontis GC, Patsopoulos NA, Vlahos AP, Ioannidis JP. Selection and presentation of imaging figures in the medical literature. **PLoS One** 2010, 5:e10888.
436. Ioannidis JPA, Tatsioni A, Karassa FB. Published articles should not be dead and buried: introducing research updates. **European Journal of Clinical Investigation** 2010, 40:767-9 (editorial). (*)
437. Castaldi P, Dehabreh I, Ioannidis JPA. An empirical evaluation of validation practices for molecular classifiers. **Briefings in Bioinformatics** 2011, 12:188-201.
438. Valdes AM, Evangelou E, Kerkhof HJM, Tamm A, Doherty SA, Kissand K, Tamm A, Kerna I, Uitterlinden A, Hofman A, Rivadeneira F, Cooper C, Dennison EM, Zhang W, Muir KR, Ioannidis JPA, Wheeler M, Maciewicz RA, van Meurs JB, Arden NK, Doherty M, Spector TD. The GDF5 rs143383 polymorphism is associated with osteoarthritis of the knee with genomewide statistical significance. **Annals of the Rheumatic Diseases** 2011, 70:873-5.
439. Panagiotou OA, Evangelou E, Ioannidis JPA. Genome-wide significant associations for variants with minor allele frequency $\leq 5\%$: an overview. **American Journal of Epidemiology** 2010, 172:869-89.
440. Jin H, Evangelou E, Ioannidis JPA, Ralston SH. Polymorphisms in the 5' flank of COL1A1 gene and osteoporosis: meta-analysis of published studies. **Osteoporosis International** 2011, 22:911-21.
441. Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal. **Trials** 2010, 11:85.
442. Ioannidis JPA, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. **BMJ** 2010, 341:762-5.
443. Bertsias GK, Ioannidis JPA, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TWJ, Isenberg D, Kallenberg c, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT. EULAR Recommendations for the Management of Systemic Lupus Erythematosus (SLE) with Neuropsychiatric Manifestations. Report of a Task Force of the EULAR Standing Committee for Clinical Affairs (ESCCA). **Annals of the Rheumatic Diseases** 2010, 69:2074-82.
444. Ioannidis JPA. Is there a glass ceiling for highly-cited scientists at the top of research universities? **FASEB Journal** 2010, 24:1635-8.
445. Katritsis DG, Siontis GCM, Kastrati A, van't Hof AWJ, Neumann FJ, Siontis KCM, Ioannidis JPA. Optimal timing of coronary angiography and potential intervention in non-ST-elevation acute coronary syndromes. **European Heart Journal** 2011, 32:32-40. Accompanied by editorial in the same issue.
446. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A, Bennett SE, Bischoff R, Bongcam-Rudloff E, Capasso G, Coon JJ, D'Haese P, Dominiczak AF, Dakna M, Dihazi H, Ehrich JH, Fernandez-Llama P, Fliser D, Frokiaer J, Garin J, Girolami M, Hancock WS, Haubitz M, Hochstrasser D, Holman R, Ioannidis JPA, Jankowski J, Julian BA, Klein JB, Kolch W, Luider T, Massy Z, Mattes WB, Molina F, Monsarrat B, Novak J, Peter K, Rossing P, Sánchez-Carbayo M, Schanstra JP, Semmes OJ, Spasovski G, Theodorescu D, Thongboonkerd V, Vanholder R, Veenstra T, Weissinger E, Yamamoto T, Vlahou A. Recommendations for biomarker identification and classifier qualification in clinical proteomics. **Science Translational Medicine** 2010, 2:46ps42. (*)
447. Ioannidis JPA, Belbasis L, Evangelou E. Fifty year fate and impact of general medical journals. **PLoS ONE** 2010, 5:e12531.
448. Langevin SM, Ioannidis JPA, Vineis P, Taioli E. Assessment of cumulative evidence for the association between glutathione S-transferase polymorphisms and lung cancer: application of the Venice interim guidelines. **Pharmacogenetics and Genomics** 2010, 20:586-97.
449. Salanti G, Dias S, Welton NJ, Ades A, Golfinopoulos V, Kyrgiou M, Mauri D, Ioannidis JPA.

- Evaluating novel agent effects in multiple-treatments meta-regression. **Statistics in Medicine** 2010, 29:2369-83.
450. *Ioannidis JPA*. A roadmap for successful applications of clinical proteomics. **Proteomics Clinical applications** 2011, 5:241-7 (invited review). (*)
 451. *Ioannidis JPA*. Meta-research: the art of getting it wrong. **Research Synthesis Methods** 2011, 1:169-84 (presidential lecture at SRSM).
 452. *Sigounas DE, Tatsioni A, Christodoulou DK, Tsianos EV, Ioannidis JPA*. New prognostic markers for outcome of acute pancreatitis: overview of reporting in 184 studies. **Pancreas** 2011, 40:522-32.
 453. *Pereira TV, Patsopoulos NA, Salanti G, Ioannidis JPA*. Critical interpretation of Cochran's Q test depends on power and prior assumptions about heterogeneity. **Research Synthesis Methods** 2010, 1:149-61.
 454. *van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JPA, Jayne DRW, Kallenberg CGM, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M*. EULAR recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases (AIIRD). **Annals of the Rheumatic Diseases** 2011, 70:414-22.
 455. *Ioannidis JPA, Siontis GCM*. Fruit and vegetable intake and overall cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) JNCI letter on fruit and vegetables. **Journal of the National Cancer Institute** 2011, 103:279-80 (letter).
 456. *Elbaz A, Ross OA, Ioannidis JPA, Soto-Ortolaza AI, Moisan F, Aasly J, Annesi G, Bozi M, Brighina L, Chartier-Harlin M-C, Destée A, Ferrarese C, Ferraris A, Gibson JM, Gispert S, Hadjigeorgiou GM, Jasinska-Myga B, Klein C, Kruger R, Lambert J-C, Lohmann K, van de Loo S, Lorient M-A, Lynch T, Mellick G, Mutez E, Nilsson C, Opala G, Puschmann A, Quattrone A, Sharma M, Silburn PA, Stefanis L, Utti RJ, Valente EM, Vilariño-Güell C, Wirdefeldt K, Wszolek ZK, Xiromerisiou G, Maraganore DM, Farrer MJ on behalf of the Genetic Epidemiology Of Parkinson's Disease (GEO-PD) consortium*. Independent and joint effects of the MAPT and SNCA genes in Parkinson's disease. **Annals of Neurology** 2011, 69:778-92.
 457. *Bonitsis NG, Tatsioni A, Bassioulas K, Ioannidis JPA*. Allergens responsible for allergic contact dermatitis among children: A systematic review and meta-analysis. **Contact Dermatitis** 2011, 64:245-57.
 458. *Kitsios GD, Tangri N, Castaldi PJ, Ioannidis JPA*. Laboratory mouse models for the human genome-wide associations. **PLoS ONE** 2010, 5:e13782.
 459. *Savović J, Harris RJ, Wood L, Beynon R, Altman D, Als-Nielsen B, Balk EM, Deeks J, Gluud LL, Gluud C, Ioannidis JPA, Jóni P, Moher D, Pildal J, Schulz KF, Sterne JAC*. Development of a combined database for meta-epidemiological research. **Research Synthesis Methods** 2010, 1:212-25.
 460. *Loizidou MA, Hadjisavvas A, Ioannidis JP, Kyriacou K*. Replication of genome-wide discovered breast cancer risk loci in the Cypriot population. **Breast Cancer Research and Treatment** 2011, 128:267-72.
 461. *van Assen S, Elkayam O, Agmon-Levin N, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M*. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases. **Autoimmunity Reviews** 2011, 10:341-52.
 462. *Panoutsopoulou K, Southam L, Elliott KS, Wrayner N, Zhai G, Beazley C, Thorleifsson G, Arden NK, Carr A, Chapman K, Deloukas P, Doherty M, McCaskie A, Ollier WE, Ralston SH, Spector TD*.

- Valdes AM, Wallis GA, Wilkinson JM, Arden E, Battley K, Blackburn H, Blanco FJ, Bumpstead S, Cupples LA, Day-Williams AG, Dixon K, Doherty SA, Esko T, Evangelou E, Felson D, Gomez-Reino JJ, Gonzalez A, Gordon A, Gwilliam R, Halldorsson BV, Hauksson VB, Hofman A, Hunt SE, Ioannidis JP, Ingvarsson T, Jonsdottir I, Jonsson H, Keen R, Kerkhof HJ, Kloppenburg MG, Koller N, Lakenberg N, Lane NE, Lee AT, Metspalu A, Meulenbelt I, Nevitt MC, O'Neill F, Parimi N, Potter SC, Rego-Perez I, Riancho JA, Sherburn K, Slagboom PE, Stefansson K, Styrkarsdottir U, Sumillera M, Swift D, Thorsteinsdottir U, Tsezou A, Uitterlinden AG, van Meurs JB, Watkins B, Wheeler M, Mitchell S, Zhu Y, Zmuda JM; arcOGEN Consortium, Zeggini E, Loughlin J. Insights into the genetic architecture of osteoarthritis from stage 1 of the arcOGEN study. **Annals of the Rheumatic Diseases** 2011, 70:864-7.
463. Evangelou E, Valdes AM, Kerkhof HJ, Styrkarsdottir U, Zhu Y, Meulenbelt I, Lories RJ, Karassa FB, Tylzanowski P, Bos SD; arcOGEN Consortium, Akune T, Arden NK, Carr A, Chapman K, Cupples LA, Dai J, Deloukas P, Doherty M, Doherty S, Engstrom G, Gonzalez A, Halldorsson BV, Hammond CL, Hart DJ, Helgadottir H, Hofman A, Ikegawa S, Ingvarsson T, Jiang Q, Jonsson H, Kaprio J, Kawaguchi H, Kisand K, Kloppenburg M, Kujala UM, Lohmander LS, Loughlin J, Luyten FP, Mabuchi A, McCaskie A, Nakajima M, Nilsson PM, Nishida N, Ollier WE, Panoutsopoulou K, van de Putte T, Ralston SH, Rivadeneira F, Saarela J, Schulte-Merker S, Shi D, Slagboom PE, Sudo A, Tamm A, Tamm A, Thorleifsson G, Thorsteinsdottir U, Tsezou A, Wallis GA, Wilkinson JM, Yoshimura N, Zeggini E, Zhai G, Zhang F, Jonsdottir I, Uitterlinden AG, Felson DT, van Meurs JB, Stefansson K, Ioannidis JP, Spector TD; Translation Research in Europe Applied Technologies for Osteoarthritis (TreatOA). Meta-analysis of genome-wide association studies confirms a susceptibility locus for knee osteoarthritis on chromosome 7q22. **Annals of the Rheumatic Diseases** 2011, 70:349-55.
464. Ioannidis JPA, Tarone R, McLaughlin JK. The false positive to false negative ratio in epidemiologic studies. **Epidemiology** 2011, 22:450-6. Accompanied by three commentaries in the same issue.
465. Panagiotou OA, Contopoulos-Ioannidis DG, Papanikolaou PN, Ntzani EE, Ioannidis JPA. Different black box warning labelling for same-class drugs. **Journal of General Internal Medicine** 2011, 26:603-10. Accompanied by editorial in the same issue.
466. Janssens ACJW, Ioannidis JPA, van Duijn CM, Little J, Khoury MJ for the GRIPS group. Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement. **PLoS Medicine** 2011, 8:e1000420. (*)
467. As above, concurrent publication in **Annals of Internal Medicine**. 2011, 154:421-5. (*)
468. As above, concurrent publication in **British Medical Journal** 2011, 342:d631. (*)
469. As above, concurrent publication in **Circulation: Cardiovascular Genetics** 2011, 4:206-9. (*)
470. As above, concurrent publication in **Journal of Clinical Epidemiology** 2011, 64:843-7. (*)
471. As above, concurrent publication in **European Journal of Clinical Investigation** 2011, 41:1004-9. (*)
472. As above, concurrent publication in **European Journal of Epidemiology** 2011, 26:255-9. (*)
473. As above, concurrent publication in **European Journal of Human Genetics** 2011, 19:833-6. (*)
474. As above, concurrent publication in **Genetics in Medicine** 2011, 13:453-6. (*)
475. As above, concurrent publication in **Genome Medicine** 2011, 3:16. (*)
476. Janssens ACJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ. Strengthening the Reporting of Genetic Risk Prediction Studies (GRIPS): Explanation and Elaboration. **European Journal of Clinical Investigation** 2011, 41:1010-35. (*)

477. As above, concurrent publication in **European Journal of Epidemiology** 2011, 26:313-37. (*)
478. As above, concurrent publication in **European Journal of Human Genetics** 2011, 19:18 p preceding 494. (*)
479. As above, concurrent publication in **Journal of Clinical Epidemiology** 2011, 64:e1-22. (*)
480. Ioannidis JPA. An epidemic of false claims. Competition and conflicts of interest distort too many medical findings. **Scientific American** 2011, 304:16 (invited commentary). (*)
481. Rizos EC, Salanti G, Kontoyiannis DP, Ioannidis JPA. Homophily and co-occurrence shape randomized trials agendas: illustration in antifungal agents. **Journal of Clinical Epidemiology** 2011, 64:830-42.
482. Pereira TV, Ioannidis JPA. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. **Journal of Clinical Epidemiology** 2011, 64:1060-9.
483. Evangelou E, Telenti A, Fellay J, Colombo S, Picado JM, Obel N, Goldstein DB, Ioannidis JPA. Impact of phenotype definition on genome-wide association signals: empirical evaluation in HIV-1 infection. **American Journal of Epidemiology** 2011, 173:1336-42.
484. Ioannidis JPA. Adjusting for bias: a user's guide to performing plastic surgery on meta-analyses of observational studies. **International Journal of Epidemiology** 2011, 40:777-9 (invited commentary). (*)
485. Tzoulaki I, Liberopoulos G, Ioannidis JPA. Use of reclassification for assessment of improved prediction: an empirical evaluation. **International Journal of Epidemiology** 2011, 40:1094-105.
486. Ioannidis JPA. Excess significance bias in the literature of brain volume abnormalities. **Archives of General Psychiatry** 2011, 68:773-80.
487. Pfeiffer T, Bertram L, Ioannidis JPA. Quantifying selective reporting and the Proteus phenomenon for multiple datasets with similar bias. **PLoS ONE** 2011, 6:e18362.
488. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Duval s, Altman DG, Moher D, Higgins JPT. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. **British Medical Journal** 2011, 343:d4002. (*)
489. Polyzos NP, Valachis A, Mauri D, Ioannidis JPA. Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test. **Canadian Medical Association Journal** 2011, 183:E337-43.
490. Ioannidis JP, Tarone R, McLaughlin JK. X-WAS, traditional epidemiology, and policy action. **Epidemiology** 2011, 22:467-8 (rejoinder to commentaries on item 464 above). (*)
491. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. **JAMA** 2011, 305:2200-10. Accompanied by editorial in the same issue.
492. Polyzos NP, Mauri D, Ioannidis JP. Guidelines on chemotherapy in advanced stage gynecological malignancies: an evaluation of 224 professional societies and organizations. **PLoS One** 2011, 6:e20106.
493. Zhu YG, Ioannidis JP, Li H, Jones KC, Martin FL. Understanding and harnessing the health effects of rapid urbanization in China. **Environmental Science and Technology** 2011, 45:5099-104. (*)
494. Papatheodorou S, Evangelou E, Makrydimas G, Ioannidis JPA. First trimester ductus venosus screening for cardiac defects: a meta-analysis. **British Journal of Obstetrics and Gynecology** 2011, 118:1438-45.
495. Chatzinasiou F, Lill CM, Kypreou K, Stefanaki I, Nicolaou V, Spyrou G, Evangelou E, Roehr JT, Kodela E, Katsambas A, Tsao H, Ioannidis JPA, Bertram L, Stratigos AJ. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. **Journal**

- of the National Cancer Institute 2011, 103:1227-35.
496. Siontis GCM, Tzoulaki I, Ioannidis JPA. Predicting death: an empirical evaluation of predictive tools for mortality. **Archives of Internal Medicine** 2011, 171:1721-6. Accompanied by editorial in the same issue.
 497. Siontis GCM, Ioannidis JPA. Risk factors and interventions with statistically significant tiny effects. **International Journal of Epidemiology** 2011, 40:1292-306.
 498. Siontis KCM, Evangelou E, Ioannidis JPA. Magnitude of effects in clinical trials published in high-impact general medical journals. **International Journal of Epidemiology** 2011, 40: 1080-91.
 499. Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JPA, Kirsch-Volders M, Matullo G, Phillips DH, Schoket B, Stromberg U, Vermeulen R, Wild C, Porta M, Vineis P. STrengthening the Reporting of OBservational studies in Epidemiology – Molecular Epidemiology (STROBE-ME): An extension of the STROBE statement. **PLoS Medicine** 2011, 8:e1001117. (*)
 500. As above, concurrent publication in **European Journal of Clinical Investigation** 2012, 42:1-16. (*)
 501. As above, concurrent publication in **Journal of Epidemiology and Community Health** 2012, 66:844-854. (*)
 502. As above, concurrent publication in **Journal of Clinical Epidemiology** 2011, 64:1350-63. (*)
 503. As above, concurrent publication in **Preventive Medicine** 2011, 53:377-87. Accompanied by editorial in the same issue. (*)
 504. As above, concurrent publication in **European Journal of Epidemiology** 2011, 26:797-810. Accompanied by editorial in the same issue. (*)
 505. As above, concurrent publication in **Mutagenesis** 2012, 27:17-29. (*)
 506. Yu Y, Bhangale TR, Fagerness J, Ripke S, Thorleifsson G, Tan PL, Souied EH, Richardson AJ, Merriam JE, Buitendijk GHS, Reynolds R, Raychaudhuri S, Chin KA, Sobrin L, Evangelou E, Lee PH, Lee AY, Leveziel N, Zack DJ, Campochiaro B, Campochiaro P, Smith T, Barile GR, Guymer RH, Hogg R, Chakravarthy U, Robman LD, Gustafsson O, Sigurdsson H, Ortmann W, Behrens TW, Stefansson K, Uitterlinden AG, van Duijn CM, Vingerling JR, Klaver CCW, Allikmets R, Brantley MA, Baird PN, Katsanis N, Thorsteinsdottir U, Ioannidis JPA, Daly MJ, Graham RR, JM Seddon. Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration. **Human Molecular Genetics** 2011, 20:3699-709.
 507. Ioannidis JPA, Garber AM. Individualized cost-effectiveness analysis. **PLoS Medicine** 2011, 8:1001058.
 508. Ross OA, Soto-Ortolaza AI, Heckman MG, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Van Broeckhoven C, Carr J, Chartier-Harlin M-C, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Ferraris A, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JPA, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyrtzi E, Lesage S, Lin C-H, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefelt K, Wszolek ZK, Wu R-M, Farrer MJ, on behalf of the Genetic Epidemiology Of Parkinson's Disease (GEOPD) consortium. LRRK2 exonic variants and susceptibility to Parkinson's disease. **Lancet Neurology** 2011, 10:898-908.
 509. Ioannidis JPA. More time for research: fund people not projects. **Nature** 2011, 477:529-31 (peer-reviewed commentary). (*)
 510. Thombs BD, Coyne JC, Cuijpers P, de Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, Turner EH, Ziegelstein RC. Rethinking recommendations for screening for depression in primary

- care. **Canadian Medical Association Journal** 2012, 184:413-8. (*)
511. *Manzoli L, De Vito C, Salanti G, D'Addario M, Villari P, Ioannidis JPA*. Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines. **PLoS One** 2011, 6:e24384.
512. *Alsbeikh-Ali AA, Qureshi W, Al-Mallah MH, Ioannidis JPA*. Public availability of published research data in high-impact journals. **PLoS One** 2011, 6:e24357.
513. *Contopoulos-Ioannidis DG, Ioannidis JPA*. Claims for improved survival from systemic corticosteroids in diverse conditions: an umbrella review. **European Journal of Clinical Investigation** 2012, 42:233-44.
514. *Sharma M, Maraganore DM, Ioannidis JPA, Riess O, Aasly JO, Annesi G, Ababuni N, Bentivoglio AR, Brice A, Van Broeckhoven C, Chartier-Harlin MC, Destée A, Djarmati A, Elbaz A, Farrer M, Ferrarese C, Gibson JM, Gispert S, Hattori N, Jasinska-Myga B, Klein C, Lesage S, Lynch T, Lichtner P, Lambert JC, Lang AE, Mellick GD, De Nigris F, Opala G, Quattrone A, Riva C, Rogaeva E, Ross OA, Satake W, Silburn PA, Theuns J, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Gasser T, Krüger R; Genetic Epidemiology of Parkinson's Disease Consortium*. Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease. **Neurobiology of Aging** 2011, 32:2108.e1-5.
515. *Ioannidis JPA*. Research needs grants, funding and money- missing something? **European Journal of Clinical Investigation** 2011, 32:349-51 (editorial). (*)
516. *Prasad V, Cifu A, Ioannidis JPA*. Reversals of established medical practices: evidence to abandon ship. **JAMA** 2012, 307:37-38 (viewpoint article). Accompanied by editorial in the same issue. (*)
517. *Panagiotou O, Ioannidis JPA for the Genome-Wide Significance Project*. What should the genome-wide significance threshold be? Empirical replication of borderline genetic associations. **International Journal of Epidemiology** 2012, 41:273-86. Accompanied by editorial in the same issue.
518. *Smit Y, Huibers MJH, Ioannidis JPA, van Dyck R, van Tilburg W, Arntz A*. The effectiveness of long-term psychoanalytic psychotherapy - a meta-analysis of randomized controlled trials. **Clinical Psychology Review** 2012, 32:81-92.
519. *Ntzani EE, Liberopoulos G, Manolio TA, Ioannidis JPA*. Consistency of genome-wide associations across major ancestry groups. **Human Genetics** 2012, 131:1057-71.
520. *Tzoulaki I, Siontis KCM, Ioannidis JPA*. Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomized trials: meta-epidemiology study. **British Medical Journal** 2011, 343:d6829.
521. *Ioannidis JP, Manzoli L, De Vito C, D'Addario M, Villari P*. Publication delay of randomized trials on 2009 influenza A (H1N1) vaccination. **PLoS One** 2011, 6:e28346.
522. *Ioannidis JP, Khoury MJ*. Improving validation practices in "omics" research. **Science** 2011, 334:1230-2 (invited). (*)
523. *Ioannidis JP, Tzoulaki I*. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. **Circulation Research** 2012, 110:658-62.
524. *Moonesinghe R, Ioannidis JP, Flanders WD, Yang Q, Truman BI, Khoury MJ*. Estimating the contribution of genetic variants to difference in incidence of disease between population groups. **European Journal of Human Genetics** 2012, 20:831-6.
525. *Nair V, Maeda L, Ioannidis JPA*. Clinical outcome prediction by microRNAs in human cancer: a systematic review. **Journal of the National Cancer Institute** 2012, 104:528-40.
526. *Boffetta P, Winn DM, Ioannidis JP, Thomas DC, Little J, Davey-Smith G, Coglian VJ, Hecht SS, Seminara D, Vineis P, Khoury MJ*. Recommendations and proposed guidelines for assessing the

cumulative evidence on joint effects of genes and environments on cancer occurrence in humans.

International Journal of Epidemiology 2012, 41:686-704. Accompanied by two editorials. (*)

527. Ioannidis JPA. Are medical conferences useful – and for whom? **JAMA** 2012, 307:1257-8 (viewpoint article). (*)
528. Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle J, Maraganore DM, Martin E, Martinez M, Myers RH, Nalls MA, Pankratz N, Payami H, Satake W, Scott WK, Sharma M, Stefansson K, Singleton AB, Toda T, Tung JY, Vance J, Wood N, Zabetian CP, 23andMe Inc., The Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium, The International Parkinson's Disease Genomics Consortium (IPDGC), The Parkinson's Disease GWAS Consortium, The Wellcome Trust Case Control Consortium 2 (WTCCC2), Young P, Tanzi RE, Khoury MJ, Zipp F, Lebrach H, Ioannidis JP, Bertram L. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. **PLoS Genetics** 2012, 8:e1002548.
529. Patel CJ, Cullen MR, Ioannidis JP, Butte AJ. Systematic evaluation of environmental factors: persistent pollutants and nutrients correlated with serum lipid levels. **International Journal of Epidemiology** 2012, 41:828-43. Accompanied by editorial in the same issue.
530. Manzoli L, Ioannidis JPA, Flacco ME, De Vito C, Villari P. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. **Human Vaccines and Immunotherapeutics** 2012, 8:851-62.
531. Panagiotou OA, Ioannidis JP. Primary study authors of significant studies are more likely to believe that a strong association exists in a heterogeneous meta-analysis compared with methodologists. **Journal of Clinical Epidemiology** 2012, 65:740-7.
532. Estrada K, Styrkarsdottir U, Evangelou E, Hsu Y-H, Duncan EL, Ntzani EE, Oei L, Albagha OME, Amin N, Kemp JP, Koller DL, Li G, Liu C-T, Minster RL, Moayyeri A, Vandenput L, Willner D, Xiao S-M, Yerges-Armstrong LM, Zheng HF, Alonso N, Eriksson J, Kammerer CM, Kaptoge SK, Leo PJ, Thorleifsson G, Wilson SG, Wilson JF, Aalto V, Alen M, Aragaki AK, Aspelund T, Center JR, Dailiana Z, Duggan DJ, Garcia M, Garcia-Giralt N, Giroux S, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Khusainova R, Kim GS, Kooperberg C, Koromila T, Kruk M, Laaksonen M, Lacroix AZ, Lee SH, Leung PC, Lewis SJ, Masi L, Mencej-Bedrac S, Nguyen TV, Nogues X, Patel MS, Prezelj J, Rose LM, Scollen S, Siggeirsdottir K, Smith AV, Svensson O, Trompet S, Trummer O, van Schoor NM, Woo J, Zhu K, Balcells S, Brandi ML, Buckley BM, Cheng S, Christiansen C, Cooper C, Dedoussis G, Ford I, Frost M, Goltzman D, González-Macías J, Kähönen M, Karlsson M, Khusnutdinova E, Koh J-M, Kollia P, Langdahl BL, Leslie WD, Lips P, Ljunggren O, Lorenc RS, Marc J, Mellström D, Obermayer-Pietsch B, Olmos JM, Pettersson U, Reid DM, Riancho JM, Ridker PM, Rousseau F, Slagboom PE, Tang NLS, Urreizti R, Van Hul W, Viikari J, Zarrabeitia MT, Aulchenko YS, Castano-Betancourt M, Grundberg E, Herrera L, Ingvarsson T, Johannsdottir H, Kwan T, Li R, Luben R, Medina-Gómez C, Palsson ST, Reppe S, Rotter JI, Sigurdsson G, van Meurs JBJ, Verlaan D, Williams FMK, Wood AR, Zhou Y, Gautvik KM, Pastinen T, Raychaudhuri S, Cauley JA, Chasman DI, Clark GR, Cummings SR, Danoy P, Dennison EM, Eastell R, Eisman JA, Gudnason V, Hofman A, Jackson RD, Jones G, Jukema JW, Khaw K-T, Lehtimäki T, Liu Y, Lorentzon M, McCloskey E, Mitchell BD, Nandakumar K, Nicholson GC, Oostra BA, Peacock M, Pols HAP, Prince RL, Raitakari O, Reid IR, Robbins J, Sambrook PN, Sham PC, Shuldiner AR, Tylavsky FA, van Duijn CM, Wareham NJ, Cupples LA, Econs MJ, Evans DM, Harris TB, Kung

- AWC, Psaty BM, Reeve J, Spector TD, Streeten EA, Zillikens MC, Thorsteinsdottir U, Ohlsson C, Karasik D, Richards JB, Brown MA, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JPA, Kiel DP, Rivadeneira F, for the GEFOS Consortium. New genomic loci for bone mineral density, osteoporosis and risk of fracture. **Nature Genetics** 2012;44:491-501.
533. Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van Broeckhoven C, Bertram L, Bozi M, Crosiers D, Clarke C, Facheris M, Farrer M, Garraux G, Gispert S, Auburger G, Vilarinho-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon B, Lesage S, Lill CM, Lin J-J, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiomerisiou G, Yueh K-C, Zhao Y, Gasser t, Maraganore D, Krüger R, on behalf of GEOPD consortium. Large-scale replication and heterogeneity in Parkinson disease genetic loci. **Neurology** 2012, 79:659-67.
534. Ioannidis JP. Genetic prediction for common diseases: will personal genomics ever work? **Archives of Internal Medicine** 2012, 172: 744-6 (invited commentary). (*)
535. Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A, Dylag T, Ehrlich J, Egido J, Findeisen P, Jankowski J, Johnson RW, Julien BA, Lankisch T, Leung HY, Maahs D, Magni F, Manns MP, Manolis E, Mayer G, Navis G, Novak J, Ortiz A, Persson F, Peter K, Riese HH, Rossing P, Sattar N, Spasovski G, Thongboonkerd V, Vanholder R, Schanstra JP, Vlahou A. Implementation of proteomic biomarkers: making it work. **European Journal of Clinical Investigation** 2012, 42:1027-36.
536. Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI) (including Ioannidis JPA). Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. **JAMA** 2012;307:1636-40. (*)
537. Knowles JW, Assimes TL, Kiernan M, Pavlovic A, Goldstein BA, Yank V, McConnell MV, Absher D, Bustamante C, Ashley EA, Ioannidis JPA. A randomized trial of personal genomics for preventive cardiology: design and challenges. **Circulation: Cardiovascular Genetics** 2012, 5:368-76.
538. Siontis GCM, Tzoulaki I, Siontis KC, Ioannidis JPA. Comparisons of established risk prediction models for cardiovascular disease: systematic review **BMJ** 2012, 344:e3318. Accompanied by editorial in the same issue.
539. Ioannidis JPA, Yu Y, Seddon J. Correction of phenotype misclassification based on high-discrimination genetic predictive risk models. **Epidemiology** 2012, 23:902-9. Accompanied by editorial commentary in the same issue.
540. Ioannidis JPA, Yu Y, Seddon J. To correct or not to correct- and how. **Epidemiology** 2012, 23:912-3. Rejoinder on commentary on 539. (*)
541. Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JPA, Mandl KD. Pediatric versus adult drug trials for conditions with high pediatric disease burden. **Pediatrics** 2012, 130:285-92.
542. Ioannidis JPA. Scientific communication is not working at the moment, please check again in the future. **Psychological Inquiry** 2012, 23:267-70. (*)
543. Ioannidis JPA. Biomarker failures. **Clinical Chemistry** 2013, 59:202-4 (invited commentary). (*)
544. Sobrin L, Ripke S, Yu Y, Fagerness J, Bhangale TR, Tan PL, Souied EH, Buitendijk GHS, Merriam JE, Richardson AJ, Raychaudhuri S, Reynolds R, Chin KA, Lee AY, Leveziel N, Zack DJ, Campochiaro P, Smith RT, Barile GR, Hogg RE, Chakravarthy U, Behrens TW, Uitterlinden AG, van Duijn CM, Vingerling JR, Brantley MA, Baird PN, Klaver CCW, Allikmets R, Katsanis N, Graham RR, Ioannidis JPA, Daly MJ, Seddon JM. Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes.

Ophthalmology 2012, 199:1874-85.

545. Contopoulos-Ioannidis DC, Seto I, Hamm MP, Thomson D, Hartling L, Ioannidis JPA, Curtis S, Constantin E, Batmanabane G, Klassen T, Williams K. Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses. **Pediatrics** 2012, 129(Supplement 3):161-84.
546. Contopoulos-Ioannidis DC, Seto I, Hamm MP, Thomson D, Hartling L, Ioannidis JPA, Curtis S, Constantin E, Batmanabane G, Klassen T, Williams K. Standard 6: age groups for pediatric trials. **Pediatrics** 2012, 129(Supplement 3):153-60.
547. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, Boletis J, Cervera R, Dörner T, Doria A, Ferrario F, Floege J, Houssiau FA, Ioannidis JP, Isenberg DA, Kallenberg CG, Lightstone L, Marks SD, Martini A, Moroni G, Neumann I, Praga M, Schneider M, Starra A, Tesar V, Vasconcelos C, van Vollenhoven RF, Zakharova H, Haubitz M, Gordon C, Jayne D, Boumpas DT. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. **Annals of the Rheumatic Diseases** 2012, 71:1771-82. (*)
548. Orozco G, Ioannidis JP, Morris A, Zeggini E; *DIAGRAM consortium*. Sex-specific differences in effect size estimates at established complex trait loci. **International Journal of Epidemiology** 2012, 41:1376-82.
549. Doufas AG, Panagiotou OA, Ioannidis JP. Concordance of sleep and pain outcomes of diverse interventions: an umbrella review. **PLoS One** 2012, 7:e40891.
550. Liu CT, Estrada K, Yerges-Armstrong LM, Amin N, Evangelou E, Li G, Minster RL, Carless MA, Kammerer CM, Oei L, Zhou Y, Alonso N, Dailiana Z, Eriksson J, García-Giralt N, Giroux S, Husted LB, Khusainova RI, Koromila T, Kung AW, Lewis JR, Masi L, Mencej-Bedrac S, Nogues X, Patel MS, Prezelj J, Richards JB, Sham PC, Spector T, Vandenput L, Xiao SM, Zheng HF, Zhu K, Balcells S, Brandi ML, Frost M, Goltzman D, González-Macías J, Karlsson M, Khusnutdinova EK, Kollia P, Langdahl BL, Ljunggren O, Lorentzon M, Marc J, Mellström D, Ohlsson C, Olmos JM, Ralston SH, Riancho JA, Rousseau F, Urreizti R, Van Hul W, Zarrabeitia MT, Castano-Betancourt M, Demissie S, Grundberg E, Herrera L, Kwan T, Medina-Gómez C, Pastinen T, Sigurdsson G, Thorleifsson G, Vanmeurs JB, Blangero J, Hofman A, Liu Y, Mitchell BD, O'Connell JR, Oostra BA, Rotter JJ, Stefansson K, Streeten EA, Stykarsdottir U, Thorsteinsdottir U, Tylavsky FA, Uitterlinden A, Cauley JA, Harris TB, Ioannidis JP, Psaty BM, Robbins JA, Zillikens MC, Vanduijn CM, Prince RL, Karasik D, Rivadeneira F, Kiel DP, Cupples LA, Hsu YH. Assessment of gene-by-sex interaction effect on bone mineral density. **Journal of Bone and Mineral Research** 2012, 27:2051-64.
551. Evangelou E, Siontis KC, Pfeiffer T, Ioannidis JP. Perceived information gain from randomized trials correlates with publication in high impact factor journals. **Journal of Clinical Epidemiology** 2012, 65:1274-81.
552. Savović J, Jones HE, Altman DG, Harris RS, Jüni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JAC. Influence of reported study design characteristics on intervention effect estimates from randomized controlled trials: combined analysis of meta-epidemiologic studies. **Annals of Internal Medicine** 2012, 157:429-38.
553. Savović J, Jones HE, Altman DG, Harris RS, Jüni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, Ioannidis JP, Schulz KF, Beynon R, Welton NJ, Wood L, Moher D, Deeks JJ, Sterne JAC. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. **Health Technology Assessment** 2012, 16:1-82. [More extended version of item 552]

554. *Ioannidis JP, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, Schulz KF, Tibshirani R.* Improving value and reducing waste in research design, conduct, and analysis. **Lancet** 2014, 383:166-175. Accompanied by editorials in the same issue.
555. *Nicholson J, Ioannidis JP.* Research grants: Conform and get funded. **Nature** 2012, 492:34-6 (peer-reviewed commentary).
556. *Morris A, Ioannidis JP.* Limitations of medical research and evidence at the patient-clinician encounter scale. **Chest** 2013, 143:1127-35.
557. *Ioannidis JP.* Extrapolating from animals to humans. **Science Translational Medicine** 2012, 4:151ps15. (*)
558. *Mischak H, Vlahou A, Ioannidis JP.* Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. **Clinical Biochemistry** 2013, 46:432-43.
559. *Ioannidis JP.* Why science is not necessarily self-correcting. **Perspectives in Psychological Sciences** 2012, 7:645-54 (invited).
560. *Janssens ACJW, Ioannidis JPA, van Duijn CM, Little J, Khoury MJ for the GRIPS group.* Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement. **Italian Journal of Public Health** 2012, 9: doi: 10.2427/6347– re-publication of article 466 above.
561. *Ioannidis JP.* Scientific inbreeding and same-team replication. **Journal of Psychosomatic Research** 2012, 73:408-10 (invited commentary).
562. *Mills EJ, Ioannidis JPA, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH.* How to use an article reporting a multiple treatment comparison meta-analysis. **JAMA** 2012, 308:1246-53. (*)
563. *Tsilidis KK, Papatheodorou SI, Evangelou E, Ioannidis JP.* Evaluation of excess statistical significance in meta-analyses of 98 biomarker associations with cancer risk. **Journal of the National Cancer Institute** 2012, 104:1867-78.
564. *IntHout J, Ioannidis JP, Borm G.* Obtaining evidence by a single well-powered trial or by several modestly powered trials. **Statistical Methods in Medical Research** 2016, 25:538-52.
565. *Ioannidis JP.* The importance of potential studies that have not existed and registration of observational data sets. **JAMA** 2012, 308:575-6 (viewpoint article). (*)
566. *Staines-Urias E, Paez MC, Doyle P, Dudbridge F, Serrano NC, Ioannidis JPA, Keating BJ, Hingorani AD, Casas JP.* Genetic association studies in pre-eclampsia: systematic meta-analyses and field synopsis. **International Journal of Epidemiology** 2012, 41:1764-75.
567. *Mills EJ, Thorlund K, Ioannidis JPA.* Calculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapies. **Journal of Clinical Epidemiology** 2012, 65:1262-8.
568. *Erhardt A, Akula N, Schumacher J, Czamara D, Karbalai N, Muller-Myhsok B, Mors O, Borglum A, Kristensen AS, Woldbye DPD, Koefoed P, Eriksson E, Maron E, Metspalu A, Nurnberger J, Philibert RA, Kennedy J, Domschke K, Reif A, Deckert J, Otowa T, Kawamura Y, Kaiya H, Okazaki Y, Tanii H, Tokunaga K, Sasaki T, Ioannidis JPA, McMahon FJ, Binder EB.* Replication and meta-analysis of TMEM132D gene variants in panic disorder. **Translational Psychiatry** 2012, 2:e156.
569. *Zeggini E, Panoutsopoulou K, Southam L, Rayner NW, Day-Williams AG, Lopes MC, Boraska V, Esko T, Evangelou E, Hofman A, Houwing-Duistermaat JJ, Ingvarsson T, Jonsdottir I, Jonsson H, Kerkhof HJM, Kloppenburg M, Bos SD, Mangino M, Metrustry S, Slagboom PE, Thorleifsson G, Raine EVA, Ratnayake M, Ricketts M, Beazley C, Blackburn H, Bumpstead S, Elliott KS, Hunt SE, Potter SC, Shin S-Y, Yadav VK, Zhai G, Sherburn K, Dixon K, Arden E, Aslam N, Battley P-K, Carluke I, Doherty S, Gordon A, Joseph J, Keen R, Koller NC, Mitchell S, O'Neill F, Paling E, Reed MR, Rivadeneira F, Swift D, Walker K, Watkins B, Wheeler M, Birrell F, Ioannidis JPA, Meulenbelt I,*

- Metspalu A, Rai A, Salter D, Stefansson K, Styrkarsdottir U, Uitterlinden AG, van Meurs JBJ, arcOGEN Consortium: Chapman K, Deloukas P, Ollier WER, Wallis GA, Arden N, Carr A, Doherty m, McCaskie A, Wilkinson JM, Ralston SH, Valdes AM, Spector TD, Loughlin J.* Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study. **Lancet** 2012, 380:815-23.
570. *Aljasir B, Ioannidis JP, Yurkiewicz A, Moher D, Higgins JP, Arora P, Little J.* Assessment of systematic effects of methodological characteristics on candidate genetic associations. **Human Genetics** 2013, 132:167-178.
571. *Tzoulaki I, Patel CJ, Okamura T, Chan Q, Brown IJ, Miura K, Ueshima H, Zhao L, Van Horn L, Daviglus ML, Stamler J, Butte AJ, Ioannidis JP, Elliott P.* A nutrient-wide association study on blood pressure. **Circulation** 2012, 126:2456-64. Accompanied by editorial in the same issue.
572. *Ioannidis JP, Schully S, Lam TK, Khoury MJ.* Knowledge integration in cancer: current landscape and future prospects. **Cancer Epidemiology Biomarkers and Prevention** 2013, 22:3-10.
573. *Pereira TV, Horwitz RI, Ioannidis JP.* Empirical evaluation of very large treatment effects of medical interventions. **JAMA** 2012, 308:1676-84. Accompanied by editorial in the same issue.
574. *Kappagoda S, Ioannidis JP.* Neglected tropical diseases: survey and geometry of randomised evidence. **BMJ** 2012, 345:e6512.
575. *Zintzaras E, Ioannidis JP.* METRADISC-XL: A program for meta-analysis of multidimensional ranked discovery oriented datasets including microarrays. **Computer Methods and Programs in Biomedicine** 2012, 108:1243-6.
576. *Goetzsche PC, Ioannidis JPA.* Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? **BMJ** 2012, 345:e7031. (*)
577. *Sigounas DE, Christodoulou DK, Tatsioni A, Katsanos KH, Baltayiannis G, Kappas A, Ioannidis JP, Tsianos EV.* Pancreatitis potentially associated drugs as a risk factor for post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective cohort study. **Pancreas** 2013, 42:601-6.
578. *Sharma M, Ioannidis JPA, Aasly J, Annesi G, Brice A, Bertram L, Bozi M, Barcikowska M, Crosiers D, Clarke C, Facheris MF, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon B, Jamrozik Z, Krygowska-Wajs A, Lesage S, Lill CM, Lin J-J, Lynch T, Lichtner P, Lang AE, Libioulle C, Murata M, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Meitner T, Zimprich A, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Strom TM, Theuns J, Tan E-K, Toda T, Tomiyama H, Uitti RJ, Van Broeckhoven C, Wirdefeldt K, Wszolek Z, Xiomerisiou G, Yomono HS, Yueh K-C, Zhao Y, Gasser T, Maraganore D, Krüger R, on behalf of GEOPD consortium.* A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. **Journal of Medical Genetics** 2012, 49:721-6.
579. *Schoenfeld J, Ioannidis JPA.* Does everything we eat cause cancer? A systematic cookbook review. **American Journal of Clinical Nutrition** 2013, 97:127-34. Accompanied by editorial in the same issue.
580. *Prasad V, Jorgenson J, Ioannidis JPA, Cifu A.* Observational studies often make clinical practice recommendations: An empirical evaluation of author attitudes. **Journal of Clinical Epidemiology** 2013, 66:361-66.
581. *Katritsis DG, Siontis KC, Thomas Bigger J, Kadish AH, Steinman R, Zareba W, Siontis GC, Bardy GH, Ioannidis JP.* Effect of left ventricular ejection fraction and QRS duration on the survival benefit of implantable cardioverter-defibrillators: meta-analysis of primary prevention trials. **Heart Rhythm** 2013, 10:200-6.

582. Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling. **Cancer Epidemiology Biomarkers and Prevention** 2013, 22:189-200.
583. Ioannidis JP, Nosek B, Iorns E. Reproducibility concerns. **Nature Medicine** 2012, 18:1736-7 (letter/comment). (*)
584. McDonald KM, Matesic B, Contopoulos-Ioannidis DG, Lonhart J, Schmidt E, Pineda N, Ioannidis JPA. Patient safety strategies targeted at diagnostic errors: a systematic review. **Annals of Internal Medicine** 2013, 158:381-9.
585. Ioannidis JPA. Informed consent, big data, and the oxymoron of research that is not research. **American Journal of Bioethics** 2013, 13:40-2 (invited commentary). (*)
586. Panagiotou OA, Willer CJ, Hirschhorn JN, Ioannidis JPA. The power of meta-analysis in genome wide association studies. **Annual Reviews of Genomics and Human Genetics** 2013, 14:441-65.
587. Haidich A-B, Pilalas D, Contopoulos-Ioannidis DG, Ioannidis JP. Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents. **Journal of Clinical Epidemiology** 2013, 66:371-8.
588. Ioannidis JP. Mega-trials for blockbusters. **JAMA** 2013, 309:239-40 (viewpoint article). (*)
589. Ioannidis JPA. Expressing death risk as condensed life experience and death intensity. **Medical Decision Making** 2013, 33:853-9.
590. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke S, Igo RP, Buitendijk GHS, Sim X, Weeks DE, Guymier RH, Merriam JE, Francis PJ, Hannum G, Agarwal A, Armbrecht AM, Audo I, Aung T, Barile GR, Benchaboune M, Bird AC, Bishop PN, Branham KE, Brooks M, Brucker AJ, Cade WH, Cain MS, Campochiaro PA, Chan C-C, Cheng C-Y, Chew EY, Chin K, Chowers I, Clayton DG, Cojocaru R, Conley YP, Cornes BK, Daly MJ, Dhillon B, Edwards AO, Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ, Gieger C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes G, Ioannidis JPA, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, Keilhauer CN, Khan JC, Kim IK, Kiyohara Y, Klein BEK, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P, Lotery AJ, Meitinger T, Mitchell P, Mohand-Saïd S, Moore AT, Morgan DJ, Morrison MA, Myers CE, Naj AC, Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C, Park KH, Pauer GJT, Peachey NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp R, Rudolph G, Ryu E, Sabel J-A, Schaumberg DA, Scholl HPN, Schwartz SG, Scott WK, Shahid H, Sigurdsson H, Silvestri G, Sivakumaran TA, Smith RT, Sobrin L, Souied EH, Stambolian DE, Stefansson H, Sturgill-Short GM, Takahashi A, Tosakulwong N, Truitt BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L, Vingerling JR, Vithana EN, Webster AR, Wichmann H-E, Winkler TW, Wong TY, Wright AF, Zelenika D, Zhang L, Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R, Baird PN, Gorin MB, Wang JJ, Klaver CCW, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates JRW, Swaroop A, Weber BHF, Kubo M, DeAngelis MM, Léveillard T, Thorsteinsdottir U, Haines JL, Farrer LA, Heid IM, Abecasis GR. Seven new loci associated with age-related macular degeneration. **Nature Genetics** 2013, 45:433-9, 439e1-2.
591. Patel CJ, Ioannidis JPA, Butte A. Systematic identification of interaction effects between genome- and environment-wide associations in type 2 diabetes mellitus. **Human Genetics** 2013, 132:495-508.
592. Tzoulaki I, Siontis KC, Evangelou E, Ioannidis JPA. Bias in associations of emerging biomarkers with cardiovascular disease. **JAMA Internal Medicine** 2013, 173:664-71
593. Stefanaki I, Panagiotou OA, Kodela E, Gogas H, Kypreou KP, Chatzinasiou F, Nikolaou V, Plaka M, Kalfa I, Antoniou C, Ioannidis JPA, Evangelou E, Stratigos AJ. Replication and predictive value

- of SNPs associated with melanoma and pigmentation traits in a Southern European case/control study. **PLoS ONE** 2013, 8:e55712.
594. *Ioannidis JPA, Doucouliagos H*. What's to know about the credibility of empirical economics? **Journal of Economic Surveys** 2013, 27:997-1004. Accompanied by editorial in the same issue.
595. *Evangelou E, Ioannidis JPA*. Methods for meta-analysis of genome-wide association studies and beyond. **Nature Reviews Genetics** 2013, 14:379-89. (*)
596. *Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, Howells DW, Ioannidis JP, Oliver S*. How to increase value and reduce waste when research priorities are set. **Lancet** 2014, 156-65. Accompanied by editorials in the same issue.
597. *Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle R, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Zauber AG, Winn DM, Schully SD*. Transforming epidemiology for 21st century medicine and public health. **Cancer Epidemiology Biomarkers & Prevention** 2013, 22:508-16. (*)
598. *Ioannidis JPA*. Clarifications on the application and interpretation of the test for excess significance and its extensions. **Journal of Mathematical Psychology** 2013, 57:184-187.
599. *Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP*. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. **British Medical Journal** 2013, 346:f707.
600. *Ioannidis JPA*. Are mortality differences detected by administrative data reliable and actionable? **JAMA** 2013, 309:1410-1 (invited editorial). (*)
601. *Ioannidis JPA, Prasad V*. Evaluating health system processes with randomized controlled trials. **JAMA Internal Medicine** 2013, 173:1279-80 (viewpoint article). (*)
602. *Ioannidis JPA, Khoury MJ*. Are randomized trials obsolete or more important than ever in the genomic era? **Genome Medicine** 2013, 5:32. (*)
603. *Ioannidis JPA*. This I believe in genetics: discovery can be a nuisance, replication is science, implementation matters. **Frontiers in Genetics** 2013, 4:33. (*)
604. *Heckman MG, Soto-Ortolaza AI, Aasly JO, Abahuni N, Annesi G, Bacon JA, Bardien S, Bozi M, Brice A, Brighina L, Carr J, Chartier-Harlin MC, Dardiotis E, Dickson DW, Diehl NN, Elbaz A, Ferrarese C, Fiske B, Gibson JM, Gibson R, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Boczarska-Jedynak M, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyratzi E, Lesage S, Lin CH, Lynch T, Maraganore DM, Mellick GD, Mutez E, Nilsson C, Opala G, Park SS, Petrucci S, Puschmann A, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Theuns J, Tomiyama H, Uitti RJ, Valente EM, Van Broeckhoven C, van de Loo S, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Hentati F, Farrer MJ, Ross OA; on behalf of the Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium*. Population-specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO-PD) consortium. **Movement Disorders** 2013, 28:1740-1744.
605. *Ioannidis JPA, Hozo I, Djulbegovic B*. Optimal type I and II error pairs when the available sample size is fixed. **Journal of Clinical Epidemiology** 2013, 66:903-10.e2.
606. *McGill SK, Evangelou E, Ioannidis JP, Soetikno RM, Kaltenbach T*. Narrow band imaging to differentiate neoplastic and non-neoplastic colorectal polyps in real time: a meta-analysis of diagnostic operating characteristics. **Gut** 2013, 62:1704-13. Accompanied by editorial in the same issue.
607. *Broer L, Lill CM, Schuur M, Amin N, Roehr JT, Bertram L, Ioannidis JP, van Duijn CM*. Distinguishing true from false positives in genomic studies: p values. **European Journal of**

- Epidemiology** 2013, 28:131-8.
608. Ioannidis JP, Chang CQ, Lam TK, Schully SD, Khoury MJ. The geometric increase in meta-analyses from China in the genomic era. **PLoS ONE** 2013, 8:e65602.
 609. Tsilidis KK, Panagiotou OA, Sena ES, Aretoudi E, Evangelou E, Howells DW, Salman RA-S, MacLeod MR, Ioannidis JPA. Evaluation of excess significance bias in animal studies of neurological diseases. **PLoS Biology** 2013, 11:e1001609. Accompanied by editorial in the same issue.
 610. Ioannidis JPA, Karassa FB, Druyts E, Thorlund K, Mills EJ. Biologic agents in rheumatology: unmet issues after 200 trials and \$200 billion sales. **Nature Reviews Rheumatology** 2013, 9:665-673 (invited).
 611. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. **British Medical Journals** 2013, 346:f2914. (*)
 612. Porta M, Vandenbroucke JP, Ioannidis JP, Sanz S, Fernandez E, Bhopal R, Morabia A, Victora C, Lopez T. Trends in citations to books on epidemiological and statistical methods in the biomedical literature. **PLoS One** 2013, 8:e61837.
 613. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. Power failure: why small sample size undermines the reliability of neuroscience. **Nature Reviews Neuroscience** 2013, 14:365-76.
 614. Ioannidis JP. What proportion of contemporary medical practices are worse than doing less or doing nothing? **Mayo Clinic Proceedings** 2013, 88:779-81 (invited editorial). (*)
 615. Stamatakis E, Weiler R, Ioannidis JP. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. **European Journal of Clinical Investigation** 2013, 43:469-75.
 616. Evangelou E, Valdes AM, Castano-Betancourt MC, Doherty M, Doherty S, Esko T, Ingvarsson T, Ioannidis JP, Kloppenburg M, Metspalu A, Ntzani EE, Panoutsopoulou K, Slagboom PE, Southam L, Spector TD, Styrkarsdottir U, Stefansson K, Uitterlinden AG, Wheeler M, Zeggini E, Meulenbelt I, van Meurs JB; arcOGEN consortium, the TREAT-OA consortium. The DOT1L rs12982744 polymorphism is associated with osteoarthritis of the hip with genome-wide statistical significance in males. **Annals of the Rheumatic Diseases** 2013, 72:1264-5.
 617. Ioannidis JP. Appropriate vs clinically useful diagnostic tests. **JAMA Internal Medicine** 2013, 173:1607-9 (invited editorial). (*)
 618. Ioannidis JP. Have pharmacogenomics failed or they just need larger-scale evidence and more replication? **Circulation: Cardiovascular Genetics** 2013, 6:413-8. Debate paper, accompanied by short rebuttals.
 619. Hernandez AV, Kaw R, Pasupuleti VM, Bina P, Ioannidis JPA, Bueno H, Boersma E, Gillinov M, for the Cardiovascular Meta-analyses Research Group. Association between obesity and postoperative atrial fibrillation in patients undergoing cardiac surgery: a systematic review and meta-analysis. **Annals of Thoracic Surgery** 2013, 96:1104-16.
 620. Boyack KW, Klavans R, Sorensen AA, Ioannidis JP. A list of highly influential biomedical researchers, 1996-2011. **European Journal of Clinical Investigation** 2013, 43:1339-1365 (perspective article).
 621. Matheson GO, Klügl M, Engebretsen L, Bendiksen F, Blair SN, Börjesson M, Budgett R, Derman W, Erdener U, Ioannidis JP, Khan KM, Martinez R, van Mechelen W, Mountjoy M, Sallis RE, Schwellnus M, Shultz R, Soligard T, Steffen K, Sundberg CJ, Weiler R, Ljungqvist A. Prevention and Management of Non-Communicable Disease: The IOC Consensus Statement, Lausanne 2013. **Sports Medicine** 2013, 43:1075-88. (*)
 622. As above, concurrent publication in **British Journal of Sports Medicine** 2013, 47:1003-11. (*)

623. As above, concurrent publication in **Clinical Journal of Sports Medicine** 2013, 23:419-27. (*)
624. Ioannidis JP. Research accomplishments that are too good to be true. **Intensive Care Medicine** 2014, 40:99-101 (invited editorial). (*)
625. Fusar-Poli P, Radua J, Frascarelli M, Mechelli A, Borgwardt S, Di Fabio F, Biondi M, Ioannidis JP, David SP. Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. **Human Brain Mapping** 2014, 35:3052-65.
626. Ioannidis JP, Henriksen L, Prochaska JJ. Endgame: engaging the tobacco industry in its own elimination. **European Journal of Clinical Investigation** 2013, 43:1366-70 (perspective article). (*)
627. Tonelli AR, Zein J, Ioannidis JP. Geometry of the randomized evidence for treatments of pulmonary hypertension. **Cardiovascular Therapeutics** 2013, 31:e138-146.
628. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP; Guideline Panel Review working group. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. **British Medical Journal** 2013, 347:f5535. (*)
629. Mills EJ, Kanfers S, Thorlund K, Chaimani A, Veroniki AA, Ioannidis JP. The effects of excluding treatments from network meta-analyses: survey. **British Medical Journal** 2013, 347:f5195.
630. Evangelou E, Kerkhof HJ, Stykarsdottir U, Ntzani EE, Bos SD, Esko T, Evans DS, Metrusky S, Panoutsopoulou K, Ramos YF, Thorleifsson G, Tsilidis KK; arcOGEN Consortium, Arden N, Aslam N, Bellamy N, Birrell F, Blanco FJ, Carr A, Chapman K, Day-Williams AG, Deloukas P, Doherty M, Engström G, Helgadóttir HT, Hofman A, Ingvarsson T, Jonsson H, Keis A, Keurentjes JC, Kloppenburg M, Lind PA, McCaskie A, Martin NG, Milani L, Montgomery GW, Nelissen RG, Nevitt MC, Nilsson PM, Ollier WE, Parimi N, Rai A, Ralston SH, Reed MR, Riancho JA, Rivadeneira F, Rodriguez-Fontenla C, Southam L, Thorsteinsdottir U, Tsezou A, Wallis GA, Wilkinson JM, Gonzalez A, Lane NE, Lohmander LS, Loughlin J, Metspalu A, Uitterlinden AG, Jonsdottir I, Stefansson K, Slagboom PE, Zeggini E, Meulenberg I, Ioannidis JP, Spector TD, van Meurs JB, Valdes AM. A meta-analysis of genome-wide association studies identifies novel variants associated with osteoarthritis of the hip. **Annals of the Rheumatic Diseases** 2013 Sep 4. doi:10.1136/annrheumdis-2012-203114. [Epub ahead of print]
631. Fanelli D, Ioannidis JP. US studies may overestimate effect sizes in softer research. **Proceedings of the National Academy of Science U S A** 2013, 110:15031-6.
632. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Siontis GC, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. **Journal of the American College of Cardiology** 2013, 62:2318-25. Accompanied by editorial in the same issue.
633. Heckman MG, Elbaz A, Soto-Ortolaza AI, Serie DJ, Aasly JO, Annesi G, Auburger G, Bacon JA, Boczarska-Jedynak M, Bozi M, Brighina L, Chartier-Harlin MC, Dardiotis E, Destée A, Ferrarese C, Ferraris A, Fiske B, Gispert S, Hadjigeorgiou GM, Hattori N, Ioannidis JP, Jasinska-Myga B, Jeon BS, Kim YJ, Klein C, Kruger R, Kyrtzi E, Lin CH, Lohmann K, Lorient MA, Lynch T, Mellick GD, Mutez E, Opala G, Park SS, Petrucci S, Quattrone A, Sharma M, Silburn PA, Sohn YH, Stefanis L, Tadic V, Tomiyama H, Uitti RJ, Valente EM, Vassilatis DK, Vilariño-Güell C, White LR, Wirdefeldt K, Wszolek ZK, Wu RM, Xiromerisiou G, Maraganore DM, Farrer MJ, Ross OA; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. **Neurobiology of Aging** 2014, 35:266.e5-266.e14.
634. David SP, Ware JJ, Chu IM, Loftus PD, Fusar-Poli P, Radua J, Munafo MR, Ioannidis JP. Potential reporting bias in fMRI studies of the brain. **PLoS One** 2013, 8:e70104.

635. *Siontis KC, Hernandez-Boussard T, Ioannidis JP*. Overlapping meta-analyses on the same topic: survey of published studies. **British Medical Journal** 2013, 347:f4501. Accompanied by editorial comment.
636. *Saquib N, Saquib J, Ioannidis JP*. Practices and impact of primary outcome adjustment in randomized controlled trials: meta-epidemiologic study. **British Medical Journal** 2013, 347:f4313.
637. *Crump C, Ioannidis JP, Sundquist K, Winkleby MA, Sundquist J*. Mortality in persons with mental disorders is substantially overestimated using inpatient psychiatric diagnoses. **Journal of Psychiatric Research** 2013, 47:1298-303.
638. *Ioannidis JP*. Meta-analyses of hydroxyethyl starch for volume resuscitation. **JAMA** 2013, 309:2209 (letter; comment). (*)
639. *Doshi P, Goodman SN, Ioannidis JP*. Raw data from clinical trials: within reach? **Trends in Pharmacological Sciences** 2013, 34:645-7. (*)
640. *Siontis KC, Siontis GC, Contopoulos-Ioannidis DG, Ioannidis JPA*. Diagnostic tests often fail to lead to changes in patient outcomes. **Journal of Clinical Epidemiology** 2014, 67:612-21.
641. *Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP*. Comparative effectiveness of medical interventions on hospitalization outcomes and mortality. **Canadian Medical Association Journal** 2013, 185:e827-37.
642. *Ioannidis JPA, Zhou Y, Chang CQ, Schully S, Khoury MJ, Freedman AN*. Potential increased risk of cancer from commonly used medications: an umbrella review of meta-analyses. **Annals of Oncology** 2014, 25:16-23.
643. *Bourgeois FT, Olson KL, Ioannidis JPA, Mandl KD*. Association between pediatric research activity and global burden of disease. **Pediatrics** 2014, 133:78-87.
644. *Kim D, Tang J, Ioannidis JPA*. Network geometry shows evidence sequestration for medical vs. surgical practices: treatments for basal cell carcinoma. **Journal of Clinical Epidemiology** 2014; 67:391-400.
645. *Ioannidis JPA*. Why “An estimate of the science-wise false discovery rate and application to the top medical literature” is false. **Biostatistics** 2014, 15:28-36; invited article with discussion in pp. 39-45. (*)
646. *Burgio M, Ioannidis JPA, Kaminski BM, DeRycke E, Rogers S, Khoury M, Seminara D*. Collaborative cancer epidemiology in the 21st century: the model of cancer consortia. **Cancer Epidemiology Biomarkers and Prevention** 2013, 22:2148-60.
647. *Patel CJ, Rebhkopf D, Leppert J, Bortz WM, Cullen MR, Chertow G, Ioannidis JPA*. Systematic evaluation of environmental and behavioral factors associated with all-cause mortality. **International Journal of Epidemiology** 2013, 42:1795-1810.
648. *Oei L, Estrada K, Duncan EL, Christiansen C, Liu CT, Langdahl BL, Obermayer-Pietsch B, Riancho JA, Prince RL, van Schoor NM, McCloskey E, Hsu YH, Evangelou E, Ntzani E, Evans DM, Alonso N, Husted LB, Valero C, Hernandez JL, Lewis JR, Kaptoge SK, Zhu K, Cupples LA, Medina-Gómez C, Vandenput L, Kim GS, Hun Lee S, Castaño-Betancourt MC, Oei EH, Martinez J, Daroszewska A, van der Klift M, Mellström D, Herrera L, Karlsson MK, Hofman A, Ljunggren Ö, Pols HA, Stolk L, van Meurs JB, Ioannidis JP, Zillikens MC, Lips P, Karasik D, Uitterlinden AG, Styrkarsdottir U, Brown MA, Koh JM, Richards JB, Reeve J, Ohlsson C, Ralston SH, Kiel DP, Rivadeneira F*. Genome-wide association study for radiographic vertebral fractures: a potential role for the 16q24 BMD locus. **Bone** 2014, 59:20-7.
649. *Tzoulaki I, Seretis A, Ntzani EE, Ioannidis JP*. Mapping the expanded use of Framingham Risk Score in the medical literature. **Journal of Clinical Epidemiology** 2014, 67:571-7.
650. *Iglesias AI, Mihaescu R, Ioannidis JP, Khoury MJ, Little J, van Duijn CM, Janssens AC*. Scientific reporting is suboptimal for aspects that characterize genetic risk prediction studies: a review of

- published articles based on the Genetic Risk Prediction Studies statement. **Journal of Clinical Epidemiology** 2014, 67:489-99.
651. Naci H, Ioannidis JP. Comparative effectiveness of exercise and drug interventions on mortality outcomes: meta-epidemiological study **British Medical Journal** 2013, 347:f5577. Accompanied by ACP Journal Club review.
 652. Ioannidis JP. More than a billion people taking statins? Potential implications of the new cardiovascular guidelines. **JAMA** 2014, 311:463-4 (viewpoint article). (*)
 653. Gordon AS, Tabor HK, Johnson AD, Snively BM, Assimes TL, Auer PL, Ioannidis JP, Peters U, Robinson JG, Sucheston LE, Wang D, Sotoodehnia N, Rotter JI, Psaty BM, Jackson RD, Herrington DM, O'Donnell CJ, Reiner AP, Rich SS, Rieder MJ, Bamshad MJ, Nickerson DA; On Behalf of the NHLBI GO Exome Sequencing Project. Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. **Human Molecular Genetics** 2014, 23:1957-63.
 654. Kanters S, Mills EJ, Thorlund K, Bucher HC, Ioannidis JP. Antiretroviral therapy for initial HIV/AIDS treatment: Critical appraisal of the evidence from over 100 randomized trials and 400 systematic reviews and meta-analyses. **Clinical Microbiology and Infection** 2014, 20:114-22.
 655. Ioannidis JP. Implausible results in human nutrition research. **British Medical Journal** 2013, 347:f6698 (invited editorial). (*)
 656. Prasad V, Ioannidis JPA. Evidence-based de-implementation for contradicted, unproven, and aspiring health care practices. **Implementation Science** 2014, 9:1. Invited, accompanied by editorial in the same issue. (*)
 657. Ioannidis JPA, Munafò M, Fusar-Poli P, Nosek BA, David S. Publication and other reporting biases in cognitive sciences: detection, prevalence and prevention. **Trends in Cognitive Sciences** 2014, 18:235-41 (invited). (*)
 658. Thoms BD, Ziegelstein RC, Roseman M, Kloda LA, Ioannidis JPA. There are no randomized controlled trials that support the United States Preventive Services Task Force Guideline on Screening for Depression in Primary Care: A systematic review. **BMC Medicine** 2014, 12:13.
 659. Djulbegovic B, Hozo I, Ioannidis JPA. Improving the drug development process: more not less randomized trials. **JAMA** 311(4):355-6 (viewpoint article). (*)
 660. Lathyris D, Panagiotou O, Batogianni M, Ioannidis JP, Contopoulos-Ioannidis DG. Safety of medical interventions in children vs. adults. **Pediatrics** 2014, 133:e666-673.
 661. Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM, Arden N, Blanco FJ, Carr A, Chapman K, Deloukas P, Doherty M, Esko T, Garces CM, Gomez-Reino JJ, Helgadottir H, Hofman A, Jonsdottir I, Kerkhof HJ, Kloppenburg M, McCaskie A, Ntzani EE, Ollier WE, Oreiro N, Panoutsopoulou K, Ralston SH, Ramos YF, Riancho JA, Rivadeneira F, Slagboom PE, Styrkarsdottir U, Thorsteinsdottir U, Thorleifsson G, Tsezou A, Uitterlinden AG, Wallis GA, Wilkinson JM, Zhai G, Zhu Y; the arcOGEN consortium, Felson DT, Ioannidis JP, Loughlin J, Metspalu A, Meulenbelt I, Stefansson K, van Meurs JB, Zeggini E, Spector TD, Gonzalez A. Assessment of osteoarthritis candidate genes in a meta-analysis of 9 genome-wide association studies. **Arthritis & Rheumatism** 2014, 66:940-9.
 662. Oei L, Hsu YH, Styrkarsdottir U, Eussen BH, de Klein A, Peters MJ, Halldorsson B, Liu CT, Alonso N, Kaptoge SK, Thorleifsson G, Hallmans G, Hocking LJ, Husted LB, Jameson KA, Kruk M, Lewis JR, Patel MS, Scollen S, Svensson O, Trompet S, van Schoor NM, Zhu K, Buckley BM, Cooper C, Ford I, Goltzman D, González-Macías J, Langdahl BL, Leslie WD, Lips P, Lorenc RS, Olmos JM, Pettersson-Kymmer U, Reid DM, Riancho JA, Slagboom PE, Garcia-Ibarbia C, Ingvarsson T, Johannsdottir H, Luben R, Medina-Gómez C, Arp P, Nandakumar K, Palsson ST, Sigurdsson G, van

- Meurs JB, Zhou Y, Hofman A, Jukema JW, Pols HA, Prince RL, Cupples LA, Marshall CR, Pinto D, Sato D, Scherer SW, Reeve J, Thorsteinsdottir U, Karasik D, Richards JB, Stefansson K, Uitterlinden AG, Ralston SH, Ioannidis JP, Kiel DP, Rivadeneira F, Estrada K. A genome-wide copy number association study of osteoporotic fractures points to the 6p25.1 locus. **Journal of Medical Genetics** 2014, 51:122-31.
663. Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users' guide to the medical literature. **JAMA** 2014, 311:405-11. (*)
664. Macleod MR, Michie S, Roberts I, Dirnagl U, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Chan AW, Glasziou P. Biomedical research: increasing value, reducing waste. **Lancet** 2014, 383:101-4. Accompanied by editorials in the same issue. (*)
665. Kappagoda S, Ioannidis JPA. Prevention and control of the neglected tropical diseases: overview of randomised trials, systematic reviews and meta-analyses. **Bulletin of the World Health Organization** 2014, 92:356-66C.
666. Dal-Ré R(+), Ioannidis JPA(+), Bracken MB(+), Buffler PA, Chan A-W, Franco EL, La Vecchia C, Weiderpass E. Making prospective registration of observational research a reality. **Science Translational Medicine** 2014, 6:224cm1. +=equal contribution (*)
667. Naci H, Ioannidis JPA. How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of clinical utility of drugs? **Annual Reviews of Pharmacology and Toxicology** 2015, 55:169-189. (*)
668. Ashbury FD, Little J, Ioannidis JPA, Kreiger N, Relton C, Taylor P. Revolution and evolution: a vision for chronic disease prevention and intervention research. **Canadian Journal of Public Health** 2014, 105:e150-3. (*)
669. Dewey FE, Grove ME, Pan C, Goldstein BA, Bernstein JA, Chaib H, Merker JD, Goldfeder RL, Enns G, David SP, Pakdaman N, Ormond KE, Caleshu C, Kingham K, Klein TE, Whirl-Carrillo M, Sakamoto K, Wheeler MT, Butte AJ, Ford JM, Boxer L, Ioannidis JPA, Yeung AC, Altman RB, Assimes TL, Snyder M, Ashley EA, Quertermous T. Clinical interpretation and implications of whole-genome sequencing. **JAMA** 2014, 311:1035-1045. Accompanied by editorial in the same issue.
670. IntHout J, Ioannidis JPA, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. **BMC Medical Research Methodology** 2014, 14:25.
671. Tonelli AR, Zein J, Adams J, Ioannidis JPA. Effects of interventions on survival in acute respiratory distress syndrome: an umbrella review of 159 published randomized trials and 29 meta-analyses. **Intensive Care Medicine** 2014, 40:769-87. Accompanied by editorial in the same issue.
672. Meo AD, Diamandis EP, Rodriguez H, Hoofnagle AN, Ioannidis JPA, Lopez L. What is wrong with clinical proteomics? **Clinical Chemistry** 2014, 60:1258-66 (invited series of comments). (*)
673. Evans JA, Shim J-M, Ioannidis JPA. Attention to local health burden and the global disparity of health research. **PLoS One** 2014, 9:e90147.
674. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. **BMJ** 2014, 348:g2035. Accompanied by editorial in the same issue.
675. Ioannidis JP. Errors (my very own) and the fearful uncertainty of numbers. **European Journal of Clinical Investigation** 2014, 44:617-8 (editorial). (*)
676. Tsilidis KK, Capothanassi D, Allen NE, Rizos EC, Lopez DS, van Veldhoven K, Sacerdote C, Ashby D, Vineis P, Tzoulaki I, Ioannidis JP. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. **Diabetes Care** 2014, 37:2522-2532.

677. Patel CJ, Ioannidis JP. Studying the elusive environment in large scale. **JAMA** 2014, 311:2173-4 (viewpoint article).
678. Rifai N, Bossuyt PM, Ioannidis JP, Bray KR, McShane LM, Golub RM, Hooft L. Registering diagnostic and prognostic trials of tests: is it the right thing to do? **Clinical Chemistry** 2014, 60:1146-1152 (invited series of comments). (*)
679. Sigounas DE, Christodoulou DK, Karamoutsios A, Tatsioni A, Dova L, Vartholomatos G, Kolaitis N, Katsanos KH, Zervou E, Ioannidis JP, Tsianos EV. Changes of serum adhesion molecules and cytokines in post-ERCP pancreatitis: adhesion molecules and cytokines in acute pancreatitis. **Clinical Biochemistry** 2014, 47:1245-9.
680. Manzoli L, Flacco ME, D'Addario M, Capasso L, De Vito C, Marzuillo C, Villari P, Ioannidis JP. Non-publication and delayed publication of randomized trials on vaccines: survey. **BMJ** 2014, 348:g3058.
681. Ioannidis JP, Mullard A. In audience with John P. A. Ioannidis. **Nature Reviews Drug Discovery** 2014, 13:328-9 (interview). (*)
682. Tzoulaki I, Ebbels T, Valdes A, Elliott P, Ioannidis JPA. Design and analysis of metabolomics studies in epidemiological research: a primer. **American Journal of Epidemiology** 2014, 180:129-139. (*)
683. Nair VS, Pritchard CC, Tewari M, Ioannidis JPA. Design and analysis for studying microRNAs in human disease: a primer. **American Journal of Epidemiology** 2014, 180:140-52. (*)
684. Kaw R, Pasupuleti V, Overby W, Deshpande A, Coleman CI, Ioannidis JPA, Hernandez AV. Inferior vena cava filters and postoperative outcomes in patients undergoing bariatric surgery: a meta-analysis. **Surgery for Obesity and Related Diseases** 2014, 10:725-33.
685. Patel C, Ioannidis JPA. Placing epidemiological results in the context of multiplicity and typical correlations of exposures. **Journal of Epidemiology and Community Health** 2014, 68:1096-100.
686. Ioannidis JP, Khoury MJ. Assessing value in biomedical research: the PQRST of appraisal and reward. **JAMA** 2014, 312:483-4 (viewpoint article). (*)
687. Ioannidis JPA. Modeling and research and research. **Clinical Chemistry** 2014, 60:1238-9 (invited, highly-cited classics series).
688. Murad MH, Montori VM, Ioannidis JPA, Jaeschke R, Devereaux PJ, Prasad K, Neumann I, Carasco-Labra A, Agoritsas T, Hatala R, Meade MO, Wyer P, Cook DJ, Guyatt G. How to read a systematic review and meta-analysis and apply the results to patient care: Users' Guide to the Medical Literature. **JAMA** 2014, 312:171-9. (*)
689. Fleurence RL, Forsythe LP, Lauer M, Rotter J, Ioannidis JPA, Beal A, Frank L, Selby JV. Engaging patients and stakeholders in research proposal review: The Patient-Centered Outcomes Research Institute. **Annals of Internal Medicine** 2014, 161:122-30.
690. Saquib N, Saquib J, Ioannidis JPA. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. **International Journal of Epidemiology** 2015, 44:264-77. Accompanied by three editorials in the same issue.
691. Macleod M, Chalmers IC, Ioannidis JPA, Salman R, Chan A-W, Glasziou P. Preclinical research: design animal studies better. **Nature** 2014, 510:35 (letter). (*)
692. Brown AW, Ioannidis JPA, CopeMB, Bier DM, Allison DB. Unscientific beliefs about scientific topics in nutrition. **Advances in Nutrition** 2014, 5:563-5. (*)
693. Koretz RL, Lin K, Ioannidis JPA, Lenzer J. Is widespread screening for hepatitis C justified? **BMJ** 2015, 350:g7809. (*)
694. Goldstein BA, Knowles JW, Salfati E, Ioannidis JP, Assimes TL. Simple, standardized incorporation of genetic risk into non-genetic risk prediction tools for complex traits: coronary heart disease as an example. **Frontiers in Genetics** 2014, 5:254.

695. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R; International Parkinson's Disease Genomics Consortium (IPDGC); Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI); 23andMe; GenePD; NeuroGenetics Research Consortium (NGRC); Hussman Institute of Human Genomics (HIHG); The Ashkenazi Jewish Dataset Investigator; Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE); North American Brain Expression Consortium (NABEC); United Kingdom Brain Expression Consortium (UKBEC); Greek Parkinson's Disease Consortium; Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. **Nature Genetics** 2014, 46:989-993.
696. Ramos YF, Metrustry S, Arden N, Bay-Jensen AC, Beekman M, de Craen AJ, Cupples LA, Esko T, Evangelou E, Felson DT, Hart DJ, Ioannidis JP, Karsdal M, Kloppenburg M, Lafeber F, Metspalu A, Panoutsopoulou K, Slagboom PE, Spector TD, van Spil EW, Uitterlinden AG, Zhu Y; arcOGEN consortium; TreatOA collaborators, Valdes AM, van Meurs JB, Meulenbelt I; arcOGEN consortium. Meta-analysis identifies loci affecting levels of the potential osteoarthritis biomarkers sCOMP and uCTX-II with genome wide significance. **Journal of Medical Genetics** 2014, 51(9):596-604.
697. Zintzaras E, Ioannidis JP. HELOW: A program for testing extreme homogeneity in meta-analysis. **Computer Methods and Programs in Biomedicine** 2014, 117:383-6.
698. Ioannidis JP, Boyack KW, Klavans R. Estimates of the continuously publishing core in the scientific workforce. **PLoS One** 2014, 9:e101698.
699. Chang CQ, Tingle SR, Filipinski KK, Khoury MJ, Lam TK, Schully SD, Ioannidis JPA. An overview of recommendations and translational milestones for genomic tests in cancer. **Genetics in Medicine** 2015, 17:431-40.
700. Ioannidis JPA. Handling the fragile vase of research practices. **Addiction** 2015, 110:9-10 (invited commentary). (*)
701. Ioannidis JPA. Not all science is created equal. **Chemistry World** (invited commentary) <http://www.rsc.org/chemistryworld/2014/10/not-all-science-created-equal> (*)
702. Ebrahim S, Sohani ZN, Montoya L, Agarwal A, Thorlund K, Mills EJ, Ioannidis JPA. Re-analyses of randomized controlled trial data. **JAMA** 2014, 312:1024-32. Accompanied by editorial in the same issue.
703. Begley CG, Ioannidis JPA. Reproducibility in science: Improving the standard for basic and preclinical research. **Circulation Research** 2015, 116:116-126.
704. Thombs BD, Benedetti A, Kloda LA, Levis B, Nicolau I, Cuijpers P, Gilbody S, Ioannidis JP, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC. The diagnostic accuracy of the Patient Health Questionnaire-2 (PHQ-2), Patient Health Questionnaire-8 (PHQ-8), and Patient Health Questionnaire-9 (PHQ-9) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. **Systematic Reviews** 2014, 3(1):124.
705. Ioannidis JP. How to make more published research true. **PLoS Medicine** 2014, 11:e1001747. (*)
706. Trinquart L, Ioannidis JP, Chatellier G, Ravaud P. A test for reporting bias in trial networks: simulation and case studies. **BMC Medical Research Methodology** 2014, 14:112.
707. Gwinn M, Ioannidis JP, Little J, Khoury MJ. Editorial: Updated guidance on human genome epidemiology (HuGE) reviews and meta-analyses of genetic associations. **American Journal of**

- Epidemiology** 2014, 180:559-561 (editorial). (*)
708. *Ioannidis JP, Boyack KW, Small H, Sorensen AA, Klavans R.* Is your most cited work your best? **Nature** 2014, 514:561-2 (comment/analysis article).
709. *Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JP.* Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. **BMJ** 2015, 350:g7607.
710. *Ioannidis JP.* A generalized view of self-citation: direct, co-author, collaborative, and coercive induced self-citation. **Journal of Psychosomatic Research** 2015, 78:7-11. (*)
711. *Athanasiadis EI, Antonopoulou K, Chatzinasiou F, Lill CM, Bourdakou MM, Sakellariou A, Kypreou K, Stefanaki I, Evangelou E, Ioannidis JP, Bertram L, Stratigos AJ, Spyrou GM.* A web-based database of genetic association studies in cutaneous melanoma enhanced with network-driven data exploration tools. **Database** 2014 Nov 7;2014. pii: bau101. doi: 10.1093/database/bau101. Print 2014.
712. *Siontis GC, Tzoulaki I, Castaldi PJ, Ioannidis JP.* External validation of new risk prediction models is infrequent and reveals worse prognostic discrimination. **Journal of Clinical Epidemiology** 2015, 68:25-34.
713. *Papatheodorou SI, Tsilidis KK, Evangelou E, Ioannidis JP.* Application of credibility ceilings probes the robustness of meta-analyses of biomarkers and cancer risk. **Journal of Clinical Epidemiology** 2015, 68:163-174.
714. *Moons KGM, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS, TRIPOD group.* Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): explanation and elaboration. **Annals of Internal Medicine** 2015, 162:W1-W73. (*)
715. *Antonopoulou K, Stefanaki I, Lill CM, Chatzinasiou F, Kypreou K, Karagianni F, Athanasiadis E, Spyrou GM, Ioannidis JPA, Bertram L, Evangelou E, Stratigos AJ.* Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: The MelGene database. **Journal of Investigative Dermatology** 2015, 135:1074-1079.
716. *Ioannidis JP.* Science research needs an overhaul. **Scientific American** November 3, 2014, <http://www.scientificamerican.com/article/science-research-needs-an-overhaul> (invited commentary). (*)
717. *Khoury MJ, Ioannidis JPA.* Big data meets public health. **Science** 2014, 346:1054-5 (invited perspective article). (*)
718. *Djulbegovic B, Hozo I, Ioannidis JPA.* Modern health care as a game theory problem. **European Journal of Clinical Investigation** 2015, 45:1-12 (perspective).
719. *Ioannidis JPA.* Clinical trials: what a waste. **BMJ** 2014, 349:g7089 (invited editorial). (*)
720. *Ioannidis JPA.* Stealth research: is biomedical innovation happening outside the peer-reviewed literature. **JAMA** 2015, 313:663-4 (viewpoint article). (*)
721. *Ioannidis JPA.* On transparency and transparent research. **Journal of Clinical Epidemiology** (invited commentary). (*)
722. *Belbasis L, Bellou V, Evangelou E, Ioannidis JPA, Tzoulaki I.* Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. **Lancet Neurology** 2015, 14:263-73.
723. *Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JPA.* Epidemiological design and analysis for proteomic studies: a primer on -omic technologies. **American Journal of Epidemiology** 2015, 181:635-47. (*)
724. *Ioannidis JPA, Horbar JD, Ovelman CM, Brosseau Y, Thorlund K, Buus-Frank ME, Mills EJ, Soll RF.* Completeness of main outcomes across randomized trials in an entire discipline: survey of chronic

- lung disease outcomes in preterm infants. **BMJ** 2015, 350:h72.
725. Patel CJ, Ioannidis JP, Cullen MR, Rebkopf DH. Systematic assessment of the correlations of household income with infectious, biochemical, physiological, and environmental factors in the United States, 1999-2006. **American Journal of Epidemiology** 2015. 181:171-179.
726. Banglawala SM, Lawrence LA, Franko-Tobin E, Soler ZM, Schlosser RJ, Ioannidis J. Recent randomized controlled trials in otolaryngology. **Otolaryngology Head and Neck Surgery** 2015, 152:418-423.
727. Ioannidis JP. Preventing tooth loss with bi-annual dental visits and genetic testing: does it work? **Journal of the American Dental Association** 2015, 146:141-3 (invited commentary). (*)
728. Ioannidis JPA. Translational research may be most successful when it fails. **Hastings Center Report** 2015, 45:39-40 (invited commentary). (*)
729. Lara-Pezzi E, Menasché P, Trowvin J-H, Badimón L, Ioannidis JPA, Wu JC, Hill JA, Koch WJ, De Felice AF, de Waele P, Steenwinckel V, Hajjar RJ, Zeiher AM. Guidelines for translational research in heart failure. **Journal of Cardiovascular Translational Research** 2015, 8:3-22. (*)
730. Flacco ME, Manzoli L, Boccia S, Capasso L, Aleksavska K, Rosso A, Scafoli G, De Vito C, Siliquini R, Villari P, Ioannidis JP. Head-to-head randomized trials are mostly industry-sponsored and almost always favour the industry sponsor. **Journal of Clinical Epidemiology** 2015, 68:811-820.
731. Ioannidis JP. Anticipating consequences of sharing raw data and code and of awarding badges for sharing. **Journal of Clinical Epidemiology** 2016, 70:258-60. (invited commentary). (*)
732. Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndambi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HH, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. **PLoS Medicine** 2015, 12(4):e1001810.
733. Dal-Ré R, Bracken MB, Ioannidis JP. Call to improve transparency of trials of non-regulated interventions. **BMJ** 2015, 350:h1323.
734. Lanini S, Zumla A, Ioannidis JP, Caro AD, Krishna S, Gostin L, Girardi E, Pletschette M, Strada G, Baritussio A, Portella G, Apolone G, Cavuto S, Satolli R, Kremsner P, Vairo F, Ippolito G. Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? **Lancet Infectious Diseases** 2015, 15:738-45.
735. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, Ioannidis JP, Straus S, Thorlund K, Jansen JP, Mulrow C, Catalá-López F, Gøtzsche PC, Dickersin K, Boutron I, Altman DG, Moher D. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. **Annals of Internal Medicine** 2015, 162:777-84. (*)
736. Int'Hout J, Ioannidis JP, Borm GF, Goeman JJ. Small studies are more heterogeneous than large ones: a meta-meta-analysis. **Journal of Clinical Epidemiology** 2015, 68: 860-9.
737. Karassa FB, Ioannidis JP. Clinical trials: A transparent future for clinical trial reporting. **Nature**

- Reviews Rheumatology** 2015, 11:324-6 (invited commentary).
738. *Naci H, Ioannidis JP*. Evaluation of wellness determinants and interventions by citizen scientists. **JAMA** 2015, 314:121-2 (viewpoint article). (*)
739. *Hsing A, Ioannidis JP*. Nationwide population science - lessons from the Taiwan National Health Insurance Research Database **JAMA Internal Medicine** 2015, 175:1527-1529 (invited commentary). (*)
740. *Hemkens L, Contopoulos-Ioannidis DG, Ioannidis JP*. Current use of routinely collected health data to complement randomized controlled trials: a meta-epidemiological survey. **CMAJ Open** 2016, 4:E132-40.
741. *Hemkens L, Contopoulos-Ioannidis DG, Ioannidis JP*. Routinely collected data and comparative effectiveness evidence: promises and limitations. **CMAJ** 2016, 188:E158-164. (*)
742. *Ioannidis JP, Fanelli D, Dunne DD, Goodman SN*. Meta-research: evaluation and improvement of research methods and practices. **PLoS Biology** 2015, 13:e1002264.
743. *Patel C, Burford B, Ioannidis JP*. Assessment of vibration of effects due to model specification can demonstrate the instability of observational associations. **Journal of Clinical Epidemiology** 2015, 68:1046-1058.
744. *Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators*. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. **Lancet Neurology** 2015, 14:1002-1009.
745. *Verghese A, Charlton B, Kassirer JP, Ramsey M, Ioannidis JP*. Inadequacies of physical examination as a cause of medical errors and adverse events: A collection of vignettes. **American Journal of Medicine** 2015, 128:1322-4.e3.
746. *Ioannidis JP*. Research and theories on the etiology of mental diseases: doomed to failure? **Psychological Inquiry** 2015, 25:239-43 (invited commentary). (*)
747. *Ioannidis JP, Stanley TD, Doucouliagos H*. The power of bias in economic research. **The Economic Journal** 2017, 127:F236-265.
748. *Ioannidis JP*. Is it possible to recognize a major scientific discovery? **JAMA** 2015, 314:1135-1137 (guest editorial for article series). (*)
749. *Boccia S, Rothman KJ, Panic N, Flacco ME, Rosso A, Pastorino R, Manzoli L, La Vecchia C, Villari P, Boffetta P, Ricciardi W, Ioannidis JP*. Registration practices for observational studies on clinicaltrials.gov indicated low adherence. **Journal of Clinical Epidemiology** 2016, 70:176-82.
750. *Ebrahim S, Bance S, Athale A, Malachowski C, Ioannidis JP*. Meta-analyses with industry involvement are massively published and report no caveats for antidepressants. **Journal of Clinical Epidemiology** 2016, 70:155-63.
751. *Serghiou S, Patel CJ, Tan YY, Koay P, Ioannidis JP*. Field-wide meta-analyses of observational associations can map selective availability of risk factors and the impact of model specifications. **Journal of Clinical Epidemiology** 2016, 71:58-67.
752. *Ioannidis JP*. Failure to replicate: sound the alarm. **Cerebrum** 2015 Nov 1;2015. pii: cer-12a-15. (invited editorial). (*)
753. *Ioannidis JP*. Most psychotherapies do not really work, but those that might work should be assessed in biased studies. **Epidemiology and Psychiatric Sciences** 2016, 25:436-438 (invited commentary).

(*)

754. *Thombs BD, Benedetti A, Kloda LA, Levis B, Riehm KE, Azar M, Cuijpers P, Gilbody S, Ioannidis JPA, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Tonelli M, Mitchell N, Comeau L, Schinazi J, Vigod S.* The diagnostic accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for detecting major depression in pregnant and postnatal women: protocol for a systematic review and individual patient data meta-analyses. **BMJ Open** 2015;5:e009742.
755. *Manzoli L, Flacco ME, Boccia S, D'Andrea E, Panic N, Marzuillo C, Siliquini R, Rocciardi W, Villari P, Ioannidis JP.* Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis. **European Journal of Epidemiology** 2016, 31:351-68.
756. *Naci H, Ioannidis JP.* Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. **British Journal of Sports Medicine** 2015;49:1414-22. Reprint of article #651. (*)
757. *Iqbal S, Wallach J, Khoury MJ, Schully S, Ioannidis JP.* Reproducible research practices and transparency across the biomedical literature. **PLoS Biology** 2016, 14:e1002333. Accompanied by editorial in the same issue.
758. *Ioannidis JP.* Salt and the assault of opinion on evidence. **International Journal of Epidemiology** 2016, 45:264-5 (invited commentary). (*)
759. *Siontis KC, Ioannidis JP, Katritsis GD, Noseworthy PA, Packer DL, Hummel JD, Jaïs P, Krittayaphong R, Mont L, Morillo CA, Nielsen JC, Oral H, Pappone C, Santinelli V, Weerasooriya R, Wilber DJ, Gersh BJ, Josephson ME, Katritsis DG.* Radiofrequency ablation versus antiarrhythmic drug therapy for atrial fibrillation: meta-Analysis of quality of life, morbidity, and mortality. **JACC: Clinical Electrophysiology** 2016, 2:170-180.
760. *Ioannidis JP.* Exposure-wide epidemiology: revisiting Bradford Hill revisited. **Statistics in Medicine** 2016, 35:1749-62 (invited, based on annual Bradford Hill lecture). (*)
761. *Ioannidis JP.* Evidence-based medicine has been hijacked: a report to David Sackett. **Journal of Clinical Epidemiology** 2016, 73:82-6 (invited commentary). (*)
762. *Manrai AK, Ioannidis JP, Kohane IS.* Clinical genomics: from pathogenicity claims to quantitative risk estimates. **JAMA** 2016, 315:1233-4 (viewpoint article). (*)
763. *Moher D, Goodman SN, Ioannidis JP.* Academic criteria for appointment, promotion and rewards in medical research: where's the evidence? **European Journal of Clinical Investigation** 2016, 46:383-5 (commentary).
764. *Bruns SB, Ioannidis JP.* p-curve and p-hacking in observational research. **PLoS One** 2016, 11(2):e0149144.
765. *Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP.* Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. **BMJ** 2016, 352:i493.
766. *Clutter DS, Fessel WJ, Rhee SY, Hurley LB, Klein DB, Ioannidis JP, Silverberg MJ, Shafer RW.* Response to therapy in antiretroviral therapy-naïve patients with isolated nonnucleoside reverse-transcriptase inhibitor-associated transmitted drug resistance. **Journal of Acquired Immune Deficiency Syndromes** 2016, 72: 171-6.
767. *Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, Moher D, Vohra S; PRISMA harms group.* PRISMA harms checklist: improving harms reporting in systematic reviews. **BMJ** 2016, 352:i157. (*)
768. *Manrai AK, Patel CJ, Gehlenborg N, Tatonetti NP, Ioannidis JP, Kohane IS.* Methods to enhance the reproducibility of precision medicine. **Pacific Symposia in Biocomputing** 2016, 21:180-2 (symposium/editorial). (*)

769. Bellou V, Belbasis L, Tzoulaki I, Evangelou E, Ioannidis JP. Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses. **Parkinsonism and Related Disorders** 2016, 23:1-9.
770. Chavalarias D, Wallach J, Li A, Ioannidis JPA. Evolution of reporting of p-values in the biomedical literature, 1990-2015. **JAMA** 2016, 315:1141-8. Accompanied by editorial in the same issue.
771. Ioannidis JPA. The mass production of redundant, misleading and conflicted systematic reviews and meta-analyses. **Milbank Quarterly** 2016, 94:485-514. Accompanied by editorial in the same issue.
772. Fleming PS, Koletsi D, Ioannidis JPA, Pandis N. High quality of the evidence for medical and other health-related interventions is uncommon in Cochrane systematic reviews. **Journal of Clinical Epidemiology** 2016, 78:34-42.
773. Ioannidis JP. Fit-for-purpose inferential methods: abandoning/changing P-values versus abandoning/changing research: a discussion of the ASA statement on statistical significance and P-values. **The American Statistician** 2016, 2:129-133, Commentary (one of 23 invited commentaries) in supplement:
<http://amstat.tandfonline.com/doi/suppl/10.1080/00031305.2016.1154108?scroll=top>. (*)
774. Ioannidis JP. Biases in obesity research: identify, correct, endorse, or abandon effort? **Obesity** 2016, 24:767-8 (invited editorial). (*)
775. Goldstein BA, Navar AM, Pencina MJ, Ioannidis JP. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. **Journal of the American Medical Informatics Association** 2017, 24:198-208.
776. Ioannidis JP. We need more randomized trials in nutrition-preferably large, long-term, and with negative results. **American Journal of Clinical Nutrition** 2016, 103:1385-6 (invited editorial). (*)
777. Thombs BD, Benedetti A, Kloda LA, Levis B, Azar M, Riehm KE, Saadat N, Cuijpers P, Gilbody S, Ioannidis JP, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Loiselle CG, Henry M, Ismail Z, Mitchell N, Tonelli M. Diagnostic accuracy of the Depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) for detecting major depression: protocol for a systematic review and individual patient data meta-analyses. **BMJ Open** 2016, 6(4):e011913.
778. Contopoulos-Ioannidis D, Tseretopoulou X, Ancker M, Walterspiel JN, Panagiotou OA, Maldonado Y, Ioannidis J. Comparative rates of harms in randomized trials from more-developed versus less-developed countries may be different. **Journal of Clinical Epidemiology** 2016, 78:10-21.
779. Ippolito G, Lanini S, Brouqui P, Di Caro A, Vairo F, Fusco FM, Krishna S, Capobianchi MR, Kyobe-Bosa H, Puro V, Wölfel R, Avsic-Zupanc T, Ioannidis JP, Portella G, Kremsner P, Dar O, Bates M, Zumla A. Non-randomised Ebola trials-lessons for optimal outbreak research. **Lancet Infectious Diseases** 2016, 16(4):407-8. (*)
780. Lu Y, Ioannidis JP. Transparent communication of radiology research: reporting guidelines and beyond. **Academic Radiology** 2016, 23(5):529-30 (invited editorial). (*)
781. Kypreou KP, Stefanaki I, Antonopoulou K, Karagianni F, Ntritsos G, Zaras A, Nikolaou V, Kalfa I, Chasapi V, Polydorou D, Gogas H, Spyrou GM, Bertram L, Lill CM, Ioannidis JP, Antoniou C, Evangelou E, Stratigos AI. Prediction of melanoma risk in a Southern European population based on a weighted genetic risk score. **Journal of Investigative Dermatology** 2016, 136:690-5.
782. Ioannidis JP. Why most clinical research is not useful. **PLoS Medicine** 2016, 13:e1002049. (*)
783. Ioannidis JP, Klavans R, Boyack K. Multiple citation indicators and their composite across scientific disciplines. **PLoS Biology** 2016, 14:e1002501.
784. Flacco ME, Manzoli L, Boccia S, Puggina A, Rosso A, Marzuillo C, Scaioli G, Gualano MR, Ricciardi W, Villari P, Ioannidis JPA. Registered randomized trials comparing generics and brand-name drugs: a survey. **Mayo Clinic Proceedings** 2016, 91:1021-1034.

785. *Bourgeois F, Olson K, Tse A, Ioannidis JP, Mandl K.* Prevalence and characteristics of interventional trials conducted exclusively in elderly persons: a cross-sectional analysis of registered clinical trials. **PLoS ONE** 2016, 11:e0155948.
786. *Ebrahim S, Montoya L, el Din MK, Sohani ZN, Agarwal A, Bance S, Saquib J, Saquib N, Ioannidis JPA.* Randomized trials are frequently fragmented in multiple secondary publications. **Journal of Clinical Epidemiology** 2016, 79:130-139.
787. *IntHout J, Ioannidis JPA, Rovers MM, Goelman JJ.* A plea for routinely presenting prediction intervals in meta-analysis. **BMJ Open** 2016, 6:e010247.
788. *Ioannidis JP.* Stealth research and Theranos: reflections and update 1 year later. **JAMA** 2016, 316:389-90 (viewpoint article). (*)
789. *Patel CJ, Ji J, Sundquist J, Ioannidis JP, Sundquist K.* Systematic assessment of pharmaceutical prescriptions in association with cancer risk: a method to conduct a population-wide medication-wide longitudinal study. **Scientific Reports** 2016, 6:31308.
790. *Debray TP, Schuit E, Efthimiou O, Reitsma JB, Ioannidis JP, Salanti G, Moons KG; GetReal Workpackage.* An overview of methods for network meta-analysis using individual participant data: when do benefits arise? **Statistical Methods in Medical Research** 2018, 27:1351-1364.
791. *Joyner MJ, Paneth N, Ioannidis JP.* What happens when underperforming big ideas in research become entrenched? **JAMA** 2016, 316:1355-1356 (viewpoint article). (*)
792. *Kennedy AE, Khoury MJ, Ioannidis JP, Brotzman M, Miller A, Lane C, Lai GY, Rogers SD, Harvey C, Elena JW, Seminara D.* The Cancer Epidemiology Descriptive Cohort Database: A tool to support population-based interdisciplinary research. **Cancer Epidemiology Biomarkers Prevention** 2016, 25:1392-1401.
793. *Kaw R, Hernandez AV, Pasupuleti V, Deshpande A, Nagarajan V, Bueno H, Coleman CI, Ioannidis JP, Bhatt DL, Blackstone EH; Cardiovascular Meta-analyses Research Group.* Effect of diastolic dysfunction on postoperative outcomes after cardiovascular surgery: A systematic review and meta-analysis. **Journal of Thoracic and Cardiovascular Surgery** 2016, 152: 1142-1153.
794. *Goodman SN, Fanelli D, Ioannidis JP.* What does research reproducibility mean? **Science Translational Medicine** 2016, 8:341ps12.
795. *Sullivan PG, Wallach JD, Ioannidis JP.* Meta-Analysis comparing established risk prediction models (EuroSCORE II, STS Score and ACEF Score) for perioperative mortality during cardiac surgery. **American Journal of Cardiology** 2016, 118:1574-1582.
796. *Ioannidis JPA.* Making optimal use of and extending beyond polygenic additive liability models. **Human Heredity** 2015, 80:158-161 (invited commentary). (*)
797. *Ioannidis JP, Boyack K, Wouters PF.* Citation metrics: a primer on how (not) to normalize. **PLoS Biology** 2016, 14:e1002542 (invited commentary). (*)
798. *Bellou V, Bellasis L, Tzoulaki I, Middleton LF, Ioannidis JPA, Evangelou E.* Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. **Alzheimer's and Dementia** 2017, 13:406-18.
799. *Serghiou S, Kyriakopoulou A, Ioannidis JP.* Long noncoding RNAs as novel predictors of survival in human cancer: a systematic review and meta-analysis. **Molecular Cancer** 2016, 15:50.
800. *Parmar D, Stavropoulou C, Ioannidis JP.* Health outcomes during the 2008 financial crisis in Europe: systematic literature review. **BMJ** 2016, 354:i4588. Accompanied by editorial in the same issue.
801. *Saini V, Garcia-Armesto S, Klemperer D, Paris V, Elshaug AG, Brownlee S, Ioannidis JPA, Fisher ES.* Drivers of poor medical care. **Lancet** 2017, 390:178-190. Accompanied by editorial in same issue. (*)

802. Nagendran M, Pereira TV, Kiew G, Altman DG, Maruthappu M, Ioannidis JP, McCulloch P. Very large treatment effects in randomised trials as an empirical marker to indicate whether subsequent trials are necessary: meta-epidemiological assessment. **BMJ** 2016, 355:i5432.
803. Sweeney TE, Haynes WA, Vallania F, Ioannidis JP, Khatri P. Methods to increase reproducibility in differential gene expression via meta-analysis. **Nucleic Acids Research** 2017, 45:e1.
804. Munafò MR, Bishop DV, Button KS, Chambers C, Nosek B, Percie du Sert N, Simonsohn U, Wagenmakers E-J, Ware JJ, Ioannidis JPA. A manifesto for reproducible science. **Nature Human Behaviour** 2017, 1:0021. (*)
805. Stodden V, McNutt M, Bailey DH, Deelman E, Gil Y, Hanson B, Heroux MA, Ioannidis JP, Taufer M. Enhancing reproducibility for computational methods. **Science** 2016, 354:1240-1. (*)
806. Ioannidis JP. Hijacked evidence-based medicine: stay the course and throw the pirates overboard. **Journal of Clinical Epidemiology** 2017, 84:11-13 (invited commentary). (*)
807. Markozannes G, Tzoulaki I, Karli D, Evangelou E, Ntzani E, Gunter MJ, Norat T, Ioannidis JP, Tsilidis KK. Diet, body size, physical activity and risk of prostate cancer: an umbrella review of the evidence. **European Journal of Cancer** 2016, 69:61-69.
808. Theodoratou E, Tomofeeva M, Li X, Meng X, Ioannidis JP. Nature, nurture and cancer risks: genetic and nutritional contributions to cancer. **Annual Reviews of Nutrition** 2017, 37:293-320.
809. Laliotis I, Ioannidis JPA, Stavropoulou C. Total and cause-specific mortality rates before and during the Greek economic crisis: an interrupted time-series analysis. **Lancet Public Health** 2016, 1:e56-65.
810. Ioannidis JPA, Bossuyt P. Waste, leaks and failures in the biomarker pipeline. **Clinical Chemistry** 2017, 63:963-972 (invited review). (*)
811. Annesley T, Scott M, Bastian H, Fonseca V, Ioannidis JP, Keller MA, Polka J. Biomedical journals and preprint services: friends or foes? **Clinical Chemistry** 2017, 63:453-458 (series of invited comments). (*)
812. Goldfeder RL, Wall DP, Khoury M, Ioannidis JP, Ashley EA. Human genome sequencing at population scale: a primer on high throughput DNA sequencing and analysis. **American Journal of Epidemiology** 2017, 186:1000-9. (*)
813. Ioannidis JP. Meta-analyses in environmental and occupational health. **Occupational and Environmental Medicine** 2018, 75:443-45.
814. Wallach JD, Sullivan PG, Trepanowski JF, Steyerberg EW, Ioannidis JPA. Sex-based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. **BMJ** 2016, 355:i5826.
815. Wallach JD, Sullivan PG, Trepanowski JF, Sainani K, Steyerberg EW, Ioannidis JP. Evaluation of evidence of statistical support and corroboration of subgroup claims in randomized clinical trials. **JAMA Internal Medicine** 2017, 177:554-560.
816. Lipworth W, Kerridge I, Ioannidis JPA, Mason PH. Ethics and epistemology in big data research. **Journal of Bioethical Inquiry** 2017, 14:489-500. (*)
817. Schuit E, Ioannidis JPA. Network meta-analyses performed by contracting companies and commissioned by industry. **Systematic Reviews** 2016, 5:198.
818. Stanley TD, Doucouliagos H, Ioannidis JP. Finding the power to reduce publication bias. **Statistics in Medicine** 2017, 36:1580-1598.
819. Szucs D, Ioannidis JPA. Empirical assessment of published effect sizes and power in the recent cognitive neuroscience and psychology literature. **BioRxiv** doi: <http://dx.doi.org/10.1101/071530> and **PLoS Biology** 2017, 15:e2000797
820. Flegal K, Ioannidis JP. A meta-analysis but not a systematic review: example of the Global BMI

- Mortality Collaboration. **Journal of Clinical Epidemiology** 2017, 88:21-9. (*)
821. Ioannidis JP. Bursting the p-value bubble. **The Biologist** 2017, 64:7 (invited editorial). (*)
822. Ioannidis JP. Meta-analyses can be credible and useful: a new standard. **JAMA Psychiatry** 2017, 74:311-312 (invited viewpoint). (*)
823. Doufas AG, Panagiotou OA, Panousis P, Wong SS, Ioannidis JP. Insomnia from drug treatments: evidence from meta-analyses of randomized trials and concordance with prescribing information. **Mayo Clinic Proceedings** 2017, 92:72-87.
824. Macciocchi D, Lanini S, Vairo F, Zumla A, Figueiredo LT, Lauria FN, Strada G, Brouqui P, Puro V, Krishna S, Kremsner P, Scognamiglio P, Köhler C, Nicastrì E, Di Caro A, Cieri RM, Ioannidis JP, Kobinger G, Burattini MN, Ippolito G. Short-term economic impact of the Zika virus outbreak. **New Microbiologica** 2016, 39:287-289.
825. Bourgeois FT, Orenstein L, Balikur S, Mandl KD, Ioannidis JPA. Exclusion of elderly persons in randomized clinical trials of drugs for ischemic heart disease. **Journal of the American Geriatrics Society** 2017, 65:2354-61.
826. Stanton M, Robinson J, Kirkpatrick S, Farzinkhou S, Avery E, Rigdon J, Offringa L, Trepanowski T, Hauser M, Hartle J, Cherin R, King AC, Ioannidis JPA, Desai M, Gardner CD. DIETFITS Study (Diet Intervention Examining The Factors Interacting with Treatment Success) – Study design and methods. **Contemporary Clinical Trials** 2017, 53:151-61.
827. Kim SK, Roos TR, Roos AK, Kleimeyer JP, Ahmed MA, Goodlin GT, Fredericson M, Ioannidis JPA, Avins AL, Dragoo JL. Genome-wide association screens for Achilles tendon and ACL tears and tendinopathy. **PLoS ONE** 2017, 12:e0170422.
828. Ioannidis JPA, Caplan AL, Dal-Ré R. Outcome reporting bias in clinical trials: why monitoring matters. **BMJ** 2017, 356:j408.
829. Ioannidis JPA. Acknowledging and overcoming nonreproducibility in basic and preclinical research. **JAMA** 2017, 317:1019-1020 (viewpoint article). (*)
830. Ioannidis JPA. Does evidence-based hearsay determine the use of medical treatments? **Social Science and Medicine** 2017, 177:256-258 (invited commentary). (*)
831. Fanelli D, Costas R, Ioannidis JPA. A meta-assessment of bias in science. **PNAS** 2017, 114:3714-3719.
832. Ioannidis JPA. The reproducibility wars: successful, unsuccessful, uninterpretable, exact, conceptual, triangulated, contested replication. **Clinical Chemistry** 2017, 63:943-945 (invited commentary). (*)
833. Ioannidis JPA. Next-generation systematic reviews: prospective meta-analysis, individual-level data, networks and umbrella reviews. **British Journal of Sports Medicine** 2017, 51:1456-8 (invited commentary). (*)
834. Neumann K, Grittner U, Piper SK, Rex A, Florez-Vargas O, Karystianis G, Schneider A, Wellwood I, Siegerink B, Ioannidis JPA, Kimmelman J, Dirnagl U. Increasing efficiency of preclinical research by group sequential designs. **PLoS Biology** 15(3):e2001307.
835. Van Ravenzwaaij D, Ioannidis JPA. A simulation study of the strength of evidence in the recommendation of medications based on two trials with statistically significant results. **PLoS ONE** 2017, 12:e0173184.
836. Holubar M, Stavroulakis MC, Maldonado Y, Ioannidis JPA, Contopoulos-Ioannidis DG. Impact of vaccine herd-protection effects in cost-effectiveness analyses of childhood vaccinations: a quantitative comparative analysis. **PLoS ONE** 2017, 12:e0172414.
837. Roos A, Avins A, Ahmed M, Kleimeyer J, Roos T, Fredericson M, Ioannidis JP, Dragoo JL, Kim S. Two genetic loci associated with medial collateral ligament injury. **International Journal of Sports Medicine** 2017, 38:501-507.

838. Flegal KM, Ioannidis JPA. A meta-analysis of individual participant data constructed to align with prior expert views: comments on Bhupathiraju et al. **Journal of Clinical Epidemiology** 2017, 88:33-36 (commentary in response to commentary on item 821). (*)
839. Azad TD, Veeravagu A, Mittal V, Esparza R, Johnson E, Ioannidis JPA, Grant GA. Neurosurgical randomized controlled trials: Distance travelled. **Neurosurgery** 2018, 82:604-612.
840. Naci H, Wouters OJ, Gupta R, Ioannidis JPA. Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. **Milbank Quarterly** 2017, 95:261-290.
841. Kim S, Kleimeyer JP, Ahmed MA, Avins AL, Fredericson M, Dragoo JL, Ioannidis JPA. A genetic marker associated with shoulder dislocation. **International Journal of Sports Medicine** 2017, 38:508-514.
842. Ioannidis JPA. Defending biomedical science in an era of threatened funding. **JAMA** 2017, 317:2483-4 (viewpoint article). (*)
843. Gall T, Ioannidis JPA, Maniatis Z. The credibility crisis in research: Can economics tools help? **PLoS Biology** 2017, 15:e2001846. (*)
844. Levis B, Benedetti A, Levis AW, Ioannidis JPA, Shrier I, Cuijpers P, Gilbody S, Kloda LA, McMillan D, Patten SB, Steele RJ, Ziegelstein RC, Bombardier CH, de Lima Osório F, Fann JR, Gjerdingen D, Lamers F, Lotrakul M, Loureiro SR, Löwe B, Shaaban J, Stafford L, van Weert HCPM, Whooley MA, Williams LS, Wittkamp KA, Yeung AS, Thombs BD. Selective cutoff reporting in studies of diagnostic test accuracy: A comparison of conventional and individual-patient-data meta-analyses of the Patient Health Questionnaire-9 depression screening tool. **American Journal of Epidemiology** 2017, 185:954-964.
845. Ioannidis JP. Meta-analysis muddle: reviews of evidence are too often flawed. **New Scientist** 2017, April 13: <https://www.newscientist.com/article/2127954-meta-analysis-muddle-reviews-of-evidence-are-too-often-flawed> (invited commentary). (*)
846. Li X, Meng X, Timofeeva M, Tzoulaki I, Tsilidis KK, Ioannidis JPA, Campbell H, Theodoratou E. Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies. **BMJ** 2017, 357:j2376.
847. Ioannidis JPA. Inconsistent guideline recommendations for cardiovascular prevention, and the debate about zeroing in on and zeroing LDL-C levels with PCSK9 inhibitors. **JAMA** 2017, 318:419-420 (viewpoint article) (*).
848. Simoneau G, Levis B, Cuijpers P, Ioannidis JPA, Patten SB, Shrier I, Bombardier CH, de Lima Os'orio F, Fann JR, Gjerdingen D, Lamers F, Lotrakul M, Loewe B, Shaaban J, Stafford L, van Weert HCPM, Whooley MA, Wittkamp KA, Yeung AS, Thombs BD, Benedetti A. A comparison of bivariate, multivariate random-effects, and Poisson correlated gamma-frailty models to meta-analyze individual patient data of ordinal scale diagnostic tests. **Biometrical Journal** 2017, 59:1317-38.
849. Moubayed SP, Ioannidis JP, Saltychev M, Most SP. The 10-item standardized cosmesis and health nasal outcomes survey (SCHNOS) for functional and cosmetic rhinoplasty. **JAMA Facial Plastic Surgery** 2018, 20:37-42.
850. Naudet F, Schuit E, Ioannidis JPA. Overlapping network meta-analyses on the same topic: survey of published studies. **International Journal of Epidemiology** 2017, 46:1999-2008.
851. Hoffmann T, Oxman AD, Ioannidis JPA, Moher D, Lasserson TJ, Tovey DI, Stein K, Sutcliffe K, Ravaud P, Altman DG, Perera R, Glasziou P. Enhancing the useability of systematic reviews by improving the consideration and description of intervention. **BMJ** 2017, 358:j2998
852. Shenkin SD, Harrison JK, Wilkinson T, Dodds RM, Ioannidis JPA. Systematic reviews: guidance relevant for studies of age and ageing. **Age and Ageing** 2017, 46:722-8 (invited review). (*)

853. Kim SK, Ahmed MA, Avins AL, Ioannidis JPA. A genetic marker associated with De Quervain's tenosynovitis. **International Journal of Sports Medicine** 2017, 38:942-8.
854. Karczewski KJ, Tatonetti NP, Manrai AK, Patel CJ, Titus Brown C, Ioannidis JPA. Methods to ensure the reproducibility of biomedical research. **Pacific Symposia on Biocomputing** 2017, 22:117-119 (symposium/editorial). (*)
855. Stergiou G, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, Frick G, Friedman B, Graß T, Ichikawa T, Ioannidis JPA, Lacy P, McManus R, Murray A, Myers M, Palatini P, Parati G, Quinn D, Sarkis J, Shennan A, Usuda T, Wang J, Wu CO, O'Brien E. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/ European Society of Hypertension/ International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. **Hypertension** 2018, 71(3):368-374. (*0
856. Stergiou G, Alpert B, Mieke S, Asmar R, Atkins N, Eckert S, Frick G, Friedman B, Graß T, Ichikawa T, Ioannidis JPA, Lacy P, McManus R, Murray A, Myers M, Palatini P, Parati G, Quinn D, Sarkis J, Shennan A, Usuda T, Wang J, Wu CO, O'Brien E. A universal standard for the validation of blood pressure measuring devices: Association for the Advancement of Medical Instrumentation/ European Society of Hypertension/ International Organization for Standardization (AAMI/ESH/ISO) Collaboration Statement. **Journal of Hypertension** 2018, 36:472-478 (concurrent publication in both Hypertension and Journal of Hypertension). (*)
857. Ioannidis JPA. Greece: crisis, smoking, and tobacco conflicts in social media. **European Journal of Clinical Investigation** 2017 Dec;47(12). doi: 10.1111/eci.12841 (commentary). (*)
858. Kim SK, Kleimeyer JP, Ahmed MA, Avins AL, Fredericson M, Dragoo JL, Ioannidis JPA. Two genetic loci associated with ankle injury. **PLoS One** 2017, 12:e0185355.
859. Hemkens LG, Ewald H, Naudet F, Ladanie A, Shaw JG, Sajeev G, Ioannidis JPA. Interpretation of epidemiological studies very often lacked adequate consideration of confounding. **Journal of Clinical Epidemiology** 2018, 93:94-102.
860. Ioannidis JPA, Stuart ME, Brownlee S, Strite SA. How to survive the medical misinformation mess. **European Journal of Clinical Investigation** 2017, 47:795-802. (*)
861. Knowles JW, Zarafshar S, Pavlovic A, Goldstein BA, Tsai S, Li J, McConnell MV, Absher D, Ashley EA, Kiernan M, Ioannidis JPA, Assimes TL. Impact of a genetic risk score for coronary artery disease on reducing cardiovascular risk: A pilot randomized controlled study. **Frontiers in Cardiovascular Medicine** 2017, 4:53.
862. Radua J, Ramella-Cravaro V, Ioannidis JPA, Reichenberg A, Phipphothatsanee N, Amir T, Thoo HY, Oliver D, Davies C, Morgan C, McGuire P, Murray RM, Fusar-Poli P. What causes psychosis? Umbrella review of risk factors. **World Psychiatry** 2018, 17:49-66.
863. Szucs D, Ioannidis JPA. When null hypothesis significance testing is unsuitable for research: A reassessment. **Frontiers in Human Neuroscience** 2017, 11:390. (*)
864. Magni P, Bier DM, Pecorelli S, Agostoni C, Astrup A, Brighenti F, Cook R, Folco E, Fontana L, Gibson RA, Guerra R, Guyatt GH, Ioannidis JP, Jackson AS, Klurfeld DM, Makrides M, Mathioudakis B, Monaco A, Patel CJ, Racagni G, Schünemann HJ, Shamir R, Zmora N, Peracino A. Improving nutritional guidelines for sustainable health policies: current status and perspectives. **Advances in Nutrition** 2017, 8:532-545. (*)
865. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of first- and second-generation antidepressants in the acute treatment of major depressive disorder: a network meta-analysis. **Lancet** 2018, 391:1357-1366. Accompanied by editorial.

866. Tedesco D, Farid-Kapadia M, Offringa M, Bhutta ZA, Maldonado Y, Ioannidis JPA, Contopoulos-Ioannidis DG. Comparative evidence on harms in pediatric RCTs from less developed versus more developed countries is limited. **Journal of Clinical Epidemiology** 2018, 95:63-72.
867. Steyerberg EW, Uno H, Ioannidis JPA, van Calster B; collaborators, Ukaegbu C, Dhingra T, Syngal S, Kastrinos F. Poor performance of clinical prediction models: the harm of commonly applied methods. **Journal of Clinical Epidemiology** 2018, 98:133-43.
868. Rezende LFM, Sá TH, Markozannes G, Rey-López JP, Lee IM, Tsilidis KK, Ioannidis JPA, Eluf-Neto J. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. **British Journal of Sports Medicine** 2018, 52:826-33.
869. Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label treatments were not consistently better or worse than approved drug treatments in randomized trials. **Journal of Clinical Epidemiology** 2018, 94:35-45.
870. Benjamin DJ, Berger JO, Johannesson M, Nosek BA, Wagenmakers E-J, Berk R, Bollen KA, Brembs B, Brown L, Camerer C, Cesarini D, Chambers CD, Clyde M, Cook TD, De Boeck P, Dienes Z, Dreber A, Easwaran K, Efferson C, Fehr E, Fidler F, Field AP, Forster M, George EI, Gonzalez R, Goodman S, Green E, Green DP, Greenwald AG, Hadfield JD, Hedges LV, Held L, Hua Ho T, Hoijsink H, Hruschka DJ, Imai K, Imbens G, Ioannidis JPA, Jeon M, Jones JH, Kirchler M, Laibson D, List J, Little R, Lupia A, Machery E, Maxwell SE, McCarthy M, Moore DA, Morgan SL, Munafò M, Nakagawa S, Nyhan B, Parker TH, Pericchi L, Perugini M, Rouder J, Rousseau J, Savalei V, Schanbrodt FD, Sellke T, Sinclair B, Tingley D, Van Zandt T, Vazire S, - Watts DJ, Winship C, Wolpert RL, Xie Y, Young C, Zinman J, Johnson. VE. Redefine statistical significance. **Nature Human Behaviour** 2018, 2:6-10. Accompanied by commentary in the same issue.
871. Ioannidis JP, Trepanowski JF. Disclosures in nutrition research: why it is different. **JAMA** 2018, 319:547-548. (viewpoint article). (*)
872. Ioannidis JP. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. **JAMA** 2018, 319:115-116 (viewpoint article). (*)
873. Grimes DR, Bauch C, Ioannidis JP. Modelling science trustworthiness under publish or perish pressure. **Royal Society Open Science** 2018, 5:171511.
874. Parish A, Boyack K, Ioannidis JP. Dynamics of co-authorship and productivity across different fields of scientific research. **PLoS One** 2018, 13(1):e0189742.
875. Roos TR, Roos AK, Avins AL, Ahmed M, Kleim JP, Ioannidis JP, Dragoo J, Kim S. Genome-wide association study identifies a locus associated with rotator cuff injury. **PLoS ONE** 2017, 12:e0189317.
876. Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, Cultrera R, Villari P, Ricciardi W, Ioannidis JPA, Contopoulos-Ioannidis DG. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB): a systematic review and meta-analysis. **Lancet Infectious Diseases** 2018, 18:461-472.
877. Ioannidis JP, Khoury MJ. Evidence based medicine and big genomic data. **Human Molecular Genetics** 2018, 27(R1):R2-R7 (invited). (*)
878. Mc Cord KA, Al-Shahi Salman R, Treweek S, Gardner H, Stretch D, Whiteley W, Ioannidis J, Hemkens LG. Routinely collected data for randomized trials: promises, barriers, and implications. **Trials** 2018, 19:29 (*).
879. Ioannidis JP. Why replication has more scientific value than original discovery. **Behavioral and Brain Sciences** 2018, 41:e137 (invited commentary). (*)
880. Ioannidis JP. Randomized controlled trials: often flawed, mostly useless, clearly indispensable: A Commentary on Deaton and Cartwright. **Social Science and Medicine** 2018, 210:53-56 (invited

- commentary). (*)
881. Moller MH, Ioannidis JP, Darmon M. Are systematic reviews and meta-analyses still useful research? Not so sure. **Intensive Care Medicine** 2018, 44:518-520 (invited commentary). (*)
 882. Rattray NJW, Deziel NC, Wallach WD, Khan SA, Vasiliou V, Ioannidis JPA, Johnson CH. Beyond genomics: Understanding exposotypes through metabolomics. **Human Genomics** 2018, 12:4 (invited review). (*)
 883. David SP, Naudet F, Laude J, Radua J, Fusar-Poli P, Chu I, Stefanick ML, Ioannidis JPA. Potential reporting bias in neuroimaging studies of sex differences. **Scientific Reports** 2018, 8:6082.
 884. Ioannidis JPA, Kim BYS, Trounson A. How to design preclinical studies in nanomedicine and cell therapy to maximize prospects for clinical translation. **Nature Biomedical Engineering** 2018, 2:797-809 (invited perspective article, accompanied by editorial).
 885. Fanelli D, Ioannidis JP, Goodman SN. Improving the integrity of published science: an expanded taxonomy of retractions and corrections. **European Journal of Clinical Investigation** 2018, 48:4 (perspective article).
 886. Serghiou S, Ioannidis JP. Altmetric scores, citation and publication of studies posted as preprints. **JAMA** 2018, 319:402-4. Accompanied by editorial in the same issue.
 887. Naudet F, Sakarovitch C, Janiaud P, Cristea I, Fanelli D, Moher D, Ioannidis JPA. Data sharing and re-analysis for randomised controlled trials in leading biomedical journals with a full data-sharing policy: a survey of studies published in The BMJ and PLOS Medicine. **BMJ** 2018, 360:k400.
 888. Djulbegovic B, Glaziou P, Klocksieben FA, Reljic T, Vandenberg M, Mhaskar R, Ioannidis JPA, Chalmers I. Larger effect sizes in non-randomized studies are associated with higher rates of EMA licensing approval. **Journal of Clinical Epidemiology** 2018, 98:24-32.
 889. Patel CJ, Bhattacharya J, Ioannidis JPA, Bendavid E. Systematic identification of correlates of HIV infection: an X-wide association study. **AIDS** 2018, 32:933-943.
 890. Gardner CD, Trepanowski JF, Del Gobbo LC, Hauser ME, Rigdon J, Ioannidis JP, Desai M, King AC. Effect of low-fat vs low-carbohydrate diet on 12-month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. **JAMA** 2018, 319:667-679.
 891. Trepanowski JF, Ioannidis JP. Limiting dependence on non-randomized studies and improving randomized trials in human nutrition research: Why and how. **Advances in Nutrition** 2018, 9:367-377. (*)
 892. Ioannidis JPA. What have we (not) learnt after millions of papers with P-values. **The American Statistician** (in press). (*)
 893. Flegal K, Ioannidis JP. The obesity paradox: a misleading term that should be abandoned. **Obesity** 2018, 26:629-630 (commentary). (*)
 894. Ioannidis JP, Bhattacharya S, Evers JLH, Van der Veen F, Somigliana E, Barrat C, Bontempi G, Crosignani PG on behalf of the ESHRE Capri Workshop Group. Protect us from poor-quality medical research. **Human Reproduction** 2018, 33:770-776. (*)
 895. Cristea I, Ioannidis JP. Improving disclosure of financial conflicts of interest for research on psychosocial interventions. **JAMA Psychiatry** 2018, 75:541-2 (viewpoint article). (*)
 896. Ioannidis JPA. Meta-research: why research on research matters. **PLoS Biology** 2018, 16:e2005468 (invited). (*)
 897. Ioannidis JPA. The proposal to lower P value thresholds to 0.005. **JAMA** 2018, 319:1429-1430 (viewpoint article). (*)
 898. Davies C, Cipriani A, Ioannidis JPA, Radua J, Stahl D, Provenzani U, McGuire P, Fusar-Poli P. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis.

World Psychiatry 2018, 17:196-209.

899. Manrai R, Patel C, Ioannidis JP. In the era of precision medicine and big data who is normal. **JAMA** 2018, 319:1981-2 (viewpoint article).
900. Moher D, Naudet F, Cristea IA, Miedema F, Ioannidis JPA, Goodman SN. Assessing scientists for hiring, promotion, and tenure. **PLoS Biology** 2018, 29:e2004089.
901. Kim SK, Ioannidis JPA, Ahmed MA, Avins AL, Kleimyer JP, Fredericson M, Dragoo JL. Two genetic variants associated with plantar fascial disorders. **International Journal of Sports Medicine** 2018, 39:314-321.
902. Dal-Re R, Janiaud P, Ioannidis JP. Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic? **BMC Medicine** 2018, 16:49.
903. Ioannidis JPA. Therapy and prevention for mental health: what if mental diseases are mostly not brain disorders? **Behavioral and Brain Sciences** 2019, 42:e13 (commentary). (*)
904. Ioannidis JPA. All science should inform policy and regulation. **PLoS Medicine** 2018, 15:e1002576 (perspective article). (*)
905. Levis B, Benedetti A, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Chiovitti MJ, Sanchez TA, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Steele RJ, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Beraldi A, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Chowdhary N, Clover K, Conwell Y, de Man-van Ginkel JM, Delgadillo J, Fann JR, Fischer FH, Fischler B, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Hambridge J, Harrison PA, Hegerl U, Hides L, Hobfoll SE, Hudson M, Hyphantis T, Inagaki M, Ismail K, Jetté N, Khamseh ME, Kiely KM, Lamers F, Liu SI, Lotrakul M, Loureiro SR, Löwe B, Marsh L, McGuire A, Mohd Sidik S, Munhoz TN, Muramatsu K, Osório FL, Patel V, Pence BW, Persoons P, Picardi A, Rooney AG, Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford L, Sung S, Tan PLL, Turner A, van der Feltz-Cornelis CM, van Weert HC, Vöhringer PA, White J, Whooley MA, Winkley K, Yamada M, Zhang Y, Thoms BD. Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. **British Journal of Psychiatry** 2018, 212:377-385.
906. Cipriani A, Salanti G, Furukawa TA, Egger M, Leucht S, Rube HG, Turner EH, Atkinson LZ, Chaimani A, Higgins JPT, Ogawa Y, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Antidepressants might work for people with major depression: where do we go from here? **Lancet Psychiatry** 2018, 5:461-3 (invited editorial). (*)
907. Cristea IA, Ioannidis JPA. P values in display items are ubiquitous and almost invariably significant: A survey of top science journals. **PLoS ONE** 2018, 13:e0197440.
908. O'Sullivan JW, Muntinga T, Grigg S, Ioannidis JPA. Prevalence and outcomes of incidental imaging findings: umbrella review. **BMJ** 2018, 361:k2387.
909. Solmi M, Correll CU, Carvalho AF, Ioannidis JPA. The role of meta-analyses and umbrella reviews in assessment of harms of psychotropic medications: beyond qualitative synthesis. **Epidemiology and Psychiatric Sciences** 2018, 27:537-542 (invited). (*)
910. Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JP, McGoldrick E. Corticosteroids for preventing neonatal respiratory morbidity after elective caesarean section at term. **Cochrane Database of Systematic Reviews** 2018, 8:CD006614 (systematic review, updated version of item 406).
911. Hardwicke TE, Ioannidis JPA. Populating the Data Ark: An attempt to retrieve, preserve, and liberate data from the most highly-cited psychology and psychiatry articles. **PLoS One** 2018, 13:e0201856.
912. Shokraneh F, Adams CE, Clarke M, Amato L, Bastian H, Beller E, Brassey J, Buchbinder R, Davoli

- M, Del Mar C, Glasziou P, Gluud C, Heneghan C, Hoffmann T, Ioannidis JP, Jayaram M, Kwong J, Moher D, Ota E, Sheriff RS, Vale L, Goldacre B.* Why Cochrane should prioritise sharing data. **BMJ** 2018, 362:k3229 (letter). (*)
913. *Janiaud P, Dal-Ré R, Ioannidis JPA.* Assessment of pragmatism in recently published randomized clinical trials. **JAMA Internal Medicine** 2018, 178:1278-1280.
914. *Machado MO, Veronese N, Sanches M, Stubbs B, Koyanagi A, Thompson T, Tzoulaki I, Solmi M, Vancampfort D, Schuch FB, Maes M, Fava GA, Ioannidis JPA, Carvalho AF.* The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. **BMC Medicine** 2018, 16:112.
915. *Solmi M, Köhler CA, Stubbs B, Koyanagi A, Bortolato B, Monaco F, Vancampfort D, Machado MO, Maes M, Tzoulaki I, Firth J, Ioannidis JPA, Carvalho AF.* Environmental risk factors and nonpharmacological and nonsurgical interventions for obesity: An umbrella review of meta-analyses of cohort studies and randomized controlled trials. **European Journal of Clinical Investigation** 2018, 48:e12982.
916. *Köhler CA, Evangelou E, Stubbs B, Solmi M, Veronese N, Bellbasis L, Bortolato B, Melo MCA, Coelho CA, Fernandes BS, Olfson M, Ioannidis JPA, Carvalho AF.* Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies. **Journal of Psychiatric Research** 2018, 103:189-207.
917. *Janiaud P, Cristea IA, Ioannidis JPA.* Industry-funded versus non-profit-funded critical care research: a meta-epidemiological overview. **Intensive Care Medicine** 2018, 44:1613-1627. Accompanied by editorial in the same issue.
918. *Guloksuz S, Rutten BPF, Pries LK, Ten Have M, de Graaf R, van Dorsselaer S, Klingenberg B, van Os J, Ioannidis JPA; European Network of National Schizophrenia Networks Studying Gene-Environment Interactions Work Package 6 (EU-GEI WP6) Group.* The complexities of evaluating the exposome in psychiatry: A data-driven illustration of challenges and some propositions for amendments. **Schizophrenia Bulletin** 2018, 44:1175-1179 (invited commentary).
919. *Ioannidis JPA, Klavans R, Boyack KW.* Thousands of scientists publish a paper every five days. **Nature** 2018, 561:167-169. (comment/analysis).
920. *Ioannidis JP.* Massive citations to misleading methods and research tools: Matthew effect, quotation error and citation copying. **European Journal of Epidemiology** 2018, 33:1021-1023 (invited commentary). (*)
921. *Ioannidis JP.* The challenge of reforming nutritional epidemiologic research. **JAMA** 2018, 320:969-70 (viewpoint article). (*)
922. *Ladanie A, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Martin-Liberal J, Schmidt T, Ewald H, Ioannidis JPA, Bucher H, Kasenda B, Hemkens LG.* The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs. **Trials** 2018, 19:505.
923. *Schuit E, Li A, Ioannidis JPA.* How often can meta-analyses of individual-level data individualize treatment? A meta-epidemiologic study. **International Journal of Epidemiology** 2019, 48:596-608.
924. *Ioannidis JP.* Rethink funding. **Scientific American** 2018, 319:52-55 (invited). (*)
925. *Ioannidis JP.* Reproducible pharmacokinetics. **Journal of Pharmacokinetics and Pharmacodynamics** 2019, 46:111-116. (*)
926. *Hardwicke TA, Ioannidis JP.* Mapping the universe of Registered Reports. **Nature Human Behaviour** 2018, 2:793-796. Accompanied by commentary in the same issue.
927. *He Y, Li X, Gasevic D, Brunt E, McLachlan F, Millenson M, Timofeeva M, Ioannidis JPA, Campbell H, Theodoratou E.* Statins and multiple non-cardiovascular outcomes: umbrella review of meta-

- analyses of observational studies and randomized controlled trials. **Annals of Internal Medicine** 2018, 169:543-553.
928. Maggio LA, Thomas A, Chen HC, Ioannidis JPA, Kanter SL, Norton C, Tannery NH, Artino AR Jr. Examining the readiness of best evidence in medical education guides for integration into educational practice: A meta-synthesis. **Perspectives on Medical Education** 2018, 7:292-301.
929. Ishihara M, Harel D, Levis B, Levis AW, Riehm KE, Saadat N, Azar M, Rice DB, Sanchez TA, Chiovitti MJ, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Arroll B, Bombardier CH, Butterworth P, Carter G, Clover K, Conwell Y, Goodyear-Smith F, Greeno CG, Hambridge J, Harrison PA, Hudson M, Jetté N, Kiely KM, McGuire A, Pence BW, Rooney AG, Sidebottom A, Simning A, Turner A, White J, Whooley MA, Winkley K, Benedetti A, Thombs BD. Shortening self-report mental health symptom measures through optimal test assembly methods: Development and validation of the Patient Health Questionnaire-Depression-4. **Depression and Anxiety** 2019, 36:82-92.
930. Djulbegovic B, Ioannidis JP. Precision medicine for individual patients should use population group averages and larger, not smaller, groups. **European Journal of Clinical Investigation** 2019, 49:e13031 (editorial). (*)
931. Ioannidis JPA. Professors should abstain from authorship of guidelines and disease definitions. **Circulation: Cardiovascular Quality and Outcomes** 2018, 11:e004889 (accompanied by commentary in the same issue).
932. Ioannidis JPA. Guidelines do not entangle practitioners with unavoidable conflicts as authors and when there is no evidence, just say so. **Circulation: Cardiovascular Quality and Outcomes** (rejoinder commentary in response to commentary on item 931). 2018, 11:e005205. (*)
933. Ioannidis JPA, Tan YJ, Blum MR. Limitations and misinterpretations of E-values for sensitivity analyses of observational studies. **Annals of Internal Medicine** 2019, 170:108-111.
934. Wallach JD, Boyack KW, Ioannidis JP. Reproducible research practices, transparency, and open access data in the biomedical literature, 2015–2017. **PLoS Biology** 2018, 16:e2006930.
935. Siontis K, Ioannidis JP. Replication, duplication and waste in a quarter million of systematic reviews and meta-Analyses. **Circulation: Cardiovascular Quality and Outcomes** 2018, 11:e005212 (invited commentary). (*)
936. Desai K, Carroll I, Asch S, Hernandez-Boussard T, Ioannidis JPA. Extremely large outlier treatment effects may be a footprint of bias in trials from less developed countries: randomized trials of gabapentinoids. **Journal of Clinical Epidemiology** 2019, 106:80-87.
937. Naci H, Salcher-Konrad M, Dias S, Blum MR, Anove S, Nunan D, Ioannidis JPA. How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 RCTs assessing exercise and medication effects on systolic blood pressure. **British Journal of Sports Medicine** 2019, 53:859-869.
938. Stergiou GS, Palatini P, Asmar R, Ioannidis JP, Kollias A, Lacy P, McManus RJ, Myers MG, Parati G, Shennan A, Wang J, O'Brien E; European Society of Hypertension Working Group on Blood Pressure Monitoring. Recommendations and Practical Guidance for performing and reporting validation studies according to the Universal Standard for the validation of blood pressure measuring devices by the Association for the Advancement of Medical Instrumentation/European Society of Hypertension/International Organization for Standardization (AAMI/ESH/ISO). **Journal of Hypertension** 2019, 37:459-466. (*)
939. Cristea IA, Cahan EM, Ioannidis JPA. Stealth research: lack of peer-reviewed evidence from healthcare unicorns. **European Journal of Clinical Investigation** 2019, 49:e13072.
940. Amann RI, Baichoo S, Blencowe BJ, Bork P, Borodovsky M, Brooksbank C, Chain PSG, Colwell

- RR, Daffonchio DG, Danchin A, de Lorenzo V, Dorrestein PC, Finn RD, Fraser CM, Gilbert JA, Hallam SJ, Hugenholtz P, Ioannidis JPA (corresponding author), Jansson JK, Kim JF, Klenk HP, Klotz MG, Knight R, Konstantinidis KT, Kyrpides NC, Mason CE, McHardy AC, Meyer F, Ouzounis CA, Patrinos AAN, Podar M, Pollard KS, Ravel J, Muñoz AR, Roberts RJ, Rosselló-Móra R, Sansone SA, Schloss PD, Schriml LM, Setubal JC, Sorek R, Stevens RL, Tiedje JM, Turjanski A, Tyson GW, Ussery DW, Weinstock GM, White O, Whitman WB, Xenarios I. Toward unrestricted use of public genomic data. **Science** 2019, 363:350-352. (Policy Forum article). (*)
941. Flegal KM, Ioannidis JPA, Doehner W. Flawed methods and inappropriate conclusions for health policy on overweight and obesity: the Global BMI Mortality Collaboration meta-analysis. **Journal of Cachexia, Sarcopenia and Muscle**. 2019, 10:9-13. (*)
942. Oren O, Kebebew E, Ioannidis JPA. Curbing unnecessary and wasted diagnostic imaging. **JAMA** 2019, 321:245-246 (viewpoint article). (*)
943. Janiaud P, Serghiou S, Ioannidis JPA. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. **Cancer Treatment Reviews** 2019, 73:20-30.
944. Adami HO, Kalager M, Valdimarsdottir U, Bretthauer M, Ioannidis JPA. Time to abandon early detection cancer screening. **European Journal of Clinical Investigation** 2019, 49:e13062 (commentary). (*)
945. Marton RM, Ioannidis JPA. A comprehensive analysis of protocols for deriving dopaminergic neurons from human pluripotent stem cells. **Stem Cells Translational Medicine** 2019, 8:366-374.
946. Yang T, Li X, Montazeri Z, Little J, Farrington SM, Ioannidis JPA, Dunlop MG, Campbell H, Timofeeva M, Theodoratou E. Gene-environment interactions and colorectal cancer risk: An umbrella review of systematic reviews and meta-analyses of observational studies. **International Journal of Cancer** 2019, 145:2315-2329.
947. Ioannidis JPA. Cochrane crisis: Secrecy, intolerance and evidence-based values. **European Journal of Clinical Investigation** 2019, 49:e13058. (*)
948. Benedetti A, Wu Y, Levis B, Wilchesky M, Boruff J, Ioannidis JPA, Patten SB, Cuijpers P, Shrier I, Gilbody S, Ismail Z, McMillan D, Mitchell N, Ziegelstein RC, Thombs BD. Diagnostic accuracy of the Geriatric Depression Scale-30, Geriatric Depression Scale-15, Geriatric Depression Scale-5 and Geriatric Depression Scale-4 for detecting major depression: protocol for a systematic review and individual participant data meta-analysis. **BMJ Open** 2018, 8:e026598.
949. Ewald H, Speich B, Ladanie A, Bucher HC, Ioannidis JP, Hemkens LG. Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: meta-epidemiological analysis. **Journal of Clinical Epidemiology** 2019, 107:12-26.
950. Agarwal A, Ioannidis JPA. PREDIMED trial of Mediterranean diet: retracted, republished, still trusted? **BMJ** 2019, 364:l341.
951. Chalkias A, Ioannidis JPA. Interventions to improve cardiopulmonary resuscitation: a review of meta-analyses and future agenda. **Critical Care** 2019, 23:210 (editorial). (*)
952. Fullana MA, Tortella-Feliu M, Fernández de la Cruz L, Chamorro J, Pérez-Vigil A, Ioannidis JPA, Solanes A, Guardiola M, Almodóvar C, Miranda-Olivos R, Ramella-Cravaro V, Vilar A, Reichenberg A, Mataix-Cols D, Vieta E, Fusar-Poli P, Fatjó-Vilas M, Radua J. Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses. **Psychological Medicine** 2020, 50:1300-1315.
953. Rasooly D, Ioannidis JPA, Khoury MJ, Patel CJ. Family history-wide association study ("FamWAS") to identify clinical and environmental risk factors for common chronic diseases. **American Journal of Epidemiology** 2019, 188:1563-1568.

954. Ladanie A, Speich B, Briel M, Sclafani F, Bucher HC, Agarwal A, Ioannidis JPA, Pereira TV, Kasenda B, Hemkens LG. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies. **Journal of Clinical Epidemiology** 2019, 114:49-59.
955. O'Brien E, Stergiou G, Palatini P, Asmar R, Ioannidis JP, Kollias A, Lacy P, McManus RJ, Myers MG, Shennan A, Wang J, Parati G; *European Society of Hypertension Working Group on Blood Pressure Monitoring*. Validation protocols for blood pressure measuring devices: the impact of the European Society of Hypertension International Protocol and the development of a Universal Standard. **Blood Pressure Monitoring** 2019, 24:163-166. (*)
956. Tatsioni A, Karassa FB, Goodman SN, Zarin DA, Fanelli D, Ioannidis JPA. Lost evidence from registered large long-unpublished randomized controlled trials: a survey. **Annals of Internal Medicine** 2019, 171:300-301.
957. Ioannidis JPA. Lethal news: The dexterous infiltration of news media by the tobacco industry agenda. **European Journal of Clinical Investigation** 2019, 47:e13125. (*)
958. Ioannidis JPA. Reproducible pharmacokinetics. **Journal of Pharmacokinetics and Pharmacodynamics** 2019, 46:111-116. (*)
959. Schulz J, Takousis P, Wohlers I, Itua IOG, Dobricic V, Rücker G, Binder H, Middleton L, Ioannidis JPA, Perneckzy R, Bertram L, Lill CM. Meta-analyses identify differentially expressed micrnas in Parkinson's disease. **Annals of Neurology** 2019, 85:835-851.
960. Ioannidis JPA. The importance of predefined rules and prespecified statistical analyses: do not abandon significance. **JAMA** 2019, 321:2067-2068 (viewpoint article). (*)
961. van Ravenzwaaij D, Monden R, Tendeiro JN, Ioannidis JPA. Bayes factors for superiority, non-inferiority, and equivalence designs. **BMC Medical Research Methodology** 2019, 19:71.
962. Ioannidis JPA. Retiring statistical significance would give bias a free pass. **Nature** 2019, 567:461 (letter). (*)
963. Manrai AK, Ioannidis JPA, Patel CJ. Signals Among signals: prioritizing nongenetic associations in massive data sets. **American Journal of Epidemiology** 2019, 188(5):846-850.
964. Vlisides PE, Ioannidis JPA, Avidan MS. Hypnotic depth and postoperative death: a Bayesian perspective and an Independent Discussion of a clinical trial. **British Journal of Anaesthesia** 2019, 122:421-427 (commentary). (*)
965. Avidan MS, Ioannidis JPA, Mashour GA. Independent discussion sections for improving inferential reproducibility in published research. **British Journal of Anaesthesia** 2019, 122:413-420.
966. Stavropoulou C, Somai M, Ioannidis JPA. Most UK scientists who publish extremely highly-cited papers do not secure funding from major public and charity funders: A descriptive analysis. **PLoS One** 2019, 14:e0211460.
967. Bzdok D, Ioannidis JPA. Exploration, inference, and prediction in neuroscience and biomedicine. **Trends in Neuroscience** 2019, 42:251-262.
968. Fiedorowicz JG, Ioannidis JPA. Are all mental disorders related to all other medical diseases and vice versa? **Journal of Psychosomatic Research** 2019, 118:71-72 (commentary). (*)
969. Iliopoulos I, Ananiadou S, Danchin A, Ioannidis JP, Katsikis PD, Ouzounis CA, Promponas VJ. Hypothesis, analysis and synthesis, it's all Greek to me. **Elife** 2019 Feb 20;8. pii: e43514. doi: 10.7554/eLife.43514.
970. Ioannidis JPA. Unreformed nutritional epidemiology: a lamp post in the dark forest. **European Journal of Epidemiology** 2019, 34:327-331 (invited commentary). (*)
971. Ioannidis JPA. Medical science and practice: does anyone want to fix them? **Foresight** 2019, 53:28-30 (invited commentary). (*)

972. *Hardwicke TA, Serghiou S, Janiaud P, Danchev V, Crüwell S, Goodman SN, Ioannidis JPA.* Calibrating the scientific ecosystem through meta-research. **Annual Review of Statistics and its Application** 2020, 7:11-37. (*)
973. *Ioannidis JPA, Thoms TD.* A user's guide to inflated and manipulated impact factors. **European Journal of Clinical Investigation** 2019, 49:e13151. (*)
974. *Dal-Ré R, Avendaño-Solà C, de Boer A, Jamesd SK, Rosendaal FR, Stephens R, Ioannidis JPA.* A limited number of medicines pragmatic trials have potential for waived informed consent following the 2016 CIOMS ethical guidelines. **Journal of Clinical Epidemiology** 2019, 114:60-71.
975. *Albajes-Eizagire A, Solanes A, Fullana MA, Ioannidis JPA, Fusar-Poli P, Torrent C, Solé B, Bonnín CM, Vieta E, Mataix-Cols D, Radua J.* Meta-analysis of voxel-based neuroimaging studies using Seed-based d Mapping with Permutation of Subject Images (SDM-PSI). **Journal of Visualized Experiments** 2019, Nov 27;(153).
976. *Lanini S, Ioannidis JPA, Vairo F, Pletschette M, Portella G, Di Bari V, Mammone A, Pisapia R, Merler S, Nguhuni B, Langer M, Di Caro A, Edwards SJL, Petrosillo N, Zumla A, Ippolito G.* Non-inferiority versus superiority for new antibiotics in an era of high antimicrobial resistance - The case for post-marketing adaptive randomized controlled trials. **Lancet Infectious Diseases** 19:e444-e451
977. *Rhee S-Y, Grant PM, Tzou PL, Barrow G, Harrigan PR, Ioannidis JPA, Shafer RW.* A systematic review of the genetic mechanisms of dolutegravir resistance. **Journal of Antimicrobial Chemotherapy** 2019, 74:3135-3149.
978. *Hardwicke TE, Ioannidis JPA.* Petitions in scientific argumentation: dissecting the request to retire statistical significance. **European Journal of Clinical Investigation** 2019, 49:e13162.
979. *Wu Y, Levis B, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Bombardier CH, Butterworth P, Carter G, Chagas MH, Chan JCN, Cholera R, Conwell Y, de Man-van Ginkel JM, Fann JR, Fischer FH, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Harrison PA, Härter M, Hegerl U, Hides L, Hobfoll SE, Hudson M, Hyphantis T, Inagaki MD, Jetté N, Khamseh ME, Kiely KM, Kwan Y, Lamers F, Liu SI, Lotrakul M, Loureiro SR, Löwe B, McGuire A, Mohd-Sidik S, Munhoz TN, Muramatsu K, Osório FL, Patel V, Pence BW, Persoons P, Picardi A, Reuter K, Rooney AG, Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford MD, Sung S, Tan PLL, Turner A, van Weert HC, White J, Whooley MA, Winkley K, Yamada M, Benedetti A, Thoms BD.* Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. **Psychological Medicine** 2020, 50:1368-80.
980. *Ioannidis JPA.* Publishing research with P-values: Prescribe more stringent statistical significance or proscribe statistical significance? **European Heart Journal** 2019, 40:2553-2554 (viewpoint article).
981. *Ioannidis JPA.* Publishing research without P-values. **European Heart Journal** 2019, 40:2555-2556 (viewpoint article).
982. *Ioannidis JP, Berkwits M, Flanagan A, Godlee F, Bloom T.* Call for Research for the Ninth International Congress on Peer Review and Scientific Publication in 2021. **BMJ** 2019, 366:l5475. (*)
983. *Ioannidis JP, Berkwits M, Flanagan A, Godlee F, Bloom T.* Call for Research for the Ninth International Congress on Peer Review and Scientific Publication in 2021. **JAMA** (in press). (*)
984. *Leichsenring F, Steinert C, Ioannidis JPA.* Towards a paradigm shift in treatment and research of mental disorders. **Psychological Medicine** 49:2111-2117. (*)
985. *Tan YJ, Crowley YJ, Ioannidis JPA.* An empirical assessment of research practices across 163 clinical trials of tumor-bearing companion dogs. **Scientific Reports** 2019, 9:11877.

986. *Ioannidis JP, Baas J, Klavans R, Boyack K*. A standardized citation metrics author database annotated for scientific field. **PLoS Biology** 2019, 17(8):e3000384.
987. *Ioannidis JP*. Air pollution as cause of mental health disease: appraisal of the evidence. **PLoS Biology** 2019, 17:e3000370. (*)
988. *Kent DM, Paulus JK, van Klaveren D, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW*. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement. **Annals of Internal Medicine** (in press).
989. *Kent DM, van Klaveren D, Paulus JK, D'Agostino R, Goodman S, Hayward R, Ioannidis JPA, Patrick-Lake B, Morton S, Pencina M, Raman G, Ross JS, Selker HP, Varadhan R, Vickers A, Wong JB, Steyerberg EW*. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration. **Annals of Internal Medicine** 2019 Nov 12. doi: 10.7326/M18-3668. [Epub ahead of print].
990. *Munkholm K, Faurholt-Jepsen M, Ioannidis JPA, Hemkens LG*. Consideration of confounding was suboptimal in the reporting of observational studies in psychiatry: a meta-epidemiological study. **Journal of Clinical Epidemiology** 2020, 119:75-84.
991. *Aczel B, Szaszi B, Sarafoglou A, Kekecs Z, Kucharský Š, Benjamin D, Chambers CD, Fisher A, Gelman A, Gernsbacher MA, Ioannidis JP, Johnson E, Jonas K, Kousta S, Lilienfeld SO, Lindsay DS, Morey CC, Monafó M, Newell BR, Pashler H, Shanks DR, Simons DJ, Wicherts JM, Albarracín D, Anderson ND, Antonakis J, Arkes HR, Back MD, Banks GC, Beevers C, Bennett AA, Bleidorn W, Boyer TW, Cacciari C, Carter AS, Cesario J, Clifton C, Conroy RM, Cortese M, Cosci F, Cowan N, Crawford J, Crone EA, Curtin J, Engle R, Farrell S, Fearon P, Fichman M, Frankenhuys W, Freund AM, Gaskell MG, Giner-Sorolla R, Green DP, Greene RL, Harlow LL, de la Guardia FH, Isaacowitz D, Kolodner J, Lieberman D, Logan GD, Mendes WB, Moersdorf L, Nyhan B, Pollack J, Sullivan C, Vazire S, Wagenmakers EJ*. A consensus-based transparency checklist. **Nature Human Behaviour** 2020, 20:4-6.
992. *Flegal KM, Graubard B, Ioannidis JPA*. Use and reporting of Bland-Altman analyses in studies of self-reported versus measured weight and height. **International Journal of Obesity** 2020, 44:1311-8.
993. *van Ravenzwaaij D, Ioannidis JPA*. True and false positive rates for different criteria of evaluating statistical evidence from clinical trials. **BMC Medical Research Methodology** 2019, 19(1):218.
994. *Koletsis D, Solmi M, Pandis N, Fleming PS, Correll CU, Ioannidis JPA*. Most recommended medical interventions reach $P < 0.005$ for their primary outcomes in meta-analyses. **International Journal of Epidemiology** 2020, 49:885-93.
995. *Blum MR, Tan YJ, Ioannidis JP*. Use of E-values for addressing confounding in observational studies - An empirical assessment of the literature. **International Journal of Epidemiology** (in press).
996. *Bruns S, Ioannidis JPA*. Determinants of economic growth: Different time different answer? **Journal of Macroeconomics** 2020, 63:103185.
997. *Marton R, Wang X, Barabasi A-L, Ioannidis JPA*. Science, advocacy and quackery in nutrition books: an analysis of conflicting advice and purported claims of nutritional best-sellers. **Palgrave Communications** 2020, 6:43
998. *Liu P, Ross JS, Ioannidis JP, Dhruva SS, Vasilioni V, Wallach JD*. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews. **Clinical Trials** 2020, 17:231-4.
999. *Ewald H, Ioannidis JPA, Ladanie A, Mc Cord K, Bucher HC, Hemkens LG*. Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study. **Journal**

of **Clinical Epidemiology** 2020 Feb;118:29-41.

1000. Liu P, Ioannidis JPA, Ross JS, Dhruva SS, Luxkaranayagam AT, Vasiliou V, Wallach JD. Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study. **BMC Medicine** 2019, 17(1):188.
1001. Ioannidis JPA. Neglecting major health problems and broadcasting minor, uncertain issues in lifestyle science. **JAMA** 2019 Oct 18:1-2. doi:10.1001/jama.2019.17576. [Epub ahead of print]. (*)
1002. He C, Levis B, Riehm KE, Saadat N, Levis AW, Azar M, Rice DB, Krishnan A, Wu Y, Sun Y, Imran M, Boruff J, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Akena DH, Arroll B, Ayalon L, Baradaran HR, Baron M, Beraldi A, Bombardier CH, Butterworth P, Carter G, Chagas MHN, Chan JCN, Cholera R, Clover K, Conwell Y, de Man-van Ginkel JM, Fann JR, Fischer FH, Fung D, Gelaye B, Goodyear-Smith F, Greeno CG, Hall BJ, Harrison PA, Härter M, Hegerl U, Hides L, Hobfoll SE, Hudson M, Hyphantis TN, Inagaki M, Ismail K, Jetté N, Khamseh ME, Kiely KM, Kwan Y, Lamers F, Liu SI, Lotrakul M, Loureiro SR, Löwe B, Marsh L, McGuire A, Mohd-Sidik S, Munhoz TN, Muramatsu K, Osório FL, Patel V, Pence BW, Persoons P, Picardi A, Reuter K, Rooney AG, da Silva Dos Santos IS, Shaaban J, Sidebottom A, Simning A, Stafford L, Sung S, Tan PLL, Turner A, van Weert HCPM, White J, Whooley MA, Winkley K, Yamada M, Thombs BD, Benedetti A. The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. **Psychotherapy and Psychosomatics** 2020;89(1):25-37.
1003. Tawfik DS, Scheid A, Profit J, Shanafelt T, Trockel M, Adair KC, Sexton JB, Ioannidis JPA. Evidence relating health care provider burnout and quality of care: a systematic review and meta-analysis. **Annals of Internal Medicine** 2019 Oct 8. doi:10.7326/M19-1152. [Epub ahead of print].
1004. Amad A, Jardri R, Rousseau C, Larochelle Y, Ioannidis JPA, Naudet F. Excess significance bias in repetitive transcranial magnetic stimulation literature for neuropsychiatric disorders. **Psychotherapy and Psychosomatics** 2019, 88:363-370.
1005. Levis B, McMillan D, Sun Y, He C, Rice DB, Krishnan A, Wu Y, Azar M, Sanchez TA, Chiovitti MJ, Bhandari PM, Neupane D, Saadat N, Riehm KE, Imran M, Boruff JT, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Comeau L, Mitchell ND, Tonelli M, Vigod SN, Aceti F, Alvarado R, Alvarado-Esquivel C, Bakare MO, Barnes J, Beck CT, Bindt C, Boyce PM, Bunevicius A, Couto TCE, Chaudron LH, Correa H, de Figueiredo FP, Eapen V, Fernandes M, Figueiredo B, Fisher JRW, Garcia-Esteve L, Giardinelli L, Helle N, Howard LM, Khalifa DS, Kohlhoff J, Kusminskas L, Kozinszky Z, Lelli L, Leonardou AA, Lewis BA, Maes M, Meuti V, Nakić Radoš S, Navarro García P, Nishi D, Okitundu Luwa E-Andjafono D, Robertson-Blackmore E, Rochat TJ, Rowe HJ, Siu BWM, Skalkidou A, Stein A, Stewart RC, Su KP, Sundström-Poromaa I, Tadinac M, Tandon SD, Tendais I, Thiagayson P, Töreki A, Torres-Giménez A, Tran TD, Trevillion K, Turner K, Vega-Dienstmaier JM, Wynter K, Yonkers KA, Benedetti A, Thombs BD. Comparison of major depression diagnostic classification probability using the SCID, CIDI, and MINI diagnostic interviews among women in pregnancy or postpartum: An individual participant data meta-analysis. **International Journal of Methods in Psychiatric Research** 2019 Sep 30:e1803. doi: 10.1002/mpr.1803. [Epub ahead of print].
1006. Mastellos DC, Blom AM, Connolly ES, Daba MR, Geisbrecht BV, Ghebrehwet B, Gros P, Hajishengallis G, Holers VM, Huber-Lang M, Kinoshita T, Mollnes TE, Montgomery RA, Morgan BP, Nilsson B, Pio R, Ricklin D, Risitano AM, Taylor RP, Mantovani A, Ioannidis JPA, Lambris JD. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. **Nature Immunology** 2019, 20:1409-1413.

1007. *Palpacuer C, Hammas K, Duprez R, Laviolle B, Ioannidis JPA, Naudet F.* Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis. **BMC Medicine** 2019, 17:174.
1008. *Razavi M, Glasziou P, Klocksieben FA, Ioannidis JPA, Chalmers I, Djulbegovic B.* US Food and Drug Administration approvals of drugs and devices based on nonrandomized clinical trials: A systematic review and meta-analysis. **JAMA Network Open** 2019, 2:e1911111.
1009. *Rocha-Singh KJ, Duval S, Jaff MR, Schneider PA, Ansel GM, Lyden SP, Mullin CM, Ioannidis JPA, Misra S, Tzafriri AR, Edelman ER, Granada JF, White CJ, Beckman JA; VIVA Physicians.* Mortality and Paclitaxel-Coated Devices: An Individual Patient Data Meta-Analysis. **Circulation** 2020, 141:1859-69.
1010. *Boccia S, Ricciardi W, Ioannidis JPA.* What Other Countries Can Learn From Italy During the COVID-19 Pandemic. **JAMA Internal Medicine** 2020, 180:927-8. (*)
1011. *Hardwicke TE, Wallach JD, Kidwell MC, Bendixen T, Crüwell S, Ioannidis JPA.* An empirical assessment of transparency and reproducibility-related research practices in the social sciences (2014-2017). **Royal Society Open Science** 2020, 7(2):190806.
1012. *O'Sullivan JW, Grigg S, Crawford W, Turakhia MP, Perez M, Ingelsson E, Wheeler MT, Ioannidis JPA, Ashley EA.* Accuracy of Smartphone Camera Applications for Detecting Atrial Fibrillation: A Systematic Review and Meta-analysis. **JAMA Network Open** 2020, 3(4):e202064.
1013. *Nagendran M, Chen Y, Lovejoy CA, Gordon AC, Komorowski M, Harvey H, Topol EJ, Ioannidis JPA, Collins GS, Maruthappu M.* Artificial intelligence versus clinicians: systematic review of design, reporting standards, and claims of deep learning studies. **BMJ** 2020, 368:m689.
1014. *Cipriani A, Ioannidis JPA, Rothwell PM, Glasziou P, Li T, Hernandez AF, Tomlinson A, Simes J, Naci H.* Generating comparative evidence on new drugs and devices after approval. **Lancet** 2020, 395(10228):998-1010.
1015. *Vollmer S, Mateen BA, Bohner G, Király FJ, Ghani R, Jonsson P, Cumbers S, Jonas A, McAllister KSL, Myles P, Granger D, Birse M, Branson R, Moons KGM, Collins GS, Ioannidis JPA, Holmes C, Hemingway H.* Machine learning and artificial intelligence research for patient benefit: 20 critical questions on transparency, replicability, ethics, and effectiveness. **BMJ** 2020, 368:l6927.
1016. *Ioannidis JPA.* Coronavirus disease 2019: The harms of exaggerated information and non-evidence-based measures. **European Journal of Clinical Investigation** 2020, 50(4):e13222. (*)
1017. *Wallach JD, Serghiou S, Chu L, Egilman AC, Vasiliou V, Ross JS, Ioannidis JPA.* Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease. **BMC Medical Research Methodology** 2020, 20(1):64.
1018. *Adibi A, Sadatsafavi M, Ioannidis JPA.* Validation and Utility Testing of clinical prediction models: time to change the approach. **JAMA** 2020, 324:235-6. (*)
1019. *Levis B, Benedetti A, Ioannidis JPA, Sun Y, Negeri Z, He C, Wu Y, Krishnan A, Bhandari PM, Neupane D, Imran M, Rice DB, Riehm KE, Saadat N, Azar M, Boruff J, Cuijpers P, Gilbody S, Kloda LA, McMillan D, Patten SB, Shrier I, Ziegelstein RC, Alamri SH, Amtmann D, Ayalon L, Baradaran HR, Beraldi A, Bernstein CN, Bhana A, Bombardier CH, Carter G, Chagas MH, Chibanda D, Clover K, Conwell Y, Diez-Quevedo C, Fann JR, Fischer FH, Gholizadeh L, Gibson LJ, Green EP, Greeno CG, Hall BJ, Haroz EE, Ismail K, Jetté N, Khamseh ME, Kwan Y, Lara MA, Liu SI, Loureiro SR, Löwe B, Marrie RA, Marsh L, McGuire A, Muramatsu K, Navarrete L, Osório FL, Petersen I, Picardi A, Pugh SL, Quinn TJ, Rooney AG, Shinn EH, Sidebottom A, Spangenberg L, Tan PLL, Taylor-Rowan M, Turner A, van Weert HC, Vöhringer PA, Wagner LI, White J, Winkley K, Thoms BD.* Patient Health Questionnaire-9 scores do not accurately estimate depression prevalence: individual participant data meta-analysis. **Journal of Clinical Epidemiology** 2020,

122:115-128.

1020. Beets MW, Weaver RG, Ioannidis JPA, Geraci M, Brazendale K, Decker L, Okely AD, Lubans D, van Sluijs E, Jago R, Turner-McGrievy G, Thrasher J, Li X, Milat AJ. Identification and evaluation of risk of generalizability biases in pilot versus efficacy/effectiveness trials: a systematic review and meta-analysis. **International Journal of Behavior Nutrition Physical Activity** 2020, 17(1):19.
1021. Kohavi R, Tang D, Xu Y, Hemkens LG, Ioannidis JPA. Online randomized controlled experiments at scale: lessons and extensions to medicine. **Trials** 2020, 21:150.
1022. Ioannidis JP, Boyack KW. Citation metrics for appraising scientists: misuse, gaming and proper use. **Medical Journal of Australia** 2020, 212(6):247-249.e1. (*)
1023. Spence J, Ioannidis JPA, Avidan MS. Achieving balance with power: lessons from the Balanced Anaesthesia Study. **British Journal of Anaesthesia** 2020 Jan 20:S0007-0912(19)31017-7. doi: 10.1016/j.bja.2019.12.027. Epub ahead of print.
1024. Chu L, Ioannidis JPA, Egilman AC, Vasiliou V, Ross JS, Wallach JD. Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk. **International Journal of Epidemiology** 2020, 49:608-18.
1025. Wu Y, Levis B, Sun Y, Krishnan A, He C, Riehm KE, Rice DB, Azar M, Yan XW, Neupane D, Bhandari PM, Imran M, Chiovitti MJ, Saadat N, Boruff JT, Cuijpers P, Gilbody S, McMillan D, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Henry M, Ismail Z, Loiselle CG, Mitchell ND, Tonelli M, Al-Adawi S, Beraldi A, Braeken APBM, Büel-Drabe N, Bunevicius A, Carter G, Chen CK, Cheung G, Clover K, Conroy RM, Cukor D, da Rocha E Silva CE, Dabscheck E, Daray FM, Douven E, Downing MG, Feinstein A, Ferentinos PP, Fischer FH, Flint AJ, Fujimori M, Gallagher P, Gandy M, Goebel S, Grassi L, Härter M, Jenewein J, Jetté N, Julião M, Kim JM, Kim SW, Kjærgaard M, Köhler S, Loosman WL, Löwe B, Martin-Santos R, Massardo L, Matsuoka Y, Mehnert A, Michopoulos I, Misery L, Navines R, O'Donnell ML, Öztürk A, Peceliuniene J, Pintor L, Ponsford JL, Quinn TJ, Reme SE, Reuter K, Rooney AG, Sánchez-González R, Schwarzbald ML, Senturk Cankorur V, Shaaban J, Sharpe L, Sharpe M, Simard S, Singer S, Stafford L, Stone J, Sultan S, Teixeira AL, Tiringier I, Turner A, Walker J, Walterfang M, Wang LJ, White J, Wong DK, Benedetti A, Thombs BD. Probability of major depression diagnostic classification based on the SCID, CIDI and MINI diagnostic interviews controlling for Hospital Anxiety and Depression Scale - Depression subscale scores: An individual participant data meta-analysis of 73 primary studies. **Journal of Psychosomatic Research** 2020, 129:109892.
1026. Castillo-Garcia A, Naci H, Valenzuela PL, Salcher-Konrad M, Dias S, Blum MR, Sahoo SA, Nunan D, Morales JS, Lucia A, Ioannidis JP. Infographic. How does exercise treatment compare with antihypertensive medications? **British Journal of Sports Medicine** 2020, 54:746-7.
1027. Tatsioni A, Ioannidis JPA. Meta-research: bird's eye views of primary care research. **Family Practice** 2020, 37:287-289.
1028. Ioannidis JPA. Controversy and debate on credibility ceilings. Paper 4: Credibility ceilings da capo. **Journal of Clinical Epidemiology** 2020, 127:217.
1029. Ioannidis JPA. Controversy and debate on credibility ceilings. Paper 2: Using credibility ceilings to explore skepticism about observational evidence. **Journal of Clinical Epidemiology** 2020, 127:211-213.
1030. Xu W, He Y, Wang Y, Li X, Young J, Ioannidis JPA, Dunlop MG, Theodoratou E. Risk factors and risk prediction models for colorectal cancer metastasis and recurrence: an umbrella review of systematic reviews and meta-analyses of observational studies. **BMC Medicine** 2020;18:172.
1031. Crowley RJ, Tan YJ, Ioannidis JPA. Empirical assessment of bias in machine learning diagnostic test accuracy studies. **Journal of the American Medical Informatics Association** 2020, 27:1092-

1101.

1032. Sigurdson MK, Khoury MJ, Ioannidis JPA. Redundant meta-analyses are common in genetic epidemiology. **Journal of Clinical Epidemiology** 2020, 127:40-48.
1033. Levis B, Sun Y, He C, Wu Y, Krishnan A, Bhandari PM, Neupane D, Imran M, Brehaut E, Negeri Z, Fischer FH, Benedetti A, Thombs BD; Depression Screening Data (DEPRESSD) PHQ Collaboration, Che L, Levis A, Riehm K, Saadat N, Azar M, Rice D, Boruff J, Kloda L, Cuijpers P, Gilbody S, Ioannidis J, McMillan D, Patten S, Shriner I, Ziegelstein R, Moore A, Akena D, Amtmann D, Arroll B, Ayalon L, Baradaran H, Beraldi A, Bernstein C, Bhana A, Bombardier C, Buji RI, Butterworth P, Carter G, Chagas M, Chan J, Chan LF, Chibanda D, Cholera R, Clover K, Conway A, Conwell Y, Daray F, de Man-van Ginkel J, Delgadillo J, Diez-Quevedo C, Fann J, Field S, Fisher J, Fung D, Garman E, Gelaye B, Gholizadeh L, Gibson L, Goodyear-Smith F, Green E, Greeno C, Hall B, Hampel P, Hantsoo L, Haroz E, Harter M, Hegerl U, Hides L, Hobfoll S, Honikman S, Hudson M, Hyphantis T, Inagaki M, Ismail K, Jeon HJ, Jetté N, Khamseh M, Kiely K, Kohler S, Kohrt B, Kwan Y, Lamers F, Asunción Lara M, Levin-Aspenson H, Lino V, Liu SI, Lotrakul M, Loureiro S, Löwe B, Luitel N, Lund C, Marrie RA, Marsh L, Marx B, McGuire A, Mohd Sidik S, Munhoz T, Muramatsu K, Nakku J, Navarrete L, Osório F, Patel V, Pence B, Persoons P, Petersen I, Picardi A, Pugh S, Quinn T, Rancans E, Rathod S, Reuter K, Roch S, Rooney A, Rowe H, Santos I, Schram M, Shaaban J, Shinn E, Sidebottom A, Simning A, Spangenberg L, Stafford L, Sung S, Suzuki K, Swartz R, Tan PLL, Taylor-Rowan M, Tran T, Turner A, van der Feltz-Cornelis C, van Heyningen T, van Weert H, Wagner L, Li Wang J, White J, Winkley K, Wynter K, Yamada M, Zhi Zeng Q, Zhang Y. Accuracy of the PHQ-2 Alone and in Combination With the PHQ-9 for Screening to Detect Major Depression: Systematic Review and Meta-analysis. **JAMA** 2020, 323:2290-2300.
1034. Thompson T, Dias S, Poulter D, Weldon S, Marsh L, Rossato C, Shin JJ, Firth J, Veronese N, Dragioti E, Stubbs B, Solmi M, Maher CG, Cipriani A, Ioannidis JPA. Efficacy and acceptability of pharmacological and non-pharmacological interventions for non-specific chronic low back pain: a protocol for a systematic review and network meta-analysis. **Systematic Reviews** 2020, 9:130.
1035. Melnick ER, Ioannidis JPA. Should governments continue lockdown to slow the spread of covid-19? **BMJ** 2020, 369:m1924. (debate) (*)
1036. Veronese N, Demurtas J, Thompson T, Solmi M, Pesolillo G, Celotto S, Barnini T, Stubbs B, Maggi S, Pilotto A, Onder G, Theodoratou E, Vaona A, Firth J, Smith L, Koyanagi A, Ioannidis JPA, Tzoulaki I. Effect of low-dose aspirin on health outcomes: An umbrella review of systematic reviews and meta-analyses. **British Journal of Clinical Pharmacology** 2020, 86:1465-1475.
1037. Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JPA, Bucher HC, Kasenda B, Hemkens LG. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. **JAMA Network Open** 2020;3):e2024406.
1038. Malicki M, Jeronic A, Ter Riet G, Bouter LM, Ioannidis JPA, Goodman SN, Aalbersberg IJ. Preprint Servers' Policies, Submission Requirements, and Transparency in Reporting and Research Integrity Recommendations. **JAMA** 2020;324:1901-1903. Accompanied by editorial in the same issue.
1039. Klau S, Hoffmann S, Patel CJ, Ioannidis JPA, Boulesteix AL. Examining the robustness of observational associations to model, measurement and sampling uncertainty with the vibration of effects framework. **International Journal of Epidemiology** 2020, 50:266-78.
1040. Janiaud P, Axfors C, Van't Hooft J, Saccilotto R, Agarwal A, Appenzeller-Herzog C, Contopoulos-Ioannidis DG, Danchev V, Dirnagl U, Ewald H, Gartlehner G, Goodman SN, Haber NA, Ioannidis AD, Ioannidis JPA, Lythgoe MP, Ma W, Macleod M, Malički M, Meerpohl JJ, Min Y, Moher D, Nagavci B, Naudet F, Pauli-Magnus C, O'Sullivan JW, Riedel N, Roth JA, Sauermann M,

- Schandelmaier S, Schmitt AM, Speich B, Williamson PR, Hemkens LG.* The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. **F1000Research** 2020, 9:1193.
1041. *Ioannidis JPA.* Hundreds of thousands of zombie randomised trials circulate among us. **Anaesthesia** 2021, 76:444-447. (commentary) (*).
1042. *Ioannidis JPA, Jha P.* Does the COVID-19 pandemic provide an opportunity to eliminate the tobacco industry? **Lancet Global Health** 2021, 9:e12-e13. (viewpoint article) (*).
1043. *Cristea IA, Naudet F, Ioannidis JPA.* Preserving equipoise and performing randomised trials for COVID-19 social distancing interventions. **Epidemiology and Psychiatric Sciences** 2020, 29:e184.
1044. *Ioannidis JP.* Scientific petitions and open letters in the era of covid-19. **BMJ** 2020 Oct 26;371:m4048. (viewpoint article) (*).
1045. *Thombs BD, Levis B, Lyubenova A, Neupane D, Negeri Z, Wu Y, Sun Y, He C, Krishnan A, Vigod SN, Bhandari PM, Imran M, Rice DB, Azar M, Chiovitti MJ, Saadat N, Riehm KE, Boruff JT, Cuijpers P, Gilbody S, Ioannidis JPA, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Comeau L, Mitchell ND, Tonelli M, Barnes J, Beck CT, Bindt C, Figueiredo B, Helle N, Howard LM, Kohlhoff J, Kozinszky Z, Leonardou AA, Radoš SN, Quispel C, Rochat TJ, Stein A, Stewart RC, Tadinac M, Tandon SD, Tendais I, Töreki A, Tran TD, Trevillion K, Turner K, Vega-Dienstmaier JM, Benedetti A.* Overestimation of Postpartum Depression Prevalence Based on a 5-item Version of the EPDS: Systematic Review and Individual Participant Data Meta-analysis. **Canadian Journal of Psychiatry** 2020, 65:835-844.
1046. *Lyubenova A, Neupane D, Levis B, Wu Y, Sun Y, He C, Krishnan A, Bhandari PM, Negeri Z, Imran M, Rice DB, Azar M, Chiovitti MJ, Saadat N, Riehm KE, Boruff JT, Ioannidis JPA, Cuijpers P, Gilbody S, Kloda LA, Patten SB, Shrier I, Ziegelstein RC, Comeau L, Mitchell ND, Tonelli M, Vigod SN, Aceti F, Barnes J, Bavle AD, Beck CT, Bindt C, Boyce PM, Bunevicius A, Chaudron LH, Favez N, Figueiredo B, Garcia-Esteve L, Giardinelli L, Helle N, Howard LM, Kohlhoff J, Kusminskas L, Kozinszky Z, Lelli L, Leonardou AA, Meuti V, Radoš SN, García PN, Pawlby SJ, Quispel C, Robertson-Blackmore E, Rochat TJ, Sharp DJ, Siu BWM, Stein A, Stewart RC, Tadinac M, Tandon SD, Tendais I, Töreki A, Torres-Giménez A, Tran TD, Trevillion K, Turner K, Vega-Dienstmaier JM, Benedetti A, Thombs BD.* Depression prevalence based on the Edinburgh Postnatal Depression Scale compared to Structured Clinical Interview for DSM Disorders classification: Systematic review and individual participant data meta-analysis. **International Journal of Methods in Psychiatric Research** 2021, 30:e1860.
1047. *Brehaut E, Neupane D, Levis B, Wu Y, Sun Y, Krishnan A, He C, Bhandari PM, Negeri Z, Riehm KE, Rice DB, Azar M, Yan XW, Imran M, Chiovitti MJ, Saadat N, Cuijpers P, Ioannidis JPA, Markham S, Patten SB, Ziegelstein RC, Henry M, Ismail Z, Loiselle CG, Mitchell ND, Tonelli M, Boruff JT, Kloda LA, Beraldi A, Braeken APBM, Carter G, Clover K, Conroy RM, Cukor D, da Rocha E Silva CE, De Souza J, Downing MG, Feinstein A, Ferentinos PP, Fischer FH, Flint AJ, Fujimori M, Gallagher P, Goebel S, Jetté N, Julião M, Keller M, Kjærgaard M, Love AW, Löwe B, Martin-Santos R, Michopoulos I, Navines R, O'Rourke SJ, Öztürk A, Pintor L, Ponsford JL, Rooney AG, Sánchez-González R, Schwarzbald ML, Sharpe M, Simard S, Singer S, Stone J, Tung KY, Turner A, Walker J, Walterfang M, White J, Benedetti A, Thombs BD.* Depression prevalence using the HADS-D compared to SCID major depression classification: An individual participant data meta-analysis. **Journal of Psychosomatic Research** 2020, 139:110256.
1048. *Ewers M, Ioannidis JPA, Plesnila N.* Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive. **Journal of Clinical Epidemiology** 2021, 130:143-46. (*)
1049. *Ioannidis JPA, Boyack KW, Baas J.* Updated science-wide author databases of standardized citation

- indicators. **PLoS Biology** 2020 Oct 16;18(10):e3000918.
1050. Haibe-Kains B, Adam GA, Hosny A, Khodakarami F; Massive Analysis Quality Control (MAQC) Society Board of Directors, Waldron L, Wang B, McIntosh C, Goldenberg A, Kundaje A, Greene CS, Broderick T, Hoffman MM, Leek JT, Korthauer K, Huber W, Brazma A, Pineau J, Tibshirani R, Hastie T, Ioannidis JPA, Quackenbush J, Aerts HJWL. Transparency and reproducibility in artificial intelligence. **Nature** 2020, 586:E14-E16.
1051. Pandis N, Fleming PS, Katsaros C, Ioannidis JPA. Dental research waste in design, analysis, and reporting: a scoping review. **Journal of Dental Research** 2021, 100:245-252.
1052. Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. **European Journal of Clinical Investigation** 2020, 50:e13423.
1053. Kim SK, Roche MD, Fredericson M, Dragoo JL, Horton BH, Avins AL, Belanger HG, Ioannidis JPA, Abrams GD. A Genome-wide Association Study for Concussion Risk. **Med Sci Sports Exerc**. 2021 Apr 1;53(4):704-711.
1054. Markozannes G, Koutsoumpa C, Cividini S, Monori G, Tsilidis KK, Kretsavos N, Theodoratou E, Gill D, Ioannidis JP, Tzoulaki I. Global assessment of C-reactive protein and health-related outcomes: an umbrella review of evidence from observational studies and Mendelian randomization studies. **European Journal of Epidemiology** 2021, 36:11-36.
1055. Bozkurt S, Cahan EM, Seneviratne MG, Sun R, Lossio-Ventura JA, Ioannidis JPA, Hernandez-Boussard T. Reporting of demographic data and representativeness in machine learning models using electronic health records. **Journal of the American Medical Informatics Association** 2020, 27:1878-1884.
1056. Tugwell P, Welch VA, Karunanathan S, Maxwell LJ, Akl EA, Avey MT, Bhutta ZA, Brouwers MC, Clark JP, Cook S, Cuervo LG, Curran JA, Ghogomu ET, Graham IG, Grimshaw JM, Hutton B, Ioannidis JPA, Jordan Z, Jull JE, Kristjansson E, Langlois EV, Little J, Lyddiatt A, Martin JE, Marušić A, Mbuagbaw L, Moher D, Morton RL, Nasser M, Page MJ, Pardo Pardo J, Petkovic J, Petticrew M, Pigott T, Pottie K, Rada G, Rader T, Riddle AY, Rothstein H, Schüneman HJ, Shamseer L, Shea BJ, Simeon R, Siontis KC, Smith M, Soares-Weiser K, Thavorn K, Tovey D, Vachon B, Valentine J, Villemaire R, Walker P, Weeks L, Wells G, Wilson DB, White H. When to replicate systematic reviews of interventions: consensus checklist. **BMJ** 2020, 370:m2864.
1057. Benedetti A, Levis B, Rücker G, Jones HE, Schumacher M, Ioannidis JPA, Thombs B; DEPRESSion Screening Data (DEPRESSD) Collaboration. An empirical comparison of three methods for multiple cutoff diagnostic test meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) depression screening tool using published data vs individual level data. **Research Synthesis Methods** 2020, 11:833-848.
1058. Kemper JM, Rolnik DL, Mol BWJ, Ioannidis JPA. Reproducible research practices and transparency in reproductive endocrinology and infertility articles. **Fertility and Sterility** 2020, 114:1322-1329.
1059. Ioannidis JPA, Cristea IA, Boyack KW. Work honored by Nobel prizes clusters heavily in a few scientific fields. **PLoS One** 2020, 15:e0234612.
1060. Szucs D, Ioannidis JP. Sample size evolution in neuroimaging research: An evaluation of highly-cited studies (1990-2012) and of latest practices (2017-2018) in high-impact journals. **Neuroimage** 2020, 221:117164.
1061. Ioannidis JPA. Spin, Bias, and Clinical Utility in Systematic Reviews of Diagnostic Studies. **Clinical Chemistry** 2020, 66:863-865. (editorial) (*).
1062. Hernandez-Boussard T, Bozkurt S, Ioannidis JPA, Shah NH. MINIMAR (MINimum Information for Medical AI Reporting): Developing reporting standards for artificial intelligence in health care. **Journal of the American Medical Informatics Association** 2020, 27:2011-2015.

1063. Rice DB, Raffoul H, Ioannidis JPA, Moher D. Academic criteria for promotion and tenure in biomedical sciences faculties: cross sectional analysis of international sample of universities. **BMJ** 2020, 369:m2081.
1064. Howick J, Koletsi D, Pandis N, Fleming PS, Loeff M, Walach H, Schmidt S, Ioannidis JPA. The quality of evidence for medical interventions does not improve or worsen: a metaepidemiological study of Cochrane reviews. **Journal of Clinical Epidemiology** 2020, 126:154-159.
1065. Peirlinck M, Linka K, Sahli Costabal F, Bendavid E, Bhattacharya J, Ioannidis J, Kuhl E. Visualizing the invisible: The effect of asymptomatic transmission on the outbreak dynamics of COVID-19. **Computer Methods in Applied Mechanics and Engineering** 2020, 372:article 113410.
1066. Ioannidis JPA, Cripps S, Tanner MA. Forecasting for COVID-19 has failed. **International Journal of Forecasting** 2020, Aug 25. doi: 10.1016/j.ijforecast.2020.08.004. Epub ahead of print.
1067. Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. **Environmental Research** 2020, 188:109890.
1068. Kasenda B, Liu J, Jiang Y, Gajewski B, Wu C, von Elm E, Schandelmaier S, Moffa G, Trelle S, Schmitt AM, Herbrand AK, Gloy V, Speich B, Hopewell S, Hemkens LG, Sluka C, McGill K, Meade M, Cook D, Lamontagne F, Tréluyer JM, Haidich AB, Ioannidis JPA, Treweek S, Briel M. Prediction of RECRUITment In randomized clinical Trials (RECRUIT-IT)-rationale and design for an international collaborative study. **Trials** 2020, 21:731.
1069. Wu Y, Levis B, Ioannidis JPA, Benedetti A, Thombs BD; *DEPRESSion Screening Data (DEPRESSD) Collaboration*. Probability of Major Depression Classification Based on the SCID, CIDI, and MINI Diagnostic Interviews: A Synthesis of Three Individual Participant Data Meta-Analyses. **Psychotherapy and Psychosomatics** 2021, 90:28-40.
1070. Chin V, Samia NI, Marchant R, Rosen O, Ioannidis JPA, Tanner MA, Cripps S. A case study in model failure? COVID-19 daily deaths and ICU bed utilisation predictions in New York state. **European Journal of Epidemiology** 2020, 35:733-742.
1071. Schandelmaier S, Briel M, Varadhan R, Schmid CH, Devasenapathy N, Hayward RA, Gagnier J, Borenstein M, van der Heijden GJMG, Dahabreh IJ, Sun X, Sauerbrei W, Walsh M, Ioannidis JPA, Thabane L, Guyatt GH. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. **CMAJ** 2020, 192:E901-E906.
1072. Tortella-Feliu M, Fullana M, Littarelli A, Solana A, Ramella-Cravaro V, Vilar A, Gonzalez-Parra JA, Adero R, Reichenberg A, Mataix-Col S, Viet E, Fusar-Poli P, Ioannidis JPA, Stein M, Radua J, Fernández de la Cruz L. Risk factors for posttraumatic stress disorder: An umbrella review of systematic reviews and meta-analyses. **Neuroscience and Biobehavioral Reviews** 2019, 107:154-165.
1073. Kirkham JJ, Penfold NC, Murphy F, Boutron I, Ioannidis JP, Polka J, Moher D. Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. **BMJ Open** 2020, 10:e041849.
1074. Ioannidis JP. Nutrition and health: setting realistic expectations and changing research targets. **Journal of Bone and Mineral Research** 2021, 36:217-218. (editorial) (*)
1075. Berthelsen DB, Woodworth TG, Goel N, Ioannidis JPA, Tugwell P, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Leong AL, Conaghan PG, Boers M, Shea BJ, Brooks PM, Simon LS, Furst DE, Christensen R; OMERACT Safety Working Group. Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an

- OMERACT working group. **Seminars in Arthritis and Rheumatism** 2021 Jun, 51(3):607-617.
1076. *Ioannidis JPA, Powe NR, Yancy C*. Recalibrating the use of race in medical research. **JAMA** 2021, 325:623-624. (viewpoint) (*)
1077. *Lewis JR, Voortman T, Ioannidis JP*. Evaluating and strengthening the evidence for nutritional bone research: ready to break new ground? **Journal of Bone and Mineral Research** 2021, 36:219-226. (*)
1078. *Danchev V, Min Y, Borghi J, Baiocchi M, Ioannidis JPA*. Evaluation of data sharing after implementation of the International Committee of Medical Journal Editors Data Sharing Statement Requirement. **JAMA Network Open** 2021, 4:e2033972.
1079. *Ioannidis JPA*. Precision shielding for COVID-19: metrics of assessment and feasibility of deployment. **BMJ Global Health** 2021, 6:e004614.
1080. *Doran M, Lott W, Barnett A, Leach J, Ioannidis J*. The future of grant proposals is video. **Nature** 2021 Feb 5. doi: 10.1038/d41586-021-00341-3. (*)
1081. *Fischer F, Lewis B, Falk C, Sun Y, Ioannidis JPA, Cuijpers P, Shrier I, Benedetti A, Thombs BD; Depression Screening Data (DEPRESSD) PHQ Collaboration*. Comparison of different scoring methods based on latent variable models of the PHQ-9: an individual participant data meta-analysis. **Psychological Medicine** 2021 Feb 22:1-12.
1082. *Nielsen MW, Stefanick ML, Peragine D, Neilands TB, Ioannidis JPA, Pilote L, Prochaska JJ, Cullen MR, Einstein G, Klinge I, LeBlanc H, Paik HY, Schiebinger L*. Gender-related variables for health research. **Biol Sex Differ.** 2021 Feb 22;12(1):23. doi: 10.1186/s13293-021-00366-3.
1083. *Janiaud P, Axfors C, Ioannidis JPA, Hemkens LG*. Recruitment and results reporting of COVID-19 randomized clinical trials registered in the first 100 days of the pandemic. **JAMA Network Open** 2021, 4:e210330.
1084. *Serghiou S, Contopoulos-Ioannidis DG, Boyack KW, Riedel N, Wallach JD, Ioannidis JPA*. Assessment of transparency indicators across the biomedical literature: How open is open? **PLoS Biology** 2021, 19:e3001107.
1085. *Mc Cord KA, Ewald H, Agarwal A, Glinz D, Aghlmandi S, Ioannidis JPA, Hemkens LG*. Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study. **BMJ** 2021, 372:n450.
1086. *Pho N, Manrai AK, Leppert JT, Chertow GM, Ioannidis JPA, Patel CJ*. Association of 152 biomarker reference intervals with all-cause mortality in participants of a general United States survey from 1999 to 2010. **Clinical Chemistry** 2021, 67:500-507.
1087. *Hardwicke TE, Thibault RT, Kosie JE, Wallach JD, Kidwell MC, Ioannidis JPA*. Estimating the prevalence of transparency and reproducibility-related research practices in psychology (2014-2017). **Perspectives in Psychological Science** 2022, 17(1):239-251.
1088. *Li X, Celotto S, Pizzol D, Gasevic D, Ji MM, Barnini T, Solmi M, Stubbs B, Smith L, López Sánchez GF, Pesolillo G, Yu Z, Tzoulaki I, Theodoratou E, Ioannidis JPA, Veronese N, Demurtas J*. Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses. **European Journal of Clinical Investigation** 2021, 51:e13536.
1089. *Ioannidis JPA*. Infection fatality rate of COVID-19 inferred from seroprevalence data. **Bulletin of the World Health Organization** 2021, 99:19-33F.
1090. *Fusar-Poli P, Correll CU, Arango C, Berk M, Patel V, Ioannidis JPA*. Preventive psychiatry: a blueprint for improving the mental health of young people. **World Psychiatry** 2021, 20:200-221.
1091. *Serghiou S, Marton RM, Ioannidis JPA*. Media and social media attention to retracted articles according to Altmetric. **PLoS One** 2021, 16:e0248625.
1092. *Boesen K, Gøtzsche PC, Ioannidis JPA*. EMA and FDA psychiatric drug trial guidelines: assessment

- of guideline development and trial design recommendations. **Epidemiology and Psychiatric Sciences** 2021, 30:e35.
1093. Pellen C, Caquelin L, Bail AJ, Gaba J, Verin M, Moher D, Ioannidis JPA, Naudet F. Intent to share Annals of Internal Medicine's trial data was not associated with data re-use. **Journal of Clinical Epidemiology** 2021, 137:241-249.
1094. Novelli M, Baldi Antognini A, Boffetta P, Ioannidis JP, Spatari G, Violante FS. Reporting only relative effect measures was potentially misleading: some good practices for improving the soundness of epidemiological results. **Journal of Clinical Epidemiology** 2021, 137:195-199.
1095. Ioannidis JPA. Educating educators on research on research. **Perspectives in Medical Education** 2022;11:137-138. (editorial) (*)
1096. Axfors C, Schmitt AM, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo EF, Abella BS, Akram J, Amaravadi RK, Angus DC, Arabi YM, Azhar S, Baden LR, Baker AW, Belkhir L, Benfield T, Berrevoets MAH, Chen CP, Chen TC, Cheng SH, Cheng CY, Chung WS, Cohen YZ, Cowan LN, Dalgard O, de Almeida E Val FF, de Lacerda MVG, de Melo GC, Derde L, Dubee V, Elfakir A, Gordon AC, Hernandez-Cardenas CM, Hills T, Hoepelman AIM, Huang YW, Igau B, Jin R, Jurado-Camacho F, Khan KS, Kremsner PG, Kreuels B, Kuo CY, Le T, Lin YC, Lin WP, Lin TH, Lyngbakken MN, McArthur C, McVerry BJ, Meza-Meneses P, Monteiro WM, Morpeth SC, Mourad A, Mulligan MJ, Murthy S, Naggie S, Narayanasamy S, Nichol A, Novack LA, O'Brien SM, Okeke NL, Perez L, Perez-Padilla R, Perrin L, Remigio-Luna A, Rivera-Martinez NE, Rockhold FW, Rodriguez-Llamazares S, Rolfe R, Rosa R, Røsjø H, Sampaio VS, Seto TB, Shahzad M, Soliman S, Stout JE, Thirion-Romero I, Troxel AB, Tseng TY, Turner NA, Ulrich RJ, Walsh SR, Webb SA, Weehuizen JM, Velinova M, Wong HL, Wrenn R, Zampieri FG, Zhong W, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. **Nature Communications** 2021, 12:2349.
1097. Chin V, Ioannidis JPA, Tanner MA, Cripps S. Effect estimates of COVID-19 non-pharmaceutical interventions are non-robust and highly model-dependent. **Journal of Clinical Epidemiology** 2021, 136:96-132.
1098. Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations. **European Journal of Clinical Investigation** 2021, 51:e13554.
1099. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, Smith ER, Haber NA, Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis. **JAMA** 2021, 325:1185-1195.
1100. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, Weissberg Z, Saavedra-Walker R, Tedrow J, Bogan A, Kupiec T, Eichner D, Gupta R, Ioannidis JPA, Bhattacharya J. COVID-19 antibody seroprevalence in Santa Clara County, California. **International Journal of Epidemiology** 2021, 50:410-419.
1101. Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R. Data sharing under the general data protection regulation: time to harmonize law and research ethics? **Hypertension** 2021, 77:1029-1035. (*)
1102. Pilz S, Chakeri A, Ioannidis JP, Richter L, Theiler-Schwetz V, Trummer C, Krause R, Allerberger

- F. SARS-CoV-2 re-infection risk in Austria. **European Journal of Clinical Investigation** 2021, 51:e13520.
1103. *Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG*. Second versus first wave of COVID-19 deaths: Shifts in age distribution and in nursing home fatalities. **Environmental Research** 2021, 195:110856.
1104. *Bendavid E, Oh C, Bhattacharya J, Ioannidis JPA*. Assessing mandatory stay-at-home and business closure effects on the spread of COVID-19. **European Journal of Clinical Investigation** 2021, 51:e13484.
1105. *Min Y, Zhao X, Stafford RS, Ma X, Chen SH, Gan D, Wei C, Huang C, Chen L, Gao P, Yang F, Winter SJ, Wu YH, Heaney CA, Baiocchi M, Ioannidis JPA, Hsing AW, Zhu S*. Cohort Profile: WELL Living Laboratory in China (WELL-China). **International Journal of Epidemiology** 2021, 50(5):1432-1443.
1106. *Junqueira DR, Phillips R, Zorzela L, Golder S, Loke Y, Moher D, Ioannidis JPA, Vohra S*. Time to improve the reporting of harms in randomized controlled trials. **Journal of Clinical Epidemiology** 2021, 136:216-220. (*)
1107. *Janiaud P, Hemkens LG, Ioannidis JPA*. Challenges and lessons learned from COVID-19 trials: should we be doing clinical trials differently? **Canadian Journal of Cardiology** 2021, 37(9):1353-1364. (*)
1108. *Parish AJ, Yuan DMK, Raggi JR, Omotoso OO, West JR, Ioannidis JPA*. An umbrella review of effect size, bias, and power across meta-analyses in emergency medicine. **Academic Emergency Medicine** 2021, 28(12):1379-1388.
1109. *Stanley TD, Doucouliagos H, Ioannidis JPA, Carter EC*. Detecting publication selection bias through excess statistical significance. **Research Synthesis Methods** 2021, 12(6):776-795.
1110. *Janiaud P, Agarwal A, Tzoulaki I, Theodoratou E, Tsilidis KK, Evangelou E, Ioannidis JPA*. Validity of observational evidence on putative risk and protective factors: appraisal of 3744 meta-analyses on 57 topics. **BMC Medicine** 2021, 19(1):157.
1111. *Ioannidis JPA*. Benefit of COVID-19 vaccination accounting for potential risk compensation. **NPJ Vaccines** 2021, 6(1):99.
1112. *Abou-El-Enin M, Angelis A, Appelbaum FR, Andrews NC, Bates SE, Bierman AS, Brenner MK, Cavazzana M, Caligiuri MA, Clevers H, Cooke E, Daley GQ, Dzau VJ, Ellis LM, Fineberg HV, Goldstein LSB, Gottschalk S, Hamburg MA, Ingber DE, Kohn DB, Krainer AR, Maus MV, Marks P, Mummery CL, Pettigrew RI, Rutter JL, Teichmann SA, Terzic A, Urnov FD, Williams DA, Wolchok JD, Lawler M, Turtle CJ, Bauer G, Ioannidis JPA*. Evidence generation and reproducibility in cell and gene therapy research: A call to action. **Molecular Therapy Methods and Clinical Develoment** 2021, 22:11-14. (commentary) (*)
1113. *Villani L, Pastorino R, Ricciardi W, Ioannidis J, Boccia S*. Inverse correlates of COVID-19 mortality across European countries during the first versus subsequent waves. **BMJ Global Health** 2021, 6(8):e006422.
1114. *Hardwicke TE, Szűcs D, Thibault RT, Crüwell S, van den Akker OR, Nuijten MB, Ioannidis JPA*. Citation patterns following a strongly contradictory replication result: four case studies from psychology. **Advances in Methods and Practices in Psychological Science** 2021, 4:1-14.
1115. *Cristea LA, Georgescu R, Ioannidis JPA*. Effect sizes reported in highly cited emotion research compared with larger studies and meta-analyses addressing the same questions. **Clinical Psychological Science** 2021.
1116. *Rice DB, Raffoul H, Ioannidis JPA, Moher D*. Academic criteria for promotion and tenure in faculties of medicine: A cross-sectional study of the Canadian U15 universities. **Facets** 2021, 6:58–70.

1117. *Ioannidis JPA*. Over- and under-estimation of COVID-19 deaths. **European Journal of Epidemiology** 2021, 36(6):581-588.
1118. *Ioannidis JPA, Berkwits M, Flanagin A, Godlee F, Bloom T*. Ninth international congress on peer review and scientific publication-call for abstracts. **BMJ** 2021, 374:n2252. (editorial) (*)
1119. *Ioannidis JPA, Berkwits M, Flanagin A, Godlee F, Bloom T*. Ninth International Congress on Peer Review and Scientific Publication: Call for Abstracts. **JAMA** 2021, 326(13):1265-1267. (editorial) (*)
1120. *Ioannidis JPA*. COVID-19 vaccination in children and university students. **European Journal of Clinical Investigation** 2021, 51(11):e13678.
1121. *Ioannidis JPA, Salholz-Hillel M, Boyack KW, Baas J*. The rapid, massive growth of COVID-19 authors in the scientific literature. **Royal Society Open Science** 2021, 8(9):210389.
1122. *Malm E, Nielsen SM, Berg J, Ioannidis JPA, Furst D, Smolen JS, Taylor PC, Kristensen LE, Tarp S, Ellingsen T, Christensen R*. Risk of harm in synthetic and biological intervention trials in patients with inflammatory arthritis: protocol for a metaepidemiological study focusing on contextual factors. **BMJ Open** 2021, 11(9):e049850.
1123. *Cho SM, Serghiou S, Ioannidis JP, Klassen TP, Contopoulos-Ioannidis DG*. Large pediatric randomized clinical trials in ClinicalTrials.gov. **Pediatrics** 2021, 148(3):e2020049771.
1124. *Flegal KM, Graubard BI, Ioannidis JPA*. Evaluation of a suggested novel method to adjust BMI calculated from self-reported weight and height for measurement error. **Obesity (Silver Spring)** 2021, 29:1700-1707.
1125. *Obstfeld AE, Patel K, Boyd JC, Drees J, Holmes DT, Ioannidis JPA, Manrai AK*. Data Mining Approaches to Reference Interval Studies. **Clinical Chemistry** 2021, 67(9):1175-1181. (panel discussion) (*)
1126. *Naji L, Kay J, Johansson I, Rodrigues M, Hu ZJ, Akula KK, Thabane L, Ioannidis JPA*. Pearls on science, collaboration, and mentorship in health research: A masterclass conversation with Dr. John Ioannidis. **Journal of Clinical Epidemiology** 2021, 139:235-239. (masterclass) (*)
1127. *Naudet F, Siebert M, Pellen C, Gaba J, Axfors C, Cristea I, Danchev V, Mansmann U, Ohmann C, Wallach JD, Moher D, Ioannidis JPA*. Medical journal requirements for clinical trial data sharing: Ripe for improvement. **PLoS Medicine** 2021, 18(10):e1003844. (perspective) (*)
1128. *Stanley TD, Doucouliagos H, Ioannidis JPA*. Retrospective median power, false positive meta-analysis and large-scale replication. **Research Synthesis Methods** 2022, 13(1):88-108.
1129. *O'Sullivan JW, Ioannidis JPA*. Reproducibility in the UK biobank of genome-wide significant signals discovered in earlier genome-wide association studies. **Scientific Reports** 2021, 11(1):18625.
1130. *Lee JJ, Price JC, Jackson WM, Whittington RA, Ioannidis JPA*. COVID-19: A catalyst for transforming randomized trials. **Journal of Neurosurgical Anesthesiology** 2022, 34(1):107-112. (*)
1131. *Axfors C, Janiaud P, Schmitt AM, Van't Hooft J, Smith ER, Haber NA, Abayomi A, Abduljalil M, Abdulrahman A, Acosta-Ampudia Y, Aguilar-Guisado M, Al-Beidh F, Alejandria MM, Alfonso RN, Ali M, AlQahtani M, AlZamrooni A, Anaya JM, Ang MAC, Aomar IF, Argumanis LE, Averyanov A, Baklaushev VP, Balionis O, Benfield T, Berry S, Birocco N, Bonifacio LB, Bowen AC, Bown A, Cabello-Gutierrez C, Camacho B, Camacho-Ortiz A, Campbell-Lee S, Cao DH, Cardesa A, Carnate JM, Castillo GJJ, Cavallo R, Chowdhury FR, Chowdhury FUH, Ciccone G, Cingolani A, Climacosa FMM, Compennolle V, Cortez CFN, Costa Neto A, D'Antico S, Daly J, Danielle F, Davis JS, De Rosa FG, Denholm JT, Denkinger CM, Desmecht D, Díaz-Coronado JC, Díaz Ponce-Medrano JA, Donneau AF, Dumagay TE, Dunachie S, Dungog CC, Erinoso O, Escasa IMS, Estcourt LJ, Evans A, Evasan ALM, Fareli CJ, Fernandez-Sanchez V, Galassi C, Gallo JE, Garcia PJ, Garcia PL, Garcia JA, Garigliany M, Garza-Gonzalez E, Gauran DTV, Gaviria García PA, Giron-Gonzalez JA, Gómez-*

Almaguer D, Gordon AC, Gothot A, Grass Guaqueta JS, Green C, Grimaldi D, Hammond NE, Harvala H, Heralde FM, Herrick J, Higgins AM, Hills TE, Hines J, Holm K, Hoque A, Hoste E, Ignacio JM, Ivanov AV, Janssen M, Jennings JH, Jha V, King RAN, Kjeldsen-Kragh J, Klenerman P, Kotecha A, Krapp F, Labanca L, Laing E, Landin-Olsson M, Laterre PF, Lim LL, Lim J, Ljungquist O, Llaca-Díaz JM, López-Robles C, López-Cárdenas S, Lopez-Plaza I, Lucero JAC, Lundgren M, Macías J, Maganito SC, Malundo AFG, Manrique RD, Manzini PM, Marcos M, Marquez I, Martínez-Marcos FJ, Mata AM, McArthur CJ, McQuilten ZK, McVerry BJ, Menon DK, Meyfroidt G, Mirasol MAL, Misset B, Molton JS, Mondragon AV, Monsalve DM, Moradi Choghakabodi P, Morpeth SC, Mouncey PR, Moutschen M, Müller-Tidow C, Murphy E, Najdovski T, Nichol AD, Nielsen H, Novak RM, O'Sullivan MVN, Olalla J, Osibogun A, Osikomaiya B, Oyonarte S, Pardo-Oviedo JM, Patel MC, Paterson DL, Peña-Perez CA, Perez-Calatayud AA, Pérez-Alba E, Perkina A, Perry N, Pouladzadeh M, Poyato I, Price DJ, Quero AKH, Rahman MM, Rahman MS, Ramesh M, Ramírez-Santana C, Rasmussen M, Rees MA, Rego E, Roberts JA, Roberts DJ, Rodríguez Y, Rodríguez-Baño J, Rogers BA, Rojas M, Romero A, Rowan KM, Saccona F, Safdarian M, Santos MCM, Sasadeusz J, Scozzari G, Shankar-Hari M, Sharma G, Snelling T, Soto A, Tagayuna PY, Tang A, Tatem G, Teofili L, Tong SYC, Turgeon AF, Veloso JD, Venkatesh B, Ventura-Enriquez Y, Webb SA, Wiese L, Wikén C, Wood EM, Yusubalieva GM, Zacharowski K, Zarychanski R, Khanna N, Moher D, Goodman SN, Ioannidis JPA, Hemkens LG. Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. **BMC Infectious Diseases** 2021, 21(1):1170.

1132. Ioannidis JP. Science with and without statistics. Discover-generalize-replicate? Discover-replicate-generalize? **Behavioral and Brain Sciences** 2022, 45:e23. (commentary) (*)
1133. Ioannidis JPA, Koutsioumpa C, Vakka A, Agoranos G, Mantsiou C, Drekolia MK, Avramidis N, Contopoulos-Ioannidis DG, Drosatos K, Baas J. Comprehensive mapping of local and diaspora scientists: A database and analysis of 63,951 Greek scientists. **Quantitative Science Studies** 2021, 2:733–752.
1134. Harel D, Levis B, Sun Y, Fischer F, Ioannidis JPA, Cuijpers P, Patten SB, Ziegelstein RC, Markham S, Benedetti A, Thombs BD; DEPRESSION Screening Data DEPRESSD PHQ Collaboration. External validation of a shortened screening tool using individual participant data meta-analysis: A case study of the Patient Health Questionnaire-Dep-4. **Methods** 2022, 204:300-311.
1135. Beets MW, von Klinggraeff L, Burkart S, Jones A, Ioannidis JPA, Weaver RG, Okely AD, Lubans D, van Sluijs E, Jago R, Turner-McGrievy G, Thrasher J, Li X. Impact of risk of generalizability biases in adult obesity interventions: A meta-epidemiological review and meta-analysis. **Obesity Reviews** 2022, 23(2):e13369.
1136. Pastorino R, Pezzullo AM, Villani L, Causio FA, Axfors C, Contopoulos-Ioannidis DG, Boccia S, Ioannidis JPA. Change in age distribution of COVID-19 deaths with the introduction of COVID-19 vaccination. **Environmental Research** 2022, 204(Pt C):112342.
1137. Ioannidis JP, Tezel A, Jagsi R. Overall and COVID-19-specific citation impact of highly visible COVID-19 media experts: bibliometric analysis. **BMJ Open** 2021, 11(10):e052856.
1138. Hozo I, Djulbegovic B, Parish AJ, Ioannidis JPA. Identification of threshold for large (dramatic) effects tha would obviate randomized trials is not possible. **Journal of Clinical Epidemiology** 2022, 145:101-111
1139. Ioannidis JP. Citation impact and social media visibility of Great Barrington and John Snow signatories for COVID-19 strategy. **BMJ Open** 2022, 12:e052891.
1140. Ioannidis JPA. Pre-registration of mathematical models. **Mathematical Biosciences** 2022,

- 345:108782. doi: 10.1016/j.mbs.2022.108782. (perspective) (*)
1141. *Leichsenring F, Steinert C, Rabung S, Ioannidis JPA*. The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. **World Psychiatry** 2022, 21(1):133-145.
1142. *Sotiriadis A, McGoldrick E, Makrydimas G, Papatheodorou S, Ioannidis JP, Stewart F, Parker R*. Antenatal corticosteroids prior to planned caesarean at term for improving neonatal outcomes. **Cochrane Database of Systematic Reviews** 2021, 12(12):CD006614.
1143. *Erasmus A, Holman B, Ioannidis JPA*. Data-dredging bias. **BMJ Evidence Based Medicine** 2022, 27:209-211. (*)
1144. *Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA*. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. **Environmental Research** 2022, 209:112911.
1145. *Axfors C, Ioannidis JP*. Infection fatality rate of COVID-19 in community-dwelling elderly populations. **European Journal of Epidemiology** 2022, 37:235-249.
1146. *Ioannidis JP*. Reproducibility: has cancer biology failed beyond repair? **Clinical Chemistry** 2022, 68:1005-1007.
1147. *Piscitelli P, Miani A, Setti L, De Gennaro G, Rodo X, Artinano B, Vara E, Rancan L, Arias J, Passarini F, Barbieri P, Pallavicini A, Parente A, D'Oro EC, De Maio C, Saladino F, Borelli M, Colicino E, Gonçalves LMG, Di Tanna G, Colao A, Leonardi GS, Baccarelli A, Dominici F, Ioannidis JPA, Domingo JL; RESCOP Commission established by Environmental Research*. The role of outdoor and indoor air quality in the spread of SARS-CoV-2: Overview and recommendations by the research group on COVID-19 and particulate matter (RESCOP commission). **Environmental Research** 2022, 211:113038. (*)
1148. *Ioannidis JPA*. The end of the COVID-19 pandemic. **European Journal of Clinical Investigation** 2022, 52:e13782. doi: 10.1111/eci.13782.
1149. *Howick J, Koletsis D, Ioannidis JPA, Madigan C, Pandis N, Loeff M, Walach H, Sauer S, Kleijnen J, Seehra J, Johnson T, Schmidt S*. Most healthcare interventions tested in Cochrane Reviews are not effective according to high quality evidence: a systematic review and meta-analysis. **Journal of Clinical Epidemiology** 2022, 148:160-169.
1150. *Ioannidis JPA*. Factors influencing estimated effectiveness of COVID-19 vaccines in non-randomised studies. **BMJ Evidence-Based Medicine** 2023, 27:324-329.
1151. *Ioannidis JPA*. High-cited favorable studies for COVID-19 treatments ineffective in large trials. **Journal of Clinical Epidemiology** 2022, 148:1-9.
1152. *Prasad V, Ioannidis JPA*. Constructive and obsessive criticism in science. **European Journal of Clinical Investigation** 2022, 52:e13839. doi: 10.1111/eci.13839.
1153. *Ioannidis JPA, Bendavid E, Salholz-Hillel M, Boyack KW, Baas J*. Massive covidization of research citations and the citation elite. **Proceedings of the National Academy of Sciences U S A**. 2022, 119(28):e2204074119.
1154. *Medić S, Anastassopoulou C, Ložanov-Crvenković Z, Vuković V, Dragnić N, Petrović V, Ristić M, Pustabija T, Gojković Z, Tsakris A, Ioannidis JPA*. Risk and severity of SARS-CoV-2 reinfections during 2020-2022 in Vojvodina, Serbia: A population-level observational study. **Lancet Regional Health Europe** 2022, 20:100453.
1155. *Parish AJ, Alina Cristea I, Schuit E, Ioannidis JPA*. 2,109 randomized oncology trials map continuous, meager improvements in progression-free and overall survival over 50 years. **Journal of Clinical Epidemiology** 2022, 150:106-115. doi: 10.1016/j.jclinepi.2022.06.013.
1156. *Levitt M, Zonta F, Ioannidis JPA*. Comparison of pandemic excess mortality in 2020-2021 across

- different empirical calculations. **Environmental Research** 2022, 213:113754.
1157. *Tao K, Tzou PL, Kosakovsky Pond SL, Ioannidis JPA, Shafer RW*. Susceptibility of SARS-CoV-2 Omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis. **Microbiology Spectrum** 2022, 10:e0092622.
1158. *Pilz S, Ioannidis JPA*. Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase? **European Journal of Clinical Investigation** 2023, 53(2):e13906.
1159. *Pezzullo AM, Axfors C, Contopoulos-Ioannidis DG, Apostolatos A, Ioannidis JPA*. Age-stratified infection fatality rate of COVID-19 in the non-elderly population. **Environmental Research** 2023, 216(Pt 3):114655.
1160. *Ioannidis JPA, Powis SH*. COVID-19 models and expectations - Learning from the pandemic. **Advances in Biological Regulation** 2022, 86:100922. doi: 10.1016/j.jbior.2022.100922. (editorial) (*)
1161. *Zavalis EA, Ioannidis JPA*. A meta-epidemiological assessment of transparency indicators of infectious disease models. **PLoS One** 2022, 17(10):e0275380.
1162. *Ioannidis JPA*. An acceptance speech. **Journal of Evaluation in Clinical Practice** 2022, 28(6):941-942. (editorial) (*).
1163. *Schippers MC, Ioannidis JPA, Joffe AR*. Aggressive measures, rising inequalities, and mass formation during the COVID-19 crisis: An overview and proposed way forward. **Frontiers in Public Health** 2022, 10:950965.
1164. *Ioannidis JPA*. Estimating conditional vaccine effectiveness. **European Journal of Epidemiology** 2022, 37(9):885-890.
1165. *Ioannidis JPA*. Systematic reviews for basic scientists: a different beast. **Physiological Reviews** 2023, 103(1):1-5. (editorial/perspective) (*).
1166. *Hardwicke TE, Thibault RT, Kosie JE, Tzavella L, Bendixen T, Handcock SA, Köneke VE, Ioannidis JPA*. Post-publication critique at top-ranked journals across scientific disciplines: a cross-sectional assessment of policies and practice. **Royal Society Open Science** 2022, 9(8):220139.
1167. *Shi X, Zhuo H, Du Y, Nyhan K, Ioannidis J, Wallach JD*. Environmental risk factors for non-Hodgkin's lymphoma: umbrella review and comparison of meta-analyses of summary and individual participant data. **BMJ Medicine** 2022, 1(1):e000184.
1168. *Serghiou S, Axfors CA, Ioannidis JP*. Lessons learned from registration of biomedical research. **Nature Human Behaviour** 2023, 7:9-12.
1169. *Mansmann U, Locher C, Prasser F, Weissgerber T, Sax U, Posch M, Decullier E, Cristea IA, Debray T, Held L, Moher D, Ioannidis JPA, Ross JS, Ohmann C, Naudet F*. Implementing clinical trial data sharing requires training a new generation of biomedical researchers. **Nature Medicine** 2023, 29:298-301. (*)
1170. *Stanley TD, Doucouliagos H, Ioannidis JPA*. Beyond random effects: when small-study findings are more heterogeneous. **Advances in Methods and Practices in Psychological Science**. 2022, 5(4): 25152459221120427
1171. *Pezzullo AM, Ioannidis JPA, Boccia S*. Quality, integrity, and utility of COVID-19 science: opportunities for public health researchers. **European Journal of Public Health** 2023, 33:157-8. (*)
1172. *Hardwicke TE, Salhoz-Hillel M, Malicki M, Szucs D, Bendixen T, Ioannidis JPA*. Statistical guidance to authors at top-ranked journals across scientific disciplines. **American Statistician** 2022 (in press).
1173. *Brehaut E, Neupane D, Levis B, Wu y, Sun Y, Ioannidis JPA, Markham S, Cuijpers P, Patten SB, Benedetti A, Thombs BD*. “Optimal” cutoff selection in studies of depression screening tool accuracy

- using the PHQ-9, EPDS, or HADS-D: A meta-research study. **International Journal of Methods in Psychiatric Research** 2022 Dec 3:e1956.
1174. *Ioannidis JPA, Hozo I, Djulbegovic B*. Federal funding and citation metrics of US biomedical researchers, 1996 to 2022. **JAMA Network Open** 2022, 5(12):e2245590.
1175. *Ballin M, Ioannidis JPA, Bergman J, Kivipelto M, Nordstrom A, Nordstrom P*. Time-varying death risk after SARS-CoV-2-infection in Swedish long-term care facilities. **BMJ Open** 2022, 12(11):e066258.
1176. *Ioannidis JP*. Medical necessity under weak evidence and no or perverse regulatory gatekeeping. **Clinical Ethics** (in press).
1177. *Hirt J, Janiaud P, Gloy VL, Schandelmaier S, Pereira TV, Contopoulos-Ioannidis D, Goodman SN, Ioannidis J, Munkholm K, Hemkens LG*. Robustness of reported postacute health outcomes in children with SARS-CoV-2 infection: a systematic review. **Archives of Disease in Childhood** Published Online First: 02 September 2022. doi: 10.1136/archdischild-2022-324455.
1178. *van 't Hooft J, van Dijk CE, Axfors C, Alfrevic Z, Oudijk MA, Khan KS, Mol BWJ, Bossuyt PM, Ioannidis JPA*. Assessing the usefulness of randomized trials in obstetrics and gynaecology. **BJOG** 2023 Jan 25. doi: 10.1111/1471-0528.17411. Epub ahead of print.
1179. *Ioannidis JPA, Zonta F, Levitt M*. Estimates of COVID-19 deaths in Mainland China after abandoning zero COVID policy. **European Journal of Clinical Investigation** 2023;53:e13956.
1180. *Wu Y, Levis B, Daray FM, Ioannidis JPA, Patten SB, Cuijpers P, Ziegelstein RC, Gilbody S, Fischer FH, Fan S, Sun Y, He C, Krishnan A, Neupane D, Bhandari PM, Negeri Z, Riehm KE, Rice DB, Azar M, Yan XW, Imran M, Chiovitti MJ, Boruff JT, McMillan D, Kloda LA, Markham S, Henry M, Ismail Z, Loiselle CG, Mitchell ND, Al-Adawi S, Beck KR, Beraldi A, Bernstein CN, Boye B, Büel-Drabe N, Bunevicius A, Can C, Carter G, Chen CK, Cheung G, Clover K, Conroy RM, Costa-Requena G, Cukor D, Dabscheck E, De Souza J, Downing M, Feinstein A, Ferentinos PP, Flint AJ, Gallagher P, Gandy M, Grassi L, Härter M, Hernando A, Jackson ML, Jenewein J, Jetté N, Julião M, Kjærgaard M, Köhler S, König HH, Krishna LKR, Lee Y, Löbner M, Loosman WL, Love AW, Löwe B, Malt UF, Marrie RA, Massardo L, Matsuoka Y, Mehnert A, Michopoulos I, Misery L, Nelson CJ, Ng CG, O'Donnell ML, O'Rourke SJ, Öztürk A, Pabst A, Pasco JA, Peceliuniene J, Pintor L, Ponsford JL, Pulido F, Quinn TJ, Reme SE, Reuter K, Riedel-Heller SG, Rooney AG, Sánchez-González R, Saracino RM, Schellekens MPJ, Scherer M, Benedetti A, Thombs BD, et al*. Comparison of the accuracy of the 7-item HADS Depression subscale and 14-item total HADS for screening for major depression: A systematic review and individual participant data meta-analysis. **Psychological Assessment** 2023, 35(2):95-114.
1181. *Axfors C, Pezzullo AM, Contopoulos-Ioannidis DG, Apostolatos A, Ioannidis JP*. Differential COVID-19 infection rates in children, adults, and elderly: Systematic review and meta-analysis of 38 pre-vaccination national seroprevalence studies. **Journal of Global Health** 2023, 13:06004.
1182. *Leichsenring F, Steinert C, Rost F, Abbass A, Heim N, Ioannidis JPA*. A critical assessment of NICE guidelines for treatment of depression. **World Psychiatry**. 2023, 22(1):43-45. (editorial) (*)
1183. *Weinerová J, Szűcs D, Ioannidis JPA*. Published correlational effect sizes in social and developmental psychology. **Royal Society Open Science** 2022, 9(12):220311.
1184. *Kolaski K, Logan LR, Ioannidis JPA*. Guidance to best tools and practices for systematic reviews. **Systematic Reviews** (in press). 1184-1190: this guidance manuscript was agreed to be jointly peer-reviewed and be published concurrently be multiple journals so as to promote this guidance for systematic reviews most widely.
1185. *Kolaski K, Logan LR, Ioannidis JPA*. Guidance to best tools and practices for systematic reviews. **JB I Evidence Synthesis** (in press).

1186. Kolaski K, Logan LR, Ioannidis JPA. Guidance to best tools and practices for systematic reviews. **Journal of Bone and Joint Surgery** (in press)
1187. Kolaski K, Logan LR, Ioannidis JPA. Guidance to best tools and practices for systematic reviews. **Journal of Pediatric Rehabilitation Medicine** (in press)
1188. Kolaski K, Logan LR, Ioannidis JPA. Guidance to best tools and practices for systematic reviews. **Acta Anaesthetica Scandinavica** (in press).
1189. Kolaski K, Logan LR, Ioannidis JPA. Guidance to best tools and practices for systematic reviews. **American Journal of Physical Medicine and Rehabilitation** (in press).
1190. Boesen K, Ioannidis JPA. Medical advertisements and scientific journals: Time for editors and publishers to take a stance. **Journal of Evaluation in Clinical Practice** 2023 Feb 19. doi: 10.1111/jep.13816. Epub ahead of print.
1191. Beets MW, Weaver RG, Ioannidis JPA, Pfladderer CD, Jones A, von Klinggraeff L, Armstrong B. Influence of pilot and small trials in meta-analyses of behavioral interventions: a meta-epidemiological study. **Systematic Reviews** 2023 Feb 18;12(1):21.
1192. Medic S, Anastassopoulou C, Lozanov-Crvenkovic Z, Dragnic N, Petrovic V, Ristic M, Pustahija T, Tsakris A, Ioannidis JPA. Incidence, Risk, and severity of SARS-CoV-2 reinfections in children and adolescents between March 2020 and July 2022 in Serbia. **JAMA Network Open** 2023 Feb 1;6(2):e2255779.
1193. Sigurdson MK, Sainani KL, Ioannidis JPA. Homeopathy can offer empirical insights on treatment effects in a null field. **Journal of Clinical Epidemiology** 2023 Feb 1:S0895-4356(23)00010-0. doi: 10.1016/j.jclinepi.2023.01.010.
1194. Zavalis E, Contopoulos-Ioannidis DG, Ioannidis JPA. Transparency in infectious disease research: meta-research survey of specialty journals. **Journal of Infectious Diseases** (in press).
1195. Mol B, Ioannidis JPA. How do we increase the trustworthiness of medical publications? **Fertility and Sterility** (in press) (commentary) (*)
1196. Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, Li T, Mayo-Wilson E, Pham B, Phillips R, Santaguida P, Scherer RW, Moher D, Ioannidis JPA, Vohra S. Update of the Consolidated Standards of Reporting Trials (CONSORT) Harms extension 2021: Checklist and Explanation. **BMJ** (in press).
1197. Muka T, Li JX, Farahani SJ, Ioannidis JPA. An umbrella review of systematic reviews on the impact of the COVID-19 pandemic on cancer prevention and management, and patient needs. **Elife**. 2023, 12:e85679.
1198. Richter E, Liebl D, Schulte B, Lehmann N, Fuhrmann C, Jöckel KH, Ioannidis JPA, Streeck H. Analysis of fatality impact and seroprevalence surveys in a community sustaining a SARS-CoV-2 superspreading event. **Scientific Reports** 2023, 13(1):5440.
1199. Pfladderer CD, von Klinggraeff L, Burkart S, Wolfenden L, Ioannidis JPA, Beets MW. Feasibility indicators in obesity-related behavioral intervention preliminary studies: a historical scoping review. **Pilot and Feasibility Studies** 2023, 9(1):46.
1200. Ioannidis JPA, Pezzullo AM, Boccia S. The rapid growth of mega-journals: threats and opportunities. **JAMA** 2023 Mar 20.
1201. Qiu X, Wu Y, Sun Y, Levis B, Tian J, Boruff JT, Cuijpers P, Ioannidis JPA, Markham S, Ziegelstein RC, Vigod SN, Benedetti A, Thombs BD; DEPRESSION Screening Data (DEPRESSD) EPDS Group. Individual participant data meta-analysis to compare EPDS accuracy to detect major depression with and without the self-harm item. **Scientific Reports** 2023, 13(1):4026.
1202. Pellen C, Le Louarn A, Spurrier-Bernard G, Decullier E, Chrétien JM, Rosenthal E, Le Goff G, Moher D, Ioannidis JPA, Naudet F. Ten (not so) simple rules for clinical trial data-sharing. **PLoS**

Computational Biology 2023, 19(3):e1010879. (*)

1203. Stanley TD, Ioannidis JPA, Maier M, Doucouliagos H, Otte WM, Bartoš F. Unrestricted weighted least squares represent medical research better than random effects in 67,308 Cochrane meta-analyses.

Journal of Clinical Epidemiology 2023, 157:53-58.

1204. Belbasis L, Bellou V, Ioannidis JPA. Conducting umbrella reviews. **BMJ Medicine** 2022 Nov 22, 1(1):e000071. (*)

1205. Levitt M, Zonta F, Ioannidis JP. Excess death estimates from multiverse analysis in 2009-2021. **European Journal of Epidemiology** (in press).

1206. Ioannidis JPA, Zonta F, Levitt M. Flaws and uncertainties in pandemic global excess death calculations. **European Journal of Clinical Investigation** (in press).

1207. Ioannidis JPA, Zonta F, Levitt M. What really happened during the massive Omicron wave in China? **JAMA Internal Medicine** (in press). (*)

1208. Kolaski K, Logan LR, Ioannidis JP. Improving systematic reviews: guidance on guidance and other options and challenges. **Journal of Clinical Epidemiology** (invited). (*)

1209. Kolaski K, Logan LR, Ioannidis JP. Guidance and principles of good scholarship in systematic reviews. **Developmental Medicine and Child Neurology** (invited). (*)

(*) denotes publications without data analyses, simulations, systematic reviews or protocols. This group includes guidelines; primers; reporting standards; conceptual and theoretical papers; reviews without systematic searches or meta-analyses; opinion/viewpoint papers without concomitant embedded data analyses/simulations/systematic reviews.

Authorship position analysis

Among these 1209 publications: first author in 346 articles (single author in 170 articles), last author in 457 articles, author in other positions in 424 articles; single/first/last author position in 65% of articles (783/1209). Among the 424 articles that are not single/first/last-authored: second author in 99, one of several senior authors with equal contributions in many others.

LISTED CONTRIBUTOR IN OTHER PUBLICATIONS WITH MODIFIED GROUP AUTHORSHIP (not simply acknowledgment):

1210. Hammer SM, et al, AIDS Clinical Trials Group 320 study Team (including Ioannidis JP). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. **New England Journal of Medicine** 1997, 337:725-33. Accompanied by editorial in the same issue.

1211. Gulick RM, et al, AIDS Clinical Trials Group protocol 373 (including Ioannidis JP). Indinavir, zidovudine, zalcitabine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects. **Journal of Infectious Diseases** 2001, 183:715-21.

1212-1221. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE initiative (including Ioannidis JP). The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies. Published in multiple journals: **J Clin Epidemiol.** 2008 Apr;61(4):344-9. **Lancet.** 2007 Oct 20;370(9596):1453-7.

Epidemiology. 2007 Nov;18(6):800-4. **Bull World Health Organ.** 2007 Nov;85(11):867-72. **Prev Med.** 2007 Oct;45(4):247-51. **BMJ.** 2007 Oct 20;335(7624):806-8. **PLoS Med.** 2007 Oct 16;4(10):e296. **Ann Intern Med.** 2007 Oct 16;147(8):573-7. **Gac Sanit.** 2008 Mar-Apr;22(2):144-50. **Rev Esp Salud Publica** 2008, 82:251-9. Many of these have also been accompanied by editorials.

1222-1227. Moher D, Liberati A, Tetzlaff JM, Altman DG, and the PRISMA Group (including Ioannidis JPA). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA

- Statement. Concurrent publication in **PLoS Medicine** 2009, 6:e1000097. **Annals of Internal Medicine** 2009, 151:264-9, W64. **BMJ** 2009, 339:b2535. **Journal of Clinical Epidemiology** 2009, 62:1006-12. **Zhong Xi Yi Jie He Xue Bao** 2009, 7:889-96. **Physical Therapy** 2009, 89:873-80. **International Journal of Surgery** 2010, 8:336-41.
1228. Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Varret M, Prakash SK, Li AH, d'Indy H, Braverman AC, Grandchamp B, Kwartler CS, Gouya L, Santos-Cortez RL, Abifadel M, Leal SM, Muti C, Shendure J, Gross MS, Rieder MJ, Vahanian A, Nickerson DA, Michel JB; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project (including Ioannidis J), Jondeau G, Milewicz DM. TGFB2 mutations cause familial thoracic aortic aneurysms and dissections associated with mild systemic features of Marfan syndrome. **Nature Genetics** 2012, 44:916-21.
1229. Emond MJ, Louie T, Emerson J, Zhao W, Mathias RA, Knowles MR, Wright FA, Rieder MJ, Tabor HK, Nickerson DA, Barnes KC; National Heart, Lung, and Blood Institute (NHLBI) GO Exome Sequencing Project (including Ioannidis J); Lung GO, Gibson RL, Bamshad MJ. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic *Pseudomonas aeruginosa* infection in cystic fibrosis. **Nature Genetics** 2012, 44:886-9.
1230. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, Gabriel S, Altshuler D, Shendure J, Nickerson DA, Bamshad MJ; NHLBI Exome Sequencing Project (including Ioannidis J), Akey JM. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. **Nature** 2013, 493:216-20.
1231. Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, Guo S, Gonzalez M, Hedges DJ, Robertson PD, Krumm N, Nickerson DA, Hershberger RE; National Heart, Lung, and Blood Institute GO Exome Sequencing Project (including Ioannidis J) and the Exome Sequencing Project Family Studies Project Team. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. **Circulation Cardiovascular Genetics** 2013, 6:144-53.
1232. Schork AJ, Thompson WK, Pham P, Torkamani A, Roddey JC, Sullivan PF, Kelsoe JR, O'Donovan MC, Furberg H; Tobacco and Genetics Consortium (including Ioannidis J); Bipolar Disorder Psychiatric Genomics Consortium; Schizophrenia Psychiatric Genomics Consortium, Schork NJ, Andreassen OA, Dale AM. All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. **PLoS Genetics** 2013, 9:e1003449.
1233. Dwan K, Gamble C, Williamson PR, Kirkham JJ; Reporting Bias Group (including Ioannidis J). Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. **PLoS One** 2013, 8:e66844.
1234. O'Connor TD, Kiezun A, Bamshad M, Rich SS, Smith JD, Turner E; NHLBIGO Exome Sequencing Project (including Ioannidis J); ESP Population Genetics, Statistical Analysis Working Group, Leal SM, Akey JM. Fine-scale patterns of population stratification confound rare variant association tests. **PLoS One** 2013, 8:e65834.
1235. Johnsen JM, Auer PL, Morrison AC, Jiao S, Wei P, Haessler J, Fox K, McGee SR, Smith JD, Carlson CS, Smith N, Boerwinkle E, Kooperberg C, Nickerson DA, Rich SS, Green D, Peters U, Cushman M, Reiner AP; NHLBI Exome Sequencing Project (including Ioannidis J). Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project. **Blood** 2013, 122:590-7.
1236. Thorgeirsson TE, Gudbjartsson DF, Sulem P, Besenbacher S, Styrkarsdottir U, Thorleifsson G, Walters GB; TAG Consortium (including Ioannidis J); Oxford-GSK Consortium; ENGAGE consortium, Furberg H, Sullivan PF, Marchini J, McCarthy MI, Steinthorsdottir V, Thorsteinsdottir U, Stefansson K. A common biological basis of obesity and nicotine addiction. **Translational Psychiatry** 2013, 3:e308.
1237. Evans DM, Brion MJ, Paternoster L, Kemp JP, McMahon G, Munafò M, Whitfield JB,

- Medland SE, Montgomery GW; GIANT Consortium; CRP Consortium; TAG Consortium (including Ioannidis J), Timpson NJ, St Pourcain B, Lawlor DA, Martin NG, Dehghan A, Hirschhorn J, Davey Smith G. Mining the human phenome using allelic scores that index biological intermediates. **PLoS Genetics** 2013, 9:e1003919.
1238. Rosenthal EA, Ranchalis J, Crosslin DR, Burt A, Brunzell JD, Motulsky AG, Nickerson DA; NHLBI GO Exome Sequencing Project (including Ioannidis J), Wijsman EM, Jarvik GP. Joint linkage and association analysis with exome sequence data implicates SLC25A40 in hypertriglyceridemia. *Am J Hum Genet.* 2013 Dec 5;93(6):1035-45. doi: 10.1016/j.ajhg.2013.10.019. Epub 2013 Nov 21.
1239. Lange LA, Hu Y, Zhang H, Xue C, Schmidt EM, Tang ZZ, Bizon C, Lange EM, Smith JD, Turner EH, Jun G, Kang HM, Peloso G, Auer P, Li KP, Flannick J, Zhang J, Fuchsberger C, Gaulton K, Lindgren C, Locke A, Manning A, Sim X, Rivas MA, Holmen OL, Gottesman O, Lu Y, Ruderfer D, Stahl EA, Duan Q, Li Y, Durda P, Jiao S, Isaacs A, Hofman A, Bis JC, Correa A, Griswold ME, Jakobsdottir J, Smith AV, Schreiner PJ, Feitosa MF, Zhang Q, Huffman JE, Crosby J, Wassel CL, Do R, Franceschini N, Martin LW, Robinson JG, Assimes TL, Crosslin DR, Rosenthal EA, Tsai M, Rieder MJ, Farlow DN, Folsom AR, Lumley T, Fox ER, Carlson CS, Peters U, Jackson RD, van Duijn CM, Uitterlinden AG, Levy D, Rotter JI, Taylor HA, Gudnason V Jr, Siscovick DS, Fornage M, Borecki IB, Hayward C, Rudan I, Chen YE, Bottinger EP, Loos RJ, Sætrom P, Hveem K, Boehnke M, Groop L, McCarthy M, Meitinger T, Ballantyne CM, Gabriel SB, O'Donnell CJ, Post WS, North KE, Reiner AP, Boerwinkle E, Psaty BM, Altshuler D, Kathiresan S, Lin DY, Jarvik GP, Cupples LA, Kooperberg C, Wilson JG, Nickerson DA, Abecasis GR, Rich SS, Tracy RP, Willer CJ; NHLBI Grand Opportunity Exome Sequencing Project (including Ioannidis J). Whole-Exome Sequencing Identifies Rare and Low-Frequency Coding Variants Associated with LDL Cholesterol. **American Journal of Human Genetics** 2014, 94:233-45.
1240. Tabor HK, Auer PL, Jamal SM, Chong JX, Yu JH, Gordon AS, Graubert TA, O'Donnell CJ, Rich SS, Nickerson DA; NHLBI Exome Sequencing Project (including Ioannidis J), Bamshad MJ. Pathogenic variants for Mendelian and complex traits in exomes of 6,517 European and African Americans: implications for the return of incidental results. **American Journal of Human Genetics** 2014, 95:183-93.
- 1241-1250. Collins GS, Reitsma JB, Altman DG, Moons KGM, TRIPOD Group (including Ioannidis JP). Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement. Published concurrently in: **Annals of Internal Medicine, BJOG, British Journal of Surgery, BMC Medicine, British Medical Journal, Circulation, Diabetic Medicine, European Journal of Clinical Investigation, European Urology, and Journal of Clinical Epidemiology.**
1251. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel (including Ioannidis JP). SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. **Gastrointestinal Endoscopy** 2015, 81:489-501.e26.
1252. Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R; SCENIC Guideline Development Panel (including Ioannidis JP). SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. **Gastroenterology** 2015, 148:639-651.e28.
1253. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, Strawbridge RJ, Pers TH, Fischer K, Justice AE, Workalemahu T, Wu JM, Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson S, Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, Wood AR, Chen J, Fehrmann R, Karjalainen J, Kahali B, Liu CT, Schmidt EM, Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL, Buyske S, Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, Kristiansson K, Mangino M, Mateo Leach I, Medina-Gomez

C, Palmer CD, Pasko D, Pechlivanis S, Peters MJ, Prokopenko I, Stančáková A, Ju Sung Y, Tanaka T, Teumer A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Ärnlöv J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Blüher M, Böhringer S, Bonnet F, Böttcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Daw EW, Deelen J, Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR, Estrada K, Eury E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, Grammer TB, Gräßler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, Hassinen M, Hayward C, Heikkilä K, Herzig KH, Helmer Q, Hillege HL, Holmen O, Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP, Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, Lichtner P, Lind L, Lindström J, Lobbens S, Lorentzon M, Mach F, Magnusson PK, Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, Moayyeri A, Monda KL, Mooijaart SP, Mühleisen TW, Mulas A, Müller G, Müller-Nurasyid M, Nagaraja R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna S, Schernagl H, Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Vernon Smith A, Stirrups K, Stringham HM, Sundström J, Swertz MA, Swift AJ, Syvänen AC, Tayo BO, Thorand B, Thorleifsson G, Tomaschitz A, Troffa C, van Oort FV, Verweij N, Vonk JM, Waite LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A, Zhang Q, Hua Zhao J, Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, Hedman ÅK, Hivert MF, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JR, Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, Westra HJ, Zondervan KT; ADIPOGen Consortium; CARDIOGRAMplusC4D Consortium; CKDGen Consortium; GEFOS Consortium (including Ioannidis JP); GENIE Consortium; GLGC; ICBP; International Endogene Consortium; LifeLines Cohort Study; MAGIC Investigators; MuTHER Consortium; PAGE Consortium; ReproGen Consortium, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Blangero J, Brown MJ, Burnier M, Campbell H, Chakravarti A, Chines PS, Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de Geus EJ, Dörr M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrières J, Forouhi NG, Forrester T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, Hattersley AT, Heliövaara M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, Homuth G, Humphries SE, Hyppönen E, Illig T, Jarvelin MR, Johansen B, Jousilahti P, Jula AM, Kaprio J, Kee F, Keinanen-Kiukkaanniemi SM, Kooner JS, Kooperberg C, Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lyssenko V, Männistö S, Marette A, Matise TC, McKenzie CA, McKnight B, Musk AW, Möhlenkamp S, Morris AD, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Shuldiner AR, Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tönjes A, Tremblay A, Tremoli E, Vohl MC, Völker U, Vollenweider P, Wilson JF, Witteman JC, Adair LS, Bochud M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ, Hamsten A, Hui J, Hveem K, Jöckel KH, Kivimäki M, Kuh D, Laakso M, Liu Y, März W, Munroe PB, Njølstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Pérusse L, Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Thorsteinsdottir U, Stumvoll M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker M, Wareham NJ, Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Stefansson K, van Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL. New genetic loci link adipose and insulin biology to body fat distribution. **Nature** 2015, 518:187-96.

1254. Iorns E, Gunn W, Erath J, Rodriguez A, Zhou J, Benzinou M; Reproducibility Initiative (including Ioannidis JP). Replication attempt: "Effect of BMAP-28 antimicrobial peptides on Leishmania

major promastigote and amastigote growth: role of leishmanolysin in parasite survival". **PLoS One** 2014, 9:e114614.

1255. Do R, Stitzel NO, Won HH, Jørgensen AB, Duga S, Angelica Merlini P, Kiezun A, Farrall M, Goel A, Zuk O, Guella I, Asselta R, Lange LA, Peloso GM, Auer PL; NHLBI Exome Sequencing Project (including Ioannidis J), Girelli D, Martinelli N, Farlow DN, DePristo MA, Roberts R, Stewart AF, Saleheen D, Danesh J, Epstein SE, Sivapalaratnam S, Hovingh GK, Kastelein JJ, Samani NJ, Schunkert H, Erdmann J, Shah SH, Kraus WE, Davies R, Nikpay M, Johansen CT, Wang J, Hegele RA, Hechter E, Marz W, Kleber ME, Huang J, Johnson AD, Li M, Burke GL, Gross M, Liu Y, Assimes TL, Heiss G, Lange EM, Folsom AR, Taylor HA, Olivieri O, Hamsten A, Clarke R, Reilly DF, Yin W, Rivas MA, Donnelly P, Rossouw JE, Psaty BM, Herrington DM, Wilson JG, Rich SS, Bamshad MJ, Tracy RP, Cupples LA, Rader DJ, Reilly MP, Spertus JA, Cresci S, Hartiala J, Tang WH, Hazen SL, Allayee H, Reiner AP, Carlson CS, Kooperberg C, Jackson RD, Boerwinkle E, Lander ES, Schwartz SM, Siscovick DS, McPherson R, Tybjaerg-Hansen A, Abecasis GR, Watkins H, Nickerson DA, Ardissino D, Sunyaev SR, O'Donnell CJ, Altshuler D, Gabriel S, Kathiresan S. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. **Nature** 2015, 518:102-6.

1256-1258. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF; STARD Group (including Ioannidis J). STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. **BMJ** 2015, 351:h5527. **Clinical Chemistry** 2015, 61:1446-52. **Radiology** 2015, 277:826-32.

1259. ASA statement on statistical significance and P-values. **The American Statistician** 2016.

1260. Cohen JF, Korevaar DA, Gatsonis CA, Glasziou PP, Hooft L, Moher D, Reitsma JB, de Vet HC, Bossuyt PM; STARD Group (including Ioannidis J). STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. **BMJ** 2017, 358:j3751.

1261. Willems SM, Wright DJ, Day FR, Trajanoska K, Joshi PK, Morris JA, Matteini AM, Garton FC, Grarup N, Oskolkov N, Thalamuthu A, Mangino M, Liu J, Demirkan A, Lek M, Xu L, Wang G, Oldmeadow C, Gaulton KJ, Lotta LA, Miyamoto-Mikami E, Rivas MA, White T, Loh PR, Aadahl M, Amin N, Attia JR, Austin K, Benyamin B, Brage S, Cheng YC, Cieszczyk P, Derave W, Eriksson KF, Eynon N, Linneberg A, Lucia A, Massidda M, Mitchell BD, Miyachi M, Murakami H, Padmanabhan S, Pandey A, Papadimitriou I, Rajpal DK, Sale C, Schnurr TM, Sessa F, Shrine N, Tobin MD, Varley I, Wain LV, Wray NR, Lindgren CM, MacArthur DG, Waterworth DM, McCarthy MI, Pedersen O, Khaw KT, Kiel DP; GEFOS Any-Type of Fracture Consortium (including Ioannidis J), Pitsiladis Y, Fuku N, Franks PW, North KN, van Duijn CM, Mather KA, Hansen T, Hansson O, Spector T, Murabito JM, Richards JB, Rivadeneira F, Langenberg C, Perry JRB, Wareham NJ, Scott RA. Large-scale GWAS identifies multiple loci for hand grip strength providing biological insights into muscular fitness. **Nature Communications** 2017, 8:16015.

1262. Trajanoska K, Morris JA, Oei L, Zheng HF, Evans DM, Kiel DP, Ohlsson C, Richards JB, Rivadeneira F; GEFOS/GENOMOS consortium (including Ioannidis JP) and the 23andMe research team. Assessment of the genetic and clinical determinants of fracture risk: genome wide association and mendelian randomisation study. **BMJ** 2018, 362:k3225.

1263. Rosenthal EA, Shirts BH, Amendola LM, Horike-Pyne M, Robertson PD, Hisama FM, Bennett RL, Dorschner MO, Nickerson DA, Stanaway IB, Nassir R, Vickers KT, Li C, Grady WM, Peters U, Jarvik GP; NHLBI GO Exome Sequencing Project (including Ioannidis J). Rare loss of function variants in candidate genes and risk of colorectal cancer. **Human Genetics** 2018, 137:795-806.

1264. Wolff RF, Moons KGM, Riley RD, Whiting PF, Westwood M, Collins GS, Reitsma JB, Kleijnen J, Mallett S; PROBAST Group (including Ioannidis J). PROBAST: A tool to assess the risk of bias and applicability of prediction model studies. **Annals of Internal Medicine** 2019, 170:51-58.

1265. Levis B, Benedetti A, Thombs BD; DEPRESSION Screening Data (DEPRESSD) Collaboration

- (including Ioannidis JP). Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. **BMJ** 2019, 365:l1476.
1266. McGrath S, Zhao X, Steele R, Thombs BD, Benedetti A; DEPRESSion Screening Data (DEPRESSD) Collaboration (including Ioannidis J). Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis. **Statistical Methods in Medical Research** 2020, 962280219889080. doi: 10.1177/0962280219889080. Epub ahead of print.
1267. Levis B, Negeri Z, Sun Y, Benedetti A, Thombs BD; DEPRESSion Screening Data (DEPRESSD) EPDS Group (including Ioannidis J). Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: systematic review and meta-analysis of individual participant data. **BMJ** 2020, 371:m4022.
1268. Harel D, Levis B, Ishihara M, Levis AW, Vigod SN, Howard LM, Thombs BD, Benedetti A; DEPRESSion Screening Data (DEPRESSD) EPDS Collaboration (including Ioannidis J). Shortening the Edinburgh postnatal depression scale using optimal test assembly methods: Development of the EPDS-Dep-5. **Acta Psychiatrica Scandinavica** 2021, 143:348-362.
1269. Bhandari PM, Levis B, Neupane D, Patten SB, Shrier I, Thombs BD, Benedetti A; Depression Screening Data (DEPRESSD) EPDS Group (including Ioannidis J). Data-driven methods distort optimal cutoffs and accuracy estimates of depression screening tools: a simulation study using individual participant data. **Journal of Clinical Epidemiology** 2021, 137:137-147.
1270. Neupane D, Levis B, Bhandari PM, Thombs BD, Benedetti A; DEPRESSion Screening Data (DEPRESSD) Collaboration (including Ioannidis J). Selective cutoff reporting in studies of the accuracy of the Patient Health Questionnaire-9 and Edinburgh Postnatal Depression Scale: Comparison of results based on published cutoffs versus all cutoffs using individual participant data meta-analysis. **International Journal of Methods in Psychiatric Research** 2021, 30(3):e1873.
1271. Negeri ZF, Levis B, Sun Y, He C, Krishnan A, Wu Y, Bhandari PM, Neupane D, Brehaut E, Benedetti A, Thombs BD; Depression Screening Data (DEPRESSD) PHQ Group (including Ioannidis J). Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression: updated systematic review and individual participant data meta-analysis. **BMJ** 2021, 375:n2183.
1272. Wu Y, Levis B, Sun Y, He C, Krishnan A, Neupane D, Bhandari PM, Negeri Z, Benedetti A, Thombs BD; DEPRESSion Screening Data (DEPRESSD) HADS Group (including Ioannidis J). Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. **BMJ** 2021, 373:n972.
1273. Nejstgaard CH, Lundh A, Abdi S, Clayton G, Gelle MH A, Laursen DRT, Olorisade BK, Savović J, Hróbjartsson A, on behalf of the COMFIT consortium (including Ioannidis J). Combining meta-epidemiological study datasets on commercial funding of randomised clinical trials: database, methods, and descriptive results of the COMFIT study. **Research Synthesis Methods** 2022, 13(2), 214-228.
1274. Wang SV, Sreedhara SK, Schneeweiss S; REPEAT Initiative (including Ioannidis J). Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. **Nature Communications** 2022, 13(1):5126.

LETTERS (COMMENTS/REPLIES) PUBLISHED IN INTERNATIONAL JOURNALS:

1. Barza M, Ioannidis J, Lau J. Single or multiple daily doses of aminoglycosides. **BMJ** 1996, 313:490-1.
2. Ioannidis JPA, De Ferranti SD, Barza M, Lau J. Antibiotics for acute sinusitis in general practice. **BMJ** 1999, 318:1623-4.
3. Ioannidis JPA, Cappelleri JC, Lau J. Comparing results from meta-analyses vs large trials. **JAMA** 1998, 280:518-9.
4. Ioannidis JPA. Time lag bias in publishing clinical trials. **JAMA** 1998, 279:1952-3.
5. Lau J, Ioannidis JPA, Schmid CH. Meta-analyses, multivariate analyses, and coping with the play of

- chance. **Lancet** 1998, 351:1062-3.
6. Cappelleri JC, Ioannidis JPA, Schmid CH, Lau J. Large trials vs. meta-analysis of smaller trials. **JAMA** 1997, 277:376-8.
7. Ioannidis JPA, Lau J, Sacks HS. Zidovudine in patients with HIV infection. **Ann Intern Med** 1996, 124:371-3.
8. Ioannidis JPA, Lau J. Safety reporting in randomised trials. **JAMA** 2001, 285:2076-8.
9. Ioannidis JPA, Contopoulos-Ioannidis DG, Lau J. Using meta-analysis to answer clinical questions. **JAMA** 2001, 286:2669-70.
10. Contopoulos-Ioannidis DG, Ioannidis JPA, Lau J. Azithromycin is effective in patients with chronic bronchitis-Reply. **Journal of Antimicrobial Chemotherapy** 2002, 50:433-4.
11. Balk E, Bonis P, Lau J, Ioannidis JP. Allocation concealment in clinical trials. **JAMA** 2002, 288:2406-9.
12. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Reply from the authors. **Kidney International** 2005, 67:779-80.
13. Contopoulos-Ioannidis DG, Ioannidis JPA. Extended-interval aminoglycosides in children: more guidance is needed: reply. **Pediatrics** 2005, 115:827-8.
14. Ioannidis JPA, Karvouni E, Katritsis DG. Creatine kinase-MB elevation following stent implantation – reply. **Journal of the American College of Cardiology** 2005, 45:1908-1909.
15. Trikalinos TA, Panidou ET, Ioannidis JP. Reply to Badri et al. on 'Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis'. **AIDS** 2005;19:1336-7.
16. Mauri D, Pavlidis N, Ioannidis JPA. Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. **Journal of the National Cancer Institute** 2005, 97:858-9.
17. Contopoulos-Ioannidis DG, Ioannidis JPA. Reply. **Journal of Allergy and Clinical Immunology** 2006, 117:222-3.
18. Ioannidis JPA. Contradictions in highly cited clinical research. **JAMA** 2005, 294:2696.
19. Ioannidis JP. Truth, probability and frameworks. **PLoS Medicine** 2005, 2(11):e398.
20. Ioannidis JPA, Papanikolaou P. Not so surprising findings – response. **CMAJ** 2006, 175:172.
21. Ioannidis JP, Mauri D, Polyzos N, Pavlidis N. **Journal of the National Cancer Institute** 2007, 99:76-7.
22. Ioannidis JPA. Why most published research findings are false: Author's reply to Goodman and Greenland. **PLoS Medicine** 2007, 4:1132-1133.
23. Patsopoulos NA, Tatsioni A, Ioannidis JPA. Claims of sex-gene interactions: In reply. **Journal of the American Medical Association** 2007, 298:2742.
24. Hernandez AV, Westerhout CM, Steyerberg EW, Ioannidis JPA, Bueno H, White H, Theroux P, Moliterno DJ, Armstrong PW, Califf RM, Wallentin LC, Simoons ML, Boersma E. The authors' reply. **Heart** 2007, 93:1293.
25. Ioannidis JPA, Katritsis D. Reply to letter on: Revisiting the role of percutaneous revascularization versus medical therapy for later infarct-related artery occlusion. **American Heart Journal** 2008, 155:e43.
26. Patsopoulos NA, Ioannidis JP. Author's response: Heterogeneity metrics: Not perfect, but would not abandon. **International Journal of Epidemiology** 2009, 39:933.
27. Lill CM, Schjerve BM, Roehr JT, Zauft U, Allen NC, Zipp F, McQueen MB, Kavvoura FK, Ioannidis JP, Khoury MJ, Tanzi RE, Bertram L. Correspondence to Sand et Al. "Critical reappraisal of a catechol-o-methyltransferase transversion variant in schizophrenia". **Biological Psychiatry** 2010, 67:e45-8.
28. Salanti G, Zeggini E, Ioannidis JPA. Three authors reply. **American Journal of Epidemiology** 2010, 171:1155-6, reply to comment on Am J Epidemiol. 2009 Sep 1;170(5):537-45.

29. Tzoulaki I, Ioannidis JP. Assessing predictive performance beyond the Framingham risk score: reply. **JAMA** 2010, 303:1369.
30. Khoury MJ, Gwinn M, Ioannidis JPA. The authors reply. **American Journal of Epidemiology** 2011, 173:718-9.
31. Siontis GCM, Tzoulaki I, Ioannidis JPA. The authors reply. **Archives of Internal Medicine** 2012, 172: 195.
32. Thombs BD, Coyne JC, Cuijpers P, De Jonge P, Gilbody S, Ioannidis JPA, Johnson BT, Patten SB, Turner EH, Ziegelstein RC. The authors respond. **Canadian Medical Association Journal** 2012, 184:438-9.
33. Siontis GC, Tzoulaki I, Siontis KC, Ioannidis JP. Authors' reply to Noble and colleagues and Liew and colleagues. **British Medical Journal** 2012, 345:e4360.
34. Ioannidis JP. Usefulness of medical conferences. **JAMA** 2012, 308:32-33.
35. Ioannidis JP, Nicholson JM. NIH funding: The critics respond. **Nature** 2013, 493:26.
36. Ioannidis JP. Personalized medicine: there is nothing personal. **Archives of Internal Medicine** 2012, 172:1691-2.
37. Ioannidis JP, Pereira TV, Horwitz RI. Emergence of large treatment effects from small trials--reply. **JAMA** 2013, 309:768-9.
38. Ioannidis JP. Mega-randomized clinical trials for blockbuster drugs--reply. **JAMA** 2013, 309:1683.
39. Ioannidis JP. In reply II-Reversal of Medical Practices. **Mayo Clin Proceedings** 2013, 88:1184.
40. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. Confidence and precision increase with high statistical power. **Nature Reviews Neuroscience** 2013, 14:585-6.
41. Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. Empirical evidence for low reproducibility indicates low pre-study odds. **Nature Reviews Neuroscience** 2013, 14:877.
42. Ioannidis JP. Research accomplishments that are too good to be true: reply to Ting. **Intensive Care Medicine** 2014 Jan 30.
43. Fanelli D, Ioannidis JPA. Reply to Nuijten et al.: Reanalyses actually confirm that US studies overestimate effects in softer research. **PNAS** 2014, 111:E714-5.
44. Glasziou P, Macleod M, Chalmers I, Ioannidis JP, Al-Shahi Salman R, Chan AW. Research: increasing value, reducing waste - Authors' reply. **Lancet** 2014, 383:1126-7.
45. Theodoratou E, Ioannidis JP. Authors' reply to Boucher. **BMJ** 2014, 348:g2927.
46. Ioannidis JP. Guidelines for cardiovascular risk assessment and cholesterol treatment--reply. **JAMA** 2014, 311:2235-6.
47. Ioannidis JP, Hozo I, Djulbegovic B. Study design and the drug development process--reply. **JAMA** 2014, 311:2023-4.
48. Ebrahim S, Ioannidis JP. Reanalyses of trial results – reply. **JAMA** 2015, 313:93.
49. Siontis GC, Ioannidis JP. Response to letter: more rigorous, not less, external validation is needed. **Journal of Clinical Epidemiology** 2016, 69:250-1.
50. Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Authors' reply to Selvapatt and colleagues, Matthews and colleagues, Badrinath, and Ward and Lee. **BMJ** 2015, 350:h674.
51. Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Authors' reply to Foster and colleagues. **BMJ** 2015, 350:h1000.
52. Tsilidis KK, Ioannidis JP. Authors' reply to editorial linked to their umbrella review of meta-analyses of observational studies on type 2 diabetes and cancer. **BMJ** 2015, 350:h711.
53. Djulbegovic B, Hozo I, Ioannidis J. Modern health care as a game theory problem: reply. **European Journal of Clinical Investigation** 2015, 45(4):443.

54. Siontis KC, Siontis GC, Contopoulos-Ioannidis DG, Ioannidis JP. Patient outcomes in randomized comparisons of diagnostic tests are still the ultimate judge. **Journal of Clinical Epidemiology** 2016, 69:267-8.
55. Hsing A, Ioannidis JP. Korean National Health Insurance database – reply. **JAMA Internal Medicine** 2016, 176:138-9.
56. Flacco ME, Manzoli L, Ioannidis JP. Noninferiority is almost certain with lenient noninferiority margins. **Journal of Clinical Epidemiology** 2016, 71:118.
57. Verghese A, Charlton B, Kassirer JP, Ramsey M, Ioannidis JP. Reply. **American Journal of Medicine** 2016, 129(7):e85.
58. Stavropoulou C, Parmar D, Ioannidis JP. Research authors' reply to Barlow and Barr and Taylor-Robinson. **BMJ** 2016, 355:i6639.
59. Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Authors' reply to Pérol and colleagues. **BMJ** 2016, 355:i6747.
60. Joyner MJ, Paneth N, Ioannidis JP. Underperforming Big Ideas in Biomedical Research-Reply. **JAMA** 2017, 317:322.
61. Ioannidis JPA. Nonreproducibility of Preclinical Research-Reply. **JAMA** 2017, 317:2453.
62. Ioannidis JPA, Trepanowski JF. Conflict of interest in nutrition research-Reply. **JAMA** 2018, 320:94-95.
63. Ladanie A, Ioannidis JPA, Stafford RS, Ewald H, Bucher HC, Hemkens LG. Off-label prescription: experience is a gloomy lantern that does not even illuminate its bearer. Author response. **Journal of Clinical Epidemiology** 2018, 101:127-128.
64. Ioannidis JPA. Lowering the P Value Threshold-Reply. **JAMA** 2018, 320:937-938.
65. Manrai AK, Patel CJ, Ioannidis JPA. Using Big Data to Determine Reference Values for Laboratory Tests-Reply. **JAMA** 2018, 320:1496.
66. Cristea IA, Ioannidis JPA. Disclosures Can Always Be Improved-Reply. **JAMA Psychiatry** 2018, 75:1303-4.
67. Cipriani A, Salanti G, Furukawa TA, Turner E, Ioannidis JPA, Geddes JR. Network meta-analysis of antidepressants - Authors' reply. **Lancet** 2018, 392:1012-1013.
68. Ioannidis JPA. Reforming nutritional epidemiologic research-Reply. **JAMA** 2019, 321:310.
69. Solmi M, Ioannidis JPA, Carvalho AF. Environmental risk factors and interventions for obesity. **European Journal of Clinical Investigation** 2019, 49:e13080.
70. Amann RI, Baichoo S, Blencowe BJ, Bork P, Borodovsky M, Brooksbank C, Chain PSG, Colwell RR, Daffonchio DG, Danchin A, de Lorenzo V, Dorrestein PC, Finn RD, Fraser CM, Gilbert JA, Hallam SJ, Hugenholtz P, Ioannidis JPA, Jansson JK, Kim JF, Klenk HP, Klotz MG, Knight R, Konstantinidis KT, Kyrpides NC, Mason CE, McHardy AC, Meyer F, Ouzounis CA, Patrinos AAN, Podar M, Pollard KS, Ravel J, Muñoz AR, Roberts RJ, Rosselló-Móra R, Sansone SA, Schloss PD, Schriml LM, Setubal JC, Sorek R, Stevens RL, Tiedje JM, Turjanski A, Tyson GW, Ussery DW, Weinstock GM, White O, Whitman WB, Xenarios I. Consent insufficient for data release-Response. **Science** 2019, 364:446.
71. Adami HO, Kalager M, Valdimarsdottir U, Bretthauer M, Ioannidis JPA. Author reply to: the name of the game: is preventive screening "cancer screening?" **European Journal of Clinical Investigation** 2019 Mar 4:e13097. doi: 10.1111/eci.13097. [Epub ahead of print]
72. Oren O, Kebebew E, Ioannidis JPA. Solutions to reduce unnecessary imaging-Reply. **JAMA** 2019, 321:2243.
73. Amad A, Jardri R, Rousseau C, Laroche Y, Ioannidis JPA, Naudet F. Reply to the Letter to the Editor: "Mixing Apples and Oranges in Assessing Outcomes of Repetitive Transcranial Stimulation Meta-Analyses". **Psychotherapy Psychosomatics** 2020, 89(2):108.

74. Ioannidis JPA. Dissenting Opinions in Nutrition Research-Reply. **JAMA** 2020, 323(10):1000-1001.
75. Tawfik DS, Ioannidis JPA. Evidence Relating Health Care Provider Burnout and Quality of Care. **Annals of Internal Medicine** 2020, 172:438-439.
76. Adibi A, Sadatsafavi M, Ioannidis JPA. Testing Clinical Prediction Models-Reply. **JAMA** 2020, 324:2000.
77. Bendavid E, Oh C, Bhattacharya J, Ioannidis JPA. Response to Letters Re: 'Assessing mandatory stay- At- Home and business closure effects on the spread of COVID- 19'. **European Journal of Clinical Investigation** 2021 51:e13553.

BOOK REVIEWS

1. Ioannidis JP. Facing up to medical error. **Lancet** 2011, 377:457-8.
2. Ioannidis JP. Medical screening: prevention can be bad for your health. **Lancet Oncology** 2012, 13:1201-2.

BOOKS, BOOK CHAPTERS AND MONOGRAPHS:

1. Lau J, Ioannidis JPA, Schmid CH. "Quantitative Synthesis". In: Systematic Reviews. Synthesis of Best Evidence for Health Care Decisions. C. Mulrow and D. Cook, Eds. American College of Physicians, Philadelphia, 1998. pp. 91-102.
2. Ioannidis JPA and Lau J. "Evidence-Based Medicine: A quantitative approach to decision making" In : Decision Making in Health Care: Theory, Psychology, and Applications. G.B. Chapman and F.A. Sonnenberg, Eds. Cambridge University Press, 2000. pp. 110-44.
3. Cappelleri J, Ioannidis JPA, Lau J. "Meta-analysis of Therapeutic Trials" In: Encyclopedia of Biopharmaceutical Statistics. S-C. Chow, Ed. Marcel Dekker, 2000.
4. Cappelleri J, Ioannidis JPA, Lau J. "Meta-analysis of Therapeutic Trials" In: Encyclopedia of Biopharmaceutical Statistics. S-C. Chow, Ed. Marcel Dekker, 2nd edition, 2002 [new expanded version].
5. Ioannidis JPA, Schmid CH, Lau J. "Meta-analysis approaches for epidemiologic research on asbestos". In: Sourcebook on Asbestos Diseases, vol 18, Lexis/Reed Elsevier, 1998.
6. Ioannidis JPA, Barza M, Lau J. Management of acute sinusitis. PIER module. American College of Physicians, Philadelphia, 2000.
7. Ioannidis JPA. Principles of evidence-based medicine (in Greek), pp. 334+xvi, Athens, 2000.
8. Ioannidis JPA, Phillips A, Johnston M, Wilkinson D. "Opportunistic Infections and HIV." In: Clinical Evidence. BMJ Publishing Group, 2000 (issue 4) and 2001 (issue 5).
9. Ioannidis JPA, Wilkinson D. "Opportunistic Infections and HIV." In: Clinical Evidence. BMJ Publishing Group, 2001 (issue 6). [new expanded version]
10. Ioannidis JPA, Wilkinson D. "Opportunistic Infections and HIV." In: Clinical Evidence. BMJ Publishing Group, June 2002 (issue 7). [new expanded version]
11. Ioannidis JPA, Wilkinson D. "Opportunistic Infections and HIV". In: Clinical Evidence-Concise Version. BMJ Publishing Group, December 2002 (issues 8, 9 and 10). [new revised version]
12. Lau J, Ioannidis JPA, et al for the New England Medical Center Evidence-based Practice Center. Evaluation of technologies for identifying acute cardiac ischemia in emergency departments. Rockville, MD: Agency for Healthcare Services and Research, 2000.
13. Goudas L, Carr DB, Block R, Balk E, Ioannidis JPA, Terrin N, Goudas M, Chew P, Lau J. Management of Cancer Pain. Evidence Report/Technology Assessment. Rockville, MD: Agency for Healthcare Research and Quality, 2001.
14. Lau J, Ioannidis JPA, Wald ER. Diagnosis and treatment of uncomplicated acute sinusitis in children. Evidence report/technology assessment no. 9, supplement. Agency for Healthcare Research and Quality publication. Rockville, MD: Agency for Healthcare Research and Quality, 2000.

15. Ioannidis JPA. Evidence-based approach to infertility, In: Infertility (in Greek), Athens 2001.
16. Jordan HS, Ioannidis JPA, Goudas LC, Chung M, Kupelnick B, Miller K, Terrin N, Lau J. Thoracic Electrical Bioimpedance [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002 Nov 27. Available from <http://www.ncbi.nlm.nih.gov/books/NBK285373/> PubMed PMID: 25905148.
17. Ioannidis JPA, Lau J. Integrating genetics in clinical trials. In: Khoury M, Little J (eds): Human Genome Epidemiology, 2003, Oxford University Press.
18. Ioannidis JPA. Presentation and dissemination of clinical trials in the medical literature. In: Japour A (ed): Where ethics meet clinical trials: the AIDS paradigm.
19. Trikalinos T, Ioannidis JPA. Assessing the evolution of effect sizes over time. In: Rothstein HR, Sutton AJ, Borestein M, eds. Publication bias in meta-analysis—prevention, assessment and adjustments. Wiley, Chichester (2005).
20. Ioannidis JPA. Differentiating bias from heterogeneity. In: Rothstein HR, Sutton AJ, Borestein M, eds. Publication bias in meta-analysis—prevention, assessment and adjustments. Wiley, Chichester (2005).
21. Associate Editor for «Encyclopedia of Clinical Trials», John Wiley and Sons (in preparation).
22. Ioannidis JPA. Preface to Greek translation of Health 21/WHO, Athens 2003.
23. Karassa FB, Ioannidis JPA. Influenza and vaccination. In: Gibson R, ed. Evidence-Based Respiratory Medicine, BMJ Publishing Group 2005.
24. Ioannidis JPA, Lau J. Science for Judges: Reviewing medical evidence. Journal of Policy and Law, Fall 2004.
25. International Campaign to Revitalise Academic Medicine (including Ioannidis JPA). The future of academic medicine: five scenarios to 2025. New York: Milbank Memorial Fund.
26. Ioannidis J, Wilkinson D. HIV: prevention of opportunistic infections. Clin Evid. 2005 Jun;(13):834-53 (updated version).
27. Lacchetti C, Ioannidis J, Guyatt G. Surprising results of randomized trials. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
28. Levine M, Ioannidis J, Haines T, Guyatt G. Harm (observational studies). In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
29. Montori V, Ioannidis J, Oxman A, Cook D, Guyatt G. Summarizing the evidence: fixed-effects and random-effects models. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
30. Guyatt G, Straus S, Meade MO, Kunz R, Cook DJ, Devereaux PJ, Ioannidis J. Therapy (randomized trials). In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
31. Montori V, Hatala R, Ioannidis J, Meade MO, Wyer P, Guyatt G. Making sense of variability in study results. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
32. Guyatt G, Wyer P, Ioannidis J. Summarizing the evidence: when to believe a subgroup analysis. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
33. Montori V, Ioannidis J, Guyatt G. Reporting bias. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
34. Montori V, Ioannidis J, Jaeschke R, Schunemann H, Bhandari M, Devereaux PJ, Guyatt G. Dealing with misleading presentations of clinical trial results. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and AMA, 2008.
35. Trikalinos TA, Salanti G, Zintzaras E, Ioannidis JP. Meta-analysis methods. In: Genetic Dissection of Complex Traits, DC Rao, ed. 2nd edition.
36. Tatsioni A, Ioannidis JP. Meta-analysis. In: Encyclopedia of public health, Elsevier, 2009.

37. Salanti G, Ioannidis JP. Hardy-Weinberg equilibrium. In: Encyclopedia of evolution, Elsevier 2009.
38. Ioannidis JPA. Validation and Confirmation of Associations. In: Molecular Epidemiology, Rebbeck, Ambrosone, Shields, eds., 2008.
39. Human Genome Epidemiology: Building the evidence for using genetic information to improve health and prevent disease, 2nd edition. Editors: Muin Khoury, Sara Bedrosian, Marta Gwinn, Julian Higgins, John Ioannidis, Julian Little. Oxford University Press, 2010 (676 pages).
40. Khoury MJ, Bedrosian SR, Gwinn ML, Higgins JPT, Ioannidis JPA, Little J. Human genome epidemiology: The road map revisited. In: Human Genome Epidemiology: Building the evidence for using genetic information to improve health and prevent disease, 2nd edition. Editors: Muin Khoury, Sara Bedrosian, Marta Gwinn, Julian Higgins, John Ioannidis, Julian Little. Oxford University Press, 2010.
41. Daniela Seminara, Muin J. Khoury, Thomas R. O'Brien, Teri Manolio, Marta L. Gwinn, Julian Little, Julian P. T. Higgins, Jonine L. Bernstein, Paolo Boffetta, Melissa Bondy, Molly S. Bray, Paul E. Brenchley, Patricia A. Buffler, Juan Pablo Casas, Anand P. Chokkalingam, John Danesh, George Davey Smith, Siobhan Dolan, Ross Duncan, Nelleke A. Gruis, Mia Hashibe, David Hunter, Marjo-Riitta Jarvelin, Beatrice Malmer, Demetrius M. Maraganore, Julia A. Newton-Bishop, Elio Riboli, Georgia Salanti, Emanuela Taioli, Nic Timpson, Andre G. Uitterlinden, Paolo Vineis, Nick Wareham, Deborah M. Winn, Ron Zimmern, and John P. A. Ioannidis. The emergence of networks in human genome epidemiology: Challenges and opportunities. In: Human Genome Epidemiology: Building the evidence for using genetic information to improve health and prevent disease, 2nd edition. Editors: Muin Khoury, Sara Bedrosian, Marta Gwinn, Julian Higgins, John Ioannidis, Julian Little. Oxford University Press, 2010.
42. Julian Little, Julian P.T. Higgins, John P.A. Ioannidis, David Moher, France Gagnon, Erik von Elm, Muin J. Khoury, Barbara Cohen, George Davey-Smith, Jeremy Grimshaw, Paul Scheet, Marta Gwinn, Robin E. Williamson, Guang Yong Zou, Kim Hutchings, Candice Y. Johnson, Valerie Tait, Miriam Wiens, Jean Golding, Cornelia van Duijn, John McLaughlin, Andrew Paterson, George Wells, Isabel Fortier, Matthew Freedman, Maja Zecevic, Richard King, Claire Infante-Rivard, Alex Stewart, and Nick Birkett. STrengthening the REporting of Genetic Association Studies (STREGA) - An extension of the STROBE statement. In: Human Genome Epidemiology: Building the evidence for using genetic information to improve health and prevent disease, 2nd edition. Editors: Muin Khoury, Sara Bedrosian, Marta Gwinn, Julian Higgins, John Ioannidis, Julian Little. Oxford University Press, 2010.
43. Ntzani EE, Khoury MJ, Ioannidis JPA. Combining molecular and genetic data from different sources. IARC textbook on molecular epidemiology 2011.
44. Looking behind the numbers. Interview at New Scientist 2008, 197:44-45
45. Papanikolaou P, Ioannidis JP. Assessment of harm. In: Randomized clinical trials of nonpharmacologic treatments, 2011.
46. Ioannidis JPA. CONSORT extension for better reporting of harms. In: User's guide to reporting guidelines, 2011.
47. The credibility of research. Interview at European Heart Journal 2011, 32:1574-5.
48. Preface to the Greek translation of the User's Guide to the Medical Literature, Parisianos, Athens, 2011.
49. Brignardello-Petersen R, Lacchetti C, Ioannidis J, Tomlinson G, Guyatt G. Surprising results of randomized trials. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
50. Levine M, Ioannidis J, Haines T, Guyatt G. Harm (observational studies). In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
51. Montori V, Ioannidis J, Oxman A, Cook D, Guyatt G. Summarizing the evidence: fixed-effects and random-effects models. In: User's Guide to the Medical Literature: A manual for evidence-based

- clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
52. Guyatt G, Straus S, Meade MO, Kunz R, Cook DJ, Devereaux PJ, Ioannidis J. Therapy (randomized trials). In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
 53. Murad MH, Montori VM, Ioannidis JPA, Neumann I, Hatala R, Meade MO, Devereaux PJ, Wyer P, Guyatt G. Understanding and applying the results of a systematic review. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition.
 54. Sun X, Ioannidis JPA, Agoritsas T, Alba C, Guyatt G. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
 55. Montori V, Ioannidis J, Guyatt G. Reporting bias. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
 56. Carrasco-Labra A, Montori V, Ioannidis JPA, Jaeschke R, Devereaux PJ, Walsh M, Schünemann H, Bhandari M, Guyatt G. Dealing with misleading presentations of clinical trial results. In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
 57. Mills EJ, Ioannidis JPA, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH. How to use an article reporting a multiple treatment comparison meta-analysis In: User's Guide to the Medical Literature: A manual for evidence-based clinical practice. McGraw Hill and JAMA, 3rd edition, 2014.
 58. Ioannidis JPA. Reproducible unbiased evidence. In: To save humanity - 100 Ideas for 1 Problem: What matters more for a healthy future. Julio Frenk and Steven Hoffman, editors. Oxford University Press, 2016.
 59. Ioannidis JP. Statistical biases in science communication: what we know about them and how can they be addressed? In: The science of science communication, Oxford University Press, 2018.
 60. Ioannidis JPA, Maniatis Z, Tufano F. When is evidence actionable? Assessing whether a program is ready to scale. The Scale-Up Effect. In: Early Childhood and Public Policy: Why Interventions Lose Impact at Scale and What We Can Do About It, 2021, pp. 126–142

MEETING ABSTRACTS:

(Co)-authored several hundreds of abstracts included in proceedings of international meetings (the majority presented as oral presentations). I don't keep detailed records.

PREPRINTS:

More than 50 preprints in medRxiv, bioRxiv, ArXiv, MetaRxiv, SSRN, OSF and elsewhere.

ACADEMIC AWARDS AND HONORS (selected)

1983	Dolashik Prize.
1984	Valedictorian, class of 1984 - highest Athens College honor. Athens College Mathematics Award, John Vakis Award for Natural Sciences, Emmanuel Benakis Prize in History.
1984	Honorary scholarship, State Scholarship Foundation for top admission rank in the University of Athens, School of Medicine (UASM)
1984	First Prize of the National Mathematical Society annual national competition.
1984-90	Honorary annual scholarships, State Scholarship Foundation for being in the top 2 % of the class of 1990.
1990	Graduated summa cum laude at top rank (n. 1) from the School of Medicine.
1992, 1993	Annual Resident Awards, Department of Radiology, Deaconess Hospital.
1995	Maxwell Finland Young Investigator Award, Massachusetts Infectious Diseases Society.

2000	Giannatos Prize
2003	Ikkos Prize
2005	Annual graduation plenary speaker, Department of Epidemiology, U Rotterdam, Rotterdam, Netherlands
2007	Great Teachers lecture series, National Institutes of Health, Bethesda
2007	Award for Excellence in Clinical Science, European Society for Clinical Investigation (award ceremony and lecture in Uppsala, Sweden, April 2007)
2007	Thomas C. Chalmers award, Cochrane Collaboration (best presentation, presenting young researcher: Nikolaos Patsopoulos).
2009	Election (regular member), Association of American Physicians
2010	Election (fellow), European Academy of Cancer Sciences
2011	Stars in Nutrition and Cancer lecture series, National Cancer Institute, National Institutes of Health, Bethesda
2012	Sigma Tau Foundation lectures in complexity, U Florence and Mario Negri Institute, Italy
2013	Commencement speaker, graduation ceremony, Department of Statistics, University of California, Berkeley
2013	Samuel O. Thier lectureship, Yale University, New Haven
2014	Honorary Member, Foundation for Research and Technology-Hellas (FORTH) (ceremony and lecture in FORTH, Crete, December 2014)
2015	Medal for Distinguished Service, Teachers College, Columbia University (awarded in convocation ceremony in the Cathedral of St John the Divine New York, May 2015)
2015	Litchfield Lectureship, Oxford University (Oxford, June 2015)
2015	Honorary professor (ομότιμος καθηγητής), University of Ioannina, Greece (official ceremony at Ioannina, June 2015)
2015	Honorary doctorate, Erasmus University Rotterdam (official ceremony in the 102th dies Natalis, November 9, 2015).
2015	Election (member), American Epidemiological Society
2015	Bradford Hill annual lecture, London School of Hygiene and Tropical Medicine, London, UK
2015	Inaugural Usher lecture, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh (also launched the Institute in launching ceremony)
2015	Election (member), European Academy of Sciences and Arts (official induction in the Festplenum of March 7, 2016)
2016	Robert Levine lectureship, Yale University
2016	William and Myrtle Harris distinguished lectureship in Science and Civilization, Caltech
2016	Berlin Health Institute inaugural lecture
2016	T.H. Seldon Memorial Lecture, International Anesthesia Research Society
2016	Snyder lectureship, University of Utah
2016	23 rd annual Anatomy Lesson, Academic Medical Center and Free University of Amsterdam, delivered at the Concergebouw, Amsterdam, Netherlands
2016	Award for lifetime contribution to science, Hellenic Pharmaceutical Society (Ελληνική Φαρμακευτική Εταιρεία), Athens, Greece
2016	Honorary PhD (health sciences), University of Athens (ceremony 2/2017)
2017	Chanchlani Global Health Award, McMaster University, Hamilton, ON, Canada (ceremony in 2/2017)
2017	Annual Distinguished Investigator, University of Connecticut School of Medicine and Health Center

2017	David-Sackett-Preis 2017 (jointly with Lars Hemkens and Despina Contopoulos-Ioannidis), Deutsche Netzwerk Evidenzbasierte Medizin (ceremony 3/2017)
2017	Election, Councilor, Association of American Physicians (term of leadership appointment: 2017-2022)
2017	Snively Visiting Professorship, UC Davis
2018	Gonatas memorial lecture, University of Pennsylvania
2018	Epiphany Science Courage Award (inaugural international award), Novim group, (award ceremony 5/2018 at Stanford at the Stanford Stadium).
2018	Einstein fellow, Berlin Institute of Health
2018	Dean's Lecture, University of Texas McGovern School of Medicine
2018	David and Rosemary Adamson Lecture on Excellence in Reproductive Medicine, American Society for Reproductive Medicine
2018	Elected member, US National Academy of Medicine
2019	CR Stephen Lecture, University of Washington St. Louis
2019	2019 NIH Robert S. Gordon Jr. Lectureship Award
2019	Honorary president, Medical and Surgical Society of Corfu (Ιατροχειρουργική Εταιρεία Κέρκυρας) (ceremony 5/2019 at the historic building of the society om Corfu)
2019	Honorary PhD, University of Tilburg (ceremony held in the Dies Natalis in November 21, 2019)
2019	Moskowitz lecture, Department of Radiology, Stanford University
2019	Honorary doctorate, University of Edinburgh (ceremony was in 2021)
2020	Honorary doctorate, Aristotle University of Thessaloniki (ceremony will be in 2023, rescheduled because of COVID-19)
2021	Elected correspondent member, Academy of Sciences of the Institute of Bologna (Accademia delle Scienze dell'Istituto di Bologna)
2021	Roy and Diana Vagelos inaugural lecture, World Hellenic Biomedical Association
2021	Wolfson Haldane lecture, Oxford University
2021	Pollock lecture, American Society of Neuroradiology
2021	Albert Srryruenberg Medal, European Society of Clinical Investigation
2022	President Elect, Association of American Physicians (serving as Vice President from April 2022 until April 2023, and then as President from April 2023 until April 2024)
2022	Inaugural Harwood Prize for Intellectual Courage, American Institute for Econoic Research (cercemony in Dallas, TX on September 2022)
2023	European Research Agency chair holder, European Commision (through University of Coimbra, 2023-2028 – senior scientific advisor role)

MEDICAL BOARDS

<i>Licensing:</i>	ECFMG certificate 8/90. FLEX: Massachusetts, 6/91. Board of Registration in Medicine of Massachusetts (8/91). Board of Physician Quality Assurance of Maryland (10/96)
<i>Board-certification</i>	Internal Medicine (1993) and Infectious Disease (1996), American Board of Internal Medicine - Also board-certified in Internal Medicine (1995) and in Infectious Diseases (1997; re-certified 2001) in Greece.
<i>Current practice:</i>	In Europe I have provided free consultation/second opinion for difficult cases in internal medicine, infectious diseases and AIDS, when requested, at the Ioannina University Hospital and whenever people ask me. I have declined any monetary enumeration or salary support for such activity and I do not have a private medical practice. My principle is that I have not accepted payment for providing medical services or consultation since I finished my specialty training. I have not practiced

medicine in the USA during my appointment at Stanford.

TEACHING EXPERIENCE (selectively)

1984-5	Gave seminars on advanced statistics and mathematics for medical students, organized in collaboration with faculty from the laboratories of anatomy and medical physics, University of Athens School of Medicine.
1987-9	Gave seminars on neurochemistry and neurobiology topics, organized in collaboration with faculty from the laboratory of experimental pharmacology, University of Ioannina School of Medicine
1990-3	Clinical fellow in Medicine, Harvard Medical School, preceptor for the Introduction to Clinical Diagnosis course; Harvard Medical School.
1993-6	Clinical and Research Fellow, New England Medical Center Hospitals, preceptor for the Introduction to Physical Diagnosis, Pharmacology (antibiotics), and Infectious Diseases courses, Tufts University School of Medicine.
1996	Intensive Course on Methods in Clinical Research, Johns Hopkins University School of Medicine.
1997	Advanced Meta-analysis course, Johns Hopkins University School of Hygiene and Public Health.
1997	Design and Analysis of Controlled Trials and Evidence-based Medicine, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health.
1999-2010	Director of faculty and teacher for the courses Evidence-Based Medicine/Epidemiology/Clinical research Methods/Public Health I (5 th semester) and Evidence-based medicine/Epidemiology/Clinical Research methods/Public Health II (6 th semester), University of Ioannina School of Medicine
2000-2010	Director of faculty and teacher for the Biomathematics and Biostatistics course (1 st semester), University of Ioannina School of Medicine
1999-2006	Medical Oncology course, (7 th semester), University of Ioannina School of Medicine
1999, 2000	Statistical Methods in Medical Research course, MSc in Biostatistics, University of Athens and University of Ioannina.
2000	Meta-analysis course, MSc in Biostatistics, University of Athens and University of Ioannina
2000-2010	Responsible for the training for 1 month of all General Medicine residents during their training at the University Hospital and General Hospital of Ioannina; several residents from other area hospitals also came for training.
2001ff	“Design of clinical research”, “Appraisal of Therapeutic Interventions”, “Causality and bias in clinical research”, MSc in Social Psychiatry, U Ioannina
2003	Genetic Epidemiology course, Sackler postgraduate program, Tufts University
2005	Evidence-Based Oncology course, European School of Oncology course, Bonn, Germany, 7/2005
2006	Clinical Studies and Objective Medicine course, Bodrum, Turkey, 4/2006
2006	European School of Genetic Medicine, 2nd Course in Statistical Genetic Analysis of Complex Phenotypes: Focus on Association Studies, Bertinoro di Romagna, Italy, 5/2006.
2006ff	Course director and teacher, Molecular and Translational Epidemiology course, Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, USA, 6/2006, 3/2009
2006	Integrating the Evidence on Gene-Disease Associations: Methods and applications of HuGE systematic reviews, MRC Biostatistics Unit, Cambridge, HuGE Net course,

	9/2006
2007	NYU Post-Graduate Medical School Clinical Research Methodology Course: Randomized Clinical Trials and the Real World, Hospital for Joint Diseases, New York, NY, December 2007.
2008	“Meta-analysis” and “Uncertainty, Bayes, and decision making”, Seminar of Epidemiology and Clinical Research Methods, Hellenic Society of Nephrology, 3/2008.
2008	Science and the Web course, Summer School organized at Mediterranean Institute for Life Sciences (MedILS), Split, Croatia, 7/26-8/2/2008
2008	Large-scale Multicenter Studies course, Erasmus Summer Programme in Quantitative Medical Research, Erasmus University Rotterdam and Nijmegen, Netherlands, 8/2008.
2008	PhD course on Clinical Epidemiology, University of Copenhagen, Denmark, courses on systematic reviews and meta-analysis, genome-wide association studies, and credibility of research findings, October 2008.
2008	Advanced course, Special topics in Epidemiology: Meta-analysis, Università Cattolica del Sacro Cuore, Rome, November 17-21, 2008.
2010	Evidence Based Epidemiology, course EPI509, Harvard School of Public Health (January 2010).
2010	Organizer, ESCI Intensive Course on the Principles and Practice of Clinical Research, October 2010.
2011	Evidence Based Epidemiology, course EPI509, Harvard School of Public Health (January 2011).
2011	Meta-research, course Statistics STATS211/Medicine MED 206/Health Research and Policy HRP206, Stanford University, winter quarter.
2011	Invited professor, 2011 Annual Haendel lectures, University of Halle-Wittenberg, Halle, Germany (October 2011).
2011	Invited professor, Replication and biases in molecular research, Iberoamerican Cochrane Center and Autonomous University of Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (October 2011).
2011	Testing for excess significance, Advanced workshop, Cochrane Colloquium, Madrid, Spain (October 2011).
2012	Evidence Based Epidemiology, course EPI519, Harvard School of Public Health (January 2012).
2012	Meta-research, course Statistics STATS211 / Medicine MED 206 / Health Research and Policy HRP206, Stanford University, winter quarter.
2012	Genetic Epidemiology course HRP228, Stanford University, spring quarter
2012	Meta-research and knowledge integration course, National Cancer Institute, National Institutes of Health (April 2012)
2012	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter
2013	Evidence Based Epidemiology, course EPI519, Harvard School of Public Health (January 2013)
2013	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206, Stanford University, winter quarter
2013	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter “Clinical trials: pitfalls in design and interpretation”
2013-now	Program Director, PhD in Epidemiology and Clinical Research, Stanford University
2013	“Dilemmas in the use of evidence for clinical decisions”, Advances and Perspectives in Medicine Lecture, Stanford Medical School
2014	Evidence Based Epidemiology, course EPI519, Harvard School of Public Health

	(January 2014)
2014	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206, Stanford University, winter quarter
2014	Invited lecturer, Genes and Environment in Disease Causation: Implications for the Practice of Medicine and Public Health course HRP 238, Stanford University, spring quarter
2014	Genetic Epidemiology course HRP228, Stanford University, spring quarter
2014-	Program Director, PhD in Epidemiology and Clinical Research, Stanford University (approved by the faculty senate in May 2014, first students started in September 2014).
2014	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter "Clinical trials: pitfalls in design and interpretation"
2015	Evidence Based Epidemiology, course EPI519, Harvard School of Public Health (January 2015)
2015	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206, Stanford University, winter quarter
2015	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter "Clinical trials: pitfalls in design and interpretation"
2016	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206, Stanford University, winter quarter
2016	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, winter quarter "Why most (prevention) research is false"
2016	Scientific method and bias, undergraduate course MED73N, Stanford University, winter quarter
2016	"Why most published (prevention) research findings are false: reproducibility, publication bias and meta-analysis", Community Health and Prevention Research MS program, Stanford University, winter quarter
2016	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter "Clinical trials: pitfalls in design and interpretation"
2016	Course director and lecturer, "Prediction and predictive markers", Erasmus Summer School, Rotterdam, August 2016
2016	Masterclass on Reproducible Research and Meta-research, University of Amsterdam and Academic Medical Center, Amsterdam, November 2016
2017	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206, / Community Health and Prevention Research CHPR 206, Stanford University, winter quarter
2017	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, winter quarter
2017	Scientific method and bias, undergraduate course MED73N, Stanford University, winter quarter
2017	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter "Clinical trials: pitfalls in design and interpretation"
2017	Course director and lecturer, "Prediction, predictive markers, predictive scores", Erasmus Summer School, Rotterdam, August 2017
2017	The Cosmopolitan Introvert: Modern Greek Poetry and its Itinerants, course COMPLIT 208 (both undergraduate and graduate students), fall quarter (Department of Comparative Literature, Stanford University School of Humanities and Sciences)
2017	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, fall quarter
2018	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research

	and Policy HRP206 / Community Health and Prevention Research CHPR 206, Stanford University, winter quarter
2018	Scientific method and bias, undergraduate course MED73N, Stanford University, winter quarter
2018	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter “Clinical trials: pitfalls in design and interpretation”
2018	Course director and lecturer, “Prognosis, predictive markers, and models”, Erasmus Summer School, Rotterdam, August 2018
2018	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, fall quarter
2019	Evidence Based Epidemiology, course EPI519, Harvard School of Public Health (January 2019)
2019	The Cosmopolitan Introvert: Modern Greek Poetry and its Itinerants, course COMPLIT 208 (both undergraduate and graduate students), winter quarter (Department of Comparative Literature, Stanford University School of Humanities and Sciences)
2019	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206 / Community Health and Prevention Research CHPR 206, Stanford University, winter quarter
2019	Scientific method and bias, undergraduate course MED73N, Stanford University, winter quarter
2019	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter “Clinical trials: pitfalls in design and interpretation”
2019	Course director and lecturer, “Biomarkers and prediction research”, Erasmus Summer School, Rotterdam, August 2019
2019	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, fall quarter
2020	The Cosmopolitan Introvert: Modern Greek Poetry and its Itinerants, course COMPLIT 208 (both undergraduate and graduate students), winter quarter (Department of Comparative Literature, Stanford University School of Humanities and Sciences)
2020	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206 / Community Health and Prevention Research CHPR 206, Stanford University, winter quarter
2020	Scientific method and bias, undergraduate course MED73N, Stanford University, winter quarter
2020	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter “Clinical trials: pitfalls in design and interpretation”
2020	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, fall quarter
2021	The Cosmopolitan Introvert: Modern Greek Poetry and its Itinerants, course COMPLIT 208 (both undergraduate and graduate students), winter quarter (Department of Comparative Literature, Stanford University School of Humanities and Sciences)
2021	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206 / Community Health and Prevention Research CHPR 206, Stanford University, winter quarter
2021	Scientific method and bias, undergraduate course MED73N, Stanford University, winter quarter

2021	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter “Clinical trials: pitfalls in design and interpretation”
2021	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, fall quarter
2022	The Cosmopolitan Introvert: Modern Greek Poetry and its Itinerants, course COMPLIT 208 (both undergraduate and graduate students), winter quarter (Department of Comparative Literature, Stanford University School of Humanities and Sciences)
2022	Meta-research, course Statistics STATS211 / Medicine MED206 / Health Research and Policy HRP206 / Community Health and Prevention Research CHPR 206, Stanford University, winter quarter
2022	Scientific method and bias, undergraduate course MED73N, Stanford University, winter quarter
2022	Invited lecturer, Clinical Trials course HRP251, Stanford University, spring quarter “Clinical trials: pitfalls in design and interpretation”
2022	Lecturer, Community Health and Prevention Research course CHRP 240, Stanford University, fall quarter

INVITED LECTURES:

I have given more than 700 invited and honorary lectures in 39 countries (USA, Greece, Canada, Netherlands, Austria, Finland, England, Scotland, France, Ireland, Italy, Spain, Portugal, Hungary, Sweden, Germany, Switzerland, Czech Republic, Belgium, Cyprus, Turkey, South Africa, China, Botswana, Japan, Norway, Croatia, Denmark, Singapore, Australia, Romania, Russia, Serbia, Iran, Luxembourg, Qatar, Taiwan, South Korea, and Thailand). I have received several thousands of invitations to give lectures.

Selected invited and honorary lectures:

1. “Introduction to the philosophy of death”, Athens College, 1984 (in Greek).
2. Opening plenary lecture: "Brain sciences, Pharmacology and the Greek Scientific Heritage", 2nd International Meeting of the European Behavioral Pharmacology Society, Athens, Greece, August 1988.
3. “Pathogenesis of HIV encephalopathy”, New England Deaconess Hospital, Boston, MA, USA, December 1992.
4. “Implications of heterogeneity for clinical trials, meta-analysis, and modeling”, Department of Biomathematical Sciences, Mount Sinai School of Medicine, New York, USA, December 1995.
5. “Modeling heterogeneity in meta-analysis”, Center for Clinical Trials, Johns Hopkins School of Medicine, Baltimore, MD, USA, September 1996.
6. “Impact of losses to follow-up in long-term trials”, 22nd AIDS Clinical Trials Group meeting, Washington D.C., USA, December 1996.
7. “Modeling non-linear relationships with neural networks: immunogenetic associations of HIV disease progression”; Statistical Center, Multicenter AIDS Cohort Study (MACS), Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA, February 1997.
8. “Overviewing overviews in HIV infection: potential and challenges”, Cochrane HIV CRG meeting, San Francisco, CA, USA, March 1997.
9. “Presence of a threshold effect in RNA and CD4 measurements”, ENAR meeting of the International Biometrics Society (HIV Surrogate Endpoints Workshop), Memphis, TN, USA, March 1997.
10. “Meta-analysis in infectious diseases”; HIV Clinic, NIH Clinical Center, Bethesda, MD, USA. April 1997.

11. "Heterogeneity in clinical trials and meta-analysis", Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA, October 1997.
12. "Neural network modeling of progression to AIDS", Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA, October 1997.
13. "Meta-analysis - pooling data or drowning by numbers: a debate", Society for General Internal Medicine, Annual meeting. Participants: JPA Ioannidis, John Bailer (Prof. Emeritus, U Chicago/Statistical Editor New England Journal of Medicine), Neil Powe (Prof. of Medicine, Johns Hopkins U). Chicago, IL, USA, April 1998.
14. "Evidence-based medicine for infectious diseases", State of the Art Interdisciplinary Review Course, U Athens, Athens, Greece, May 1998.
15. "Differing perspectives: Is meta-analysis a reasonable alternative to large randomized trials?", debate session – debating participants: JPA Ioannidis and Carl Kupfer (Director, National Eye Institute, National Institutes of Health). International Cochrane Colloquium, Baltimore, MD, USA, October 1998.
16. "Prostate cancer: epidemiology and risk factors", Institute of Pathology, U Ioannina, Ioannina, Greece, October 1999.
17. "Neural networks in modeling complex immunologic associations", American Society of Tropical Medicine and Hygiene, Washington, D.C., USA, December 1999.
18. "Meta-epidemiology of research and evaluation research", 2nd Conference of the National School of Public Health (ESDY), Athens, Greece, February 2000.
19. "Epidemiology of salivary gland cancer", Institute of Pathology, U Ioannina, Ioannina, Greece, May 2000.
20. "Research projects for cumulative randomized evidence in mental health", EU-PSI meeting, Helsinki, Finland, September 2000.
21. "Meta-epidemiology of meta-analysis", European workshop on meta-analysis of epidemiologic studies, Santorini, Greece, October 2000.
22. "Epidemiology of lung cancer: evidence from meta-analyses", European School of Oncology, Nicosia, Cyprus, November 2000.
23. "Analytical issues in the meta-epidemiology of meta-analysis", Brown University School of Medicine, Department of Community Health and Center for Statistical Sciences, Providence, RI, USA, February 2001.
24. "Empirical methodological research with large-scale evidence", Division of Clinical Care Research, Department of Medicine, New England Medical Center, Boston, MA, USA, February 2001.
25. "Safety reporting in randomized trials", CONSORT meeting, Barcelona, Spain, September 2001.
26. "Evidence-based medicine and meta-epidemiology", Keynote lecture at opening ceremony of 7th Congress of the European Association of Hospital Pharmacists, Vienna, Austria, March 2002.
27. "Evolution of effects over time: recursive cumulative meta-analysis in randomized research and molecular medicine", Mathematical Sciences Research Institute, Berkeley, CA, USA, May 2002.
28. "Comparison of randomized vs. non-randomized studies", Mathematical Sciences Research Institute, Berkeley, CA, USA, May 2002.
29. "Meta-analysis in genetics", Tufts-New England Medical Center, Boston, MA, USA, May 2002.
30. "Critical meta-analysis of lupus nephritis treatment", 5th European Conference on SLE, Athens, Greece, May 2002.
31. "How to evaluate the outcome measures in a multisystemic and multidisciplinary disease", 5th European Conference on SLE, Athens, Greece, May 2002.
32. "Incorporating adverse events in systematic reviews", 4th Symposium on Systematic Reviews, St. Catherine's College, Oxford University, Oxford, UK, July 2002.
33. "Evolution of treatment effects for mental health interventions", EU-PSI meeting, Bristol, UK, September 2002.

34. "Appraisal of guidelines - AGREE dissemination in Greece", AGREE meeting, Paris, France, November 2002.
35. "Ethical issues in biomedical research", Workshop on perinatal HIV-1 transmission, Roundtable, Kasane, Botswana, January 2003.
36. "Meta-analysis of polygenes", 2nd Workshop on the Genetic of Bone Diseases, European Calcified Tissue Society, Davos, Switzerland, February 2003.
37. "Meta-analysis and evidence-based medicine in rheumatology", Marmaris, Turkey, May 2003.
38. "Safety reporting in randomized trials", CONSORT meeting, Ottawa, Canada, May 2003.
39. "Including adverse events in trial reports", Workshop on Rare Events, British Medical Journal and Cochrane Collaboration, London, UK, June 2003.
40. "Publication bias: new insights", Publication bias Workshop, Vail, CO, USA, August 2003.
41. "Problems and promises of genetic association studies", Genetics of Common Disorders, Academy of Athens, Institute for Medical and Biological Research, Athens, October 3, 2003.
42. "Large-scale evidence and meta-analysis in genetic epidemiology", Institute of Medical Sciences, Aberdeen, Scotland, January 23, 2004.
43. "Meta-analysis in human genetics", National Tumor Institute, Milan, Italy, March 29, 2004.
44. "Genetic epidemiology", 14th European Conference on Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 2, 2004.
45. "Coreceptor mutations and HIV-1 disease progression", University of Regensburg, Germany, May 13, 2004.
46. "CONSORT guidelines for reporting of harms", LENT V Workshop, Rochester, NY, USA, May 20, 2004.
47. "Quantitating the effects of polygenes by meta-analysis", European Calcified Tissue Society, Nice, France, June 8, 2004.
48. "What does secondary research and meta-analyses tell us about effectiveness of mental health interventions?", Paulo Foundation Symposium 2004: Effectiveness Research in Psychiatry, Lahti, Finland, May 27, 2004.
49. "Using randomized evidence for understanding adverse events", Epidemiology Days WEON, University of Leiden, Leiden, Netherlands, June 11, 2004.
50. "The value of meta-analysis in rheumatology research", Autoimmune Rheumatic Disease Days, in honor of Prof. HM Moutsopoulos, Athens, June 24-26, 2004.
51. "Antiretroviral therapy: past, present and future", European Society for Clinical Microbiology and Infectious Diseases, Athens, Greece, June 26, 2004.
52. "Immunogenetics of mother-to-child transmission", Federation of Mediterranean Obstetrics and Gynecological Societies, Palermo, Italy, October 9, 2004.
53. "Reporting biases", Meta-analysis in genetic epidemiology workshop, Cambridge, UK, November 3, 2004.
54. "Meta-analysis of individual participant data", Meta-analysis in genetic epidemiology workshop, Cambridge, UK, November 3, 2004.
55. "Meta-analysis", SNP and human disease workshop, Erasmus Medical Center and University of Rotterdam, Rotterdam, Netherlands, November 2004.
56. "Integration bioinformatics: promises and challenges", First International Meeting on Pharmacogenetics of Osteoarticular Disorders, Florence, Italy, January 21-22, 2005.
57. "Meta-analysis in molecular medicine", National Institute of Public Health / University of Tokyo, Tokyo, Japan, February 2005.
58. "Meta-analysis in molecular medicine", University of Kyoto School of Public Health, Kyoto, Japan, February 2005.
59. "Do pharmacogenetics and pharmacogenomics fulfill their promises?" Debate with Hugh E. Montgomery from University College London, plenary at the 10th meeting of the European

- Association of Hospital Pharmacists, Lisbon, Portugal, March 2005.
60. "Meta-analysis in molecular medicine", Erasmus University Rotterdam, Department of Epidemiology and Biostatistics, Netherlands, April 4, 2005.
 61. "Quantitative issues and biases in molecular research", Department of Biological Chemistry, University of Ioannina School of Medicine, Ioannina, Greece, April 6, 2005.
 62. "Host genetics: methodology perspective for research in observational databases", Plenary presentation, 9th International Workshop on HIV Observational Databases, Budapest, Hungary, April 21-24, 2005.
 63. "Meta-analysis in human genome epidemiology with application in Parkinson's disease", Workshop on Advances in Molecular Genetics and Epidemiology of Parkinson's Disease, Pitie-Salpetriere Hospital, Paris, France, May 13, 2005.
 64. "Meta-analysis in genetics", Tele-presentation at Genetics of Prematurity Workshop, Office of Genomics and Disease Prevention, CDC, Atlanta, USA, May 23, 2005.
 65. "Translation and replication: empirical evidence", Plenary talk, Symposium on Translational Research for Innovative Infectious Disease Control, WHO, Geneva, Switzerland, May 30, 2005.
 66. "Common pitfalls in the reporting of systematic reviews", QUOROM meeting, Ottawa, Canada, June 1-3, 2005.
 67. "Molecular bias", Annual Graduation Plenary Lecture, Department of Epidemiology and Biostatistics, Erasmus University Rotterdam, Netherlands, June 22, 2005.
 68. "Using evidence at the bedside: generalizability, external validity and subgroup analysis", European School of Oncology, Evidence-Based Oncology, Bonn, Germany, July 2005.
 69. "Selected methodological issues of evidence review", Plenary lecture, KDIGO guideline development on kidney disease and hepatitis C infection, Boston, USA, July 2005.
 70. "Candidate genes in endocrinology- pitfalls", plenary at European Congress of Endocrinology, Goteborg, Sweden, September 7, 2005.
 71. "Replication issues and large-scale evidence in pharmacogenomics", Joint Cold Spring Harbor Laboratory/Wellcome Trust Conference on Pharmacogenomics, Hinxton, Cambridge, UK, September 14-18, 2005.
 72. "Guideline development – procedures and instruments for appraisal", EULAR recommendations for SLE workshop, Zurich, Switzerland, Sept 30-Oct 1, 2005.
 73. "Bias in molecular epidemiology", Bradford Hill Seminar, Cambridge University, Cambridge, UK, October 2005.
 74. "A network of investigator networks in human genome epidemiology", Cambridge, UK, October 6-7, 2005.
 75. "Is really HIV multi-drug resistance a marker of poor survival?", Workshop on HIV Multi-drug Resistance, Rome, Italy, October 14-15, 2005.
 76. "Candidate genes and meta-analysis", Erasmus University Rotterdam, Netherlands, October 21, 2005.
 77. "Ethics and integrity in scientific research", Erasmus University, Medical Faculty/Molecular Medicine Program, Rotterdam, Netherlands, October 2005.
 78. "Meta-analysis in public health: potential and problems", plenary workshop, European Public Health Association annual conference, Graz, Austria, November 11, 2005.
 79. "Association studies", CHAVI meeting, London, UK, December 16, 2005.
 80. "Human Genome Epidemiology Roadmap: the Network of Networks", plenary lecture, ECNIS Workshop, Athens, Greece, January 11, 2006.
 81. "Reporting of harms in non-pharmacological trials", CONSORT meeting, Paris, France, Feb 8-10, 2006.
 82. "Evidence-based molecular medicine", Top 10 on infectious diseases, Henry Dunant Hospital, Athens, Greece, February 2006.
 83. "Credibility, replication and translation of research findings", grand rounds, University of California

- Davis, Medical Center, Davis/Sacramento, USA 2/21/2006.
84. "Estimating the odds of truth in a research finding", plenary lecture, 6th International Campbell Colloquium, Los Angeles, USA, 2/23/2006 (discussants: Jeremy Grimshaw, William Shadish).
 85. "Methodological problems in discovery-oriented research", Molecular Medicine Tri-conference, Moscone Center, San Francisco, USA, 2/24/2006.
 86. "Meta-analysis", In: The Role of DNA Polymorphisms in complex Diseases", Colloquium organized by the Royal Dutch Academy of Arts and Sciences (KWAN), Trippenhuis, Amsterdam, Netherlands, 15/3/2006.
 87. "Neo-adjuvant vs. adjuvant therapy: evidence from randomized trials", plenary at 5th European Breast Cancer Conference, Nice, France, 23/3/2006.
 88. "Assessing the credibility of clinical research findings", grand rounds in Pediatrics, University Hospital, Ioannina, Greece, 29/3/2006.
 89. "The significance of statistically significant findings", Debate, 14th national Conference on Clinical Oncology, Ioannina, Greece, April 2006.
 90. "Meta-analysis", Clinical Studies and Objective Medicine course, Bodrum, Turkey, April 14-16, 2006.
 91. "Reporting adverse events in randomized trials", Clinical Studies and Objective Medicine course, Bodrum, Turkey, April 14-16, 2006.
 92. "Meta-analysis for association studies", in European School of Genetic Medicine, 2nd Course in Statistical Genetic Analysis of Complex Phenotypes: Focus on Association Studies, Bertinoro di Romagna, Italy, May 5, 2006.
 93. "Testing lifestyle interventions in randomized clinical trials", LifeGENE workshop, Karolinska Institute, Sigtuna, Sweden, May 8-9, 2006.
 94. "Estimating effects of risk alleles in populations using multicentre approaches and by meta-analysis", plenary talk at Genetic Aspect of Bone Disease: methods and applications, Prague, Czech Republic, May 10, 2005.
 95. "Why most published research findings should not be put into clinical practice", plenary talk, Society for Clinical Trials 27th Annual Meeting, Orlando, USA, May 24, 2006.
 96. "Developing guidelines for genetic association research", EQUATOR workshop, Oxford, UK, May 31, 2006.
 97. "Methodological problems and replication in discovery-oriented clinical research", Centro Nacional de Investigaciones Oncologicas, Genomics and Medicine lecture series, Madrid, Spain, June 13, 2006.
 98. "Road map for efficient and reliable human genome epidemiology", STREGA workshop, Ottawa, Canada, June 15-16, 2006.
 99. "Empirical evidence on reporting of genetic association studies", STREGA workshop, Ottawa, Canada, June 15-16, 2006.
 100. "Inferences on causation on single studies", STREGA workshop, Ottawa, Canada, June 15-16, 2006.
 101. "The use of meta-analyses on the safety of medications", plenary talk, International Conference on Pharmacoepidemiology, International Society for Pharmacoepidemiology, Lisbon, Portugal, August 24, 2006.
 102. "Whole genome association study (LEAPS) replication findings", 2nd annual meeting of Genetic Epidemiology in Parkinson disease, Santorini, Greece, September 10-12, 2006.
 103. "The Human Genome Epidemiology Network (HuGENet)", 2nd annual meeting of Genetic Epidemiology in Parkinson disease, Santorini, Greece, September 10-12, 2006.
 104. "Meta-analysis in molecular epidemiology", University of Alabama Birmingham School of Public Health, Department of Biostatistics, Division of Statistical Genetics, Birmingham, Alabama, USA, September 2006.
 105. "Why most published research findings are false", Symposium on "Statistics, Images, and Perceptions of Truth: Detecting Research Bias and Misconduct", University of Alabama Birmingham

- School of Philosophy and Center for Ethics and Office of Research Integrity, plenary, Birmingham, Alabama, USA, September 14-15, 2006.
106. "Is molecular profiling ready for use in clinical decision making?", plenary symposium, European Society for Medical Oncology, Istanbul, Turkey, Sept 29-Oct 2, 2006.
 107. "Genetic epidemiology: where are we? Where we should go?", closing plenary, Spanish Society of Epidemiology, Annual Conference, Logrono, Spain, October 6, 2006.
 108. "Nesting lifestyle randomized trials in biobanks", Life GENE meeting, tele-presentation, Sigtuna, Sweden, October 2006.
 109. "The Human Genome Epidemiology Network: making sense of 10,000,000 postulated genetic risk factors", Cochrane Colloquium, plenary, Dublin, Ireland, October 26, 2006.
 110. "HIV treatment: are we doing the right studies?", plenary talk Austrian National AIDS annual conference, October 27-29, Innsbruck, Austria, October 27-29.
 111. "Literature-based vs. individual participant data meta-analysis", Integrating the Evidence on Gene-Disease Associations: Methods and applications of HuGE systematic reviews, MRC Biostatistics Unit, Cambridge, HuGE Net course, Cambridge, UK, November 6-8, 2006.
 112. "Reporting bias", Integrating the Evidence on Gene-Disease Associations: Methods and applications of HuGE systematic reviews, MRC Biostatistics Unit, Cambridge, HuGE Net course, Cambridge, UK, November 6-8, 2006.
 113. "The bigger picture: networks, consortia and field synopses", Integrating the Evidence on Gene-Disease Associations: Methods and applications of HuGE systematic reviews, MRC Biostatistics Unit, Cambridge, HuGE Net course, Cambridge, UK, November 6-8, 2006.
 114. "Meta-analysis in human genome epidemiology", plenary talk, annual meeting, International Genetic Epidemiology Society, Tampa, FL, USA, November 16-17, 2006.
 115. "Meta-analyses in genetic epidemiology: making sense of 10,000,000 postulated genetic risk factors", Institute Mario Negri, Milano, Italy, November 27, 2006.
 116. "Evidence-based medicine: a tool to verify and evaluate uncertainty, plenary at Symposium on "Areas of Uncertainty in Medicine", Instituto Superiore di Sanita, Roma, Italy, November 28, 2006.
 117. "Genetic epidemiology: a HuGE experience", invited lecture, London School of Hygiene and Tropical Medicine, London, UK, January 30, 2007.
 118. "Replication and non-replication: from candidate genes to genome-wide associations", invited lecture, Wellcome Trust Centre for Human Genetics and Oxford University, Oxford, UK, January 31, 2007.
 119. "Claims that do not replicate in medical trials", symposium lecture, American Association for the Advancement of Science (AAAS) annual meeting, San Francisco, CA, USA, February 16, 2007.
 120. "Translation, replication and credibility of research findings", Great Teachers series, grand rounds at NIH Clinical Center, Bethesda, MD, USA, March 14, 2007.
 121. "Molecular evidence-based medicine: evolution and integration of information in the genomic era", lecture on the receipt of the European Award for Excellence in Clinical Science, European Society for Clinical Investigation annual meeting, Uppsala University main amphitheater, Sweden, April 2007.
 122. "Meta-analysis in the genome-wide association setting", SNP and complex diseases symposium, Amsterdam, Netherlands, April 2007.
 123. "Replication and validation for complex pathways in molecular epidemiology", invited lecture, Approaches to Complex Pathways in Molecular Epidemiology, AACR/MEG joint meeting, New Mexico, USA, May 30-June 2, 2007.
 124. "Credibility and translation of medical research", grand rounds, Encino-Tarzana Medical Center, UCLA/USC, Los Angeles, USA, June 2007.
 125. "Why most published research findings are false", grand rounds/plenary to all principal investigators, Academic Medical Center Amsterdam, Amsterdam, Netherlands, June 2007.

126. "Can we trust any positive finding? Sources of and cures for bias", plenary at the 32nd annual meeting of the WEON (Working-party Epidemiologic Research in the Netherlands), Maastricht, Netherlands, June 22, 2007.
127. "Genes and meta-analysis", Erasmus Summer Lectures, Erasmus University Rotterdam, Rotterdam, Netherlands, August 30, 2007.
128. "To err is science", invited professor lecture at German Institute for Quality and Efficiency in Health Care, Cologne, Germany, September 2007.
129. "The future of academic medicine", plenary at 3rd Turkish-Greek Rheumatology Days, Kusadasi, Turkey, September 2007.
130. "Personalized therapies: can tumor gene profiling live up to expectations", Debate lecture, Media event for the 25th anniversary of the European School of Oncology, Rome, Italy, October 2007.
131. "Meta-analysis", Symposium on SNPs and complex diseases, Erasmus University Rotterdam, Netherlands, November 2007.
132. "Calibrating the credibility of research findings", Rheumatology Grand Rounds, Tisch Hospital, New York University, NY, USA, December 2007.
133. "Why some/many (all?) published clinical trials are false", NYU Post-Graduate Medical School Clinical Research Methodology Course: Randomized Clinical Trials and the Real World, Hospital for Joint Diseases, New York, NY, USA, December 2007.
134. "Translational Research: bench to where?", NYU Post-Graduate Medical School Clinical Research Methodology Course: Randomized Clinical Trials and the Real World, Hospital for Joint Diseases, New York, NY, USA, December 2007.
135. "Replication and inconsistency: a meta-analytic view", invited professor lecture, Department of Social Medicine, Bristol University, Bristol, UK, January 15, 2008.
136. "Meta-analysis", TREAT-OA meeting, London, January 16, 2008.
137. "Human genome epidemiology: building the knowledge base for genetic variation and human health", plenary for CDC Celebration of 10 Years of Public Health Genomics: Translating Gene Discoveries into Population Health Benefits, Atlanta, GA, USA, January 23, 2008.
138. "Meta-analysis in complex genetics", symposium in honor of Prof. Andre Uitterlinden, Erasmus University Rotterdam, Netherlands, February 8, 2008.
139. "Assessing cumulative evidence", Networks, Genome-Wide Association Studies, and the Knowledge Base on Genetic Variation and Human Health, HuGENet Workshop, Atlanta, GA, USA, January 24, 2008.
140. "Meta-analysis of GWA", GEFOS meeting, Rotterdam, Netherlands, March 2008.
141. "Meta-analysis", In: "The Role of DNA Polymorphisms in complex Diseases", Colloquium organized by the Royal Dutch Academy of Arts and Sciences (KWAN), Trippenhuis, Amsterdam, Netherlands, March 18-21, 2008.
142. "Is molecular profiling currently ready for use in clinical decisions?", Molecular Oncology workshop, Metsovo, Greece, March 28-30, 2008.
143. "Meta-analysis", National Medical Conference, Athens, Greece, May 2008.
144. "Future vision for large-scale genomic research", plenary, P3G meeting on biobanks, Barcelona, Spain, May 30, 2008.
145. "Meta-analysis: an advance on the RCT?", plenary symposium on "How do I treat this patient? Deciding what to do", American Thoracic Society, annual meeting, Toronto, Canada, May 20, 2008.
146. "Meta-analysis of GWA studies and replication thereof", 3rd meeting of Genetic Epidemiology in Parkinson disease, Trondheim, Norway, June 9-11, 2008.
147. "Genome wide association studies", plenary, RIDE symposium, Royal Academy of Sciences, Amsterdam, Netherlands, June 18, 2008.
148. "Evaluating cumulative evidence in genomic epidemiology", plenary, IARC-EARC-AACR joint symposium, Lyon, France, July 2008.

149. Five contributed papers presented at the annual meeting of the Society for Research Synthesis Methodology, Achilleion, Corfu, Greece, July 2008.
150. “Early published research findings: the false and the inflated”, Mediterranean Institute for Life Sciences, Split, Croatia, July 2008.
151. “Adverse effects of antidiabetic drugs”, hot topic plenary, International Conference on Pharmacoepidemiology, International Society for Pharmacoepidemiology annual meeting, Copenhagen, Denmark, August 19, 2008.
152. “Integrating randomized and observational evidence”, symposium on “Balancing benefits and harms”, UK Academies of Medical Sciences, London, UK, September 5, 2008.
153. “Evidence-based healthcare: large-scale evidence to improve outcomes for single patients?”, “Evidence-Based Dentistry in Practice” symposium, International Association for Dental Research, London, UK, September 10, 2008
154. “Guidelines for neuropsychiatric lupus: methodological issues”, EULAR task force, Zurich, September 2008.
155. “Large-scale evidence on lifestyle and gene-environment effects in biobanks and genetic consortia”, International Society for Nutrigenetics/Nutrigenomics (ISNN), Geneva, Switzerland, October 7, 2008
156. “Concepts and challenges of personalized medicine”, University of Copenhagen, Copenhagen, Denmark, October 8, 2008.
157. “Integrating genomics into population health”, Life Science Institute Distinguished Lecture Series, National University of Singapore, Singapore, October 2008
158. “Calibrating the credibility of research findings”, American College of Rheumatology annual meeting, San Francisco, USA, October 27, 2008.
159. “Meta-analyses of GWAS and online meta-analyses”, Imperial College, London, UK, December 8, 2008.
160. “Meta-analysis in the GWA setting”, Winter Meeting of the UK Molecular Epidemiology Group, Barcelona, Spain, December 2008.
161. “Can lessons learned from genome-wide research be applied to nutrition-wide and exposure-wide evidence?” International Life Sciences Institute workshop on Decision making for recommendations and communication based on totality of food-related research, Washington, D.C., December 15, 2008.
162. “Assessing cumulative evidence in genetic associations”, Personal Genomics workshop: Establishing the Scientific Foundation for Using Personal Genome Profiles for Risk Assessment, Health Promotion and Disease (jointly organized by CDC, NHGRI, NHLBI, NCI), Bethesda, MD, USA, December 17, 2008
163. “Panel discussion on personal genomics”, Personal Genomics workshop (jointly organized by CDC, NHGRI, NHLBI, NCI), discussants and panel: Francis Collins, Kari Stefansson, John Ioannidis, Coleen McBride, Sharon Terry, Sharon Kardia, Bethesda, MD, USA, December 18, 2008
164. “Selected issues of evidence review for development of recommendations”, EULAR guidelines for immunizations in autoimmune diseases, Zurich, Switzerland, March 2009.
165. “Significance versus credibility in epidemiological research”, International Epidemiology Institute, Maryland, USA, March 23, 2009.
166. “Meta-analysis for meta-genetics: the bright, the grey, and the dark matter”, Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA, March 30, 2009.
167. “Statistically significant findings: the false, the inflated, and the useless”, Department of Epidemiology, Harvard School of Public Health, Boston, USA, April 1, 2009
168. “Design and bias issues in biomedical investigation”, European Society for Clinical Investigation Annual meeting, Frankfurt, Germany, April 2009.
169. “Assessing cumulative evidence on gene disease associations”, IARC-NCI-HuGENet

- workshop on gene-environment interactions, IARC, Lyon, France, May 2009
170. “Significance-chasing biases in biomedical publications”, Center of Interdisciplinary Research, Faculty of Medicine, Paris Descartes University, Paris, May 2009.
 171. “Replication strategies for GWA studies”, Genetic Epidemiology of Parkinson’s Disease meeting, Tuebingen, Germany, July 2009.
 172. Six contributed papers in the annual meeting of the Society for Research Synthesis Methodology, Seattle, USA, July 2009.
 173. “Genetic associations: candidate claims versus genome-wide discoveries versus the dark matter”, Psychosis Masterclass, organized by King’s College, Athens, Greece, Oct 31, 2009.
 174. “Why most research findings are false and what to do about this”, 40 years of Epidemiology in Erasmus, Rotterdam, Netherlands, November 2009.
 175. “GWAS: successes and dark matter”, Tufts Molecular Medicine Series, Boston, January 5, 2010.
 176. “Pitfalls in analysis of large-scale data”, Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA, February 2010
 177. “Significance versus credibility in medical research”, Grand rounds, Stanford University School of Medicine, Stanford, CA, USA, February 2010
 178. “Introduction to translational medicine”, European Society for Clinical Investigation, annual meeting, Bari, Italy, February 2010.
 179. “Meta-research: the art of getting it wrong”, presidential address, Society for Research Synthesis Methodology, Cartagena, Spain, July 2010.
 180. Two contributed papers at the annual Society for Research Synthesis Methodology meeting, Cartagena, Spain, July 2010.
 181. “Genome-wide, exposure-wide, phenotype-wide associations”, Distinguished Lecture series, invited lecture at Wellcome Trust Sanger Institute, Cambridge/Hinxton, UK, July 2010.
 182. “Comparative effectiveness of treatments in children versus adults: it really does matter”, plenary at Star Summit on Child Health, Vancouver, Canada, September 2010.
 183. “Genome-wide, exposurome-wide, phenotype-wide associations”, Current Issues in Genomics, Department of Genetics, Stanford University School of Medicine, Stanford, USA, September 2010.
 184. “Network meta-analysis and meta-analysis networks”, Department of Statistics, School of Humanities and Sciences, Stanford University, Stanford, USA, September 2010.
 185. “Evidence-based personalized health”, Inaugural seminar, SPRC seminar series, Clarke Center Auditorium, Stanford University School of Medicine, Stanford, USA, September 2010.
 186. “Efficiency and reliability of translational research”, Pulmonary and Critical Care Medicine and Biology Grand Rounds, Stanford University School of Medicine, Stanford, USA, September 2010.
 187. “Genome-wide association studies, field synopsis and the genetics knowledge base for complex diseases”, opening plenary, 5th Biologic Prospective, Functional Genomics Towards Personalized Health Care, Santorini, Greece, September 2010.
 188. ““Genetic associations: genome-wide discoveries versus candidate claims versus the dark matter”, opening plenary at the World Congress of Psychiatric Genetics, International Society for Psychiatric Genetics, Athens, Greece, October 2010.
 189. “Large-scale multicenter studies and collaborative consortia”, ESCI course on clinical research, Bioacademy, Athens, October 2010.
 190. “The ratio of false-positives to false-negatives in epidemiologic studies and exposure-wide epidemiology”, opening plenary, 5th CELSE, Paphos, Cyprus, October 2010.
 191. “False positives, false negatives, inflated effects, deflated effects?”, Department of Health Research and Policy, Epidemiology lecture series, Stanford University, Stanford, USA, October 2010.
 192. “Evidence-based translational personalized –omics”, CIP meeting, Stanford, USA, November

- 2011.
193. "Exposurome research", Annual SPRC Symposium, Stanford University, Stanford, USA, November 2010.
194. "Why most published research findings are false", Bay Area Clinical Research Symposium, San Francisco, USA, December 2010.
195. "Hierarchy of research questions", dinner talk to Stanford-UCSF HHMI Medical Research Fellows, Stanford, USA, January 2011.
196. "Efficiency and reliability of translational research", Public Policy Lunchtime Colloquium, Landau Economics, Stanford University, USA, February 2011.
197. "False positives, false negatives, and effect estimates in epidemiological studies", Cancer Prevention Institute of California (CPIC), Fremont, USA, February 2011.
198. "Translational research: replication, credibility, and efficiency", Stanford Cardiovascular Institute, Frontiers in Cardiovascular Science lecture series, Stanford, USA, March 2011.
199. "False positives, false negatives and effect sizes: genome, exposome, and nutrition", Stars in Nutrition and Cancer honorary lecture series, National Cancer Institute, NIH, Bethesda, USA, March 2011.
200. "What are the barriers in translating the cancer genome into diagnostics: introductory", American Association of Cancer Research annual meeting, Orlando, USA, April 2011.
201. "False and inflated results in biomedical research", Plenary lecture in Symposium on "Ethics and Methodology", Nijmegen, Netherlands, April 2011
202. "Empirical testing of excess significance bias", Statistics seminar, Department of Statistics, Stanford University, Stanford, USA, March 2011
203. "Are there too many significant research findings?", Stanford Neurosciences student retreat, Hopkins Marine Center, Monterey, USA, April 2011.
204. "Efficiency and reliability of translational biomedical research", Varian, Palo Alto, May 2011.
205. "Omics in 2011", Women's Health Initiative meeting, Seattle, USA, May 2011.
206. "Biomedical research: do we have too many significant results?", Center for Biomedical Ethics, Stanford, USA, May 2011.
207. "Evidence-based personalized –omics", Program in Biomedical Informatics, Stanford, USA, June 2011.
208. "Validity and translational potential in omics research", Invited professor lecture at Cyprus Institute for Neurology and Genetics, Nicosia, Cyprus, August 2011.
209. "Do we have too many significant research findings?", Invited lecture, Iberoamerican Cochrane Center and Autonomous University of Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, October 2011.
210. "Geometry of the evidence: agenda-wide views of research", Plenary lecture at the Cochrane Colloquium, Madrid, Spain, October 2011.
211. Q&A session, Office of Communication & Public Affairs, Stanford University, November 2011.
212. Osler Evening Interview (coordinated by Abraham Verghese, MD), Stanford University School of Medicine, December 2011.
213. "Do we have too many significant biomedical research findings?", Grand Rounds, Department of Psychiatry and Behavioral Sciences, Medical Center, UC Davis, Sacramento, December 2011.
214. "Comparative effectiveness research: understanding and designing the geometry of the research agenda", Plenary lecture, Comparative Effectiveness Research symposium, University of California San Francisco, San Francisco, CA, January 2012.
215. "Geometry of comparative evidence and informational optimization of research designs", Lecture at SPRC/General Medical Disciplines seminar series, Stanford University, January 2012.

216. "Geometry of the evidence", Presentation to the Board of Directors, Stanford Hospital and Clinics, Palo Alto, CA, January 2012.
217. "Excess significance bias in translational medical research", Grand rounds, Stanford Research International, Menlo Park, CA, March 2012.
218. "The pressure to get it right: biases in biomedical research", Mind the Gap lecture series, National Institutes of Health, Bethesda, MD, April 2012
219. "Are there too many significant research findings?", Renaissance Technologies colloquium lecture, Long Island, NY, April 2012.
220. "Predictive medicine and predictive effects: true or false", opening plenary lecture, Society of Behavioral Medicine annual meeting, New Orleans, LA, April 2012.
221. "Understanding, exploring, and designing the geometry of the comparative evidence", keynote plenary lecture, Translational Science 2012 meeting, Washington, D.C., April 2012
222. "Empirical testing of excess significance bias", Q Center lecture series, Northwestern University, Evanston, IL, April 2012
223. "False positives and inflated effects: a meta-research view", grand rounds, Computational Institute, University of Chicago, Chicago, IL, April 2012
224. "The future of StaR Child Health: challenges and opportunities", closing plenary lecture, StaR Child Health meeting, Winnipeg, Canada, May 2012
225. "Geometry of the evidence", opening plenary lecture, 2012 Annual Canadian Cochrane conference, Winnipeg, Canada, May 2012
226. "The problem of having too many significant research findings and what to do about it", keynote lecture at 2012 Napa Valley Research Forum, Meadowood, CA, May 2012
227. "Designing and dissecting the geometry of the randomized evidence", closing plenary lecture, Society for Clinical Trials annual meeting, Miami, FL, May 2012
228. "Replication, reproducibility and curbing the epidemic of false-positive claims: a view from the biosciences", Panel on "The Development and Use of Public Data Bases: It's Complicated!", roundtable lecture at 2012 SLAC/NASA meeting, Progress on Statistical Issues in Searches, Kavli Auditorium, Stanford Linear Accelerator, CA, June 2012
229. "Predictive medicine: false claims, incremental effects, or paradigm shift?", Distinguished invited professor lecture series, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain, June 2012.
230. "Inflated and decreasing effects in biomedicine", plenary at Society for Research Synthesis Methodology, Aix-en-Provence, France, June 2012.
231. "Complex partnerships: Genome, exposurome, and predictive medicine", Sigma Tau Foundation 2012 lecture on complexity, University of Florence, Firenze, Italy, July 2012.
232. "Complex partnerships: Genome, exposurome, and predictive medicine", Sigma Tau foundation 2012 lecture on complexity, Mario Negri Institute, Milano, Italy, July 2012.
233. "Predictive medicine: can we trust it? Can we practice it?", Grand Rounds, Department of Medicine, Stanford University School of Medicine, Stanford, CA, August 2012.
234. "Cardiovascular genomics and personalized medicine", Debate, Stanford Cardiovascular Institute annual member retreat, Stanford, CA. September 2012.
235. "Pitfalls of cancer research", The Sixth Comprehensive Cancer Research Training Program at Stanford, Palo Alto, CA, September 2012.
236. "Significant research findings: caveats in search of reproducible research", Grand Rounds, Baylor College of Medicine, Houston, TX, September 2012.
237. "Predictive and personalized medicine: false, inflated, and true effects", Grand Rounds, Division of Internal Medicine, MD Anderson Cancer Center, Houston, TX, September 2012.
238. "Genetic prediction models: practice, metrics, and a discovery extension", Seminar, Quantitative Sciences Unit, Stanford University, Stanford, CA, October 2012.

239. "Data sharing for clinical research: experiences, techniques, methodologies", Institute of Medicine workshop on Sharing Clinical and Research Data, Washington, DC, October 2012 (by webinar).
240. "Geometry of the evidence: solid or crumbling?", Grand rounds, Institute for Public Health, University of Calgary, Calgary, Canada, October 2012.
241. "Translation of medical evidence into practice: failures and improvements", Opening plenary, 2012 RTNA conference on knowledge translation, Banff, Canada, October 2012.
242. "Reporting and reproducible research: salvaging the self-correction principle of science", 4th annual EQUATOR lecture, Freiburg, Germany, October 2012.
243. "Having too many significant research findings: problems and solutions", University of Cyprus, Nicosia, Cyprus, October 2012.
244. "Having too many significant research findings: problems and solutions", Technological University of Cyprus and Harvard-Cyprus International Institute for Environmental and Public Health, Limassol, Cyprus, October 2012.
245. "Credibility and geometry of the evidence: Are recommendations and decisions based on appropriate clinical studies?", Opening plenary, 17th meeting of Spanish Society of Primary Care Pharmacy, Madrid, Spain, October 2012.
246. "Mapping the global cancer burden", Session leader, World Oncology forum on "are we winning the war on cancer?", Lugano, Switzerland, October 2012.
247. Doctoral Epidemiology Seminar, School of Public Health, University of California Berkeley, November 2012.
248. "Large scale evidence and meta-research: annual update", Annual SPRC scientific symposium, Stanford University, November 2012.
249. "Halting the epidemic of non-fraudulent false research", Opening plenary lecture, Public Responsibility in Medicine and Research 2012 Advancing Ethical Research Conference, San Diego, CA, December 2012.
250. "The role of epidemiology in knowledge integration and meta-research", plenary at Trends in 21st Century Epidemiology: From Scientific Discoveries to Population Health Impact, National Institutes of Health, Bethesda, MD, December 2012.
251. "Personalized –omics medicine: promises and reality", Distinguished professor lecture series, University of South Florida School of Medicine, Tampa, FL, December 2012.
252. "Predictive medicine: reality or utopia?", Invited plenary lecture, Mount Sinai Medical Center, New York, NY, January 2013.
253. "Nesting randomized trials in biobanks and cohorts", Invited keynote plenary, Cancer Canada and Ontario Health Study, Toronto, Canada, January 2013.
254. "Improving the credibility and reproducibility of published research", Invited keynote plenary, annual meeting of the Annals of Emergency Medicine editorial board, Coronado, San Diego, CA, February 2013.
255. "Why is the evidence failing us?", Grand rounds, University of California San Diego, San Diego/La Jolla, CA, February 2013.
256. "What is wrong with reported medical research?" Invited keynote plenary, annual meeting of the Obstetrics and Gynecology editorial board, Dana Point, CA, February 2013.
257. "The reliability of biomedical evidence and how to improve it", invited lecture, Stanford Law School, Stanford, CA, April 2013.
258. "Exercise and chronic disease prevention", Consensus meeting on chronic disease prevention, International Olympic committee, Lausanne, Switzerland, April 2013.
259. "Publish or perish", invited lecture in research methodology course, annual meeting of the European Society for Clinical Investigation, Albufeira, Portugal, April 2013
260. "Credibility and replication of research findings", Invited lecture, Stanford/MIT/Harvard

- alumni clubs in Greece, Evgenidion planetary, Athens, Greece, April 2013
261. “Why scientific research is not necessarily self-correcting itself?”, Keynote plenary, 3rd Word conference on research integrity, Montreal, Canada, May 2013
 262. “Assessing and improving the credibility of biomedical evidence”, Distinguished professor lecture series, McGill/Jewish General Hospital, Montreal, Canada, May 2013
 263. “Understanding the geometry of clinical evidence”, CTSA Grand rounds, Mayo Clinic, Minnesota, May 2013
 264. Commencement speaker, graduation ceremony of UC Berkeley (Statistics), Berkeley, CA, May 2013
 265. “Geometry of the randomized evidence: rational, opportunistic, or conflicted?”, Medical grand rounds, Department of Medicine, Stanford University School of Medicine, Stanford, CA, June 2013
 266. “Reliability and validation in research”, Invited professor lecture, Department of Dermatology, University of Athens School of Medicine, Athens, Greece, June 2013
 267. “Selective reporting”, roundtable, University of Liverpool, Liverpool, UK, July 2013
 268. “Reliability of biomedical evidence: current state and how to improve it”, Invited distinguished professor lecture, University of Rome La Sapienza, Rome, Italy, July 2013
 269. “Predictive medicine: promises and caveats”, Invited distinguished professor lecture, University of Pescara and Chieti Gabriele d’Annunzio, Chieti, Italy, July 2013
 270. “How reliable is evidence in medicine?”, Invited plenary lecture and discussion, European Forum Alpbach, Alpbach, Austria, August 2013
 271. “Replication and reproducible research: utopia or reality?”, Opening plenary, International Congress of Peer Review and Biomedical Publication, Chicago, IL, September 2013
 272. “Replication and reproducible research”, Annual Samuel O. Thier Lecture, Yale University School of Medicine, New Haven, CT, September 2013
 273. “In personalized medicine ready for prime time?”, roundtable, Stanford Cardiovascular Institute, annual retreat, Stanford, CA, September 2013
 274. “Predictive, personalized, individualized medicine: promises and caveats”, Invited lecture, Department of Microbiology, University of Washington School of Medicine, Seattle, WA, September 2013
 275. “Randomized trials in more versus less developed countries”, Research journal club workshop, Department of Global Health, University of Washington of Washington School of Medicine, Seattle, WA, September 2013
 276. “Bias and reproducible research”, Biomedical Research Integrity lecture series, University of Washington School of Medicine, Seattle, WA, September 2013
 277. “Statistical and clinical inference: the credibility of evidence”, invited lecture/short course, Scientific Inference Conference, PERF, San Diego, September 2013
 278. “The evolution of evidence: when is enough, enough?”, Plenary lecture, Vermont Oxford network annual meeting, Chicago, IL, October 2013
 279. “Predictive and personalized medicine”, invited workshop lecture, Vermont Oxford network annual meeting, Chicago, IL, October 2013
 280. “Improving the reproducibility of biomedical research”, Plenary lecture at the joint meeting of the editorial boards of Anesthesiology and of Anesthesia and Analgesia, San Francisco, CA, October 2013
 281. “Improving the validity of research”, Invited lecture and roundtable discussion, Philanthropy Roundtable, Terranea, CA, October 2013
 282. “Bias and reproducible research”, Invited lecture, Institute of Medicine interest group meeting, Washington, DC, October 2013
 283. “Bias and reproducible research”, Keynote, Trottier Symposium, McGill University, Montreal, Canada, October 2013

284. "Replication in science", McGill University, Montreal, Canada, October 2013.
285. "Large-scale evidence and meta-research", Annual SPRC Symposium, Stanford, CA, November 2013.
286. "Funding research: impact, conformity, and reproducibility", Keynote, Séance de réflexion, Swiss National Science Foundation, Berne, Switzerland, November 2013.
287. "Uses and re-uses of big data", plenary lecture at meeting on Secondary use of big data from critical care, MIT, Boston, MA, January 2014.
288. "The long road from animal studies to clinical trials on the way to FDA approval", plenary lecture, 1st annual UC Davis Stem cell research policy and ethics symposium, University of California Davis, Davis, CA, January 2014.
289. "Scientific standards and data integrity/quality", panel contribution, Public workshop of the Committee on strategies for responsible sharing of clinical trial data, Institute of Medicine, Washington D.C., February 2014.
290. "Overarching and cross-cutting issues in data sharing", panel contribution, Public workshop of the Committee on strategies for responsible sharing of clinical trial data, Institute of Medicine, Washington D.C., February 2014.
291. "Systematic Approaches to Assessing the Internal and External Validity of Randomized Controlled Trials", invited lecture at IOM workshop on Characterizing and Communicating Uncertainty in the Assessment of Benefits and Risks of Pharmaceutical Products, Institute of Medicine, Washington, D.C. (presentation through webinar), February 2014.
292. "Reproducible research: utopia and reality", invited lecture, Center for Advanced Studies in the Behavioral Sciences, Stanford, CA, March 2014.
293. "Metrics of appraising research", NHLBI Retreat, webinar, March 2014.
294. "Promises and pitfalls in reusing and combining data", invited plenary talk, Association of University Anesthesiologists conference, Stanford, CA, April 2014.
295. "Is everything we eat associated with cancer? A systematic cookbook review", invited talk in Experimental Biology annual conference, American Society for Nutrition, San Diego, CA, April 2014.
296. "Improving value and reducing waste in genomics", invited plenary talk, EQUATOR annual meeting, Paris, France, May 2014.
297. "Geometry and future of randomized trial agendas", European Organization for Research on Treatment of Cancer (EORTC) headquarters, Brussels, Belgium, May 2014.
298. "Credibility and bias in the results of clinical trials", invited plenary, International Clinical Trials Day, ECRAN, Luxembourg, May 2014.
299. "Genomic medicine", invited plenary and panel discussion, Stanford Big data Conference, Stanford, CA, May 2014.
300. "Proactive planning of the preclinical research agenda", invited talk and panel discussion, Workshop on Reproducibility Issues in Research with Animals and Animal Models, Institute for Laboratory animal Research and U.S. National Academy of Sciences, Washington D.C., June 2014 (via webinar).
301. "Reproducible research: true or false?", invited lecture, Google, Mountain View, CA, June 2014.
302. "Improving reproducible research", Invited lecture, Institute for Complex Systems, Paris, France, July 2014.
303. "Reproducibility in biomedical research", Distinguished lecture, Institut Pasteur, Paris, France, July 2014.
304. "Big data: promises and caveats in their use and reuse", Invited lecture, Istituto Rizzoli, Bologna, Italy, July 2014.
305. "Improving reproducibility in empirical research", Invited lecture, Stanford Law School, Stanford, September 2014.

306. "Policies regarding knowledge representation", Webinar presentation, AMIA 2014 Policy Invitational Meeting: Harnessing Next-Generation Informatics for Personalizing Medicine, Washington, DC, September 2014.
307. "Tracking and improving research practices", Keynote lecture, Symposium on 'Improving scientific practice: dealing with the human factors', University of Amsterdam and University of Tilburg, Aula of the University of Amsterdam, Amsterdam, Netherlands, September 2014.
308. "Credibility in empirical economics", Keynote lecture, Meta-analysis of economics research (MAER) network, annual colloquium, Athens, Greece, September 2014.
309. "Rethinking science", 25th European Student Conference, Charite Hospital, Berlin, Germany, September 2014.
310. "Multi-level data integration: sharing some data and some thoughts", Keynote lecture (via webinar), Novel Approaches and Challenges to Data Harmonization Workshop, National Cancer Institute, NIH, Rockville, MD, October 2014.
311. "Overcoming statistical biases in science communication", Invited lecture (via webinar), Annenberg Science of Science Communication Conference, Annenberg Public Policy Center of the University of Pennsylvania, Philadelphia, PA, October 2014.
312. "Towards truth in published research", Keynote lecture, PLoS Medicine 10th anniversary celebration, San Francisco, CA, October 2014.
313. "Increasing research reproducibility", Invited lecture, Prostate Cancer Foundation annual meeting, San Diego, CA, October 2014.
314. "Big data in genomic medicine", Invited lecture (via webinar), Big Data and Precision Medicine, 2014 East-West Alliance Global Symposia, Hong Kong, China, October 2014.
315. "Big data and the patient", Roundtable discussion, NCCN Patient Advocacy Summit: Patient Concerns in 2014 – Big Data, Access, and Palliative Care, The National Press Club, Washington, DC, November 2014.
316. "Significance and credibility of research findings", Lecture series, Nowzari symposium, Beverly Hills, CA, November 2014.
317. "Large-scale evidence and meta-research", SPRC annual research symposium, Stanford, CA, November 2014.
318. "Making nonsense of big data", Plenary lecture, Workshop on How to Transform big Data into Better Health, Science Europe, Majorana Foundation, Erice, Italy, November 2014.
319. "How to make more published research true", Keynote lecture, Advanced Retina Therapy annual conference, Medical University of Vienna, Austrian Academy of Sciences, Vienna, Austria, November 2014.
320. "Improving reproducible research", Honorary lecture, Foundation for Research and Technology – Hellas, Herakleion, Crete, Greece, December 2014.
321. "Lessons and pitfalls from medical research", plenary keynote lecture, Transparency forum, Berkeley Initiative for Transparency in the Social Sciences, Berkeley, CA, December 2014.
322. "Research practices and reproducible research", Harvard Catalyst lecture, Department of Biostatistics, Harvard School of Public Health, Boston, MA, January 2015.
323. "Exposure-wide association studies", invited lecture, Department of Epidemiology, Harvard School of Public Health, Boston, MA, January 2015.
324. "Better research for better global health decisions", invited plenary lecture, Global Health Research Convening, Center for Innovation in Global Health, Stanford University, Stanford, CA, January 2015.
325. "Why most published clinical research is wrong", Hoffman lecture, American Society of Pediatric Neurosurgery, Hawaii, January 2015.
326. "Discussion: Assessment of factors affecting reproducibility", Workshop, National Academy of Sciences workshop on reproducibility, Washington, D.C., February 2015 (webinar presentation)

327. “Improving reproducible research”, keynote, American Academy of Allergy, Asthma, and Immunology annual meeting, Houston, February 2015.
328. “Clinical trials: pitfalls in design and interpretation”, Lown Institute meeting, San Diego, March 2015.
329. “Improving reproducible research practices”, opening keynote, US-HUPO (Human Proteome Organization) annual meeting, Tempe, Arizona, March 2015.
330. “Objective Academic and Research Evaluation: Challenges and Opportunities for Quality Improvement”, Delta Omega 2015 annual lecture, Arnold School of Public Health, University of South Carolina, Columbus, SC, April 2015.
331. “Improving clinical research”, Invited distinguished professor lecture, Columbia University and New York State Psychiatric Institute, New York, NY, April 2015.
332. “Evidence-based medicine caveats”, closed session and open public lecture and discussion, Global Think-In, Columbia University, New York, NY, April 2015.
333. “Exposure-wide associations: epidemiology revisited”, Grand Rounds, Department of Epidemiology, Albert Einstein Yeshiva School of Medicine, Bronx, NY, April 2015.
334. “How to make more published research true”, invited plenary, University of Toronto and Toronto Sickkids Symposium on research integrity, Toronto, April 2015.
335. “Bias and reproducible research”, Distinguished professor invited lecture, Michigan State University, East Lansing, Michigan, May 2015.
336. Convocation ceremony remarks on the occasion of awarded the Medal for distinguished service, Teachers College, Columbia University, Cathedral of Saint John the Divine, New York, NY, May 2015.
337. “What treatments really improve treatment outcomes and by how much”, keynote lecture, Swiss Society of Internal Medicine, annual meeting, Basel, Switzerland, May 2015.
338. “Reducing waste in research”, keynote lecture, Italian Cochrane Collaboration annual meeting, Torino, Italy, May 2015.
339. “Journals, publishing, and how to questions”, Meet-the-editor-in-chief plenary session, European Society of Clinical Investigation, 49th annual meeting, Cluj-Napoca, Romania, May 2015
340. “How to improve research”, Litchfield lecture, Oxford University, Oxford, June 2015
341. “Reproducible research: true or false”, invited plenary lecture, SkeptiCal 2015 conference, Oakland, California, June 2015
342. “The exodus of Greek scientists – a meta-analysis”, First annual Dimitri Trichopoulos memorial lecture, Athens, Panhellenic Medical Conference, Athens, June 2015
343. “Reproducible research: crisis or opportunity”, invited plenary lecture, International Society for Stem Cell Research, annual conference, Stockholm, Sweden, June 2015
344. “Evidence based medicine, public health genomics and personalized medicine”, honorary lecture, University of Rome La Sapienza and Roman Academy of Public Health, Rome, Italy, June 2015
345. “What is meta-research and what does it aspire to”, keynote lecture, The 2015 Southampton Conference on the Credibility of Empirical Research, Southampton, UK, June 2015
346. “Exposure-wide epidemiology: revisiting Bradford Hill”, Bradford Hill annual lecture, London School of Hygiene and Tropical Medicine, London, UK, July 2015
347. “Evaluating science: making research better, not worse”, invited keynote, Governance, Performance & Leadership of Research and Public Organizations, Bavarian Academy of Sciences, Munich, Germany, July 2015
348. Panel on preclinical data reproducibility, University of California San Francisco, San Francisco, California, September 2015, <https://vimeo.com/139970369>
349. “How reliable information on medical interventions and products is”, invited lecture series, Academy of Reconstructive Dentistry, Academy of Banking, Taipei, Taiwan, September 2015.

350. “Launching the Wellness Living Laboratory”, speech at ceremony celebrating collaboration between SPRC/Stanford and Fu Jen University, signing of MOU with president of Fu Jen University, Taipei, Taiwan, September 2015.
351. “Why and how to study wellness and wellness interventions”, Taipei, Taiwan, September 2015.
352. “Mediocracy versus meritocracy”, TedXAcademy, Athens Megaron, Athens, Greece, September 2015 (in Greek).
353. “REWARD Action plan and launch of the REWARD campaign”, plenary panel, REWARD/EQUATOR conference, Edinburgh, Scotland, September 2015.
354. “Meta-research: an emerging scientific discipline”, Closing plenary, REWARD/EQUATOR conference, Edinburgh, Scotland, September 2015.
355. “What does reproducible research mean for population health and big data?”, Usher inaugural annual lecture, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, October 2015.
356. “Increasing value, decreasing waste in research: a role for meta-epidemiology”, keynote lecture, Annual Methods Symposium, Cochrane, Vienna, Austria, October 2015.
357. “Can too many systematic reviews and meta-analyses do harm?”, plenary lecture, Annual Cochrane Colloquium, Vienna, Austria, October 2015.
358. “Personalized medicine: how precise and how reproducible?”, plenary lecture, 2nd Transatlantic Conference on Personalized Medicine, Rotterdam, Netherlands, October 2015.
359. “Boosting reliable research: data analysis”, Nature, webcast, October 2015.
360. “Meta-research: an emerging discipline”, METRICS Forum, Stanford, October 2015.
361. “Wellness Living Laboratory”, plenary, 9th Sino-USA symposium on medicine in the 21st century, Stanford, CA, USA, October 2015.
362. “Gender variables: review of some methods challenges”, Workshop on gender variables for health research, Stanford, October 2015.
363. “Reducing waste in clinical research”, Grand rounds, Department of Medicine, Northwestern University School of Medicine, Chicago, USA, October 2015.
364. “Big data, genomics, and reproducible research”, Keynote, Genomic data conference, American Dental Association, Chicago, USA, October 2015.
365. “Boring discoveries, innovative replications”, Acceptance speech for honorary doctorate, Erasmus University Rotterdam, Netherlands, November 2015. Laudatio: http://www.eur.nl/fileadmin/ASSETS/icb/Dies_Natalis/2015/Laudatio_Myriam_Hunink.pdf and acceptance speech: http://www.eur.nl/fileadmin/ASSETS/icb/Dies_Natalis/2015/Acceptance_speech_John_Ioannidis.pdf
366. “Old and new methods for the scientific basis of medical care”, Keynote, workshop on quantitative medicine, Erasmus University Rotterdam, Netherlands, November 2015.
367. “Large-scale evidence and meta-research”, SPRC Annual Research Symposium, November 2015.
368. “Improving clinical research”, keynote plenary (via videoconference), International Student Congress of Research Integrity & Evidence Based Practice, Kish Island, Iran, December 2015.
369. “Reading a couple of million papers with P-values”, Biostatistics workshop, Stanford University, Stanford, December 2015.
370. “Reproducibility crisis and reproducibility solutions”, Tripodi annual lecture, University of California Berkeley, Berkeley, January 2016.
371. Panel on reproducibility of data, software and code. Arnold reproducibility workshop, American Association for the Advancement of Science, Washington DC, February 2016.
372. “Variations on the art of the fugue”, invited lecture, Reading Society of Corfu (Αναγνωστική Εταιρεία), Corfu, Greece, March 2016 (in Greek).

373. "Reproducible research: where are we?", keynote plenary lecture, Molecular Medicine Day 2016, Erasmus University Rotterdam, Netherlands, March 2016.
374. "How to improve the credibility of research findings", invited lecture, Harvard Medical School, March 2016.
375. "Meta-research: where do we stand on research in research", invited lecture, Broad Institute-MIT, Boston, March 2016.
376. "How to improve clinical research", University of Chicago, Department of Medicine grand rounds, March 2016.
377. "Defining meta-research, an evolving discipline", keynote, Science of Science meeting, Library of Congress, Washington D.C., March 2016.
378. "Reflections on the Greek brain drain", Society for the Preservation of the Greek Heritage, Washington, D.C., March 2016.
379. "Empirical evidence on reproducibility of research", annual Robert Levine lecture, Yale Interdisciplinary Center for Bioethics, New Haven, March 2016.
380. "Empirical research on research and the reproducibility crisis", William and Myrtle Harris distinguished lecture on Science and Civilization, Caltech, Pasadena, April 2016.
381. "Performing, communicating and rewarding reproducible research", Year of Open Science lecture, University of Texas at Austin, Austin, April 2016.
382. "Evidence-based medicine has been hijacked", keynote lecture, Lown Conference, Chicago, April 2016.
383. "Medical misinformation vs. reliable and clinically useful evidence for truly informed consent and improved outcomes", workshop presentation, Lown Conference, Chicago, April 2016.
384. "Reproducibility", Biomedical ethics panel, joint AAP/ASCI/APSA meeting, Chicago, April 2016.
385. "Reproducibility and improving research practices", Inaugural lecture, Berlin Health Institute, Berlin, Germany, May 2016.
386. "Common pitfalls in the conduct and interpretation of meta-analysis", invited lecture, National University of Singapore, Singapore, May 2016.
387. "Future directions of meta-analysis: novel methods and applications", invited lecture, National University of Singapore, Singapore, May 2016.
388. "Capturing the value of prevention", Keynote, Public Health Thought Leadership Dialogue, National University of Singapore School of Public Health, Singapore, May 2016.
389. "How to make risk estimates more reliable", closing keynote, International Committee for Insurance Medicine annual meeting, Maastricht, Netherlands, May 2016.
390. "Reproducible research: impact in evidence-based decision making", T.H. Seldon Memorial Lecture, keynote, International Anesthesia Research Society, San Francisco, May 2016.
391. "How can the systematic review community promote better research instead of just damning bad research?", Evidence-based Practice Centers meeting, May 2016.
392. "Quality of evidence for health care: scary tales and fairy tales", invited lecture, Innovative Health Care Leader Program, Stanford University, California, May 2016.
393. "How to make clinical research useful", Grand rounds, Department of Pediatrics, Stanford University School of Medicine, Stanford, June 2016.
394. "Evidence for prevention", Center for Advanced Studies in Behavioral Sciences, Stanford, June 2016.
395. "What should we seek with reproducible research", National Library of Medicine, Conference on reproducibility, FNLM, Washington D.C., June 2016.
396. "How to improve clinical research", European School of Internal Medicine, Sardinia, Italy, June 2016.
397. "To be or not to be – a personal anecdote", European School of Internal Medicine, Sardinia,

- Italy, June 2016.
398. “More or less – why most published research is false”, European School of Internal Medicine, Sardinia, Italy, June 2016.
 399. “How to apply scientific results to the care of the single patient”, European School of Internal Medicine, Sardinia, Italy, June 2016.
 400. “Credibility of medical research”, invited honorary lecture, Medical School, University of Sacred Heart, Rome, Italy, June 2016.
 401. “Why most clinical research is not useful”, plenary lecture, Evidence Live, Oxford, UK, June 2016.
 402. “Nutrition evidence: population and individuals”, lecture at the Lorenzini Institute meeting on nutrition guidelines, Venice, Italy, July 2016.
 403. Three contributed papers presented at the Society for Research Synthesis Methodology, Annual meeting, Florence, Italy, July 2016.
 404. “Reproducible research: current status and future prospects”, Keynote, American Psychological Association annual meeting, Denver, August 2016.
 405. “Improving research practice”, presidential keynote, annual meeting of the American Academy for Cerebral Palsy and Developmental Medicine, Hollywood, Florida, September 2016.
 406. “Clinical trial design in the future”, keynote, annual meeting of the World Congress of Pediatric Gastroenterology, Hepatology and Nutrition, Montreal, Canada, October 2016.
 407. “How to make medical research both more credible and more useful”, Keynote lecture, annual meeting of the Society for Medical Decision Making, Vancouver, Canada, October 2016.
 408. “Large-scale evidence and meta-research”, SPRC Annual Research Symposium, November 2016.
 409. “What can universities do to make research more true/reproducible?”, Snyder annual lecture, University of Utah, Salt Lake City, November 2016.
 410. “Biomedical research: the unfinished musical score”, 23rd Anatomy Lesson, University of Amsterdam and Academic Medical Center, Concertgebouw symphony hall, Amsterdam, Netherlands, November 2016.
 411. “Improving the credibility of clinical research”, Keynote, Swiss Pain Society annual meeting, Montreux, Switzerland, November 2016.
 412. “Improving reproducible research practices”, Keynote, Hellenic Bioinformatics Conference, annual meeting, Thessaloniki, Greece, November 2016.
 413. “Brain drain and solutions”, Invited lecture, Department of Computer Science and Telecommunications, University of Athens, Athens, Greece, November 2016 (in Greek).
 414. “Assessing the credibility of the scientific literature”, Keynote, Hellenic Society for Pharmaceutical Sciences meeting, Athens, Greece, November 2016 (in Greek).
 415. “Improving research: why, who, when and what are you talking about”, lecture, SPRC/General Medical Disciplines lecture series, Stanford, CA, December 2016.
 416. “Observational studies versus RCTs in nutrition: what are the tradeoffs?”, Keynote, American Society for Nutrition, Advances and Controversies in Clinical Nutrition conference, Orlando, Florida, December 2016 (via webinar).
 417. “Data analysis and interpretation: be sure you’re right, then go ahead”, webinar presentation, Center for Evaluation and Coordination of Training and Research in Tobacco Regulatory Science, January 2017, Rockville, MD, January 2017.
 418. “Truth or Consequences”, San Francisco Exploratorium, San Francisco, January 2017.
 419. “Improving research practices: a global challenge”, Chanchlani Global Health Award, McMaster University, Hamilton, February 2017.
 420. “Basic science to clinical research: how best to translate evidence”, grand rounds, McMaster University, Hamilton, February 2017.

421. “Reproducible research: what it means for epidemiology”, invited lecture, Yale University School of Public Health, New Haven, February 2017.
422. “What is wrong with health research and how to fix it”, Weill Cornell Qatar, February 2017 (via videoconference)
423. “Επιστημονικές φυγές και επιστροφές: μια προσωπική τοκάτα” (“Scientific fugues and returns: a personal toccata”, Acceptance lecture for PhD honoris causa, University of Athens (in Greek), February 2017, Athens, Greece.
424. “Towards more credible and useful biomedical research”, Annual Distinguished Investigator lecture, University of Connecticut School of Medicine and Health Center, Farmington, CT, March 2017.
425. “Wat does reproducible basic and preclinical research mean”, invited lecture, Cold Spring Harbor Laboratory, NY, March 2017.
426. “Reproducibility in preclinical and clinical research”, invited lecture, Department of Pharmacology, Stony Brook University, Stony Brook, NY, March 2017.
427. “Tractatus on the sixth fame and reflection of Greek brain drain and its diaspora”, Center for Hellenic Studies, Stony Brook University, Stony Brook, NY, March 2017.
428. “Quality of evidence for health care: scary tales and fairy tales”, invited lecture, Innovative Health Care Leader Program, Stanford University, California, March 2017.
429. “Medical research can be both credible and useful”, honorary Nicholas A. Vick annual lecture, Northshore University Health System, Chicago, Illinois, April 2017.
430. “How to make scientific research more credible and useful”, Sverbank seminar lecture, Stanford Graduate School of Business, Stanford University, California, April 2017.
431. “How to make clinical research more reproducible and useful”, honorary annual Heldrich lecture, Rutgers University School of Medicine, New Jersey, April 2017.
432. “Reproducibility”, The Big Data to Knowledge (BD2K) Guide to the Fundamentals of Data Science, webinar presentation, May 2017.
433. “Intervention research: promises and challenges”, keynote, Stockholm Conference on behavioral and social intervention research, Wenngarn Castle, Stockholm, Sweden, May 2017.
434. “The reproducibility crisis as an opportunity for improving research practices”, invited lecture, Max Planck Institute for Human Development, Berlin, Germany, May 2017.
435. “Reproducibility challenges towards improving the evidence base for modern science”, invited lecture, Karolinska Institute, Stockholm, Sweden, May 2017.
436. “Towards more credible and more useful research”, invited lecture, Gothenburg Science Festival, Gothenburg, Sweden, May 2017.
437. “Increasing transparency and raising value in clinical research”, invited panel lecture, Friends of the National Library of Medicine meeting on “Consequential Clinical Research: Accelerating Continuous Improvement”, NLM, June 2017 (telepresentation).
438. “Why most published research findings don’t need to be false”, invited lecture, Split University School of Medicine, Split, Croatia, June 2017.
439. “Reproducibility: new challenges and solutions”, invited lecture, University of Tuebingen School of Medicine, Tuebingen, Germany, July 2017.
440. “Meta-analyses in 2017: state of the art, state of the network”, Closing keynote lecture, 4th course on network meta-analyses, Oxford University, Oxford, UK, July 2017.
441. “The crisis in credibility and efficacy in scientific research. Which solutions?”, invited lecture, University of Ferrara School of Medicine, Ferrara, Italy, July 2017.
442. “Lessons from meta-epidemiological assessments”, plenary lecture, 38th annual conference of the International Society for Clinical Biostatistics, Vigo, Spain, July 2017.
443. “Is there a reproducibility crisis and should something be done about it?”, keynote lecture, 15th European Congress of Psychology, Amsterdam, Netherlands, July 2017.

444. “Reflections on research and science communication”, introductory lecture, Seminar with John Ioannidis and Science Journalism and Responsible Research and Innovation, Erasmus University Rotterdam, Rotterdam, Netherlands, August 2017.
445. “Conceptual and statistical issues on reproducibility”, opening keynote, CEN-ISBS Joint Conference on Biometrics and Biopharmaceutical Statistics, Vienna, Austria, August 2017.
446. “Reproducibility”, panel on reproducibility, Joint Conference on Biometrics and Biopharmaceutical Statistics, Vienna, Austria, August 2017.
447. “Are systematic reviews and meta-analyses the tip of the pyramid of research studies?”, plenary, annual research workshop, European Society of Reproductive Endocrinology, Capri, Italy, September 2017.
448. “Credibility of modern studies”, plenary, annual research workshop, European Society of Reproductive Endocrinology, Capri, Italy, September 2017.
449. “Predating data: integrity of methods and statistics”, keynote, Integrity of Data conference, Crete, Greece, September 2017.
450. “Credibility and utility of big data”, keynote, annual Hellenic Bioinformatics conference, Crete, Greece, September 2017.
451. “Changing research practices towards reproducible research”, closing keynote, Open Science Fair, Athens, Greece, September 2017.
452. “Evidence-based practice of medicine: evolving standards”, keynote, Association of VA Hematology/Oncology annual meeting, Denver, Colorado, September 2017.
453. “What is meta-research and what can it achieve”, closing keynote, Meta-Research Symposium, Farr Institute of Health Informatics Research, University of Edinburgh, Edinburgh, Scotland, September 2017 (telepresentation).
454. “How to make research more reproducible and more useful”, invited lecture, University of Berne School of Medicine, Berne, Switzerland, September 2017.
455. “Making research more useful: reproducibility, translation, and incentives”, keynote, University of British Columbia and BC Children’s Hospital Research Institute, Vancouver, Canada, September 2017.
456. “Meta-analyses: can we trust them, can we improve them?”, Pediatrics Grand Rounds, BC Children’s Hospital Research Institute, Vancouver, Canada, September 2017.
457. “Meet the professor”, workshop, BC Children’s Hospital Research Institute, Vancouver, Canada, September 2017.
458. “Meta-analyses and meta-research: evidence synthesis and bird’s eye views of science”, keynote lecture for the inauguration ceremony of the Deakin Laboratory on Meta-Analysis Research (DelMAR), Deakin University, Melbourne, Australia, October 2017.
459. “What have we (not) learnt from millions of scientific papers with p-values?”, opening keynote, American Statistical Association Symposium on Statistical Inference, Bethesda, Maryland, October 2017 (telepresentation).
460. “Why everything we know is wrong”, opening keynote, ANZICS/ACCCN Intensive Care Annual Scientific Meeting, Gold Coast, Australia, October 2017.
461. “What should you believe and what do you need to know”, plenary, ANZICS/ACCCN Intensive Care Annual Scientific Meeting, Gold Coast, Australia, October 2017.
462. “Is our evidence base fatally flawed?”, Plenary debate, ANZICS/ACCCN Intensive Care Annual Scientific Meeting, Gold Coast, Australia, October 2017.
463. “Evidence-based medicine: precisely”, Frontiers in Cardiovascular Science lecture, Cardiovascular Institute, Stanford, California, October 2017.
464. “False and not useful clinical research: how can we increase its value?”, opening keynote, 8th International conference for Evidence-Based Healthcare Teachers and Developers, Taormina, Italy, October 2017 (telepresentation).

465. "Meta-research: improving research", Dr. J. David Grimes annual lecture, keynote, annual Ottawa Hospital Research Institute, Ottawa, Canada, November 2017.
466. "Evidence-Based Medicine: where are we?", Grand rounds, Department of Community and Family Medicine, University of California Davis, Sacramento, CA, November 2017.
467. "Biomedical research: the false and the true, the waste and the useful", George Snively lecture, University of California Davis, Sacramento, CA, November 2017.
468. "Towards more reproducible and unbiased research", invited professor at the SAGE center, University of California Santa Barbara, Santa Barbara, November 2017.
469. "Reproducible science: key challenges", invited lecture in ILAR and National Academies of Science, Medicine, and Engineering workshop, November 2017 (telepresentation by videoconference).
470. "Making research more reproducible and useful", annual Morriston Davies memorial lecture, keynote at the British Thoracic Society annual meeting, London, UK, December 2017.
471. "Scientific research: an overview of science, antiscience, and distorted science", Opening keynote lecture, annual Public Health meeting, University of Patras, Patras, Greece, December 2017.
472. "Evidence based medicine: segmented, fragmented, broken, and collated", Opening keynote lecture, annual national meeting on Management and Health Economics, Athens, Greece, December 2017.
473. "Some ethical implications of the epistemological quagmire surrounding Big Data", closing keynote lecture, "Biobanking, Big Data Research and the Remaking of Medicine" conference, University of Ghent and University Hospital Ghent, Ghent, Belgium, December 2017.
474. "Evidence on evidence", keynote, Herrenhausen conference "Lost in the Maze? Navigating Evidence and Ethics in Translational Neuroscience" (via videopresentation), Hannover, Germany, February 2018.
475. "Extent of Reproducibility Issues in Scientific and Engineering Research", presentation and briefing at National Academy of Science panel on reproducibility, February 2018 (via videopresentation).
476. "Large scale evidence and meta-research: update", SPRC Annual research symposium, Stanford, March 2018.
477. "Challenges for investigators – generating reproducible research results", keynote, University of Minnesota, Minneapolis, March 2018.
478. "True and useful research results: mission impossible?", keynote, Orthopedics Research Society annual meeting, New Orleans, March 2018.
479. "Reproducibility in crisis", webinar, American Association for the Advancement of Science, March 2018.
480. "Present and future of network meta-analyses", lecture and panel, American Medical Informatics Association, San Francisco, March 2018.
481. "Reproducible research: challenges and improvements", Department of Energy Joint Genome Institute, annual meeting on Genomics and Environment, keynote, San Francisco, March 2018.
482. "Reproducibility and utility: improving research practices", Gonatas memorial lecture, University of Pennsylvania School of Medicine, Philadelphia, March 2018.
483. "Reproducibility challenges and translation", invited lecture, SPARK Translational Research Program, Stanford University, Stanford, April 2018.
484. "Improving research practices", keynote lecture, Improving reproducible research practices in schools of public health, Yale University School of Public Health, New Haven, April 2018.
485. "The power of bias and what to do about it", invited lecture, Michigan Institute of Data Science, University of Michigan, Ann Arbor, April 2018.
486. "Precision health, big data and evidence-based medicine – contradictions or companions", invited lecture, Institute of Healthcare Policy and Innovation, University of Michigan, Ann Arbor, April 2018.

487. “Reproducible and useful clinical research: mission impossible?”, Grand rounds, Department of Medicine, University of Michigan, Ann Arbor, April 2018.
488. “Training the scientific workforce around the issue of reproducibility”, invited lecture, MIT Ideathon, Boston, April 2018.
489. “The Wellness Living Laboratory”, invited lecture, Rise Thailand meeting, Bangkok, April 2018.
490. “Evidence-based medicine: lost cause or new opportunities?”, opening keynote, National Conference on Medical Oncology, Thessaloniki, Greece, May 2018.
491. “Credible and useful clinical research: a utopia?”, keynote plenary, 7th National Conference of the Hellenic Society of Neonatology, Athens, Greece, May 2018 (in Greek).
492. “Reproducible and useful epidemiology: why and how”, invited lecture series, Pharmacoepidemiology Festival, University of Bordeaux, France, May 2018.
493. “Can we save medicine? An appraisal of the biomedical ecosystem”, invited plenary lecture, European Calcified Tissue Society annual meeting, May 2018.
494. “The role of bias in nutrition science”, invited lecture, BMJ and SwissRe Nutrition Conference, Zurich, June 2018 (via videopresentation).
495. “Mega-data to assess risk and treatment effect in the compromised host: promises and caveats”, plenary keynote, Immunocompromised Host Society conference, Athens, Greece, June 2018.
496. “Meta-epidemiology methods”, invited lecture, University of Bologna, Italy, June 2018.
497. “Challenges with big data”, invited lecture, University of Bologna, Italy, June 2018.
498. “Is there a reproducibility crisis and what should be done about it?”, invited lecture, University of Bologna, Italy, June 2018.
499. “Enhancing reproducible research”, EuroScience Open Forum (ESOF), Toulouse, France, July 2018.
500. “Reproducible research: an overview of current challenges”, invited lecture, International Conference on Machine Learning, Stockholm, Sweden, July 2018.
501. “Irreproducible research in the artificial intelligence era”, invited lecture, AI in Medicine Inclusion and Equity symposium, Stanford, CA, August 2018.
502. “Replication and credibility of research”, panel presentations, ESEM conference, Cologne, Germany, August 2018.
503. “Knowledge is truth? Generating medical evidence in a digital age”, invited lecture, CERES, University of Cologne, Cologne, Germany, August 2018.
504. “Meet the professor” session, European Conference of Internal Medicine, Wiesbaden, Germany, August 2018.
505. “What is the value of screening and early therapeutic strategies?”, keynote plenary, annual European Conference of Internal Medicine, Wiesbaden, Germany, August 2018.
506. “Reproducibility with big and small data”, opening keynote, 18th European Conference on Computational Biology and Bioinformatics, Athens, Greece, September 2018.
507. “Research practices for reproducible and useful scientific investigation”, annual Dean’s Lecture, University of Texas McGovern School of Medicine, Houston, Texas, October 2018.
508. “Is clinical research reproducible, transparent, and useful?”, keynote, David and Rosemary Adamson Lecture on Excellence in Reproductive Medicine, 74th American Society for Reproductive Medicine, Denver, Colorado, October 2018.
509. “Reproducibility crisis”, opening lecture in Better Science lecture series, Stanford University, Stanford, CA, October 2018.
510. “Do antidepressants work? Review with network meta-analysis”, keynote, 4th Annual Innovations in Psychiatry and Behavioral Health: Adult Disorders, Technology, and Provider Wellbeing Symposium, Stanford, California, October 2018.
511. “Reproducibility, research credibility and excellence”, opening keynote, Philadelphia

- symposium on Research Credibility and Excellence, Philadelphia, October 2018.
512. “Reproducibility in research”, Keynote lecture, Research Funders Summit, organized by Elsevier, Rockville, October 2018.
 513. “Is the crisis of science a crisis of reproducibility of results?”, keynote lecture, Austrian Day of Science 2018, Austrian Research Association, Vienna, Austria, October 2018.
 514. “In search of useful clinical research”, invited plenary, National Conference of the Hellenic Cardiology Society, Athens, Greece, October 2018.
 515. “Looking through experimental studies: advantages, pitfalls and remedies”, invited seminar lecture, Department of Public Health, Karolinska Institute, Stockholm, Sweden, October 2018.
 516. “The bad, the best and the “good enough” in the evaluation of medical and public health interventions”, invited distinguished professor lecture, Department of Public Health, Karolinska Institute, Stockholm, Sweden, October 2018.
 517. “Prolific science, prolific authors, prolific data and statistics: how about good research practices?”, invited distinguished professor lecture, office of the vice chancellor, Uppsala University, Uppsala, Sweden, October 2018.
 518. “Lessons and pitfalls from medical research”, Distinguished professor lecture, Conferencia magistral, Spanish National School of Public Health, Madrid, Spain, November 2018.
 519. “Hijacked evidence-based medicine”, keynote lecture, 13th Scientific Reunion of the Asociación Española de Evaluación de Tecnologías Sanitarias, Salamanca, Spain, November 2018.
 520. “Reproducible and useful research for public health and policy decisions”, Public Health Annual Lecture, Cambridge Institute of Public Health, Cambridge University, Cambridge, UK, November 2018.
 521. “How can you help make more research true and reproducible”, invited lecture, Journal of Hepatology annual editorial meeting, San Francisco, CA, November 2018.
 522. “The challenges of evidence-based medicine”, Institute for Functional Medicine, Celveland Clinic, Grand rounds, November 2018.
 523. “Most studies on the effects of nutrients, foods and diets are false”, Grand rounds debate, Stanford University School of Medicine, Department of Medicine, Stanford, CA, January 2019.
 524. “Reproducible and useful research: building trust in our science”, University-wide lecture, UC Davis Forum lecture, University of California Davis, Davis, CA, January 2019.
 525. “Reproducible, transparent, true, useful Research”, CR Stephen lecture, Department of Anesthesiology, Washington U St. Louis, St. Louis, March 2019.
 526. “Evidence-based medicine vs precision medicine: fighting with small and big data”, closing plenary keynote, Annual meeting of the German Evidence Based Medicine network, Berlin, Germany, March 2019.
 527. “Scientific evidence: reproducible and useful”, METRIC B Inaugural Lecture, Berlin, Germany, March 2019.
 528. “Nutritional science: epidemiology, bias, and trials”, invited professor lecture, Memorial Sloan Kettering Cancer Center, New York, NY, April 2019.
 529. «Ο βίος όχι τόσο βραχύς, η δε τάχνη απόμακρη: οξέα, σφαλερά, και χαλεπά γραπτά», invited lecture, Department of Philology, School of Philosophy, National University of Athens, Athens, Greece, May 2020 (in Greek).
 530. “Ιατρική επιστήμη: τεκμηρίωση και αξιοπιστία”, invited lecture, Medical and Surgical Society of Corfu, Corfu, Greece, May 2020 (in Greek).
 531. “Changing landscape in reproducible biomedical research”, invited lecture, EMBL workshop, Athens, Greece, May 2020.
 532. “Why most research is flawed”, invited lecture, Annual ESCI meeting, Coimbra, Portugal, May 2019.
 533. “Methodological and bibliometric issues as well as conflict of interest in cardiovascular

- research”, invited lecture, Annual ESCI meeting, Coimbra, Portugal, May 2019.
534. “Statistical analysis (not) enough for publishing”, invited lecture, Annual ESCI meeting, Coimbra, Portugal, May 2019.
 535. “Publishing your paper: the editor’s perspective”, invited lecture, Annual ESCI meeting, Coimbra, Portugal, May 2019.
 536. “Reproducibility and translation in biomedical research”, Closing keynote, Award Ceremony of the BIH Charité Clinician Scientist Program, Berlin, Germany, June 2019
 537. “Improving the reproducibility of research”, Closing keynote, 45th Psychology and Brain meeting, Dresden, Germany, June 2019
 538. “Are IVF children different? Alarming findings when using administrative databases and national registries”, invited plenary, European Society of Human Reproduction and Embryology annual meeting, Vienna, Austria, June 2019
 539. “Meta-epidemiology methods”, invited lecture, University of Bologna, Italy, Advanced epidemiology course, June 2019.
 540. “Challenges with big data”, invited lecture, University of Bologna, Italy, Advanced epidemiology course, June 2019.
 541. “Is there a reproducibility crisis and what should be done about it?”, invited lecture, University of Bologna, Italy, Advanced epidemiology course, June 2019.
 542. “Αγαπημένη πο[ολη μη επιστροφής» (in Greek), Ηράκλεια Πυθαγόρεια, Samos, Greece, July 2019
 543. “Re-evaluating the quest for reproducible research”, President’s lecture, 40th annual meeting of the International Socoeity of Clinical Biostatistics, Leuven, Belgium, July 2019.
 544. “Reproducible Evidence for Healthcare: Current and Future”, Closing keynote (“Legend” lecture), EBM Live, Oxford, UK, July 2019
 545. “Unpacking irreproducibility in science”, EMBL Forum/Distinguished Visitor Lecture, European Molecular Biology Laboratory, Heidelberg, Germany, July 2019
 546. “Reducing waste in healthcare research”, keynote, Scandinavian Society of Anesthesiology and Intensive Care, Copenhagen, Denmark, August 2019
 547. “Research agenda and the patient perspective: peer review, pre or post”, invited lecture, Scandinavian Society of Anesthesiology and Intensive Care, Copenhagen, Denmark, August 2019
 548. “Reproducible and useful research: current status and future prospects”, invited lecture, European Research Council, Brussels, Belgium, September 2019
 549. “Improving biomedical research through openness and reproducibility”, Inaugural lecture for Robert Merton Center on Science of Science, Humboldt University, Berlin, Germany, September 2019
 550. “Incorporating harms reporting to every clinical trial – the ideal world”, invited keynote, CONSORT Harms meeting, Edmonton, Canada, September 2019
 551. “Sharing data - and more: leveraging transparency and repeatability”, invited lecture, Indiana University Bloomington School of Public Health, Sloan meeting, October 2019
 552. “The reproducibility crisis in academic research”, invited keynote lecture, Annual meeting of presidents of Swedish universities, Karolinska, Stockholm, Sweden, October 2019
 553. “Reproducibility crisis in animal research”, invited lecture, Karolinska Institute, Stockholm, Sweden, October 2019
 554. “Redefining research quality: The reproducibility challenge”, invited lecture, Karolinska Institute, Stockholm, Sweden, October 2019.
 555. “Medical evidence: flawed, but possible to fix”, Distinghuihed invited professor lecture, ITMO University, Saint Petersburg, Russia, October 2019.
 556. “European Initiatives for Health Research and Development, invited lecture, World Health Summit workshop, World Health Summit, Berlin, Germany, November 2019
 557. “Reproducible research: transparency and translational impact”, invited lecture, Ludwig Maximilian University, Munich, Germany, November 2019.

558. “The epidemic proliferation of useless systematic reviews”, invited plenary lecture, International Conference on Evidence Based Health Care, Taormina, Italy, November 2019
559. “Transparency, Bias, and Usefulness in Biomedical Research”, Annual Moskowitz lecture, Department of Radiology, Stanford University, CA, November 2019
560. “Meta-research in different scientific fields: What lessons can we learn from each other?”, Closing keynote, Meta-Research Day, Tilburg, Netherlands, November 2019.
561. “Meta-research to transform science”, Opening keynote, MiROR meeting, National Academy of Medicine, Paris, France, November 2019
562. “Reproducible preclinical research and translation: mission possible”, Opening keynote, Symposium “After translational strategies”, Utrecht University, Utrecht, Netherlands, November 2019
563. “Meta-research: building trust and research integrity”, Keynote, INSERM directrs meeting, Paris, France, February 2020 (by videoconference)
564. STOA meets experts, panel speaker, European Parliament, Science and Technology, April 2020 (by videoconference)
565. “Reproducibility in the life sciences”, invited lecture, European Society of Human Genetics, Berlin, Germany, June 2020 (by videoconference)
566. “COVID-19: high risks, high prevalence, high-level evidence, and high-stake decisions”, invite lecture, Stanford Alumni Club, June 2020 (by videoconference)
567. “COVID-19: high risks, high prevalence, high-level evidence, and high-stake decisions”, invited lecture, University of California Santa Barbara, Santa Barbara, CA, USA, June 2020 (by videoconference)
568. “Science, hypocrisy, and lies”, invited lecture, How the Light Gets In, Institute of Arts and Ideas, September 2020 (by videoconference)
569. “COVID-19”, Young Presidents Organization, California, USA, September 2020 (by videoconference)
570. “COVID-19: of models and evidence”, invited lecture, Festival of Science, bologna, Italy, September 2020 (by videoconference)
571. “COVID-19: models, risks, evidence, debates and decisions”, invited lecture, Berlin Institute of Health, Berlin, Germany, September 2020 (by videoconference)
572. “COVID-19 epidemiology: risk, evidence and decisions”, invited lecture, University of North Carolina at Chapel Hill, School of Dentistry and School of Public Health, Chapel Hill, NC, USA, October 2020 (by videoconference)
573. “Dealing with COVID-19: models, evidence, risk and choosing the best interventions”, invited lecture, European University of Cyprus, Cyprus, October 2020 (by videoconference)
574. “How to make medical research credible and useful”, invited plenary, 8th Congress of the European Academy of Pediatric Societies, October 2020 (by videoconference)
575. “COVID-19 epidemiology and risk stratification”, inaugural webinar lecture, Hellenic Society of Ultrasound in Obstetrics and Gynecology, Greece, November 2020 (by videoconference)
576. “Fake news in scientific research”, invited keynote, 32nd Congress of the European Society of Pathology and XXXIII International Congress of the International Academy of Pathology, December 2020 (by videoconference)
577. “Reproducibility in research”, invited lecture, Baltimore City College, Baltimore, MD, USA, December 2020 (by videoconference).
578. “Predictive modeling: are models using artificial intelligence superior to standard statistical models?”, invited lecture, City of Hope National Medical Center, CA, USA, December 2020 (by videoconference)
579. “COVID-19 pandemic: known, unknown, and forgotten essentials of epidemiology”, keynote lecture, Annual National Conference on Economics of Health and Health Policy, Athens, Greece, December 2020 (by videoconference) (in Greek), <https://www.youtube.com/watch?v=4-ftO6Nx2Uc>

580. “COVID-19 epidemiology: evidence, models, and shifting sand”, Grand rounds lecture, Cedars-Sinai, Los Angeles, CA, USA, February 2021 (by videoconference)
581. “COVID-19 epidemiology: evidence, risks and misconceptions”, invited lecture, IHU Méditerranée-Infection, Marseille, France, February 2021 (by videoconference), <https://www.youtube.com/watch?v=9szCNNZrPK8>
582. “Evidence-based public health”, inaugural lecture, Public Health lecture series, European University of Cyprus, Cyprus, February 2021 (by videoconference), <https://www.youtube.com/watch?v=ydcy-9IX-og>
583. “Race: A complex variable that requires careful use in research”, invited lecture, Boston University School of Medicine, Boston, MA, USA, February 2021 (by videoconference), https://www.bu.edu/ctsi/files/2021/03/Ioannidis_BUrace.pdf
584. “Reproducible and useful research: changing research practices”, invited lecture, the Center for Philosophy of Science, University of Pittsburgh, Pittsburgh, PA, USA, February 2021 (by videoconference)
585. “COVID-19: Evidence base underlying measures to fight the pandemic”, invited lecture, University of Oldenburg, Oldenburg, Germany, February 2021 (by videoconference)
586. “Zero COVID”, invited lecture and debate webinar, BMJ Webinars, March 2021 (by videoconference)
587. “What COVID-19 has taught us about clinical trials”, invited lecture, 2021 Papper event, Department of Anesthesiology, New York – Presbyterian Hospital, Columbia University School of Medicine, New York, NY, USA, April 2021 (by videoconference)
588. “Reproducible and useful evidence for cancer prevention”, keynote lecture, Gloria and Mark Snyder Symposium, Innovative Discovery in Cancer Population Science to Improve Public Health, Stony Brook Cancer Center, Stony Brook University, Stony Brook, NY, USA, April 2021 (by videoconference)
589. “Reproducible research in 2021”, invited lecture, City University of New York, School of Public Health, New York, NY, USA, April 2021 (by videoconference)
590. “COVID-19 epidemiology: understanding and ending the pandemic”, invited lecture, Boston College Hellenic Society, Boston, MA, USA, April 2021 (by videoconference)
591. “COVID-19: Συνέπειες, λύσεις και προτάσεις”, invited lecture, George Papandreou Institution, Athens, Greece, April 2020 (by videoconference)
592. “Challenges and opportunities in health research methods during the COVID-19 pandemic”, invited keynote, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada, April 2021 (by videoconference)
593. “Meta-research: in quest of reproducible and useful evidence”, Wolfson Haldane annual lecture, Wolfson College, Oxford University, Oxford, UK, May 2021 (by videoconference)
594. “Reproducible and useful research: images of the present and imagining the future”, J Arliss Pollock Award and Memorial Lecture at the American Society of Neuroradiology annual meeting in recognition of exceptional leadership and commitment to medicine in the area of socioeconomics and health policy at a national level, May 2021, (by videoconference)
595. “Large scale evidence and meta-research”, SPRC Symposium, Stanford University, Stanford, USA, May 2021 (by videoconference)
596. “Reproducible and useful biomedical research in 2021”, Roy and Diana Vagelos Lecture, inaugural lecture, World Hellenic Biomedical Association, May 2021 (by videoconference)
597. “COVID-19 epidemiology: understanding and ending the pandemic”, invited lecture, Accademia delle Scienze, Bologna, May 2021 (by videoconference)
598. “COVID-19 epidemiology: a learning experience in evidence”, invited keynote speaker, Annual meeting for the Swedish Association for General Medicine, Sweden, May 2021 (by videoconference)

599. “Environmental security and public health”, invited expert speaker, Organization for Security and Co-operation in Europe, Parliamentary debate session, Vienna, May 2021 (by videoconference)
600. “Reproducible, pragmatic, collaborative, useful: clinical research that matters”, invited keynote, European Society of Pediatric and Neonatal Intensive Care, Athens, Greece, June 2021 (by videoconference)
601. “COVID-19 epidemiology: risks, measures, and ending the pandemic”, invited lecture, New York University, NY, USA, June 2021 (by videoconference)
602. “Exercise or drugs? What is the evidence”, Morris/Paffenbarger Exercise is Medicine® Keynote Lecture, 12th World Congress on Exercise is Medicine, American College of Sports Medicine, June 2021 (by videoconference)
603. “COVID-19 epidemiology: risks, measures, and ending the pandemic”, University of Salzburg, Salzburg, Austria, June 2021
604. “Meta-research in artificial intelligence”, Berlin Institute of Health, Berlin, Germany, June 2021
605. “Reproducible and useful research in biomedicine and beyond: an overview of the current situation”, invited lecture, Serbian Academy of Sciences, Belgrade, Serbia, July 2021
606. “Reproducible research: true or false?”, invited keynote, World Conference of Anesthesiology, September 2021 (by videoconference)
607. “COVID-19 epidemiology: risks, measures, and ending the pandemic”, keynote, 13th Aegean Conference in Complement Therapeutics, Ioannina, Greece, September 2021
608. “Advancing the science of scientific publishing”, virtual symposium, September 2021 (by videoconference)
609. “Evidence, bias, reproducible research, and open science in 2021”, IHU Mediterranee Infection, Marseille, France, October 2021
610. “Methods from meta-analysis for meta-research”, opening keynote, Meta-Analysis in Economics Research (MAER), annual international meeting, Piraeus, Greece, October 2021
611. “Reproducible, transparent, useful evidence: tangible goals?”, keynote, Evidence-Based Medicine conference, University of Lisbon, Lisbon, Portugal, October 2021
612. “Challenges for Epidemiology and Credible Scientific Literature during the Covid19 Pandemic”, University of Coimbra, Coimbra, Portugal, October 2021
613. “Reproducibility in scientific research”, University of Coimbra, Coimbra, Portugal, October 2021
614. “Meta-epidemiological assessments of evidence”, keynote, Nothing But the Truth Symposium, University of Groningen, Groningen, Netherlands, November 2021
615. “COVID-19 epidemiology lessons for ending the pandemic”, Festival of Medical Sciences, Bologna, Italy, November 2021
616. “16 years after “Why most published research findings are false”, University of Bern, Bern, Switzerland (by videoconference)
617. “Meta-research and the quest for better science”, Ecole Polytechnique, Paris, France, November 2021
618. “COVID-19 epidemiology, interventions and measures: some lessons learned”, European University of Cyprus, Nicosia, Cyprus, November 2021
619. “Create a future for data sharing”, Future of Privacy Forum, December 2021 (by videoconference)
620. “Science reproducibility”, University of Coimbra, Coimbra, Portugal, December 2021 (by videoconference)
621. Parliamentary meeting on Open Science, Parliamentary Office For Scientific and Technological Assessment (OPECST), French Parliament (Assemblée nationale), December 2021 (by videoconference).
622. “Recalibrating the use of race in medical research”, Department of Epidemiology and

- Population Health supper club, Stanford, California, January 2022 (by videoconference)
623. “Reproducibility and transparency indicators across diverse scientific fields”, Department of Psychology, Cambridge University, February 2022 (by videoconference)
 624. “Are Reproducibility and Transparency Improving and Biases Decreasing across Diverse Scientific Fields?”, invited keynote, Ben Gurion University, Israel, March 2022 (by videoconference)
 625. Panel presentation at the Post-COVID Summit, Conversation 2: Risk assessment and prevention, European Parliament, March 2022 (by videoconference)
 626. “Why does the pandemic still hold strong? Are there alternative escape routes”, closing lecture, Internal Medicine annual meeting, University of Athens, Greece, April 2022 (by videoconference)
 627. “The end of the COVID-19 pandemic”, invited lecture, University of California San Francisco, April 2022 (by videoconference)
 628. Panel presentation on the Strategic Council for Research Excellence, Integrity and Trust committee meeting, National Academy of Sciences, USA, April 2022 (by videoconference)
 629. “Reproducibility, Transparency, and Lessons from Meta-research for Music Medicine”, invited keynote, International Association for Music and Medicine, 7th international conference, Athens, May 2022 (by videoconference).
 630. “The end of the pandemic”, UCSF, San Francisco, USA (by videoconference), May 2022.
 631. “An evidence-based, reproducible end of the COVID-19 pandemic”, Berlin Institute of Health, Berlin, Germany, May 2022.
 632. “Science and pandemic: lessons learned”, invited lecture, University of Cyprus, Nicosia, Cyprus (in Greek), May 2022.
 633. “The replication crisis Part A. The context”, University of Coimbra graduate program lecture, Coimbra, Portugal, May 2022 (by videoconference).
 634. “The replication crisis. Part B. Fighting the replication crisis”, University of Coimbra graduate program lecture, Coimbra, Portugal, May 2022 (by videoconference).
 635. “Reproducible, useful clinical research: methods and ethics”, Grand rounds, Pediatrics, Hackensack Joseph M. Sanzari Children’s Hospital, NJ, USA, June 2022 (by videoconference).
 636. “Personalized health: evidence, prediction, ethics, and reproducibility”, invited keynote, World Health Summit, Rome, Italy, June 2022.
 637. “Reproducibility in biomedical research: what next”, invited keynote, European Society of Hypertension, Athens, Greece, June 2022.
 638. “Replication crisis: a 2005-2022 retrospective and future prospects”, Berlin Institute of Health, Berlin, Germany, June 2022.
 639. “Reproducible and useful research on risk factors and treatments”, invited keynote, 19th International Conference on Behcet’s Disease, Athens, Greece, July 2022.
 640. “Reproducible research and scientific publishing in 2022”, invited lecture, Innate Immunity conference, Aegean Conference, Ioannina, Greece, July 2022.
 641. “The past, present, and future of randomized clinical trials”, invited keynote, NCORP annual meeting, National Cancer Institute, Bethesda, Maryland, August 25, 2022, (by videoconference)
 642. “Problems in the current research practice and the role of meta-research”, Yonsei University, Seoul, Seoul, South Korea, September 2022
 643. “Reproducible science for knowledge and decision-making”, invited keynote, International Society for Environmental epidemiology, Athens, Greece, September 2022.
 644. “Meta-epidemiology of infectious disease models”, Infectious Disease Outbreaks lecture series, invited seminar, University of Bordeaux, Bordeaux, France, October 2022.
 645. “Meta-epidemiology of modeling and forecasting in epidemiology”, invited webinar, Philosophy of medical corona science, Bertalanffy Center for the Study of Systems Science, Vienna, Austria, October 2022 (by videoconference)
 646. “What happens when a scientist gets results about COVID-19 that are unwelcome?”,

- Conference on Lack of Scientific Freedom: Causes, Consequences, and Cures, Copenhagen, Denmark, October 2022.
647. “Reproducibility in science”, invited keynote, BSF, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK, October 2022.
 648. “Meta-research: latest developments for evaluating and improving research practices”, invited lecture, Department of Health Policy, London School of Economics, London, UK, October 2022.
 649. “Context of the replication crisis”, University of Coimbra graduate program lecture, Coimbra, Portugal, November 2022 (by videoconference).
 650. “Fighting the replication crisis”, University of Coimbra graduate program lecture, Coimbra, Portugal, November 2022 (by videoconference).
 651. “Academic freedom in medicine”, invited presentation/panel, Academic Freedom Conference, Graduate School of Business, Stanford University, Stanford, California, November 2022.
 652. “Replication and validity issues in observational studies”, invited lecture, University of Wisconsin, Madison, Wisconsin, November 2022 (by videoconference)
 653. “Revisiting COVID-19 models and epidemiology”, invited keynote, POLI-COVID-22, Salute, Scienza e Società alla prova della pandemia, Torino, Italy, November 2022 (by videoconference)
 654. “Reproducibility in biomedical science”, invited distinguished professor, Gerald Bronfman Department of Oncology Distinguished Lecture, McGill University, Montreal, Canada, November 2022.
 655. “Models, evidence, bias, and speculation: revisiting the COVID-19 pandemic”, invited plenary keynote lecture, 13th Conference of the Panhellenic Association of Bioscientists, Thessaloniki, Greece, December 2022 (by videoconference).
 656. “Navigating the world of statistical modeling on health outcomes”, invited lecture, Medicine in the Media Workshop, Medical Journalism conference, organized by Dartmouth College, Washington D.C., January 2023 (by videoconference).
 657. “Reproducibility and usefulness in biomedical research”, invited lecture, Epidemiology seminar series, Jewish General Hospital, Montreal, Canada, January 2023.
 658. “Reproducibility and usefulness in biomedical research”, Grand Rounds, Department of Psychiatry, Zucker Hillside Hospital, New York, NY, March 2023.

EDITOR, PEER-REVIEWER, CONSULTANT, AND OTHER APPOINTMENTS (selectively)

Editor-in-Chief (elected in 2008, started being responsible for manuscripts as of July 2009, first issue under my editorship published in January 2010) for the European Journal of Clinical Investigation until the end of 2019. Last impact factor reflecting my editorship period: 5.722

Member of the editorial board for other international peer-reviewed journals - current

Clinical Chemistry (2014-)
 Physiological Reviews (2022-)
 Royal Society Open Science (2021-)
 International Journal of Epidemiology (2007-)
 Journal of Clinical Epidemiology (2005-)
 Research Integrity and Peer Review (2021-)
 Journal of Translational Medicine (2012-)
 BioMed Central Infectious Diseases (2000-)
 Journal of Evaluation in Clinical Practice (2008-)
 Biomarker Research (2012-)
 SPOUDAI – Journal of Economics and Business (2023-)

Member of the editorial board for other international peer-reviewed journals – past

Annals of Internal Medicine (2007-2010)
Journal of the National Cancer Institute (2005-2015)
Lancet (2005-2016)
Science Translational Medicine (2011-2014)
PLoS Medicine (2007-2019)
PLoS Biology (2010-2020)
PLoS ONE (2006-2022)
AIDS (2004-2010)
Cancer Treatment Reviews (2006-2014)
Molecular and Cellular Proteomics (2012-2017)
Cochrane Library (1998-2010), editor, HIV/AIDS CRG
Guest editor, Seminars in Hematology (2008 issue)
BioMed Central Medical Research Methodology (2000-13)
Clinical Trials (was Controlled Clinical Trials, 2004-13)
Journal of Empirical Research in Human Research Ethics (2006-12)
Open Medicine (2007-2012)
Cases Journal (2008-2010)
Research Synthesis Methods (2010-2013)
Italian Journal of Public Health (2009-2013)
Human Genomics and Proteomics (2008-2011)
International Journal of Molecular Epidemiology and Genetics (2009-)
GAPP Reviews (2009-); then PLoS Currents: Evidence on Genomic Tests
Annals of Gastroenterology (published in Greek, 1999)

Peer-reviewer for several hundreds of manuscripts in >120 different peer-reviewed journals:

AIDS, AIDS Research and Human Retroviruses, American Journal of Epidemiology, American Journal of Human Genetics, American Journal of Medicine, American Journal of Psychiatry, Annals of Internal Medicine, Annals of Neurology, Annals of the Rheumatic Diseases, Antiviral Therapy, Archives of General Psychiatry, Archives of Internal Medicine, Arthritis and Rheumatism, Arthritis Research and Therapy, Atherosclerosis, Thrombosis and Vascular Biology, Biometals, Biotechniques, Blood Coagulation and Fibrinolysis, BMC Anesthesiology, BMC Bioinformatics, BMC Gastroenterology, BMC Health Services Research, BMC Infectious Diseases, BMC Medical Research Methodology, BMC Medicine, BMC Psychiatry, BMC Public Health, BMJ (British Medical Journal), British Journal of Hematology, Calcified Tissue International, Cancer Epidemiology, Biomarkers and Prevention, Cancer Letters, Cancer Treatment Reviews, Circulation, Clinical Cancer Research, Clinical Endocrinology, Clinical Infectious Diseases, Clinical Trials, CMAJ (Canadian Medical Association Journal), Contemporary Clinical Trials, Controlled Clinical Trials, Drug Discovery Today, Drugs and Aging, Drug Safety, Emerging Infectious Diseases, Epidemiology, European Cytokine Network, European Journal of Cancer, European Journal of Clinical Investigation, European Journal of Epidemiology, European Journal of Human Genetics, FASEB Journal, Genetic Epidemiology, Genetics in Medicine, Genomics, Gut, HIV Clinical Trials, HIV Immunology Database, Human Genetics, Human Heredity, Human Immunology, Human Reproduction, Human Reproduction Update, International Journal of Biochemistry and Cell Biology, International Archives of Allergy and Immunology, International Journal of Cancer, International Journal of Epidemiology, International Journal of Immunogenetics, JAMA (Journal of the American Medical Association), Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, Journal of Antimicrobial Chemotherapy, Journal of Bone and Mineral Research, Journal of Clinical Epidemiology, Journal of

Epidemiology and Community Health, Journal of General Internal Medicine, Journal of Infectious Diseases, Journal of Medical Genetics, Journal of Reproductive Immunology, Journal of Rheumatology, Journal of the National Cancer Institute, Kidney International, Lancet, Lancet Infectious Diseases, Lancet Neurology, Lung Cancer, Lupus, Maturitas, Mayo Clinic Proceedings, Molecular Genetics and Metabolism, Molecular Psychiatry, Nature, Nature Clinical Practice Cardiovascular Medicine, Nature Clinical Practice Rheumatology, Nature Genetics, Nature Reviews Genetics, NEJM (New England Journal of Medicine), Obstetrics and Gynecology, Paediatric and Perinatal Epidemiology, Pediatric Infectious Diseases Journal, Pharmacogenetics and Genomics, Pharmacogenomics, Pediatrics, Physiology and Behavior, PLoS Computational Biology, PLoS Medicine, PLoS ONE, PNAS (Proceedings of the National Academy of Sciences USA), Psychiatric Research, Quarterly Journal of Medicine, Rheumatology, Scandinavian Journal of Rheumatology, Science, Scientometrics, The Cochrane Library, Tissue Antigens, Trials, Trends in Genetics, Trends in Microbiology, Trends in Pharmacological Sciences, Urology

- Invited external expert for the National Health Research and Development Program of Canada (1995).
- Invited peer-reviewer for strategic plan grant application, Medical Research Council (MRC), UK (1998).
- Primary reviewer for antiretroviral trials sponsored through ACTG and CPCRA at the Clinical Science Review Committee of the Division of AIDS, National Institutes of Health (1996 -8).
- Invited to contribute and assess questions for the Certification Examinations of the American Board of Internal Medicine, subspecialty Infectious Diseases (1997 and 1998).
- Peer-reviewer, Minority AIDS Training Program Fellowship, ACTG (1998).
- Consultant, Workshop on Research Needs for the Design of Surrogate Endpoints in Clinical Trials, Office of Science Policy, Office of the Director, National Institutes of Health (1998).
- Invited external reviewer for grant applications at the Committee for Biomedical Research, Central Health Council, Greece (1999).
- Reviewer for research grant applications and physician and director appointments, Hellenic Center for Infectious Disease Control, Greece (2000, 2001)
- Editor for therapeutics, prognostics, and diagnostics, HIV/AIDS Collaborative Review Group, International Cochrane Collaboration. (1998-)
- Member, Committee for Approval of Clinical Trials, Hellenic Foundation for Medicines, Greece, 1999-2000
- Member, Committee for Antibiotic Use, Hellenic Foundation for Medicines, Greece, 2000-2002
- Vice President, Board of Directors, Hellenic Center for Infectious Disease Control, Ministry of Health, Greece, 2000-1
- Member (expert), Greek delegation, European Union Council of Ministers of Health, Luxembourg, 6/2000
- Expert, High Level Round Table on Infectious Diseases and Poverty Reduction, European Commission/WHO/UNAIDS, Brussels, 9/2000
- Co-ordinating committee, MSc Program in Social Psychiatry, University of Ioannina, 2001-
- Director, Sector of Social Medicine and Mental Health, University of Ioannina School of Medicine, 2001-2002, 2003-2004, 2005-2006, 2007-2008
- Member, Administrative Council, University of Ioannina School of Medicine, 2001-2 and 2003-2004.
- Collaborating Scientist, Biomedical Research Institute, Foundation for Research and Technology-Hellas, Ioannina, 2001-.
- External reviewer, MRC, UK, 2003
- Book reviewer, Wiley, 2003, 2004, 2006
- Associate Editor, Encyclopedia of Clinical Trials, Wiley

- Member, Executive Committee, Human Genome Epidemiology (HuGE) Network, Centers for Disease Control and Prevention, Atlanta, USA, 3/2004-
- Adverse Event Reporting in Oncology (AERO), Executive Committee, 4/2004-
- Reviewer, European Science Foundation, 2004
- Member, Working Party, International Campaign to Revitalise Academic Medicine, 2004- (sponsored by BMJ and Lancet)
- External Reviewer, Swiss National Science Foundation, 2005
- Invited methodologist expert, KDIGO guidelines (international guidelines on kidney diseases), 2005-
- Founding member, Society for Research Synthesis Methodology, 2006-
- Member, Faculty of 1000 Medicine
- Evaluator, MacArthur Fellowship nominations, 2007, 2012, 2014
- Research grant evaluator, FP7, European Commission, 2007
- External reviewer, Research Grant council of Hong Kong, 2007
- Member of review panel/study section, NIMH, NIH, 2008
- President-elect, Society for Research Synthesis Methodology, 2008-9
- President, Society for Research Synthesis Methodology, 2009-10
- Reviewer of consensus report: “What Works in Health Care: Standards for Systematic Reviews”, Institute of Medicine, 2010
- Member, Program 10, Stanford Cancer Institute, 2010-
- Member, Methodology Committee, Patient-Centered Outcomes Research Institute (PCORI), appointed by U.S. Government Accountability Office, 2011-2013
- Organizer/convenor, Innovation awards in population science, Stanford University, 2011-2012
- Book reviewer, Yale University Press, 2011
- Scientific Advisor, AlzBiomarkers database, AlzForum, 2011-
- Member, Research Priorities Working Group, PCORI, 2011
- Member, Women’s Health Initiative Scientific Resources Working Group, 2011-
- Member, Women’s Health Initiative Genomics Scientific Interest Group, 2011-
- Member, Biosciences advisory committee, National Council for Research and Technology, Greece, 2011-
- Member, Faculty Senate, Stanford University, 2011-2013
- Member, Implementation group, Population health sciences initiative, Stanford University, 2012-2013
- Member, Scientific Advisory Board, International Epidemiology Institute, Rockville, MA, 2012-
- Senior Advisor on Knowledge Integration, National Cancer Institute, National Institutes of Health, 2012-
- Scientific Advisory Board, Reproducibility Initiative, 2012-
- Scientific Advisory Board, Center for Open Science, 2013-
- Member, consensus panel on prevention of chronic non-communicable diseases, International Olympic Commission, 2013
- Reviewer of proposals, Sloan Foundation, 2013 and 2015
- Book reviewer, Oxford University Press, 2013
- Executive Advisory Board, Rapid Science, 2014-
- Invited, SciFoo Camp, Nature and Google, August 2014
- Advisory Board, Berkeley Initiative for Transparency in Social Sciences (BITSS), 2014-
- Chair, Scientific Advisory Board, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, UK, 2015-
- Scientific Advisory Panel, QUEST-Center for Transforming Biomedical Research, Berlin Institute of

Health, Berlin, Germany, 2017-2019

- Scientific Advisory Board, REPEAT Initiative, 2017-
- I have been invited repeatedly on hundreds of occasions by dozens of other national and international research grants organizations to act as reviewer, but have declined most of them, especially when physical presence has been required and travel is involved.

CHAIRMAN IN SESSIONS OF CONFERENCES: ~30

MEMBER OF SCIENTIFIC COMMITTEES OF CONFERENCES: ~30, most recently Co-Director of the International Congress on Peer Review and Scientific Publication (to be held in Chicago in September 2022).

EXTERNAL REFEREE FOR FACULTY PROMOTIONS: for ~50 different universities, research institutions and national/royal academies in Greece, USA, Canada, Cyprus, UK, Australia, and the Netherlands.

EXTERNAL REFEREE FOR PhD THESES: 15

TRAINEES:

Primary supervisor for awarded PhD titles (n=20)

1. Maria Baltogianni, currently attending in neonatal intensive care unit at University Hospital Ioannina, Greece; h=4
2. Evangelos Evangelou, currently associate professor (tenured) in epidemiology, University of Ioannina School of Medicine, Greece. Also senior lecturer at Imperial College London, UK; h=78
3. Ioannis Giannakakis, currently in private practice in internal medicine in Ioannina, Greece, h=4
4. Anna-Bettina Haidich, currently professor in hygiene and medical statistics (tenured), Aristotelean University of Thessaloniki, Greece, h=39
5. Petros Isaakidis, currently senior leader, Medecins sans Frontiers, Capetown, South Africa, h=34
6. Dimitrios Lathyris, currently attending in intensive care unit at university hospital in Thessaloniki, Greece, h=11
7. George Liberopoulos, currently in fellowship training, h=7
8. Fotini Kavvoura, currently junior faculty/consultant in endocrinology and diabetes at Oxford University, Oxford Centre for Diabetes, Endocrinology & Metabolism, and consultant, Royal Berkshire NHS Foundation Trust, Royal Berkshire Hospital, UK, h=20
9. Davide Mauri, assistant professor of Oncology, University of Ioannina School of Medicine, Greece, h=32
10. Evangelia Ntzani, currently professor and head of hygiene and epidemiology (tenured) at University of Ioannina School of Medicine, Greece. Also adjunct appointment at Brown University, Providence, USA; h=40
11. Emiliios Pakos, currently associate professor (tenure-track) in orthopedics research at University of Ioannina School of Medicine, Greece, h=22
12. Panagiotis Papanikolaou, currently attending consultant in ENT, Cleveland Clinic Abu Dhabi, Abu Dhabi, h=6
13. Nikolaos Patsopoulos, currently Biomarker Development Therapeutic Area Lead, Novartis Institutes for BioMedical Research (NIBR), formerly assistant professor of neurology at Harvard Medical School and associate member, Broad Institute, Boston, USA, h=41
14. Nikolaos Polyzos, currently professor and head of reproductive medicine, Dexeus University Hospital, Barcelona, Spain and associate professor at the Vrije Universiteit Brussel and medical co-director in the

- Center for Reproductive Medicine in the Universitair Ziekenhuis Brussels, Belgium, h=52
15. George Siontis, consultant in cardiology, University of Bern University hospital (Inselspital), Bern, Switzerland, h=32
 16. Athina Tatsioni, currently professor and head of general medicine (tenured) at University of Ioannina School of Medicine, also adjunct appointment at Tufts University School of Medicine, Boston, USA, h=36
 17. Thomas Trikalinos, currently professor (tenured) and director of the Center for Evidence-Based Medicine at Brown University School of Public Health, Providence, USA, h=69
 18. Joshua D Wallach, currently assistant professor, Department of Epidemiology, Emory University School of Public Health, h=18 (the first student to graduate from the new PhD program in epidemiology and clinical research at Stanford)
 19. Stelios Serghiou, currently resident physician, Google Research, h=11
 20. Yuan Jin (YJ) Tan, currently Data Analyst, Social Determinants of Health, New York City Department of Health and Hospitals, h=5

Many of these scientists also worked with me either at pre-doctoral level (before starting their thesis) and/or at post-doctoral level before moving on with their careers to other positions. Overall, they currently hold appointments in 8 different countries.

Hirsch h-index values above are as per Google Scholar, February 2022 (median h=27).

Other trainees (selectively):

Besides these PhD recipients where I was the main supervisor, several dozens of other young researchers who trained* with me as fellows or research associates or collaborated with me in the first stages of their careers already have faculty positions in various countries around the world.

*I don't like a lot the term "trained", but I use it here for convention – I consider that I am the one who tries to get trained when I work with younger colleagues. I enjoy working with young researchers and training with them, regardless of the distance involved, and some of them are not physically located where I am located. My "lab" is dispersed around the world.

Selected researchers who have published two or more peer-reviewed papers as first authors in manuscripts where I am the senior author:

A. Trained with me as fellows, doctoral students or junior faculty at Stanford:

21. Kim Boesen, currently Researcher at University of Basel, has been research affiliate at METRICS. H=7
22. Stephan Bruns, Assistant Professor in the Environmental Economics Group at the Centre for Environmental Sciences at Hasselt University in Belgium, also affiliated with the Econometrics and Statistics Group, University of Goettingen, Germany, h=11. Was visiting scholar at Stanford.
23. Ioana-Alina Cristea, Associate Professor of Psychology, University of Padova, Italy, h=33. Was visiting scholar at Stanford.
24. Sean P. David, Program Director for Translational Science, Outcomes Research, Clinical Professor and Vice Chair for Research, Department of Family Medicine, University of Chicago, Pritzker School of Medicine, Chicago, USA, h=34. Was junior faculty at Stanford.
25. Shanil Ebrahim, currently Partner and the Life Sciences & Health Care Artificial Intelligence (AI) Leader at Deloitte Canada and Assistant Professor, Department of Health Research Methods, Evidence, and Impact, McMaster University, Canada, h=25. Was postdoctoral fellow at Stanford.

26. Daniele Fanelli, currently Fellow in Quantitative Methodology, Department of Methodology, London School of Economics and Political Science, London, UK, h=23. Was research scholar at METRICS.
27. Tom Hardwicke, currently Marie Skłodowska-Curie Fellow, Department of Psychology, University of Amsterdam, Amsterdam, Netherlands, h=15. Was METRICS postdoctoral fellow at Stanford.
28. Lars Hemkens, currently Senior Scientist and deputy Director, Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland, h=33. Was Commonwealth Fund/postdoctoral fellow at Stanford.
29. Perrine Janiaud, currently Research Fellow, Department of Clinical Research, University Hospital Basel, h=13. Was METRICS post-doctoral fellow at Stanford.
30. Shanthi Kappagoda, currently Clinical Associate Professor in Medicine - Infectious Diseases, Stanford, USA, h=8. Was fellow at Stanford Medicine.
31. Rebecca Marton, currently Senior Scientific Researcher, Genentech, San Francisco, h=8. Was doctoral student at Stanford, working with METRICS.
32. Edward Mills, currently Professor (Part-Time), Department of Health Research Methods, Evidence, and Impact, McMaster University School of Medicine, Hamilton, Canada and Founder of Global Evaluation Sciences, Vancouver, Canada, h=108. Was adjunct/consulting faculty at Stanford.
33. Visvam Nair, currently Assistant Professor, Clinical Research Division, Fred Hutchinson Cancer Center and Assistant Professor, Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington, USA, h=19. Was postdoctoral researcher at Stanford.
34. Florian Naudet, currently Professor of Therapeutics, University of Rennes School of Medicine, Rennes, France, h=22. Was METRICS postdoctoral fellow at Stanford.
35. Orestis Panagiotou, currently Assistant Professor of Health Services Policy and Practice, Brown University School of Public Health, Providence, RI, USA, h=25. Was visiting fellow at Stanford (I was also his PhD advisor until I left from Ioannina).
36. Jack W. O'Sullivan, currently resident in Medicine/Cardiovascular Medicine at Stanford, h=15. Was T32 postdoctoral fellow at METRICS.
37. Austin Parish, currently Emergency Medicine resident, Lincoln Medical Center, Bronx, New York, h=3. Was postdoctoral fellow at Stanford.
38. Chirag Patel, currently Associate Professor, Department of Biomedical Informatics, Harvard Medical School, Boston, USA, h=38. Was NHLBI/T32 postdoctoral fellow at Stanford.
39. Nazmus Saquib, currently Associate Professor, Sulaiman Al Rajhi College of Medicine, Saudi Arabia, h=31. Was NHLBI/T32 postdoctoral fellow at Stanford.
40. Ewoud Schuit, currently assistant professor at the Julius Center, UMC Utrecht, University of Utrecht, Netherlands, h=30. Was postdoctoral fellow supported by a Rubicon grant at Stanford.
41. Matthew Sigurdson, currently PhD student at Stanford under my supervision.
42. Denes Szucs, currently Professor in Psychology, Cambridge University, Cambridge, UK, h=49. Was visiting collaborator/scholar at Stanford.
43. Emmanuel Zavalis, currently medical student at Karolinska Institute, Stockholm, Sweden. Visiting researcher at METRICS.

B. Trained/worked with me at the University of Ioannina

44. Despina Contopoulos-Ioannidis, currently Clinical Associate Professor of Pediatrics, Stanford, USA, h=40
45. Fotini Karassa, currently Lecturer in Rheumatology (tenure track), University of Ioannina School of Medicine, Ioannina, Greece, h=23
46. Ioannis Kosmas, currently in ob/gyn practice in Greece, h=10

47. Panagiotis Kyzas, currently Consultant OMFS Head & Neck Surgeon Clinical Lead H&N NCA and Lecturer, University of Manchester, Manchester, UK, h=25
48. George Mantzavinis, currently in family medicine practice in Greece, h=5
49. Christos Ntais, currently in general practice in Greece, h=8
50. Stefania Papatheodorou, currently Lecturer in Reproductive Epidemiology, Harvard University and Lecturer in Epidemiology, Cyprus International Institute for Environmental and Public Health, Cyprus University of Technology, Limassol, Cyprus, h=24
51. Tiago Pereira, currently Professor at Universidade de São Paulo, Sao Paulo, Brazil, h=16
52. Anastasia Polycarpou, currently in general practice in Greece, h=8
53. Evangelos Rizos, currently Consultant Diabetologist, Attending in Internal Medicine, Ioannina University Hospital, Ioannina, Greece, h=27
54. Georgia Salanti, currently Research group leader and Associate Professor in Epidemiology and Biostatistics (tenured), Institute for Social and Preventive Medicine, University of Bern, Switzerland, h=80
55. Konstantinos Siontis, currently Assistant Professor of Medicine, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA, h=30
56. Alexandros Sotiriadis, currently Associate Professor of Obstetrics - Gynaecology - Fetal Medicine, Aristotelean University of Thessaloniki, Thessaloniki, Greece, h=39
57. Kostas Tsilidis, currently Associate Professor in Epidemiology (tenured), University of Ioannina School of Medicine, Ioannina, Greece, and Senior Lecturer, Imperial College London and Senior Lecturer, University of Bristol, h=53
58. Ioanna Tzoulaki, currently Associate Professor of Epidemiology, University of Ioannina School of Medicine, and Professor of Epidemiology, Imperial College London, London, UK, h=74

C. Other scientists with ≥ 2 papers where they are first authors and I am senior/last author

59. David Chavalarias, currently Director, Institute of Complex Systems, Paris, France, h=13
60. Stefania Boccia, currently Professor of Hygiene, Catholic University of Rome, Rome, Italy, h=58
61. Rafael dal-Re, currently Director of Clinical Analysis in BUC (Biosciences UAM+CSIC) Program, International Campus of Excellence, Universidad Autónoma, Madrid, Spain, h=30
62. Anthony Doufas, currently Professor of Anesthesia, Stanford University School of Medicine, Stanford, CA, USA, h=35
63. Benjamin Djulbegovic, currently Professor of Medicine, City of Hope National Medical Center, Duarte, CA, USA, h=71
64. Maria Elena Flacco, currently Assistant Professor of Hygiene, University of Ferrara, Ferrara, Italy, h=36
65. Katherine Flegal, currently Consulting Professor of Medicine, Stanford University, USA, h=107
66. Kat Kolaski, currently Associate Professor of Orthopedics and of Pediatrics, Wake Forest University School of Medicine, Salem, Winston-Salem, NC, USA. h=10
67. Demosthenes Katritsis, currently Director of Cardiology, Athens Euroclinic, Athens, Greece and Honorary Consultant, St. George's, London, UK, and Lecturer, Harvard University, USA, h=62
68. Muin J. Khoury, currently Director, Office of Public Health Genomics, CDC, Atlanta, Georgia, and National Cancer Institute, NIH, Bethesda, Maryland, USA, h=120
69. Stuart Kim, current Professor Emeritus of Developmental Biology, Stanford University, USA, h=50.
70. Falk Leichsenring, currently Professor of Psychotherapy Research, Justus Leibig University of Giessen, Giessen, Germany, h=54
71. Michael Levitt, currently Professor of Structural Biology, Stanford University, USA, h=100.
72. Arjun Manrai, currently Assistant Professor of Biomedical Informatics, Harvard Medical School,

- h=21
73. Lamberto Manzoli, currently Professor of Epidemiology and Healthcare Services, University of Bologna, Bologna, Italy, h=57
 74. Sneza Medic, currently Senior scientist at Institute of Public Health of Voivodina, Serbia, h=12.
 75. Harald Mischak, currently Professor of Proteomics, University of Glasgow, Glasgow, UK and Mosaiques Diagnostics, Hannover, Germany, h=98
 76. Huseyin Naci, currently Associate Professor of Health Policy and Director of Teaching in the Department of Health Policy, London School of Economics LSE, London, UK, h=33
 77. Vinay Prasad, currently Professor of Epidemiology and Biostatistics, UCSF, San Francisco, USA, h=44
 78. Stefan Pilz, currently Associate Professor of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria, h=75
 79. Tom D. Stanley, currently Professor of Economics and Business, Hendrix College, Arizona, USA, h=42.
 80. George H. Swingler, currently professor of pediatrics and child care, University of Cape Town, Cape town, South Africa, h=30
 81. Evropi Theodoratou, currently Professor of Cancer Epidemiology and Public Health, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK, h=60
 82. Adriano Tonelli, currently attending in Pulmonary Medicine and Critical Care, Cleveland Clinic, Cleveland, USA, h=16
 83. Don van Ravenzwaaij, currently Professor of Bayesian Statistics, University of Groningen, Groningen, Netherlands, h=26
 84. Vana Spoulou, currently Professor of Pediatric Infectious Diseases, National and Kapodistrian University of Athens, Athens, Greece, h=20
 85. Elias Zintzaras, currently Professor of Bioinformatics, University of Thessaly, Larissa, Greece, h=62

Hirsch h-index values above are as per Google Scholar, February 2022 (median h=30).

- D. 104 other researchers who have published one peer-reviewed paper as first author in manuscripts where I am the senior author (most of them were young researchers who trained with me, a minority are senior scientists with whom I collaborated; many of these young researchers are currently faculty and leaders).

Abou-El-Enin M
 Adami HO
 Adibi A
 Agarwal A
 Alsheikh-Ali AA
 Axfors C
 Banglawada SM
 Begley CG
 Bellou V
 Bendavid E
 Berger W
 Blum MR
 Boesen K

Bonitsis NG
Bourgeois FT
Boyack KW
Bzdok D
Castaldi P
Castillo-Garcia A
Chalkias A
Chang CQ
Christou MAC
Crowley RJ
Danchev V
Danas PG
Desai K
Doran M
Doshi P
Economou M
Efstathiadou Z
Elliott KS
Erasmus A
Evans JA
Fang Y
Fiedorowicz JG
Fusar-Poli P
Goetzsche PC
Goldstein BA
Golfinopoulos V
Goodman SN
Grimes DR
Guloksuz S
Howick J
Hozo I
Hsing A
Iqbal S
Joyner MJ
Kanters S
Karczewski KJ
Karvouni E
Katsifis GE
Kemper JM
Kent DM
Kitsios GD
Knowles JW
Kohavi R
Koletsis D
Kraft P
Kyrgiou M

Kyriakidi M
Lee JJ
Lenzer J
Levitt M
Lewis JR
Lu Y
Makrydimas G
McDonald KM
Mol B
Morris A
Muka T
Munafo MR
Naji L
Nicholson J
Oren O
Pan Z
Pandis N
Panidou EJ
Papanikolaou GN
Parmer D
Pastorino R
Pezzullo AM
Pfeiffer T
Ralston SH
Schoenfeld J
Seminara D
Shenkin SD
Sigounas DE
Stamatakis E
Stavropoulou C
Stergiou GS
Tawfik DS
Telenti A
Thompson T
Trepanowski JF
Tsianos GI
Tzioras S
Uitterlinden AG
Van't Hooft J
Verghese A
Verma M
Vlahoyiannopoulos P
Weinerova J
Zeggini E
Ziavra N

COMPETITIVE RESEARCH FUNDING

Funded grants since moving to Stanford University:

HHSN268201100003C (Stefanick) 10/2010-9/2015

NIH/NHLBI

Women's Health Initiative Extension 2010-2015

Role: co-investigator, mentor for junior faculty

R21 NIH/NIGMS (Bhattacharya) 9/2011-9/2013

Exploring Medicare Provider Networks: Implications for Adoption of CER findings

Role: co-investigator

R01 NIH/NIDDK (Gardner) 9/2012 – 9/2017

Do Genotype Patterns Predict Weight Loss Success for Low Carb vs. Low Fat Diets?

Role: investigator.

Nutritional Science Initiative matching grant to extend the R01 on low carb vs. low fat diets

9/2013-8/2016

Role: investigator

R21 NIH/NICHHD (Ioannidis, Stanford PI) 7/2012-6/2014

Establishing surveillance of the pediatric evidence base for drug therapy

Role: Stanford PI

IPA NIH/NCI (Ioannidis) 6/2012 – 4/2016

Senior Advisor for Knowledge Integration

Role: senior consulting appointment

R01 NIH/NEI (Seddon) 10/2012-09/2014

Etiologic Studies of Age-Related Macular Degeneration

Role: investigator (subcontract to Stanford)

R21 NIH (Ioannidis, Stanford PI) 04/2012-03/2015

Exclusion of Older Patients in Clinical Drug Trials

Role: Stanford PI

Laura and John Arnold Foundation (Ioannidis/Goodman) 12/2013-09/2017

Meta-Research Innovation Center at Stanford

Role: Principal Investigator

R21 Office of Research Integrity, NIH (Fanelli/Ioannidis) 10/2013-9/2016

1 ORIIR130001-01-00

Research of the Responsible Conduct of Research

Role: Stanford PI

5R01DA030005-05 NIH/NIDA (Sundquist/Ioannidis) 6/2014-6/2015

Genetics, family environment, and neighborhood: impact on mental disorders

Role: Stanford PI

R01 AI 68581-06A1 NIH/NIAID (Shafer) 9/2014-9/2017
Public HIV Drug Resistance Database
Role: co-investigator

1R01HL116381-01A1 NIH/NHLBI (Sundquist/Ioannidis) 9/2014-4/2019
Neighborhoods and Coronary Disease: Exploring Mechanisms and Improving Methods
Role: Stanford PI

R01 NIH/NIAID (Bendavid) 06/2016-05/2022
Big Data Analysis of HIV Risk
Role: co-investigator

METRICS Postdoctoral fellowship (Ioannidis) 10/2017 – 06/2024
Sponsor: Arnold Foundation
Post-doctoral fellowship in meta-research
Role: principal investigator

2R01LM01136905 (Shah) 09/2017-08/2022
National Institutes of Health
From Enrichment to Insights
Role: investigator

NIH/SBIR (Ioannidis) 10/2017 – 4/2020
National Institutes of Health / SciTech Strategies, Inc.
Creation of an accurate model of the topical structure of PubMed and associated indicators
Role: principal investigator (subcontract)

R24 NIH/NIAID (Shafer) 5/2018-4/2023
HIV Drug Resistance database
Role: co-investigator

Grant Number: R01 HL149141 7/2019-6/2023
National Heart, Lung, And Blood Institute, National Institutes of Health
A Meta-Epidemiological Assessment of the Role of Pilot Studies in the Design of Well-Powered Trials - the Pilot Project
Role: Stanford PI

Also I have been investigator at several other federal/other grants without requesting salary support, as well as senior (co-)investigator in 4 pilot/innovation awards from the Stanford Clinical and Translational Science Institute and the Stanford Cardiovascular Institute, co-PI on a Canadian Institute of Health Research grant on network meta-analysis (PI: David Moher, U Ottawa), and a co-PI on a Templeton Foundation award to create a Metaknowledge Network (PI: James Evans, U Chicago).

I have also received several unrestricted gifts from philanthropy donors. Among them, most notable in particular is a \$10 million unrestricted gift that was made in August 2014 through the Nutrilite Health Institute Wellness Fund to Stanford University to help launch under my direction the Wellness Living Laboratory (WELL), a next-generation cohort focused on wellness outcomes with embedded multiple randomized trials on wellness and a concurrent biobank for biomarker studies. WELL has been launched initially in California, China (Hangzhou), Taiwan (Taipei) and Singapore with a core of 10,000 participants

in each site.

Indicative prior grants at the University of Ioannina (before moving to Stanford):

From NIH, U.S. AHRQ, European Commission, Canadian Institute of Health Research, General Secretariat for Research and Technology (Greece), Michael J. Fox Foundation, Gani Foundation. The list of grants with principal investigator role (single PI or one of several PIs (Co-PI)) while at University of Ioannina includes:

2000-2003	Funder: European Commission
Title: Evidence based treatment in mental health: optimized use of databases, grant # QLRT-1999-31201, 2000-0201	
	Role: Co-PI
2002-2005 and European Commission	Funder: General Secretariat for Research and Technology, Greece
	Title: Meta-analysis in genetic informatics, grant #01ED237
	Role: PI
2002-2006	Funder: European Commission
Title: GENOMOS: Genetic markers of osteoporosis, grant # QLRT-2001-02629	
	Role: Co-PI
2002-2004	Funder: European Commission
Title: AGREE: Towards effective health care policy in Europe: promoting a coherent approach to the development, dissemination, and assessment of clinical guidelines through established networks, grant # QLAM-2001-0057	
	Role: Co-PI
2003-2005	Funder: European Commission
Title: Evidence for Drugs and Alcohol Policy (EDAP): Cochrane Systematic Reviews, grant # 2002454	
	Role: Co-PI
2003-2005	Funder: Esther and Joseph Gani foundation
Title: International meta-analysis on anti-P antibodies in SLE, grant # 1516	
	Role: PI
2004-2005	Funder: Michael J. Fox Foundation
Title: Meta-analysis of genetic epidemiology studies for Parkinson's disease.	
	Role: Co-PI
2005-2008 and European Commission	Funder: General Secretariat for Research and Technology, Greece
Title: Large scale evaluation of genetic information for multifactorial disease, grant #03ED14	
	Role: PI
2005-2006	Funder: Michael J. Fox Foundation
Title: Large-scale validation of whole genome association findings for Parkinson's disease	
	Role: Co-PI
2007-2008	Funder: Canadian Institute of Health Research (CIHR)
Title: Development of optimal methods for synthesizing evidence on gene disease associations and related interventions, grant #83116	
	Role: Co-PI
2008-2012	Funder: European Commission, FP-7-Health-2007
Title: Translational Research in Europe – Applied Technologies for Osteoarthritis (TREAT-OA), grant #FP7-HEALTH-2007-200800	
	Role: Co-PI

2008-2012 Funder: European Commission, FP-7-Health-2007
 Title: Genetic factors for osteoporosis (GEFOS) grant # FP7-Health-2007-2.4.5-4
 Role: Co-PI

2010-2012 Funder: Cyprus Research Promotion Foundation
 Title: Meta-analysis of genome-wide association data and large-scale replication aiming to identify novel breast cancer susceptibility loci, grant # health/bios/0308
 Role: Investigator

Total: >\$40 million in grants and gifts where I have been principal investigator. Several-fold more including grants where I have been an investigator.

LITERARY WORKS:

For details, see separate webpage: sites.google.com/view/johnpaioannidis

I have published 9 books, 8 of them in the Greek language and 1 in English. I consider these writings at least as important as my scientific work and I work on them as such – actually, it is very likely they are more important, given that in research I am still considering myself no more than a learning novice who is passionately eager to learn more. The first three books comprise a trilogy and were published by Govostis editions (a leading publishing house for literature in Greece) in 1989, 1990, and 1991 – two of them carried original cover and frontispiece lithograph engravings by the late Vassilis Charos (1938-2000, arguably one of the greatest Greek engravers of the 20th century). The “Toccata for the Girl with the Burnt Face” was published by Kedros editions in the summer of 2012 and it was shortlisted for the best book of the year Anagnostis awards in Greece in 2013 (www.oanagnostis.gr). The “Variations on the Art of the Fugue and a Desperate Ricercar” was published by Kedros editions in July 2014 and it was also shortlisted for the best book of the year Anagnostis awards in Greece in 2015. An English version of this book along with extensive annotations will be published in 2022 by Kedros. The “Tractatus on the sixth fame” was published by Kedros editions in the summer of 2016. My seventh book, (Μετά τα Αφύσικα, “Meta-a-Physics”) was published in late summer 2018 by Kedros editions (also shortlisted for the best book of the year Anagnostis award in 2019). My eight book (Λόγω κρυμμένα λογοκριμένα, “Censored sensors” was published in November 2020 also by Kedros editions. My most recent book was published in May 2022 by Kedros and it is the English version of the “Variations on the Art of the Fugue and a Desperate Ricercar” hyperlinked with a new book, called “Annotations” (e-book edition).

In addition, I have written libretti for four operas. The first three have been set to music by composer Haris Vrontos.

1. Η Επέτειος (The Anniversary), I have written the libretto (in Greek) for the arias.
2. Η Συνάντηση (The Reunion), I have written the full libretto (in Greek).
3. Το Περιδέραιο (The Necklace), I have written the full libretto in both Greek and English.
4. Behrenstrasse 2.15am, I have written the full libretto in English.

Poetry from my book “Toccata for the girl with the burnt face” has been set to music by composer Miran Tsalikian. Miran Tsalikian was a winner in the Y2 competition for young composers in Athens in May 2022 where the symphonic poem “I write in a language that I do not wish to speak” based on my poetry was performed.

In May 2019 I was inducted as a corresponding member to the Hellenic Authors’ Society (Εταιρεία Συγγραφέων), the most prestigious literary society in Greece.

FILM

“Out to see: A film with John Ioannidis” by director Patricia Marchart was released in October 2022, see website: <https://www.out-to-see.com/>

SELECTED VIDEOS FROM LECTURES, INTERVIEWS, AND DISCUSSIONS OF WORK FOR GENERAL AUDIENCE

A selection of a few videos of talks that I have given that are available online:

1. Invited lecture at Google, 2014. <https://www.youtube.com/watch?v=GPYzY9I78CI>
2. Invited lecture at Center for Law and Biosciences, Stanford Law School, 2013. <https://www.youtube.com/watch?v=VXiy51A-gP8>
3. Annual keynote EQUATOR lecture, Freiburg, 2012. <https://www.youtube.com/watch?v=KEAAHJDNCMQ>.
4. Grand rounds at Stanford Department of Medicine on predictive medicine, 2012. <https://www.youtube.com/watch?v=mOpV30sMePk>.
5. Lecture on genetic studies in Paris, 2014. http://www.dailymotion.com/video/x1w8llkl_john-ioannidis-genetic-studies_school
6. Data sharing in clinical trials, Institute of Medicine, 2014. <https://www.youtube.com/watch?v=m8V1wmd-q0>. <https://www.youtube.com/watch?v=5mSd4CaYOHo>
7. Grand rounds at Stanford on Geometry of Evidence, 2013. https://www.youtube.com/watch?v=h_nXt0rsZVQ
8. Interview at European Forum Alpbach on Greek austerity, 2013. <http://vimeo.com/72494420>
9. Interview at TV3, Barcelona, Spain, 2011. <http://www.324.cat/noticia/1440926/societat/Ioannidis-reclama-mes-control-public-de-la-recerca-cientifica-biomedica-per-tenir-estudis-de-mes-qualitat>
10. Lessons and pitfalls from medical research, Berkeley, December 2014, <https://www.youtube.com/watch?v=Cs9dkey5BPo>
11. Proactive planning in the preclinical research arena, National Research Council, 2014. http://www.youtube.com/watch?v=1tcr_xO6ZRY
12. John Ioannidis on moving towards truth in scientific research, Public Library of Science Q&A, San Francisco, 2014. <https://www.youtube.com/watch?v=KOZAV9AvIQE&feature=youtu.be>
13. Reproducible research: replication practices and how to improve them, SREE 2014, <https://www.sree.org/video/index.php?s=2014SBall1>
14. 2015 Delta Omega lecture, Arnold School of Public Health, University of South Carolina, April 2015, <https://www.youtube.com/watch?v=1hVoAAkvbns>
15. Berlin Institute of Health inaugural lecture, May 12, 2016, <https://www.youtube.com/watch?v=xGLF6oIIZYY>
16. Remarks, Medal for distinguished Service, Teachers College, Columbia University, May 2015. <https://www.youtube.com/watch?v=IISIMQVHz0A>
17. Bradford hill lecture, London School of Hygiene and Tropical Medicine, London, July 2015, <https://panopto.lshhtm.ac.uk/Panopto/Pages/Viewer.aspx?id=a00111f1-78b8-4875-9b41-6e7d713a022a>
18. Evidence based medicine has been hijacked, Lown conference keynote, Chicago, April 2016, <https://www.youtube.com/watch?v=N63skNtYaJw>
19. Capturing the value of prevention, Singapore, May 2016, <https://www.youtube.com/watch?v=xaPnY7eDoFA>
20. Evidence Live keynote, Oxford, June 2016, Why most published clinical research is not useful, <https://www.youtube.com/watch?v=Uok-7NPFn4k>
21. Εκτίμηση της αξιοπιστίας της επιστημονικής βιβλιογραφίας, National Research Institute, November 2016, Athens, <http://www.blod.gr/lectures/Pages/viewlecture.aspx?LectureID=3144> (in Greek)

22. Capturing the value of prevention, National University of Singapore, 2016, <http://www.nus.edu.sg/thought-leaders?search-keyword=Prof+John%7CIOannidis>
23. Interview at Erasmus University Rotterdam, <https://www.coursera.org/learn/deceptiondetox/lecture/DtDDk/optional-video-full-length-interview-with-john-ioannidis>
24. The 23rd Anatomy Lesson, “Biomedical research: the unfinished musical score”, Concertgebouw symphony hall, Amsterdam, November 2016, <https://www.youtube.com/watch?v=AbJmfcxeASc>
25. The role of bias in nutritional research, Zurich 2018, <https://www.youtube.com/watch?v=KTAbx4i8Dyg>
26. Reproducible and useful research: building trust in our science, UC Davis Forum, 2019, <https://www.youtube.com/watch?v=OBzcvS34>
27. Enhancing reproducible research, Keynote at ESOF, Toulouse 2018, <https://www.youtube.com/watch?v=fAeLMEmLIoE>
28. Why most published research findings don't need to be false, Split 2017, <https://www.youtube.com/watch?v=iHNySjbSQhM>
29. Snyder lecture, University of Utah, 2016, https://www.youtube.com/watch?v=8Zgs_UPsibI
30. Precision health, big data and evidence-based medicine – contradictions or companions?, University of Michigan, 2018, <https://www.youtube.com/watch?v=KxXo1KZRlw4>
31. Comments at the International Science Festival Gothenburg, 2017, <https://www.youtube.com/watch?v=a3AORS7kisU>
32. Open science fair, 2017, https://www.youtube.com/watch?v=fb1Sjzy_174
33. Research on research interview, MiRoR, 2017, <http://miror-ejd.eu/2017/11/13/interview-with-professor-john-ioannidis/>
34. Scientific Standards for Data Integrity/Quality, NASEM, 2017, <http://www.nationalacademies.org/hmd/Activities/Research/SharingClinicalTrialData/2014-FEB-03/Day%202/Scientific%20Standards%20and%20Data%20Integrity%20and%20Quality/38-Ioannidis-Video.aspx>
35. Capturing the value of prevention, National University of Singapore, 2018, <https://www.nus.edu.sg/thought-leadership/-in-category/thoughtleaders/i/prof-john-ioannidis>
36. Interview at Cleveland Clinic, 2018, <https://www.youtube.com/watch?v=-S8bhRlnZOk>
37. Interview with Eric Topol, Medscape, 2018, <https://www.medscape.com/viewarticle/898405>
38. Enhancing reproducible research, keynote ESOF, Toulouse, 2018, <https://metrics.stanford.edu/resources/videos/enhancing-reproducible-research-keynote-esof-toulouse-2018>
39. In scientific method we don't just trust, or why replication has more value than discovery, Gordon award, NIH, 2019, <https://prevention.nih.gov/news-events/robert-s-gordon-jr-lecture-epidemiology/2019-awardee>
40. Reproducibility in crisis: Sample quality and the importance of early and ongoing analysis, Science/AAAS, 2018, <https://www.sciencemag.org/custom-publishing/webinars/reproducibility-crisis-sample-quality-and-importance-early-and-ongoing>
41. Scientific evidence: reproducible and useful, visiting Einstein fellow METRIC B inaugural lecture, 2019, <https://www.bihealth.org/en/research/private-excellence-initiative-johanna-quandt/einstein-bih-visiting-fellows/john-ioannidis/>
42. EMBL Forum Science and Society Seminar: John Ioannidis - Unpacking irreproducibility in science, 2019, <https://www.youtube.com/watch?v=Tr7fdPrCP74>
43. Perspectives on the pandemic, 2020, <https://www.youtube.com/watch?v=cwPqmLoZA4s>
44. Science, hypocrisy, and lies, 2020, <https://iai.tv/video/science-hypocrisy-and-lies-john-ioannidis>
45. Data-Driven vs. Non-Data-Driven Decision Making During the COVID-19 Pandemic, Dana Farber Cancer Institute, 2020, <https://www.youtube.com/watch?v=g4TS38h81JE>
46. Reproducible and useful research: changing research practices, 2020, <https://www.youtube.com/watch?v=L1-fNM0uJQA>
47. Zero COVID known unknown, BMJ, <https://blogs.bmj.com/bmj/2021/03/22/zero-covid-known->

[unknowns/](#)

48. Keynote at annual Research Day at McMaster University,
https://www.macvideo.ca/media/HEI+Research+Day+2021+John+Ioannidis+Plenary+Session/1_9zs04f29
49. IHU Méditerranée-Infection invited lecture on COVID-19 epidemiology, 2021
<https://www.youtube.com/watch?v=8KzZXvT1g-k>
50. Evidence-based public health, European University of Cyprus, 2021,
<https://www.youtube.com/watch?v=ydcy-9IX-og>
51. COVID-19 epidemiology, University of Salzburg, 2021,
<https://www.youtube.com/watch?v=e4grP1718Ps>
52. Invited lecture at the Ecole Polytechnique in Paris, <https://www.youtube.com/watch?v=-PWoiKrted8>
53. Invited lecture at IHU Mediterannee Infection in Marseille, <https://www.youtube.com/watch?v=eYV-BRRhp5Y>
54. Interview with Vinay Prasad on COVID-19 and more, 2021,
<https://www.youtube.com/watch?v=YvEOwKUyur0>

A selection of a few podcasts

55. The Recommended Dose, <https://soundcloud.com/therecodo/09-john-ioannidis>
56. STEM talk, <https://www.iheart.com/podcast/269-stemtalk-29336701/episode/episode-77-john-ioannidis-discusses-why-30182494/>
57. Health News Review, The scourge of sloppy science,
<https://www.healthnewsreview.org/podcastmedia/podcast-john-ioannidis-scurge-sloppy-science/>
58. EconTalk, John Ioannidis on Statistical Significance
<https://podcasts.apple.com/de/podcast/john-ioannidis-on-statistical-significance-economics/id135066958?i=1000400420269&l=en>
59. Rationally Speaking, What happened to evidence-based medicine
<http://rationallyspeakingpodcast.org/show/rs-174-john-ioannidis-on-what-happened-to-evidence-based-med.html>
60. Mendelspod, Who is John Ioannidis <https://www.mixcloud.com/mendelspodpodcast/who-is-john-ioannidis/>
61. Munk Debate, High-stakes decisions on COVID-19 without reliable data, 4/2020,
<https://www.youtube.com/watch?v=9VtRDVa21rI>
62. Munk Debate, Lockdowns, 8/2020
<https://www.youtube.com/watch?v=6pazKScT-FM>
63. Plenary Session, Building a meta-research center and constructing COVID-19 policy,
<https://soundcloud.com/plenarysession/ep341>
64. Berlin Institute of Health: How did the coronavirus influence research? 2021
<https://www.bihealth.org/de/aktuell/how-did-the-coronavirus-influence-research>
65. Podcast with Peter Attia, <https://peterattiamd.com/johnioannidis/>
66. Podcast at JAMA with Howard Bauchner,
<https://podcasts.apple.com/us/podcast/recalibrating-the-use-of-race-in-medical-research/id410339697?i=1000506518295>

A selection of a few interviews:

67. John Ioannidis: Uncompromising gentle maniac. BMJ. 2015 Sep 24;351:h4992
68. Interview at NRC, The Netherlands, <http://www.nrc.nl/handelsblad/2015/11/14/gesel-van->

- [de-wetenschap-ziet-licht-aan-de-horizo-1556180](#)
69. Interview with Steve Hsu, vice President for Research and Graduate Studies, Michigan State University, May 2015, <https://www.youtube.com/watch?v=knWdMFTVXH4>
 70. From One to One Million Article Views: Q&A with Author John Ioannidis. Interview at PLoS blogs, <http://blogs.plos.org/speakingofmedicine/2014/06/23/one-one-million-article-views-qa-author-john-ioannidis/>
 71. Lies, Damn Lies, and Medical Science, Brave Thinkers, The Atlantic. <http://www.theatlantic.com/magazine/archive/2010/11/lies-damned-lies-and-medical-science/308269/>
 72. The man who would prove all studies wrong. Interview at the New Scientist. <http://www.newscientist.com/article/mg19726432.000-interview-the-man-who-would-prove-all-studies-wrong.html>
 73. Excerpt from David Freedman's Wrong. New York Times. <http://www.nytimes.com/2010/06/11/books/excerpt-wrong.html?pagewanted=all&r=0>
 74. Is science funding encouraging conformity. Interview at Boston Globe. <http://www.boston.com/news/science/blogs/science-in-mind/2012/12/06/science-funding-encouraging-conformity/kKikhMYowmAjpzCIEIGQcK/blog.html>
 75. Waarom (bijna) alles wat u weet, niet klopt. Interview at de Volkskrant (Netherlands). <http://www.volkskrant.nl/wetenschap/waarom-bijna-alles-wat-u-weet-niet-klopt~a3770924/>
 76. Interview at Horizons, magazine of the Swiss National Science Foundation and Swiss Academy of Sciences, March 2014 issue. <http://www.snf.ch/en/researchinFocus/research-magazine-horizons/archive/Pages/default.aspx>
 77. Collaboration and transparency. Interview at People and Perspectives, Public Responsibility in Medicine and Research. <http://www.peopleandperspectives.org/story/interview-ioannidis-2>
 78. I am happy to find my own errors. Interview at Lab Times, http://www.labtimes.org/i50/i_07.lasso
 79. De wetenschap zit op 't foute pad. Interview at De Trouw (Netherlands), 13/9/2014.
 80. Q&A: overhaul the funding system. Interview at The Scientist. <http://www.the-scientist.com/?articles.view/articleNo/31258/title/Q-A--Overhaul-the-Funding-System/>
 81. Can we Trust the Claims in Scientific Research Findings? February 27, 2015. An interview with John Ioannidis reporting from the American Association for the Advancement of Science annual meeting. By Ian Sample, Science Weekly, Guardian. <http://www.theguardian.com/science/audio/2015/feb/27/scientific-research-papers-climate-control-aaas-meeting-san-jose>
 82. John Ioannidis has Dedicated his Life to Quantifying How Science is Broken. February 16, 2015, The author of "Why Most Published Research Findings are False", remains optimistic about improving science through meta-research. By Julia Belluz, Vox Media. <http://www.vox.com/2015/2/16/8034143/john-ioannidis-interview>
 83. Η ζωή είναι ένα μη τυχαίο πείραμα (Life is a non-randomized experiment), συνέντευξη στον Ερμή, (in Greek) 7/2015, http://www.saka.gr/ermis51/Hermes_51.html
 84. BBC World Newshour, August 2015, <http://www.bbc.co.uk/programmes/p030csz8> (after 45.00 minute)
 85. National Public Radio KPCC Los Angeles, Take Two, August 28, 2015, <http://www.scpr.org/programs/take-two/> (after 8.50 minute)
 86. Interviews at United Daily News, Taiwan, 9/2015, <http://udn.com/news/story/7266/1201482> and <http://udn.com/news/story/9/1199252>
 87. Interview at the Lown conference, Chicago, 4/2016, <https://www.youtube.com/watch?v=PkieEZl66sw>
 88. Bloomberg, Is it science or hype behind Theranos claims,

- <https://www.bloomberg.com/news/videos/2016-05-27/is-it-science-or-hype-behind-theranos-claims>, May 27, 2016
89. National Public Radio, Reviews Of Medical Studies May Be 'Tainted By Funders' Influence, 10/16/2016, <http://www.npr.org/sections/health-shots/2016/10/12/497550681/reviews-of-medical-studies-may-be-tainted-by-funders-influence> Are big ideas too entrenched? Health Report, Australian Broadcasting Corporation, <http://www.abc.net.au/radionational/programs/healthreport/are-big-ideas-too-entrenched/8002076>
 90. The conforing feeling of the numbers, Volkskrant, 10/8/2016, <http://www.volkskrant.nl/magazine/de-troostrijke-werking-van-het-getal~a4391395/> (in Dutch)
 91. Rationally speaking, John Ioannidis on what happened to evidence-based medicine, <http://rationallyspeakingpodcast.org/show/rs-174-john-ioannidis-on-what-happened-to-evidence-based-med.html>
 92. Warum sind die meisten Studien falsch, Herr Ioannidis, Zeit, June 13, 2017, <http://www.zeit.de/2017/25/medizin-studien-forschung-fehler-pharmaindustrie-john-ioannidis>
 93. Nature Index interview, February 2018, <https://www.natureindex.com/news-blog/john-ioannidis-biomedicine-warms-to-preprints>
 94. MedScape interview: Most research is flawed: let's fix it., 2018, <https://www.medscape.com/viewarticle/898405>
 95. Interview at Tagesspiegel, 2019, <https://www.tagesspiegel.de/berlin/stanford-forscher-ueber-die-gesundheitsstadt-berlin-wissenschaftler-brauchen-eine-siegermentalitaet/25147624.html>
 96. Interview at Lakartidningen, 2019, <https://lakartidningen.se/Aktuellt/Nyheter/2019/11/Professorn-som-gar-till-attack-mot-dalig-forskning/>
 97. L'Obs (Le Nouvel Observateur), 2020, <https://www.nouvelobs.com/art/ccbbf6bc-8081-448a-8a6c-6b325458c6ba>
 98. Interview at CNN, 2020, <http://www.cnn.com/video/data/2.0/video/tv/2020/05/01/making-sense-of-emerging-coronavirus-data.cnn.html>
 99. Interview at Spiegel, 2020, <https://www.spiegel.de/politik/ausland/corona-krise-ist-das-virus-weniger-toedlich-als-angenommen-a-a6921df1-6e92-4f76-bddb-062d2bf7f441>
 100. Interview at Wall Street Journal, 2020 <https://www.wsj.com/articles/the-bearer-of-good-coronavirus-news-11587746176>
 101. Intelligence squared, <https://aca.st/578c30>
 102. Morgenbladet (Norway), 2020 <https://www.morgenbladet.no/aktuelt/forskning/2020/05/29/hva-feiler-det-koronaforskningen/>
 103. L'Obs (Le Nouvel Observateur), 2020, <https://www.nouvelobs.com/art/223a9f14-10f6-498b-9d5c-da121382cf7e>
 104. Interview at Science et Avenir, 2020, https://www.sciencesetavenir.fr/sante/interview-le-chercheur-john-ioannidis-defend-son-etude-sur-le-confinement_151510
 105. Interview at Die Welt, 2021, <https://www.welt.de/gesundheit/plus228783145/John-Ioannidis-Wissenschaft-ist-zu-einer-Waffe-geworden.html>
 106. Interview at Vanity Fair (France), 2021, Procès Elizabeth Holmes : Le système est en place pour un nouveau Theranos, <https://www.vanityfair.fr/pouvoir/article/proces-d-elizabeth-holmes-le-systeme-est-en-place-pour-un-nouveau-theranos>

A few select narrative stories on my work at Stanford and Tufts magazines

107. Taylor McNeal. The man who did the math. Tufts Now. <http://now.tufts.edu/articles/man-who-did-math>
108. Joan O'Connell Hamilton. Something doesn't add up. Stanford Magazine. Stanford Alumni Association. https://alumni.stanford.edu/get/page/magazine/article/?article_id=53345
109. Esther Landhuis. Research re-examined: New claims get all the attention, even if they're exaggerated or false. Stanford Medicine Plus. <http://stanmed.stanford.edu/2014fall/research-re-examined.html>
110. Alexandra Bourdillon. Prevention Research Center to Launch Wellness Living Laboratory. Stanford Daily. <http://www.stanforddaily.com/2014/11/03/prevention-research-center-to-launch-wellness-living-laboratory/>

A few op-eds for Guardian, LA Times, Sunday Times:

111. <http://www.theguardian.com/commentisfree/2015/aug/28/psychology-experiments-failing-replication-test-findings-science>
112. <http://www.latimes.com/opinion/op-ed/la-oe-ioannidis-economics-is-a-science-20171114-story.html>
113. <https://www.thetimes.co.uk/article/the-science-is-becoming-clear-lockdowns-are-no-longer-the-right-medicine-k5c652wk8>

Some essays in Boston Review and Tablet

114. Ioannidis JPA. A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data. STAT March 17, 2020, <https://www.statnews.com/2020/03/17/a-fiasco-in-the-making-as-the-coronavirus-pandemic-takes-hold-we-are-making-decisions-without-reliable-data/>
115. Ioannidis JPA. The totality of the evidence. Boston Review May 26, 2020. <http://bostonreview.net/science-nature/john-p-ioannidis-totality-evidence>
116. Ioannidis JPA. How the pandemic has changes the norms of science. Tablet 2021, <https://www.tabletmag.com/sections/science/articles/pandemic-science>
117. Ioannidis JPA, Schippers M. Saving democracy from the pandemic. Tablet 2022, <https://www.tabletmag.com/sections/science/articles/saving-democracy-from-pandemic>

A few select discussions of my work in the Economist, New York Times and Sueddeutsche Zeitung.

118. Metaphysicians. The Economist. <http://www.economist.com/news/science-and-technology/21598944-sloppy-researchers-beware-new-institute-has-you-its-sights-metaphysicians>
119. Money and science: To he that hath. The Economist 8/12/2010. <http://www.economist.com/news/science-and-technology/21567878-americas-national-institutes-health-may-not-support-best-researchers-he>
120. Medical statistics: signs of the times. The Economist 22/2/2007. <http://www.economist.com/node/8733754>
121. Scientific journals: publish and be wrong. The Economist 9/10/2008. <http://www.economist.com/node/12376658>
122. Scientific accuracy ... and statistics. The Economist 1/9/2005. <http://www.economist.com/node/4342386>
123. Trouble at the lab. The Economist. <http://www.economist.com/news/briefing/21588057-scientists-think-science-self-correcting-alarming-degree-it-not-trouble>
124. New truths that only one can see. New York Times.

- <http://www.nytimes.com/2014/01/21/science/new-truths-that-only-one-can-see.html>
125. When studies are wrong: A coda. George Johnson, New York Times 7/3/2014.
<http://www.nytimes.com/2014/03/07/science/when-studies-are-wrong-a-coda.html>
 126. Exercise as potent medicine. Gretchen Reynolds, New York Times, 11/12/2013.
<http://well.blogs.nytimes.com/2013/12/11/exercise-as-potent-medicine/>
 127. Do clinical trials work. Clinton Leaf, New York Times 13/7/2013.
<http://www.nytimes.com/2013/07/14/opinion/sunday/do-clinical-trials-work.html?pagewanted=all>
 128. What do scientific studies show. Garry Gutting, New York Times, 25/4/2103.
<http://opinionator.blogs.nytimes.com/2013/04/25/what-do-scientific-studies-show/>
 129. Gier nach Fliegensexgeschichten. Sueddeutsche Zeitung. 26/6/2014.
<http://www.sueddeutsche.de/wissen/verruetzte-studien-gier-nach-fliegensexgeschichten-1.2015966>
 130. Blutwerte ohne wert. Sueddeutsche Zeitung. 11/6/2011.
<http://www.sueddeutsche.de/gesundheit/biomarker-blutwerte-ohne-wert-1.1104021>
 131. Pillen mit Vergangenheit Meist vergehen Jahrzehnte, bis die Wirkung eines Medikaments gut untersucht ist und es zugelassen werden kann. Sueddeutsche Zeitung 10/5/2010.
<http://www.sueddeutsche.de/wissen/pillen-mit-vergangenheit-meist-vergehen-jahrzehnte-bis-die-wirkung-eines-medikaments-gut-untersucht-ist-und-es-zugelassen-werden-kann-1.368762>
 132. Kleine Untersuchung, große Wirkung. Sueddeutsche Zeitung 24/10/2012.
<http://www.sueddeutsche.de/gesundheit/medizinische-studien-kleine-untersuchung-grosse-wirkung-1.1504536>

A few more select discussions of my work

133. Stuart Blackman: The man who'd prove all studies wrong. The Scientist, 12/9/2005.
<http://www.the-scientist.com/?articles.view/articleNo/16676/title/The-man-who-d-prove-all-studies-wrong/>
134. Sharon Begley: Why almost everything you hear about medicine is wrong. Newsweek.
<http://www.newsweek.com/why-almost-everything-you-hear-about-medicine-wrong-66947>
135. Julia Belluz: When science is not science-based: in class with John Ioannidis. Maclean's.
<http://www.macleans.ca/society/life/when-science-isnt-science-based-in-class-with-dr-john-ioannidis/>
136. Gavin Yamey: The bias busters. BMJ 2014; 349 doi: <http://dx.doi.org/10.1136/bmj.g4748>
137. Richard Smith: Time for science to be about truth rather than careers. BMJ blog. 9/9/2013.
<http://blogs.bmj.com/bmj/2013/09/09/richard-smith-time-for-science-to-be-about-truth-rather-than-careers/>
138. Ulrich Dirnagl: 10 years after: Ioannidis revisits his classic paper. <http://dirnagl.com/> 23/10/2014.
139. Washington Post, July 3, 2015: <http://www.washingtonpost.com/news/to-your-health/wp/2015/07/03/the-insanely-influential-stanford-professor-behind-biotech-firms-push-to-get-fda-approval-it-probably-doesnt-need/>
140. Washington Post, Sept 16, 2015:
<http://www.washingtonpost.com/news/wonkblog/wp/2015/09/16/how-the-doctor-patient-relationship-has-become-a-prisoners-dilemma/>

A few interviews in Greek

141. Op-eds in Huffington Post, Greece edition, a full list can be retrieved in:

- <http://www.huffingtonpost.gr/ioannis-ioannidis/>
142. Op-eds in Kathimerini can also be retrieved with name search in the newspaper's site
 143. Free Greek science from political hampering (<http://www.euroscientist.com/free-greek-science-from-political-hampering>), Euroscientist, October 5, 2015. See also Huffington Post: http://www.huffingtonpost.gr/ioannis-ioannidis/-_2283_b_8458912.html, Απελευθερώστε την ελληνική επιστήμη από τα πολιτικά εμπόδια.
 144. Interview at Ημερησία, Η Ελλάδα μπορεί να μην υπάρχει σαν χώρα σε 50 χρόνια (Greece may not exist as a country in 50 years), September 27, 2015, <http://www.imerisia.gr/article.asp?catid=31205&subid=2&pubid=113754664>
 145. Op-ed in Κεφάλαιο, Ελληνική Ιστορία, Σεπτέμβριος 2015 (Hellenic History, September 2015), <http://www.capital.gr/arthra/3066096/elliniki-istoria-septembrios-2015>
 146. Op-ed, Καθηγητές και επιστήμονες ψηφοδελτίων επικρατείας (Professors and scientists in politics), <http://www.amna.gr/article-featured.php?id=88127>, Athens News Agency, September 15, 2015.
 147. Κατατάξεις Πανεπιστημίων: πόσο αξιόπιστες είναι; (University ranking systems: how reliable are they), Καθημερινή, September 13, 2015 – special edition on education.
 148. Can Greece become prosperous again?, Al Jazeera America, July 27, 2015 <http://america.aljazeera.com/opinions/2015/7/could-greece-become-prosperous-again.html>
 149. Athens News Agency press release following my Dimitri Trichopoulos lecture with extensive coverage, June 2015, e.g. http://www.huffingtonpost.gr/2015/06/15/-diethnes-epistimonese-ellines-eksoteriko_n_7582842.html
 150. See also related TV interview in SKAI TV in September 2015 <http://www.skai.gr/tv/show/?showid=65576>
 151. TEDxAcademy talk: Mediocracy versus meritocracy, Athens, September 2015, <http://www.tedxacademy.com/talks/john-q-a--ioannidis>
 152. Interview with Achilleas Papadionysiou, <https://www.youtube.com/watch?v=rQ8QUc8mwEc> (45 minutes)
 153. Interview with Achilleas Papadionysiou, Second part, <https://www.youtube.com/watch?v=JK9lO46MVhk> (59 minutes)
 154. Interview with Achilleas Papadionysiou, Third part, https://www.youtube.com/watch?v=mxI_rqBUD1c (49 minutes)
 155. Interview at Βήμα της Κυριακής, Επιστημονικά παραστρατήματα στο φως, <https://www.tovima.gr/2016/12/09/science/epistimonika-parastratimata-sto-fws/>
 156. Αντιθέσεις, Interview, 2017, <https://www.youtube.com/watch?v=XL-3P3pF9b4&t=5318s>
 157. Αντιθέσεις, Πανδημία και δεύτερο lockdown, 11/2020, <https://www.youtube.com/watch?v=5txdE8mpH0g>
 158. Αντιθέσεις, Πανδημία και διαφάνεια: μύθοι και αλήθειες, 2/2021 <https://www.youtube.com/watch?v=8ytZrFJKwNg&t=41s>
 159. Αντιθέσεις, Η ηθική της επιστήμης σε καιρούς δυστοπίας και πανδημίας, 6/2021, <https://www.youtube.com/watch?v=2sx1h14Sl8M>
 160. Ράδιο 98.4, Αυτά που συμβαίνουν στην Ελλάδα με ξεπερνούν, 2021 <https://www.youtube.com/watch?v=fiRvQ3STkA8>
 161. Kontra24 interview, 10/2021, <https://www.youtube.com/watch?v=aCLGvo8KpG0>
 162. Athens Voice, Ο Γιάννης Ιωάννιδης και η ιατρική με επίκεντρο τον άνθρωπο, https://www.athensvoice.gr/life/health/721635_o-giannis-ioannidis-kai-i-iatriki-me-epikentro-ton-anthropo
 163. Αντιθέσεις, Επιστήμη-Ηθική-αποκαλύψεις και συστήματα επιβολής, Ιούλιος 2022, <https://www.youtube.com/watch?v=Mw6fFTg37Wk>
 164. Ανοιχτές σελίδες, Υγεία και συστήματα υγείας, ηθική στην ιατρική και την ιατρική έρευνα,

Νοέμβριος 2022, <https://www.youtube.com/watch?v=-7u8A9UjOak>

A Yahoo documentary on Silicon Valley and Theranos

165. Valley of Hope, <https://www.youtube.com/watch?v=to2GSibbrv0>

CITATION IMPACT:

- Consistently listed as one of the most highly cited researchers with all databases that provide citation-based rankings (Highly Cited Researchers by Clarivate ISI/Essential Science Indicators, Scopus/Map of Science, Microsoft Academic Search).
- According to Web of Knowledge ~250,000 citations, according to Scopus ~250,000 citations, according to Google Scholar ~500,000 citations to-date.
- Current citation rate (rate of increase of citations): >3,500 citations per month per ISI, >3,500 citations per month per Scopus; ~6,000 citations per month per Google Scholar, i.e. among the top 6 most-cited living scientists among 20+ million authors across all science (most-cited physician worldwide based on this current citation rate).
- Probably the only scientist to date to have 116 papers as single or first author that have >100 citations each (per Google Scholar)
- Hirsch citation indices (per Hirsch, PNAS 2005) based on Web of Knowledge: h index=180, i.e. 180 papers have ≥ 180 citations each, m index = 6+ where $m=h/y$, y=number of years publishing peer-reviewed papers; h=180 according to Scopus and h=242 according to Google Scholar (thus, m index = 8 per Google Scholar) as of April 2023.
- Highly Cited Researcher 2014, according to Clarivate (previously Thomson Reuters) (main field concentration: Clinical Medicine)
- Highly Cited Researcher 2015, according to Clarivate, in both Clinical Medicine and Social Sciences
- Highly Cited Researcher 2016, according to Clarivate, in both Clinical Medicine and Social Sciences
- Highly Cited Researcher 2017, according to Clarivate, in both Clinical Medicine and Social Sciences.
- Highly Cited Researcher 2018, according to Clarivate, in both Clinical Medicine and Social Sciences.
- Highly Cited Researcher 2019, according to Clarivate, in both Clinical Medicine and Social Sciences.
- Highly Cited Researcher 2020, according to Clarivate, in both Clinical Medicine and Social Sciences.
- Highly Cited Researcher 2021, according to Clarivate, in both Clinical Medicine and Social Sciences.
- Highly Cited Researcher 2022, according to Clarivate, in both Clinical Medicine and Social Sciences.
- The PLoS Medicine paper on “Why most published research findings are false” is the most-cited scientific article of all times with a corresponding author address from Greece and the “Replication validity of genetic association studies” (Nature Genetics 2001) is the 7th most-cited of all times with a corresponding author address from Greece.
- 5 of my papers were among the top 200 highest Altmetric-score papers across the scientific literature as of April 2022 (among ~135 million published papers in dimensions.ai) with Altmetric scores >10,000. 25 of my papers were among the top-5000 papers across the scientific literature (altmetric scores >1,770). 36 papers with Altmetric score >1,000. 67 papers with Altmetric score >500.

OTHER IMPACT

- Over 150 publications have been accompanied by editorials in the same journal issue as they were published.
- Many publications have been covered by press releases by Reuters or Associated Press. Comments and coverage on my work have appeared repeatedly in Science, Nature, New Scientist, Scientist, Science AAAS

News, Scientific American, Chronicle of Higher Education, general journals (e.g. Economist, New Yorker, Forbes, Newsweek, Wall Street Journal, Wired, Technology Review), CNN.com, and thousands of international newspapers and news media around the world. I have given interviews for my work on the National Public Radio, and national radio/TV channels in Australia (Australian Broadcasting Corporation), Canada, Switzerland, Austria, Germany, Denmark, Italy, Spain, and Greece among others. I was selected as the Brave Thinker scientist for 2010 by The Atlantic (see article by David H. Freedman in November 2010 issue). Several bestseller books include interviews that I have given to different authors about issues of scientific methods and bias. The 2005 paper on “Why most published research findings are false” is the most frequently accessed/downloaded article in the history of the Public Library of Science with over 3 million hits to-date. It is also the most used paper across all science in Mendeley.

OTHER INTERESTS:

History, classical music, painting, visiting remote islands of the Mediterranean, hiking (e.g. in the magnificent, noble mountains surrounding Ioannina), sports (swimming, basketball, and epee fencing), walking across the beautiful Stanford campus to meet people who know far more than I do, finding out errors and mistakes I have made (there is no end to them), spending time with my wife and my daughter.